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Preface
Molecular imaging aims to visualize specific molecular and cellular targets that are
relevant to tissue characterization. Molecular imaging technologies have rapidly
developed worldwide in recent years. Among such developments, nuclear medicine
technologies using PET and SPECT have come to play important roles in quanti-
tative analysis of biological processes in vivo and are now widely used in clinical
settings. In particular, serial assessments of molecular function are commonly used
for monitoring efficacy of various treatments. Prediction of treatment outcome is
also an attractive field, in which nuclear medicine technologies may be applied.
Indeed, a new era has arrived with the clinical use of nuclear medicine and
molecular imaging for personalized medicine. However, in order to further facili-
tate the use of these technologies for the precise assessment of tissue function and
planning of treatment strategies, significant improvement in imaging modalities,
selection of optimal imaging biomarkers, and appropriate clinical applications are
required.
We conducted international symposia on PET and molecular imaging in 1999,
2003, and 2009 and published the proceedings each time. Rapid progress has been
made since then; therefore, we decided to organize another international sympo-
sium in order to extend our discussion on the recent progress and future perspec-
tives on nuclear medicine in terms of molecular diagnosis and integrated therapy.
Accordingly, we invited our old and new colleagues all over Japan and overseas to
this latest international symposium entitled “Perspectives on Nuclear Medicine for
Molecular Diagnosis and Integrated Therapy.” Over 100 physicians and scientists
attended our symposium for two days on July 31 to August 1, 2015. It was a great
and unique opportunity to interactively exchange ideas and information among
researchers on various related fields.
In order to keep a record of the symposium and share our great experiences with
many specialists worldwide who are interested in these research fields, we decided
to publish this new volume on the proceedings of the symposium. This volume
should be helpful for understanding new advances of nuclear medicine and molec-
ular imaging technologies and their applications to integrated medical therapy and
v
future drug development. We sincerely hope that this volume will benefit
researchers in various fields of life sciences, including those working in drug
development, molecular imaging, and medical therapy, as well as physicians who
utilize diagnostic imaging.
Finally, we would like to express our thanks to Drs. Masako Wada and Eriko
Suzuki for their support during the preparation of the manuscripts.
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Part I
Instrument and Data Analysis
Chapter 1
Advances in 4D Gated Cardiac PET Imaging
for Image Quality Improvement and Cardiac
Motion and Contractility Estimation
Benjamin M.W. Tsui, Tao Feng, Jizhe Wang, Jingyan Xu,
M. Roselle Abraham, Stefan L. Zimmerman, and Thomas H. Schindler
Abstract Quantitative four-dimensional (4D) image reconstruction methods with
respiratory and cardiac motion compensation are an active area of research in ECT
imaging, including SPECT and PET. They are the extensions of three-dimensional
(3D) statistical image reconstruction methods with iterative algorithms that incorpo-
rate accurate models of the imaging process and provide significant improvement in
the quality and quantitative accuracy of the reconstructed images as compared to
that obtained from conventional analytical image reconstruction methods. The new
4D image reconstruction methods incorporate additional models of the respiratory
and cardiac motion of the patient to reduce image blurring due to respiratory motion
and image noise of the cardiac-gated frames of the 4D cardiac-gated images. We
describe respiratory motion estimation and gating method based on patient PET list-
mode data. The estimated respiratory motion is applied to the respiratory gated data
to reduce respiratory motion blur. The gated cardiac images derived from the list-
model data are used to estimate cardiac motion. They are then used in the cardiac-
gated images summing the motion-transformed cardiac-gated images for significant
reduction in the gated images noise. Dual respiratory and cardiac motion compen-
sation is achieved by combining the respiratory and cardiac motion compensation
steps. The results are further significant improvements of the 4D gated cardiac PET
images. The much improved gated cardiac PET image quality increases the visi-
bility of anatomical details of the heart, which can be explored to provide more
accurate estimation of the cardiac motion vector field and cardiac contractility.
Keywords 4D gated cardiac PET • 4D image reconstruction methods • Respiratory
and cardiac motion estimation and compensation
B.M.W. Tsui (*) • T. Feng • J. Wang • J. Xu • S.L. Zimmerman • T.H. Schindler
Department of Radiology, Johns Hopkins Medical Institute, Baltimore, MD, USA
e-mail: btsui1@jhmi.edu
M.R. Abraham
Department of Medicine, Johns Hopkins Medical Institute, Baltimore, MD, USA
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1.1 Introduction
The development of quantitative image reconstruction in medical imaging, includ-
ing emission computed tomography (ECT) and x-ray CT [1, 2], has recently shifted
from three-dimensional (3D) to four-dimensional (4D), i.e., the inclusion of the
time dimension. There are two major goals for this development. First is to reduce
reconstructed image artifacts due to patient motion. In particular, compensation of
involuntary patient motion, e.g., respiratory motion, that causes resolution loss has
received much attention [3–6]. Second is to improve the temporal resolution of
dynamic images for improved detection of global and regional motion abnormal-
ities [7, 8]. An important application is gated myocardial perfusion (MP) ECT
imaging. Despite extensive research in other imaging modalities over the last two
decades, MP ECT, especially gated SPECT and more recently PET, has continued
to be the major biomedical imaging technique for the assessment of MP in clinical
practice. The potential of extracting additional quantitative information, such as
abnormalities from existing data without additional clinical studies, radiation dose
or discomfort to the patients, has great significance in biomedical imaging [9–13].
The long-term goal of the study is to integrate the two aforementioned goals of
the current quantitative 4D imaging reconstruction methods, i.e., to improve the
quality and quantitative accuracy of the 4D cardiac gated MP PET images while
reducing the blurring caused by respiratory motion (RM) and cardiac motion (CM).
This is in addition to compensation of other image degrading factors, e.g., statistical
noise, photon attenuation and scatter, and collimator-detector blur, to improve both
spatial and temporal resolution. In this work, we present the development of a data-
driven RM estimation method and quantitative 4D statistical image reconstruction
methods that compensate for RM and CM separately, and for dual respiratory and
cardiac (R&C) motion for improved lung and cardiac PET imaging. We hypothe-
size that by applying a statistical 4D image reconstruction method that accurately
compensates for RM and CM and other image degrading factors, we would be able
to minimize image artifacts caused by the image degrading factors, improve image
resolution and reduce image noise. This would result in two significant clinical
benefits, i.e., (a) reduction of false positives and false negatives for improved
diagnosis, and (b) reduction of imaging time and/or radiation dose to the patient.
In addition, the much improved 4D gated cardiac PET image quality increases
the visibility of details of cardiac structures. The information can be explored in a
feature-based motion estimation method to determine the cardiac motion vector
field and cardiac contractility.
4 B.M.W. Tsui et al.
1.2 Materials and Methods
1.2.1 Data-Driven Respiratory Motion Detection and Gating
Method
There are two general approaches to obtain respiratory gated PET data [14]. One is
to use an external tracking device that directly measures a RM surrogate [3, 15].
The other is to derive RM information from the acquired data [16–19]. These data-
driven RM detection methods can avoid the cost and effort and directly provide a
surrogate RM signal. We developed two data-driven methods that estimated the
RM from 13NH3 and
18F-FDG cardiac gated list-mode PET data. In Fig. 1.1a, b, the
13NH3 images show more liver uptake than the
18F-FDG images. Our data-driven
method for the 13NH3 was based on the total counts in each consecutive short
segment (200–500 ms) of PET data. For the 18F-FDG, RM signal was extracted
based on the axial center-of-mass of the short segment PET data. Figure 1.1c shows
the relative RM gating signal amplitude as a function of time obtained from the
13NH3 list-mode data. The estimated RM signal compared well with that obtained
from an external tracking device. It was used to divide the RM into multiple
respiratory gates. The respiratory gated image data were used to estimate the
motion vector field of the RM and incorporated in the 4D image reconstruction
method to achieve motion compensation.
From the estimated RM signal in Fig. 1.1c, we divided the list-mode data into six
equal-count respiratory frames, each of which is further divided into eight cardiac-
gated frames using the ECG R-wave markers. The result was a full set of dual
six-frame respiratory gated and eight-frame cardiac-gated dataset. We then applied
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Fig. 1.1 Sample respiratory-gated projection images from (a) 13NH3 cardiac and (b)
18F-FDG
cardiac images. (c) Comparison of a RM signal derived from an external tracking device and from
the total count variation of the short segment projections of the 13NH3 cardiac PET data
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1.2.2 4D PET Image Reconstruction Methods
with Attenuation, and Respiratory and Cardiac Motion
Compensation
The 4D PET image reconstruction methods used in this study were applied to the
respiratory-gated and cardiac-gated projection data. Specifically, for the 4D PET
image reconstruction method with dual R&C motion compensation, we divided the
acquired list-mode data into six equal-count respiratory frames each with eight
cardiac-gated frames as described in Sect. 1.2.1. Image reconstructions without
attenuation correction were performed on this dataset to estimate the RM in lung
PET studies and both RM and CM in cardiac PET studies. A special feature of our
method was the modeling of the RM-induced deformations of the PET image and
CT-based attenuation map in RM estimation and during PET image reconstruction
for accurate and artifact-free attenuation corrected PET images.
1.2.2.1 4D PET Image Reconstruction with Respiratory Motion
and Attenuation Compensation
We developed a 4D PET image reconstruction method with RM and attenuation
compensation to improve the image quality of 18F-FDG PET images for improved
small lung lesion detection [20, 21]. First, a reference respiratory gated frame was
chosen from the six equal-count respiratory frames. Then the PET image at the
reference frame and the RM from the reference frame to the other respiratory-gated
PET frames were estimated by minimizing the Poisson log-likelihood function. As
shown in Fig. 1.2, the RM-induced deformations of both the PET image and
CT-based attenuation map were modeled in the RM estimation and during PET
image reconstruction. Our method is applicable to respiratory-gated PET data from
current clinical PET/CT imaging procedures with only one CT-based attenuation
map. We solved the image reconstruction problem in two steps: (1) estimated the
RM using an iterative approach, and (2) modeled the estimated RM in a 4D OS-EM
image reconstruction algorithm [21] that achieved 6 ~ 10 times acceleration over
the 4D ML-EM algorithms proposed by others [22, 23]. The final estimated
RM-induced deformations were applied to transform and registered all the respi-
ratory gated frame images to the reference frame. The corresponding eight cardiac-
gated frames from within the transformed respiratory-gated frames were summed
resulting in the eight cardiac-gated image with respiratory compensation, that is,
without RM blurring effect.
In a practical implementation of the above method [24], the RM was estimated
from the 4D respiratory- gated PET images obtained without attenuation correction.
The estimated RM was used in the 4D image reconstruction shown in Fig. 1.2
without further update. It provided respiratory-gated attenuation effect that matches
the respiratory-gated PET images for accurate attenuation compensation.
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1.2.2.2 4D Image Reconstruction with Cardiac Motion Compensation
In CM compensation, a reference frame was chosen from the eight-frame cardiac-
gated images. As shown in Fig. 1.3, a B-spline non-rigid transformation and
registration was applied to each cardiac-gated image and registered it to the
reference frame and summed. The procedure was repeated at different cardiac-
gated frames in the cardiac cycle to form the CM compensated gated cardiac image
set.
1.2.2.3 4D Image Reconstruction with Dual Respiratory and Cardiac
Motion Compensation
The 4D image reconstruction with dual R&C motion compensation was achieved
by combining the RM and CM compensation described in Sects. 1.2.2.1 and
1.2.2.2. After estimating the accurate RM and respiratory gated attenuation maps
based on Sect. 1.2.2.1, 48-frame dual R&C gated images were obtained. For each
cardiac gate, the RM compensation described in Sect. 1.2.2.1 was used. The result
was RM compensated cardiac-gated images. Cardiac motion compensation was
achieved by applying the same approach in Sect. 1.2.2.2. The resultant eight-frame




































Fig. 1.2 A flowchart of the 4D image reconstruction method with RM and attenuation compen-
sation. A snap-shot CT image was acquired from which a static attenuation map was derived. A
reference respiratory gated frame was chosen. The updated PET image at the reference frame and
the RM from the reference frame to the other respiratory-gated PET frames were jointly estimated
by minimizing the log-likelihood function
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1.2.3 Evaluation of the 4D PET Image Reconstruction
with Respiratory and Attenuation Compensation
We evaluated the 4D image reconstruction method with respiratory and attenuation
compensation to two clinical applications. They were the detection of small lung
lesions and the improvement of image quality in gated cardiac PET images. In the
lung lesion detection study, we used realistic simulated 4D respiratory gated lung
PET projection data. In the gated cardiac study, patient data from a 13NH3 MP PET
study and a 18F-FDG cardiac PET study were used. The goal was to assess the
reduction of image resolution from blurring due to RM.
1.2.3.1 Evaluation Using Realistic Simulated PET Study with Small
Lung Lesions
We evaluated the 4D PET image reconstruction with respiratory and attenuation
compensation method using a realistic Monte Carlo (MC) simulated PET dataset
from the 4D XCAT (eXtended CArdiac Torso) phantom [25]. The 4D XCAT
phantom is an extension of the 4D NCAT (Nurbs-based CArdiac Torso) phantom
[26], which provides realistic models of the anatomical structures of the entire
human body based on the visible human data [27]. In addition, the 4D XCAT
phantom includes realistic models of normal RM based on respiratory-gated CT
data [28], and normal cardiac motion based on tagged MRI data. The cardiac
motion model in the new 4D XCAT is based on state-of-the-art high-resolution
Frame #1 Frame #2 Frame #3 Frame #4 Frame #5 Frame #6 Frame #7 Frame #8 
B-spline non-rigid transform and registration of all 8-frame 
gated cardiac images to each frame of the final gated 
cardiac image set with cardiac motion compensation 
8-frame gated cardiac images 
Frame #1 Frame #2 Frame #3 Frame #4 Frame #5 Frame #6 Frame #7 Frame #8 
8-frame gated cardiac images with cardiac motion compensation 
Fig. 1.3 In the CM compensation, a B-spline non-rigid transformation and registration was
applied to each cardiac-gated image and registered it to the reference frame and summed
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cardiac-gated CT and tagged MRI data [29]. A 4D activity distribution phantom
that modeled the uptake of the PET tracer in the different organs and a
corresponding 4D attenuation coefficient distribution phantom that modeled the
attenuation of different organs at the 511 keV photon energy were generated based
on the 4D XCAT phantom. In addition, three small lung lesions with increased
activity uptakes were inserted at different locations in the lung. The 4D activity
distribution also served as the truth in the quantitative evaluation study.
Realistic respiratory-gated PET projection data were generated from the 4D
activity and attenuation distributions using a combined SimSET [30] and GATE
[31] MC simulation software that took advantage of the high efficiency of the
former in computing the photon transport in the voxelized phantom and the ability
of the latter to model the complex detector geometry and imaging characteristics of
a clinical GE PET system [32]. The 4D PET image reconstruction method with RM
and attenuation compensation was applied to the simulated RM-gated projection
data. The results were compared to those obtained with conventional 3D and 4D
image reconstruction methods without motion compensation.
1.2.3.2 Evaluation Using Data from Clinical Gated Cardiac PET
Studies
We also evaluated the clinical efficacy of the 4D image reconstruction method with
RM and attenuation compensation using clinical 13NH3 MP PET and
18F-FDG
cardiac PET data. A GE Discovery VCT (RX) PET/CT system was used in the
patient studies. Prior to the PET scan, a low-dose CT scan was acquired from the
patient. In the 13NH3 MP PET study, ~370 MBq of
13NH3 was infused intra-
venously as a bolus over 10 s. List-mode PET data were acquired for 20 min. In
the 18F-FDG cardiac PET study of a different patient, ~370 MBq of 18F-FDG was
administered through IV injection. A list-mode PET data acquisition was performed
~60 min post injection. The 4D image reconstruction method with RM and atten-
uation compensation as described in Sect. 1.2.1 were applied to the acquired list-
mode data. The resultant MP PET and cardiac PET images were compared to those
obtained with the conventional image reconstruction method without RM compen-
sation. Specifically, they were evaluated for improved lung lesion detection from
the reduction of resolution loss due to RM blur.
1.2.4 Evaluation of the 4D PET Image Reconstruction
Method with Dual Respiratory and Cardiac Motion
Compensation
The evaluation of the 4D PET image reconstruction method with dual R&C motion
compensation was performed on the same clinical 13NH3 MP PET and
18F-FDG
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cardiac PET datasets used in Sect. 1.2.3.2. Here, the goal was to assess the
improvement of the quality of the gated cardiac PET images in terms of image
resolution and image noise.
1.3 Results and Discussion
1.3.1 Improvement of Small Lung Lesion Detection
with Respiratory and Attenuation Compensation
We evaluated the 4D PET image reconstruction with respiratory and attenuation
compensation method using a realistic simulated PET dataset from the 4D XCAT
phantom [19, 20] and the Monte Carlo (MC) method as described in Sect. 1.2.3. The
method included RM detection using the data-driven gating method as described in
Sect. 1.2.1. The results are shown in Fig. 1.4. The activity distribution of the 4D
XCAT phantom with three small lung lesions is shown in Fig. 1.4a. The
reconstructed PET images without RM compensation in Fig. 1.4b show the reso-
lution loss due to RM blur. Also the reconstructed images with RM and attenuation
compensation using the known RM from the 4D XCAT phantom (Fig. 1.4c) and
using the estimated RM (Fig. 1.4d) were compared. The results indicate the
effectiveness of the RM estimation method and the 4D image reconstruction
Fig. 1.4 Results from a simulation study to evaluate the 4D PET image reconstruction with
respiratory and attenuation compensation for improved lung lesion detection. A realistic MC
simulated PET dataset from the 4D XCAT phantom was used. A sample (Top row) coronal slice
and (Bottom row) sagittal slice through the lung showing three small lung nodules. (a) Activity
distribution of the 4D XCAT phantom. Reconstructed images obtained from using (b) the 3D
ML-EM method with no RM compensation, and the 4D ML-EM method (c) with modeling of the
true RM from the 4D XCAT phantom, and (d) with the RM estimation described in Sect. 1.2.1
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method with RM and attenuation compensation to reduce resolution loss due to RM
blur and to improve small lung lesion detection in lung PET images.
1.3.2 Improvement of Gated Cardiac PET Images
with Respiratory Motion and Attenuation
Compensation
We applied the 4D image reconstruction method with RM and attenuation compen-
sation to the clinical 13NH3 MP PET and
18F-FDG cardiac PET datasets described
in Sect. 1.2.3.2. The results are shown in Figs. 1.5 and 1.6, respectively. Figures 1.5a
Fig. 1.5 (a) Sample images from one of the six respiratory-gated frames and from selected sample
(Left) short-axis, (Middle) horizontal long-axis, and (Right) vertical long-axis slice images
obtained using a 3D OS-EM image reconstruction without any motion compensation from a
13NH3 MP PET study. (b) The sum of all six respiratory gated images from (a) showing the effect
of RM blur. (c) Corresponding sample images as in (b) obtained using the 4D OS-EM image
reconstruction with RM and attenuation compensation showing the reduction of RM motion blur
in the reconstructed images
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and 1.6a are sample images from one of the six respiratory-gated frames and from
selected sample short-axis, horizontal long-axis, and vertical long-axis slice images
obtained using a 3D OS-EM image reconstruction without any motion compen-
sation are shown. Figures 1.5b and 1.6b are the sum of all six respiratory-gated
frame images demonstrating the effect of RM blur. The corresponding images
obtained using the 4D OS-EM image reconstruction with RM and attenuation
compensation are shown in Figs. 1.5c and 1.6c. They show the reduction of
RM motion blur in the reconstructed images.
Fig. 1.6 (a) Sample images from one of the six respiratory-gated frames and from selected sample
(Left) short-axis, (Middle) horizontal long-axis, and (Right) vertical long-axis slice images
obtained using a 3D OS-EM image reconstruction without any motion compensation from a
18F-FDG cardiac PET study. (b) The sum of all six respiratory-gated frames from (a) showing
the effect of RM blur. (c) Corresponding sample images as in (b) obtained using the 4D OS-EM
image reconstruction with RM and attenuation compensation showing the reduction of RMmotion
blur in the reconstructed images
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1.3.3 Improvement of Gated Cardiac PET Images with Dual
Respiratory and Cardiac Motion Compensation
We applied the 4D image reconstruction method with dual R&C motion compen-
sation to the clinical 13NH3 MP PET and
18F-FDG cardiac PET datasets described
in Sect. 1.2.3.2. The results are shown in Figs. 1.7 and 1.8, respectively. Figures 1.7a
and 1.8a and sample images from one of the eight cardiac-gated frames and from
selected sample short-axis, horizontal long-axis, and vertical long-axis slice images
obtained using a 3D OS-EM image reconstruction without motion compensation.
Figures 1.7b and 1.8b show the corresponding images obtained using the 4D
OS-EM image reconstruction with dual R&C motion compensation. They show
the significant improvement in image quality in terms of improved image resolution
from RM compensation and much lower image noise level from the CM
compensation.
Fig. 1.7 (a) Sample images from one of the eight cardiac gates from selected sample (Left) short-
axis, (Middle) horizontal long-axis, and (Right) vertical long-axis slices images obtained using a
3D OS-EM with no motion compensation from a 13NH3 MP PET study. (b) Corresponding images
obtained using the 4D OS-EM with R&C motion compensation
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1.4 Conclusions
Three-dimensional (3D) statistical image reconstruction methods using iterative
algorithms and with models of the imaging physics and imaging system character-
istics have shown to provide significant improvements in both the quality and
quantitative accuracy of static SPECT and PET images. They have led to improved
clinical diagnosis and, by trading off the improved image quality, for reduced
patient dose and imaging time. In this work, we described newly developed 4D
statistical image reconstruction methods that provided RM and CM compensation
for further improvement in image quality and quantitative accuracy in PET images.
We evaluated the effectiveness of the 4D image reconstruction methods using
simulation and patient data.
Our results showed that a 4D image reconstruction method with RM and
attenuation compensation provided quantitative lung PET images with reduced
resolution loss due to RM blur and improved the detection of small lung lesions.
We also evaluated a 4D image reconstruction method with dual R&C motion
compensation using data from a clinical 13NH3 MP PET and a clinical
18F-FDG
cardiac PET study. The results showed 4D gated cardiac PET images with
improved image resolution from RM compensation and much lower image noise
level from the CM compensation.
The improved 4D gated cardiac PET images reveal anatomical details, such as
the papillary muscle and interventricular sulcus, of the heart that were not possible
with conventional 3D image reconstruction methods. The anatomical details
allowed the development of feature-based myocardial motion vector estimation
methods [33, 34] that overcame the aperture problem in traditional motion
Fig. 1.8 (a) Sample images from one of the eight cardiac gates from selected sample (Left) short-
axis, (Middle) horizontal long-axis, and (Right) vertical long-axis slices images obtained using a
3D OS-EM with no motion compensation from a 18F-FDG cardiac PET study. (b) Corresponding
images obtained using the 4D OS-EM with R&C motion compensation
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estimation methods. The accuracy of CM estimation will be further improved with
continued improvement of the 4D image reconstruction methods and of the imaging
characteristics in the next generation PET scanners that are coming into the market.
It will allow extraction of new information about the contractility of the heart and
provide additional diagnostic information for improved patient care.
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Chapter 2
The Need for Quantitative SPECT in Clinical
Brain Examinations
Hidehiro Iida, Tsutomu Zeniya, Miho Yamauchi, Kazuhiro Koshino,
Takashi Temma, Satoshi Iguchi, Makoto Yamazaki, Junichiro Enmi,
Naoya Kondo, Nobutoku Motomura, and Jyoji Nakagawara
Abstract This report describes details of the requirements and practical procedures
for quantitative assessments of biological functional parametric images of the brain
using 123I-labeled tracers and clinical SPECT systems. With due understanding of the
physics and the biological background, this is considered achievable even under
clinical environments, provided that data are appropriately acquired, processed, and
analyzed. This article discusses how potential hurdles have been overcome for
quantitatively assessing quantitative functional parametric images in clinical settings,
with successful examples that provided additional clinically useful information.
Keywords SPECT • Quantitation • 123I-labeled radiopharmaceuticals •
Reconstruction • Functional imaging
2.1 Introduction
Current clinical practice using SPECT relies largely on the interpretation of qual-
itative images reflecting physiologic functions. However, a quantitative analysis
could provide further information to assist in the interpretation of disease status and
treatment decisions. Methodological progress has made a quantitative determina-
tion of physiological functions through imaging feasible for brain scans, including
parameters like the cerebral blood flow (CBF) and cerebral flow reactivity (CFR)
after pharmacological vasodilatation and also neuro-receptor functions and others.
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The usefulness of such data has generally been limited to research due to the logistical
complexity of quantitative examinations. Extensive work has then been carried out to
make quantitative study doable in clinical environments, and some relevant study
protocols are today generally accepted in clinical institutions in Japan.
Statistics show that 20 % of all SPECT clinical scans, namely approximately
20,000 scans annually, are carried out for the brain, mostly on patients with neuro-
logical (67 %) and cerebral vascular diseases (33 %), which is a much larger number
than in other countries. Quantitative assessments of CBF (mostly with CFR) using
123I-iodoamphetamine (IMP) comprise 5.6 % of all SPECT scans. Further, software
programs assisting in the diagnosis are utilized with most brain scans, employing
statistical analysis such as the 3D-SSP of Minoshima and others [1–5].
123I-IMP and other 123I-labeled tracers such as 123I-iomazenil and 123I-FP-CIT
are approved for clinical use and can be employed in a quantitative analysis for
demonstrating biological parametric images. Attenuation correction and scatter
correction are necessary factors when conducting quantitative studies. Additional
unique error of septal penetration is present when employing 123I-labeled
radiopharmaceuticals.
With SPECT scans there is the advantage over PET in the availability of the
necessary scanner in clinical institutions. Availability of radiopharmaceuticals is
another factor which would make conducting of such clinical research simple and
straightforward. Standardization of the techniques is essential to be able to generate
quantitative functional images that are consistent among institutions and SPECT
scanners. This is important particularly when applying diagnosis-assisting software
programs, to ensure consistent results independent of the SPECT devices installed
at different institutions. The ability to refer to and compare results from different
institutions or databases created at different institutions also requires that quantita-
tive and reproducible results are needed.
This article describes how an integrated system was developed to enable a
quantitative assessment of images of biological functions consistent among insti-
tutions in clinical setting with 123I-labeled radiopharmaceuticals. To achieve this
we describe the physics and technical background needed for the quantitation.
Application and verification of the developed software packages as clinical diag-
nostic tools, and how users have been supported, will also be discussed for
123I-IMP, 123I-IMZ, and 123I-FP-CIT examinations.
2.2 Requirements for Quantitative Reconstructions
in SPECT
2.2.1 Scatter Correction
It is commonly accepted that the scatter and attenuation occurring in an object are
the two major error factors with SPECT, and these need to be compensated for in
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the quantitative imaging. One technique to estimate the scatter distribution is to
acquire projection data for additional energy windows in addition to the main
window that covers the main peak. Selecting two additional windows below and
above the main peak, the so-called triple-energy window (TEW) [6] method, is a
commonly applied technique, in which acquired counts of the lower and upper
windows are subtracted from those of the main window, and the reconstruction is
then performed using the scatter-subtracted projection data. An advantage of this
technique is that the procedures automatically compensate for the photons pene-
trating the collimator (see below).
An alternative approach is based on estimating the scatter from the scatter-
uncorrected reconstructed images using the attenuation coefficient distribution. A
formulation like the Klein-Nishina formula is commonly applied to simulate the
scatter projection for a given tracer distribution and is termed the single scatter
simulation (SSS) method [7]. This calculation can also be performed by Monte
Carlo simulation (MCS), where simplification is effective to accelerate the calcu-
lations and ensure minimal loss of accuracy [8]. One further simplified approach is
also feasible, by referring to the emission and attenuation data available in the
projection domain; this was originally proposed by Meikle et al. [9] and was further
optimized for 99mTc [10], 201Tl [11, 12], and 123I [13] in our group. A scatter
fraction is empirically defined for a radioisotope as a function of the attenuation
factor, which is then used to scale the simulated scatter distribution. This is the
transmission-dependent convolution subtraction (TDCS) method and is applied to
the geometric mean projection data. A number of verification studies have been
carried out to ensure the accuracy of this method, but it must be noted that accuracy
with the SSS and MCS theoretical methods is often limited because a number of
factors are not taken into account. Our earlier work by a careful Monte Carlo
simulation demonstrated that a non-negligible amount of scatter originates from
outside objects such as the detector and scanner itself [14] and that this may be a
source of errors if not taken into account.
With the software developed by our group for quantitative SPECT reconstruc-
tion (QSPECT), we have incorporated MCS- and TDCS-based scatter correction
methods, and extensive work has shown support for this in the verification of the
TDCS method for brain SPECT examinations. Due to the robustness and applica-
bility when combined with other correction procedures, all results in the following
will be with the TDCS scatter correction.
2.2.2 Septal Penetration in the Collimator
In addition to scatter and attenuation, 123I has a further error arising from penetrat-
ing photons generated by high-energy gamma rays (>500 keV) emitted from the
123I. These penetrating photons cause a down-scatter through the collimator and
escaping photons from the scintillator, resulting in non-negligible levels of bias in
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the energy spectrum and therefore an offset in the projection data for the selected
energy window (see Fig. 2.1).
Here it must be noted that the magnitude of the offset in the projection data due
to the penetrating photons varies dependent on the collimator. With typical
low-energy collimator sets, this represents a large amount, due to the thin walls
of such collimators, while with typical 123I-specifically designed collimator, the
amount of offset is suppressed, due to thicker collimator walls. An example of a
comparison of projection data obtained from two collimator sets of a typical
low-energy high-resolution collimator (LEHR-para) and a 123I-specific low-
medium-energy general-purpose collimator (LMEGP-para) from one vendor is
shown in Fig. 2.2. Collimator penetration is clearly visible with LEHR-para, but
a
b
Fig. 2.1 (a) Error sources which need to be compensated for in quantitative reconstruction of
brain SPECT images, attenuation, scatter, and photon penetration. (b) Energy spectrum for 123I in
a typical LEHR collimator. The significantly high background signal is a source of errors, caused
by the high-energy photons emitted by the 123I itself
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not with LMEGP-para for a 123I-syringe and also on the striatal brain phantom
(Fig. 2.2a). This difference causes the different reconstructed images of uniform
cylindrical phantoms (Fig. 2.2b). It is important to note that the counts are decreased
in the center of the cylindrical phantom when the attenuation correction is not applied
to the data obtained with LMEGP-para collimator, while the decreased counts in the
center is not visible with LEHR-para. The TEW technique is effective to compensate
for the penetrating high-energy photons. With the scatter correction performed by the
TEW technique, these penetrating photons are automatically compensated for. This is
practical and effective, but at the expense of increased statistical noise.
In the QSPECT software, the penetration component is determined empirically
for a collimator, as an extension of the TDCS scatter correction, as described in an
earlier report [13].
2.2.3 Attenuation Correction
The Chang method [15] is the most common approach for attenuation correction
(AC) in brain SPECT. This method utilizes an attenuation coefficient (μ) map
a b
Fig. 2.2 (a) Typical projection data for a syringe-shaped phantom (left) and for a striatum
phantom from Radiology Support Devices (Long Beach, LA, USA) (right) measured with 123I-
dedicated LMEGP-para and conventional LEHR-para collimator sets. (b) Reconstructed images
for a uniform cylindrical phantom filled with 123I-solution with and without attenuation correction
(AC), scatter correction (SC), and photon penetration correction (PC). Different amounts of
photon penetration are clearly visible as a high background outside the phantom on the projection
data. In the projection data of the striatum phantom, striatum-to-whole brain ratio is also altered
due to the penetrating photons. The reconstructed images also became different when not com-
pensated. An appropriate correction procedure is important to compensate for the penetration for
each set of the collimator
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which is commonly generated by detecting the head contours of the reconstructed
images to which the AC is applied. The μmap can also be obtained from CT or from
images of other modalities. The AC factors are then estimated for each pixel as an
average over the 360 views with the attenuation coefficient (μ) map and is
multiplied into the non-AC reconstructed images. The Chang method is empirical
but the results are considered acceptable in most brain examinations. For the
quantitative reconstruction, a uniform μmap is feasible if errors< 5 % are accepted
in the deep parts of the brain. However, absolute values have to be carefully defined
so as to make the pixel counts of the reconstructed images independent of the size of
the object. This is also the case if a CT-based μmap is utilized in the reconstruction.
2.2.4 Attenuation Coefficient Map
Two possibilities are given to define the attenuation μ map in QSPECT software.
One is to import externally generated attenuation μ maps, typically calculated from
the Hounsfield unit (HU) images generated from a CT scan. Careful attention is
needed to correct for the beam hardening effects when converting the attenuation
map assessed with the continuous and rather low-energy photons to the quantitative
HU and μ values corresponding to photons with single energy included in the
energy window. Another possibility is to generate a homogeneous μ map by
detecting the head contours. Extensive efforts have been made to provide the best
accuracy in the head-contour detection algorithm, and a threshold was determined
from the sinogram rather than the projection or the reconstructed images, and sine
wave constraint was applied to the scatter-uncorrected data when defining the edge
of the sinogram. Reconstruction was made for the filtered sinogram, and a threshold
was applied again to determine the head contour, ensuring that an accurate head
contour is generated. An empirically defined attenuation coefficient which effec-
tively included the contribution of the bone value was then applied [13].
An attenuation coefficient map is utilized for the attenuation correction during
the OSEM procedures and also for the scatter and penetration correction prior to the
reconstruction if one utilizes one of the SSS, MCS, or TDCS methods for scatter
correction. This attenuation coefficient map was utilized during the OSEM pro-
cedures as well as for the scatter and penetration correction prior to the reconstruc-
tion, by using the TDCS method as discussed earlier.
2.2.5 Implementation of the Collimator Aperture Model
It has been shown that implementation of a collimator aperture during the forward
projection process on the three-dimensional domain makes the SPECT reconstruc-
tion more accurate [16]. Effects of this are increased, resulting in improved contrast
and also suppression of statistical noise. The collimator aperture model shown in
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Fig. 2.4 was implemented with the QSPECT reconstruction software for both the
geometric mean and normal projection data. See further below.
2.2.6 SPECT Reconstruction
Two methods are known to quantitatively reconstruct images in the brain SPECT
which will be discussed here. The filtered back projection (FBP) method is the one
and has been the standard for reconstruction. For the FBP, the scatter correction has
to be applied to the projection data before the reconstruction, and TEW is a well-
established technique compensating for the septal penetration during the recon-
struction. An attenuation correction is performed after the reconstruction in most
cases based on the Chang method with an edge detection technique to generate
homogeneous μ maps. The use of CT-based attenuation coefficient images is also
possible, but selection of the absolute μ values needs careful consideration, and
there are no published reports on how consistent results can be obtained with this
technique with different equipment arrangements. A preliminary study carried out
in Europe [17] showed unacceptable levels of variation and inconsistencies among
sites. The reasons for the inconsistencies are unknown, but it was suggested that
further careful evaluations are needed to standardize the detailed procedures.
Although the FBP approach is straightforward and has been considered a standard,
the method is limited when implementing new functionality to maximize the
accuracy and image quality.
An alternative reconstruction method for SPECT is based on the maximum-
likelihood expectation maximization (MLEM) algorithm, in which images are
calculated with iterative procedures. Attenuation can be implemented in the for-
ward projection process, so that the calculated reconstructed images are corrected
for attenuation. The ordered-subset maximum-likelihood expectation maximization
(OSEM) method is often utilized to accelerate convergence, as will be discussed
later in this article. It must be noted that the TEW-based scatter correction includes
correction also for the penetration, while currently the existing simulation-based
scatter correction method does not include a penetration correction, and thus
requires further development.
The QSPECT software employs the OSEM approach. A schematic representa-
tion of the process of the reconstruction in QSPECT software is shown in Fig. 2.3.
Systematic errors arise due to neglecting higher μ values in the skull, but the effect
is within 5 % in the middle part of the brain and also in other areas outside the
cerebral tissue [13]. The following three formulations were implemented in the
program. Suitable formulation can then be selected to best fit each clinical protocol.
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2.2.6.1 OSEM on 2D Domains for the Pre-scatter Corrected Geometric
Mean Projection
The first formulation is essentially identical to the one also described in earlier
studies [9–11, 13]. Reconstruction is performed for each two-dimensional tomo-
graphic slice, with the projection corrected for scatter before the reconstruction.
The pixel counts of the reconstructed image λnþ1j are calculated from the counts of
the previous image λnj . The scatter compensated projection data by the TDCS
method [18] was applied, and the formulation for the geometric mean projection
data is given as follows:
Fig. 2.3 Diagram illustrating the quantitative reconstruction protocol implemented in the
QSPECT reconstruction software. The emission data are initially reconstructed with filtered
back projection (top right image) to allow the brain outline to be determined and the μ map for
the attenuation correction to be determined by assigning a uniform attenuation coefficient value of
0.1603 cm1 to the detected brain volume. The μ map is forward projected to provide the
attenuation projections for the scatter correction to calculate scatter- and penetration-compensated
projection. The scatter correction is carried out using TDCS method; thus, the projection data
becomes geometric mean data. Then, OSEM reconstruction is applied with the attenuation
correction to generate the attenuation and scatter corrected images. The collimator aperture
correction (APC) can also be applied in the reconstruction process using Eq. (2.2) (Figure is
from Iida et al. [28])
















where yi is the count in the projection data corrected for the scatter and the
collimator penetration, cij is a factor for the contributions from the projection
pixel to the image pixel, exp μLið Þ is the net attenuation factor for each of the
geometric mean projections. Note that the projection data has to be corrected before
the reconstruction calculations, eg by the TDCS scatter correction.
2.2.6.2 OSEM on 3D Domains for the Pre-scatter Corrected Geometric
Mean Projection
This formulation includes the collimator aperture correction, and the reconstruction
is carried out nearly wholly in a three-dimensional domain. The scatter compen-
sated projection data by the TDCS method [18] was applied, giving the formulation
















where wij represents the collimator dependent blurring of the spatial resolution
shown in Fig. 2.4. Note that the projection data has to be corrected for the scatter
before the reconstruction calculations as in the eq. 2.1 in which yi is the geometric
mean projection data already corrected for scatter by means of the TDCS method,
and cij represents the calculation of the geometric mean.
2.2.6.3 OSEM on 3D Domains Including the Scatter Correction Process





















The scatter projection at the i-th iteration, si, has to be estimated at each iteration
either by the SSS or MCS methods from the i-th reconstructed images. It is also
possible to use the TEW-based scattered projection for si. In QSPECT, an
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was assumed to decrease
linearly with the distance
from the collimator with an
initial value. The
contribution weights, wij,
calculated from this model
were implemented in
Eqs. (2.2) and (2.3), which
compensated for the
blurring effects due to the
collimator aperture
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accelerated MCS [8] is implemented. Consequently, yi it is not necessarily the
geometric mean but may be the normal projection.
2.2.7 Calibration to Bq/mL
The QSPECT program is designed so that the pixel values correspond to the
radioactivity concentration, the cps/mL. An experiment with a syringe filled with
a 123I-labeled radioactive pharmaceutical of known radioactivity gives a calibration
factor to convert the pixel counts to the absolute radioactivity concentration which
has units of Bq/mL. The accuracy of the absolute quantitation was 10 % for 123I
in uniform cylindrical phantoms provided that the diameter is less than 16 cm. For
the future, this feature could be of use in internal dosimetry quantitation of
radiotherapy agents such as 177Lu peptides.
2.2.8 Dead Time Count Loss
The counting rate performance should be sufficiently high in clinical SPECT
scanners, e.g., count losses <1 % up to a counting rate of 70 kcps. This would
hold for 99mTc and other commonly used SPECT radiopharmaceuticals, but may
not in 123I-labeled tracers. The true counting rate of the system could be much
higher than the observed rate for the given main window, attributed to the incidence
of a large amount of penetrating photons originated from the high-energy gamma
rays (>500 keV). Particularly, low-energy dedicated collimators such as LEHR
collimators can accept large amounts of penetrating photons, and there may be a
significant counting loss at counting rates much below 70kcps. Errors could be
mostly in phantom experiments but may be smaller in clinical scans. It is however
important to confirm the maximum counting rate that maintains the linearity of the
SPECT counts to the true radioactivity.
2.3 Phantom Experiments
A number of studies have been carried out to evaluate the adequacy of the QSPECT
reconstruction programs. The experiments were on geometrically shaped phantoms
such as cylindrical phantoms and also on phantoms simulating the cerebral blood
flow distribution and striatum structure with realistic head contours and skull
structures. These phantom experiments are useful in validating the reconstruction
procedures and also to ensure quality control of the data acquisition procedures.
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2.3.1 Uniform Cylindrical Phantom
The cylindrical phantom gives information of how uniform images are obtained for
uniform distributions of radioactivity. Image homogeneity could be degraded by
several factors in relation to inappropriate corrections for attenuation, to scatter and
penetration, and also to the insufficient quality control. The quality control includes
the procedures for adjusting and correcting for inhomogeneous sensitivity,
mistuned position linearity, misaligned center of rotation, large attenuations in
the head holder, and other factors. Experiments to confirm the homogeneity for
uniform phantom are highly suggested to ensure that the regional activity quanti-
tation is not suffered from one of error factors mentioned above. However, it should
be noted that inappropriate definition of the head contour and inconsistently defined
attenuation coefficient values in relation to the presence of the skull may not be
evaluated from the uniform cylinder phantom experiment.
2.3.2 3D Brain Iida Phantom for CBF Quantitation
Geometrically shaped phantoms are limited in simulating realistic head contours,
the presence of the bone and trachea, and also the realistic radioactivity distribution.
Therefore, dedicated brain-simulating phantoms are often desired to evaluate the
overall accuracy of reconstructed images in realistic situations. We have developed
a three-dimensional brain phantom (Iida phantom) that simulates the CBF distri-
bution in cortical gray matter, with bone, trachea, and realistic head contours
[19]. As shown in Fig. 2.5, accuracy of the QSPECT software can be evaluated
by referring regional radioactivity concentration on the reconstructed images with
those of design images of this phantom. This experiment would be useful if one
wish to evaluate the accuracy of reconstructed images for multicenter clinical
studies using SPECT techniques.
Differences in the spatial resolution have to be assessed when comparing SPECT
images acquired from different SPECT systems, because the differences in the
spatial resolution causes different quantitative values due to the partial volume
effect [20]. Hoffman 3D phantoms [21] was utilized to assess and to compensate for
the different spatial resolution in the cerebral FDG uptake images acquired at
different institutions using different PET systems on healthy volunteers [20]. The
Iida brain phantom is also useful to evaluate and equalize the spatial resolution of
SPECT images obtained from different sites and probably better suited to SPECT,
due to its importance in the determination of head contour in SPECT scans.
Yamauchi et al. [22] demonstrated that equalization of the spatial resolution
significantly reduced the inter-institutional variation of the normal database of
rest- and acetazolamide-CBF images among three institutions. The Iida brain
phantom may be better suited than the 3D Hoffman phantom when one intends to
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assess attenuation or scatter-related variations among different PET/SPECT
scanners.
2.3.3 Striatum Phantom for Dopamine Transporter Imaging
For dopamine transporter imaging using 123I-FP-CIT, a phantom simulating the
striatum uptake of 123I-FP-CIT with homogeneous background in the whole brain
region (Radiology Support Devices, Long beach, LA, USA) was utilized to eval-
uate the accuracy and also to calibrate the inter-institutional variations in
Fig. 2.5 (Top) X-ray CT images of the developed phantom, which contain water and bone-
equivalent liquid in the cortical gray matter and bone components of the phantom, (Middle) digital
design of the gray matter area of the phantom after smoothing with a 16 mm full-width at half
maximum Gaussian filter, and (Bottom) SPECT images of the phantom filled with 123I solution in
the gray matter compartment and K2HPO4 solution in the bone compartment. All images are
aligned to the digital design. The SPECT images showed good agreement with the digitally
designed images. Spots shown with arrows (a–e) demonstrated are examples which indicated
good agreement between the digital design and 123I-SPECT images (Figure is from Iida et al. [19])
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multicenter evaluations in the EU [23]. The QSPECT reconstruction program was
also evaluated using this phantom to assess the accuracy of the specific binding
ratio (SBR) values [24], by referring the values calculated from the true radioac-
tivity in the striatum compartments relative to the whole-brain background concen-
tration. Results demonstrated that the SBR values measured using QSPECT
software agreed well with those determined from the true radioactivity concentra-
tions. Variation was less than 1/3 of those with FBP reconstruction including the
attenuation corrections. This suggested smaller inter-institutional/inter-vendor var-
iations less than 1/3 with QSPECT when compared with FBP. This difference
corresponds to the decline of both sensitivity and specificity from 97 to 78 % in
our preliminary simulation study. It is therefore of a paramount importance to
establish an accurate reconstruction methodology in order to provide a good
diagnostic performance in clinical settings. Further careful evaluation is to be
carried out.
2.3.4 QSPECT Program Packages
The program package of QSPECT uses a wrapper written in JAVA to run several
programs written in C language for Microsoft Windows systems and also includes
programs for reconstructing SPECT images, co-registering images, re-slicing,
calculating functional images, and printing summary logs. Packages are prepared
for the given data processing protocols for the given radiopharmaceuticals. Of
those, a package to calculate the rest- and acetazolamide-CBF images with 123I-
IMP and the specific binding ratio (SBR) values with the distribution volume ratio
(DVR) images with 123I-FP-CIT have been utilized to support clinical diagnosis.
The programs are also utilized to support clinical research.
2.4 Adequacy and Impact in Clinical Scans
2.4.1 Dopamine Transporter Function (SBR Quantitation)
Using 123I-FP-CIT
Figure 2.6 shows an example of an image of a 123I-FP-CIT scan on a young healthy
volunteer (29 years old, male) acquired using a three-head SPECT camera from
Toshiba (Tochigi, Japan) fitted with a LHR-fan collimator. The reconstruction was
carried out according to Eq. (2.2), which includes the TDCS scatter correction for
the geometric projection data and the collimator aperture correction. It can be seen
that the head contour was well delineated, as indicated by the red arrows. This is
attributed to the carefully designed algorithm: the contour detection with the sine
function constraint on the sonogram prior to the scatter correction. With the
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improved sensitivity and spatial resolution achieved using the triple head SPECT
camera with a fan beam collimator designed for 123I-nuclides, the collimator
aperture model was effective to enhance and provide better striatum-to-background
contrast with minimal enhancement of the background noise, though the SBR
values essentially remained without changes. There may be lots of application
areas where improved image quality can make contributions in clinical settings.
Fig. 2.6 An example of an image of 123I-FP-CIT for a healthy 29-year-old male volunteer. The
scan was made using the Toshiba 9300R (three-head camera) fitted with an LMEGP-fan collima-
tor. Reconstruction was carried out according to Eq. (2.2) and includes the collimator aperture
correction. The head contour is well delineated using the edge detection method implemented in
the QSPECT software, as shown with the red arrows
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2.4.2 Central Benzodiazepine Receptor Imaging Using
123I-IMZ (Neuron Damage/Residual)
The radiopharmaceutical 123I-iomazenil (IMZ) is a radiopharmaceutical approved
for clinical diagnosis to assess local neuronal damage in patients with epilepsy in
Japan. There are also other applications to identify the presence of neuronal damage
in the prefrontal areas of patients with neurological deficits after chronic ischemia
(or Moyamoya disease) and traumatic brain injuries. We have aimed to highlight
significantly damaged areas using 123I-IMZ and SPECT in such patients by refer-
ring to normal patterns by means of 3D-SSP [1] [3, 5]. The challenge is to verify
that identical data can be obtained from different SPECT systems installed in
different institutions. Consistency is essential in order to utilize a common (normal)
database rather than generating separate ones at each institution. At present, we
have confirmed that a normal database for 123I-IMZ generated at two independent
institutions installed with different vendor SPECT systems showed smaller varia-
tions when QSPECT with AC, SC, and PC was utilized, as compared with vendor
FBP reconstruction employing AC only. It was also observed that while vendor
reconstruction provided different damage regions with the 3D-SSP analysis using
the normal database generated at different institutions, only small differences could
be seen between two sets of the normal database with QSPECT reconstruction. This
is one area where the standardization of SPECT can make a significant contribution.
2.4.3 Rest- and Acetazolamide-CBF Using 123I-IMP (The
Dual-Table Autoradiography Method)
Extensive work has been conducted to establish and validate quantitative assess-
ments of CBF at rest and after administration of acetazolamide with 123I-IMP and
dynamic SPECT using the QSPECT program packages (Fig. 2.7). At present, the
QSPECT software packages have been shown to be able to handle the data obtained
from most SPECT cameras fitted with parallel beam collimators (see Table 2.1). A
total of more than 60,000 scans have been carried out in Japan between 2006 and
January 2015, with 16,000 scans in 2014. The scans were mainly to assess the risk
of hyper-perfusion after revascularization therapy in patients who are candidates for
coronary artery stents and for coronary endarterectomy.
The 123I-IMP has a high first-pass extraction fraction and is capable of assessing
quantitative CBF values for a physiologically wide range of blood flows
[25, 26]. The object was to make the quantitative assessment of the rest- and
acetazolamide-CBF images from scans obtained in a single session, with two
injections of 123I-IMP at 30 min intervals, to establish the ischemic status in the
scans of each patient. A sophisticated compartment model was applied (called dual-
table ARG) [27] to make it possible for the stress CBF images to be calculated using
table look-up procedures without the need for image subtraction. This method
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appeared not to result in increases in statistical noise and more importantly was able
to provide quantitative CBF images with minimal errors and only little inconsis-
tency between the rest- and acetazolamide-CBF assessments. A number of studies
were carried out to verify the method in clinical settings, funded by the Ministry of
Health, Labour and Welfare Research Foundation from the year of 2007 for 3 years
as follows:
(a) There was a fairly good intra-institutional reproducibility of rest- and
acetazolamide-CBF images for the same patient, approximately 10 % with
44 patients at nine institutions [28].
(b) Inter-institutional reproducibility of rest- and acetazolamide-CBF images was
approximately 6 % in nine patients on 18 data points [29]. An example case is
shown in Fig. 2.8.
(c) Consistent results for rest and acetazolamide CBF at rest and after acetazol-
amide in healthy volunteers among three institutions (a total of 32 healthy
volunteers) [22].
(d) Agreement with PET scan results both on relative distribution and absolute
values was shown in one institution for five patients [28].
Fig. 2.7 MR and CBF images at rest and after acetazolamide stress assessed with 123I-IMP and
the dual-table ARG method on two typical low-risk patients (stage I) and a patient with high-risk
(stage II) ischemia (Figure is from Iida et al. [28])
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This examination is one good example that demonstrates the contribution of
quantitative SPECT in clinical settings. Results of 3D-SSP shown in Fig. 2.8 are
helpful in understanding the severity of ischemia and the risk status in patients with
major artery occlusion or stenosis. This would also contribute to evaluate a number
of therapeutic trials in the future.
2.5 Quality Control of the SPECT Scanner
It must be noted that standardization of the quantitative SPECT examination
requires detailed self-defined protocols, including for the procedures of the admin-
istration, blood sampling, instructions to patients and patient movement, QC of
SPECT devices, SPECT acquisition workflow, data pre-processing, and QSPECT
reconstruction. Active feedback to deal with possible adverse events related to
above procedures at clinical institutions appeared to be effective to maintain the
reliability of the clinical scan findings. From July 2009 till May 2011, 139 cases
were defined as potentially posing problems or possibly resulting in adverse events
Table 2.1 List of SPECT camera (3/8 NaI scintillator) and collimator combinations to which
QSPECT can be applied. TDCS parameters have been defined for those systems prior to the first
clinical examination
SPECT camera Collimator
Toshiba GCA-9300 3/8inch N2(LEHR fan),
N1(LESHR fan). LEHR
para
GCA-7200 N2(LEHR fan), N1
(LESHR fan), LEHR para
LEGP para
ECAM N2(LEHR fan), LMEGP
para
Symbia LMEGP para
Siemens ECAM 3/8inch LEHR para, LMEGP para
Symbia LEHR para, LMEGP para
GE Millennium VG 3/8inch LEGP para, LEHR para
Infinia ELEGP para, LEHR para
Hitachi
(Philips)
ADAC forte JET stream Philips
BrightView Philips SKYLight
3/8inch VXGP para
CHR para, LEHR para,
MEGP para





IRIX 3/8inch LEGP para, LEHR para
AXIS LEGP para
PRISM2000 LEHR para
PRISM3000 LEGP para, LEHR para
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at 67 institutions. Claims were mostly unexpected low CFR values or unexpectedly
low or high absolute CBF values. The software package was designed to keep a
record of the complete calculation process, and among the data obtained in this
manner, the tissue time-activity curve (tTAC) analysis for sequential short frame
dynamic images and dynamic projections appeared to be helpful to identify the
sources of errors. Of the 139 cases identified, 64 (42 %) did not suggest errors in the
data or in the calculation process, as the observed CFR or small CBF values could
be confirmed from results of the tTAC analysis, both in the dynamic reconstructed
images as well as in the projection data. In other studies, the tTAC analysis was able
to identify errors in the blood radioactivity concentrations (n¼ 26), in the cross
calibration procedures (n¼ 25), in the IMP administration (n¼ 17) due to the
patient motion (n¼ 11), and other factors including insufficient SPECT QC
(n¼ 11). Errors in the software program were not identified in any of the studies.
Fig. 2.8 Stereotactic extraction estimates based on the JET study (SEE-JET) images [4] of a
patient obtained in institutions O and Y. The Rt Lat and Lt Lat indicate the right and left
hemisphere outer lateral images, respectively. Cerebral blood flow at rest (rest CBF), CBF after
the acetazolamide challenge (Diamox CBF), the cerebrovascular reserve (vascular reserve), and
severity of hemodynamic cerebral ischemia (STAGE) are shown as three-dimensional cerebral
surface images. Images are almost visually identical, from institutions O and Y (Figure is from
Yoneda et al. [29])
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The feedback provided in the information to the clinical institution was evaluated to
be effective to improve the quality of the examination results.
It is possible that the quality of reconstructed SPECT images is degraded by
inaccurate reconstruction parameter settings in relation to the attenuation coeffi-
cients, accuracy of the head contour determination, inefficient statistical treatment,
and also poor quality control (QC) of the SPECT device. It should be noted that
there are no standard guidelines (like the NEMA standard) for reconstructed
SPECT images, only for projection data. One contribution of the QSPECT recon-
struction package is the ability to evaluate the image quality and accuracy on one
domain with different systems. It was apparent that the engineers at the vendors
should be encouraged to make effort to improve the quality of the reconstructed
images rather than only on the projection data. Active feedback to the users at the
clinical institutions is also essential to improve the quality of the examination in the
quantitation. We also considered the FBP reconstruction with the scatter correction
of Chang, for the scatter corrected-projection with TEW would be another possi-
bility for standardization among different institutions. Systematic study has to be
coordinated to validate the technique in multicenter settings.
2.6 Summary and Future Directions
The QSPECT package is able to reconstruct quantitative tomographic images from
projection data acquired using commercial SPECT equipment. The adequacy was
demonstrated with a series of phantom experiments. More importantly, the ade-
quacy of images of biological functions and the use of stereotactic statistical
analysis software were shown for some protocols in patient populations. Overall,
this suggests the adequacy of using clinical SPECT devices for multicenter clinical
studies. It is also possible to encourage the use of quantitative reconstruction with
diagnosis-assisting software in clinical settings; this would enable an extension of
the contribution of SPECT in evaluations of disease severity and so assist in
decision making. Further systematic work should be designed to prove this concept
for the various tracers in the various clinical settings.
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Chapter 3
PET Imaging Innovation by DOI Detectors
Taiga Yamaya
Abstract Positron emission tomography (PET) plays important roles in cancer
diagnosis, neuroimaging, and molecular imaging research. However potential
points remain for which big improvements could be made, including spatial reso-
lution, sensitivity, and manufacturing costs. Depth-of-interaction (DOI) measure-
ment in the radiation sensor will be a key technology to get any significant
improvement in sensitivity while maintaining high spatial resolution. We have
developed four-layered DOI detectors based on our original light-sharing method.
DOI measurement also has a potential to expand PET application fields because it
allows for more flexible detector arrangement. As an example, we are developing
the world’s first, open-type PET geometry, “OpenPET,” which is expected to lead
to PET imaging during treatment. The DOI detector itself continues to evolve with
the help of recently developed semiconductor photodetectors, often referred to as
silicon photomultipliers (SiPMs). We are developing a SiPM-based DOI detector
“X’tal cube” to achieve sub-mm spatial resolution, which is reaching the theoretical
limitation of PET imaging. Innovation of SiPMs encourages our development of
PET/MRI, which is attracting great notice in terms of smaller radiation exposure
and better contract in soft tissues compared with current PET/CT.
Keywords PET • Depth-of-interaction • DOI • In-beam PET • Brain PET • SiPM •
PET/MRI
3.1 Introduction
Positron emission tomography (PET) plays important roles in cancer diagnosis,
neuroimaging, and molecular imaging research, but potential points remain for
which big improvements could be made, including spatial resolution, sensitivity,
and manufacturing costs. For example, the sensitivity of present PET scanners does
not exceed 10 %. This means that more than 90 % of the gamma rays emitted from a
subject are not utilized for imaging. Therefore, research on next generation PET
technologies remains a hot topic worldwide.
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The Imaging Physics Team at National Institute of Radiological Sciences
(NIRS) has carried out basic studies on radiation detectors, data acquisition sys-
tems, image reconstruction algorithms, and data correction methods to improve
image quality and quantity in nuclear medicine as well as to explore innovative
systems.
A depth-of-interaction (DOI) detector, for which various methods have been
studied [1–7], will be a key device to get any significant improvement in sensitivity
while maintaining high spatial resolution (Fig. 3.1). In order to maintain enough
detection efficiency, the scintillation crystals should be 2–3 cm long. In conven-
tional detectors, the crystal thickness causes uncertainty in position identification,
which results in degraded spatial resolution at the peripheral area of a field-of-view.
On the other hand, DOI can reduce the parallax error while maintaining the
efficiency.
We have developed four-layered DOI detectors based on a light-sharing method
[8, 9]. One successful proof of concept was the “jPET” project, in which we
developed brain prototype PET with our DOI detectors; almost uniform spatial
resolution around 2 mm all over the field-of-view was obtained with iterative image
reconstruction with geometrically defined system matrix [10]. We have also
succeeded to upgrade the DOI detector to have better spatial resolution with
cheaper production costs: successful identification of 32 32 4 array of LYSO
crystals sized in 1.45 1.45 4.5 mm3 with a 64ch flat panel PMT (H8500,
Hamamatsu Photonics K.K., Japan) [11], which has enabled Shimadzu’s new
products of positron emission mammography.
DOI measurement also has a potential to expand PET application fields because
it allows for more flexible detector arrangement. As an example, we are developing
the world’s first, open-type PET geometry, “OpenPET,” which is expected to lead
to PET imaging during treatment. In addition, flexible system design of OpenPET
Fig. 3.1 Comparison between a conventional PET detector (a) and our depth-of-interaction (DOI)
detector. The DOI detector (b) eliminates the parallax error, which is caused by the thickness of
crystals in conventional 2D detectors
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prototypes is enabling us to develop an innovative brain scanner “helmet-chin
PET.” The DOI detector itself continues to evolve with the help of recently
developed semiconductor photodetectors, often referred to as silicon photomul-
tipliers (SiPMs). We are developing a SiPM-based DOI detector “X’tal cube” to
achieve sub-mm spatial resolution, which is reaching the theoretical limitation of
PET imaging. Innovation of SiPMs encourages our development of PET/MRI,
which is attracting great notice in terms of smaller radiation exposure and better
contract in soft tissues compared with current PET/CT. By using our SiPM-based
DOI detectors, we are developing a novel, high-performance, and low-cost brain
PET/MRI to meet demands for earlier diagnosis of Alzheimer’s disease. The key
concept is a RF coil with DOI PET detectors, which has a potential to upgrade any
existing MRI to PET/MRI. In this paper, an overview of above developments is
shown.
3.2 The OpenPET: A Future PET for Therapy Imaging
OpenPET is our original idea to realize the world’s first open-type 3D PET scanner
for PET-image guided particle therapy such as in situ dose verification and direct
tumor tracking. The principal of dose verification for particle therapy is based on
the measurement of positron emitters which are produced through fragmentation
reactions caused by proton or 12C ion irradiation. Even with a full-ring geometry,
the OpenPET has an open gap between its two detector rings through which the
treatment beam passes, while conventional positron cameras applied to particle
therapy imaging have been basically limited to planar imaging with lower detection
efficiency [12–14]. Following our initial proposal of the dual-ring OpenPET
(DROP) in 2008 (Fig. 3.2a) [15], we developed a small prototype in 2010 to
show a proof of concept (Fig. 3.2b) [16]. In 2011, we also proposed the single-
ring OpenPET (SROP), which is more efficient than DROP in terms of manufactur-
ing cost and sensitivity [17]. We developed two small SROP prototypes in 2012 and
2013 (Fig. 3.2d, e) [18, 19], and we succeeded in visualizing a 3D distribution of
beam stopping positions inside a phantom with the help of radioactive beams (11C
beam and 10C beam) used as primary beams (Fig. 3.2f) [20]. Following these good
results, in 2014, we have finally developed a whole-body prototype of DROP
(Fig. 3.2g) [21].
The key technology which enabled OpenPET is our original, four-layered DOI
detector. In order to measure radiations from the limited activity produced though
fragmentation reactions, Zr-doped GSO (GSOZ), which contains less natural radio-
activity, was chosen for the scintillators instead of Lu-based scintillators although
timing performance was compromised. In order to compensate for the limited light
yield, on the other hand, we used 64-channel, flat-panel PMTs with a super-bialkali
photocathode (Hamamatsu R10552-100-M64), which had a 30 % higher quantum
efficiency [22]. In order to enable stable in-beam PET measurement even under
high background radiations, voltage divider circuits were designed so as to have
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five times higher linearity. In order to avoid severe radiation damage, in addition,
gain control ASICs were not implemented in the front-end circuits, and position
analyzer circuits were placed with a 15-m cable extension. A data acquisition
system was developed based on the single events collection.
The prototype consisted of two detector rings, and each detector ring had two
subrings of 40 detectors. Each detector consisted of 16 16 4 array of GSOZ
(2.8 2.8 7.5 mm3). The portable gantry had a compact design; each detector
ring had a 940 mm outer diameter and 171 mm thickness for the detector inner bore
of 640 mm diameter and 113 mm thickness.
3.3 The Helmet-Chin PET for Super High-Sensitive Brain
Imaging
For a potential demand for brain molecular imaging, prototypes of brain dedicated
PET scanners have been developed. However all previous developments are based
on a cylindrical geometry [3, 10, 23–25], which is not the most efficient for brain
imaging. Making the detector ring as small as possible is essential in PET, because
sensitivity can be increased with a limited number of detectors. With appropriate
DOI detectors, which reduce the parallax error caused by the thickness of the
scintillators, spatial resolution can be maintained, or even improved by reducing
Fig. 3.2 Conceptual sketches and prototypes of the OpenPET geometries: the dual-ring OpenPET
(DROP) (a–b) and the single-ring OpenPET (c–e). Following proofs-of-concept of in-beam
imaging (f), a whole-body DROP was developed (g)
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the angular deviation effect. Therefore, we developed the world’s first helmet-chin
PET, in which DOI detectors are arranged to form a hemisphere, for compact, high-
sensitivity, high-resolution, and low-cost PET imaging [26, 27].
Our basic idea relies on the evidence that the average sensitivity of a hemisphere
PET is about 1.5-times higher than that of a cylinder PET of the same radius and
height, while surface area is the same for both geometries (Fig. 3.3a, b). In addition,
use of 12 % more detectors for “chin detectors,” which are placed like a chin strap,
improves sensitivity especially at the central area (Fig. 3.3c). In the prototype,
47 block detectors were used to form a hemisphere of 25 cm inner diameter and
50 cm outer diameter, and seven block detectors were used for the chin strap
(Fig. 3.3d). The total number of detectors was about only 1/5 of that to be used in
whole body PET. Each detector block was a four-layered DOI detector, which
consisted of 1024 Zr-doped GSO crystals (2.8 mm 2.8 mm 7.5 mm) and a high-
sensitivity type of 64-channel flat-panel PMT. The data acquisition system was
Fig. 3.3 Comparison between a conventional cylinder PET (a) and the proposed helmet-chin PET
(b, c); the hemisphere detector arrangement obtains 1.5 times higher sensitivity, and adding only
12 % more detectors gets three times higher sensitivity at the central area. A prototype of the
helmet-chin PET (d) succeeded in obtaining excellent sensitivity and resolution performance (e)
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developed based on single event collection. An iterative reconstruction method
with detector modeling was applied.
Measured sensitivity was 5 % at the cerebellum region and 10 % at the parietal
region for a standard 400–600 keV energy window. Averaged FWHM of point
sources was 3.0 mm (FBP) and 1.4 mm (iterative) (Fig. 3.3e).
3.4 The X’tal Cube: 0.8 mm Isotropic Resolution, a World
Record
X’tal (crystal) cube is a future DOI detector we are developing. SiPMs, multi-pixel
photon counters (MPPCs), are coupled on all sides of a scintillation crystal block,
which is segmented into a 3D array of cubes [28] (Fig. 3.4a). Crystal segmentation
is made by irradiating a laser to a monolithic crystal (Fig. 3.4b) [29]. No reflector is
inserted into the crystal block so that scintillation light originating in one of the
cubic segment spreads 3-dimensionally and distributes among all MPPCs on the
crystal block. In 2012, we achieved 1-mm cubic resolution with 18 18 18
segments made by 3D laser processing (Fig. 3.4c, d) [30, 31]. In the last year, we
succeeded in identifying (0.8 mm)3 crystal segments, which is a world record [32].
Fig. 3.4 Conceptual sketch of the X’tal cube (a) and a prototype X’tal cube detector (c) with a
monolithic crystal block segmented by the 3D laser processing (b). A flood histogram shows
position identification performance of 18 18 18 array of 1 mm3 crystal segments (d)
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3.5 The Add-On PET: A PET Insert to Upgrade Existing
MRI to PET/MRI
One of the major innovations made in recent years is combined PET/MRI
(Fig. 3.5a) [33–46], but utilization of DOI measurement in PET detectors has not
been studied well. DOI measurement, which allows for use of a smaller detector
ring, is essential for PET in order to exploit the excellent potentials of PET imaging
in terms of improved spatial resolution and sensitivity as well as reduced production
costs of PET instrument. Therefore we proposed a new combined PET/MRI that
makes full use of DOI measurement (Fig. 3.5b) [47, 48].
In order to make a PET detector ring as small as possible while placing
electronic parts such as photodetectors and front-end circuits outside of a RF coil,
PET detector modules were placed between spokes of the birdcage RF coil
(Fig. 3.5c). For each detector module, electronic parts were covered with a Cu
shielding box with a hole in front of the photodetectors, and scintillators were
sticking out of the shielding box to allow their placement inside of the birdcage coil
(Fig. 3.5e). In theory, the proposed birdcage coil integrated with PET detectors can
be applied to any existing MRI as an additional choice of RF coils. For a proof of
Fig. 3.5 Concept comparison between conventional PET/MRI (a) and the proposed add-on
PET/MRI (b). A prototype (c, d) combined with DOI detector modules (e) was applied to 3T
MRI (f) to demonstrate simultaneous PET/MRI imaging (g)
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concept, we developed a full-ring prototype (four-layered arrays of 2.0 mm-LYSO
with MPPCs) (Fig. 3.5d), which was applied to a 3T MRI (MAGNETOM Verio,
Siemens) (Fig. 3.5f).
After evaluating interference between PET and MRI, no undesirable effect was
seen in the PET imaging in terms of energy resolution and position identification.
While a uniform static magnetic field was obtained, about a 20 % decrease in
signal-to-noise ratio was observed in MR images; we suspected this was due to
noise contamination from outside the MRI room. Although further optimization is
required for shielding, we demonstrated a proof of concept of the proposed head
coil with DOI PET detectors (Fig. 3.5g).
3.6 Conclusions
In PET, DOI measurement is a key technology to get significant improvement in
sensitivity while maintaining high spatial resolution. DOI measurement also has a
potential to expand PET application fields because it allows for more flexible
detector arrangement. In this paper, two current developments, the OpenPET
toward PET-image guided particle therapy and the helmet-chin PET for high-
sensitive brain imaging, were shown. Current development status of the next-
generation DOI detector X’tal cube, which uses SiPMs as a photosensor, was also
described. SiPM-based DOI detector enabled the add-on PET, which is a PET insert
having a potential to upgrade existing MRI to PET/MRI.
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Abstract Semiconductor detectors have the potential to improve the quantitative
accuracy of nuclear medicine imaging with their better energy and intrinsic spatial
resolutions than those of conventional scintillator-based detectors. The fine energy
resolution leads to a better image contrast due to better scatter rejection. The fine
intrinsic spatial resolution due to a pixelated structure leads to a better image
contrast and lower partial volume effect. Their pixelated structures also improve
the count-rate capability. The authors developed CdTe semiconductor detector-
based positron emission tomography (CdTe-PET) and single-photon emission com-
puted tomography (CdTe-SPECT) in order to test the potential of using semicon-
ductor detectors in nuclear medicine. The physical performances of both systems
were measured in several phantom experiments. The capability of using CdTe-PET
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to measure the metabolic distribution of tumors was evaluated through scans of
cancer patients and rat tumor models. The feasibility of using CdTe-SPECT for
simultaneous dual-radionuclide imaging was evaluated through scans of phantoms
and healthy volunteers. The results suggest that the prototype CdTe-PET can
identify intratumoral metabolic heterogeneous distribution and that CdTe-SPECT
can accurately acquire dual-radionuclide images simultaneously. Although there are
still problems to be solved, semiconductor detectors will play significant roles in the
future of nuclear medicine.
Keywords Semiconductor detector • Solid-state detector • CdTe • Intratumoral
heterogeneity • Dual radionuclide
4.1 Introduction
Nuclear medicine plays a significant role in diagnosis, treatment planning, and
treatment response evaluation. In particular, in oncology, biological imaging by
positron emission tomography (PET) permits not only tumor detection but also
gross tumor delineation and identification of biological heterogeneities [1, 2]. In the
delineation of tumor boundaries by PET, achieving a good spatial resolution and
quantitative accuracy are physical imaging concerns. The spatial resolution of the
current PET images as used in clinical practice is 7–9 mm after reconstruction with
many systems. The achievable spatial resolution depends primarily on the size of
the detector elements. The typical PET scanner used in current clinical study is
comprised of scintillation detectors 4 4 mm in size.
In nuclear cardiology and brain nuclear medicine, functional imaging by PET and
single-photon emission computed tomography (SPECT) can measure the functional
state of the myocardium and brain. Unlike PET, SPECT has the potential to enable
simultaneous multi-radionuclide imaging. The scanning of multi-radionuclide pharma-
ceuticals will enable various kinds of functional images to be obtained without position
error or time difference. The recent development of several cardiac SPECT systems that
use solid-state detectors with a fine energy resolution [3–5] has led to simultaneous
multi-radionuclide imaging recapturing the spotlight. A number of simultaneous multi-
radionuclide imaging studies have been reported, especially for myocardial perfusion
diagnosis [4, 5]. To enable accurate simultaneous multi-radionuclide imaging, a detec-
tor with a good energy resolution is necessary. In addition, improving the sensitivity of
gamma-ray detection is also important for realizing simultaneous multi-radionuclide
imaging with an appropriate dose of radiopharmaceuticals.
As mentioned above, the performance of nuclear medicine imaging depends on
spatial resolution, energy resolution, and sensitivity. Semiconductor detectors, e.g.,
CdZnTe or CdTe detectors, provide improved energy resolution due to the direct
conversion of gamma rays to charge carriers. This fine resolution leads to a better
image contrast due to better scatter rejection. Semiconductor detectors also easily
provide a pixelated structure that improves the count-rate capability and intrinsic
spatial resolution. Flexibility in both sizing and a fine arrangement of semiconductor
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detectors is expected not only to improve the spatial resolution but also to obtain
depth-of-interaction (DOI) information in PET and pixel-of-interaction in SPECT
when the multidetector pixels are placed within each collimator hole. A high energy
resolution is expected to reduce scattered components in detected signals and to
improve the quantitative accuracy of the reconstructed images. These features of
semiconductor detectors may lead to improved PET and SPECT images. The
authors previously developed CdTe semiconductor detector-based PET (CdTe-
PET) [1, 2] and SPECT (CdTe-SPECT) [6, 7]. The physical and clinical perfor-
mances of the systemswere evaluated through phantom, animal, and clinical studies.
4.2 Materials and Methods
4.2.1 Development and Performance Evaluation of Prototype
CdTe-PET
4.2.1.1 Outline of CdTe-PET and Its Parameter Settings
CdTe-PET is a prototype semiconductor PET scanner for human brain imaging.
This scanner is described in detail in a previous report [1]. In brief, the scanner uses
CdTe detectors for dedicated three-dimensional emission scanning. It has a patient
port with a diameter of 350 mm, a transaxial FOV of 310 mm, and an axial FOV of
250 mm. The size of a detector is 1.0 4.0 7.5 mm. The detector channel is
composed of two CdTe elements in the radial direction and two CdTe elements in
the tangential direction. To utilize the depth-of-interaction (DOI) technique, three
detector channels (six detectors) in the tangential direction are used. The transverse
and axial spatial resolutions near the center are 2.3 and 5.1 mm, respectively. The
energy resolution is 4.1 % at 511 keV (FWHM), which is superior to that of
available scintillation detectors, e.g., 10–20 %. The long-term stability of the
energy resolution of the CdTe detectors was assured by periodically resetting the
bias [8]. No significant variances in the spectral peak position and energy resolution
of the CdTe detectors were observed for over a year [9].
The energy of detected gamma rays is recorded in list-mode data. This data
contains the energy information of two gamma rays in the coincidence detection.
The size of an energy bin is 4 keV. Two energy windows, described below, were
used. One energy window (390–540 keV) was used as a wide energy window
(WEW), and another (494–540 keV) was used as a photopeak energy window
(PEW). Sinogram data using both WEW and PEW were made by sorting the list-
mode data by recorded energy. For all measured sinogram data and energy spectra,
random coincidences were removed by using the delayed coincidence subtraction
technique. The size of the sinogram data is 256 in the radial direction, 256 in the
angular direction, 87 in the axial direction, and 44 in the oblique angular direction,
i.e., ring difference. The matrix size of the reconstructed images is 256 256 87
with voxels of 1.21 1.21 2.8 mm.
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To bring out the potential of CdTe detectors in human imaging, the main
challenge to be solved is sensitivity. The effective atomic number of the CdTe is
smaller than the scintillation detectors of the current PET scanner. The crystal size
is also smaller than those detectors. To overcome the sensitivity problem, the
following improvements were made.
To improve sensitivity, a novel signal processing method was developed
[1]. The effective atomic number of the CdTe is 50, so the whole absorption rate
of the 511-keV gamma ray is smaller than the current scintillation detectors, and a
considerable amount of scattered gamma rays are generated and absorbed in nearby
detectors. In the improved signal processing method, when the sum of the energy of
two gamma rays detected in a neighborhood channel in a limited time window
(64 ns) is around 511 keV, the record of the gamma rays detected at the opposing
detector unit in the coincidence time window (14 ns) is checked for the coincidence
detection. With this signal processing, the detector of our system is considered to be
a continuous mass of CdTe from the viewpoint of sensitivity, although the position
is determined digitally.
4.2.1.2 Image Reconstruction Method
A reconstruction system of the developed scanner coped with the sensitivity
problem, avoiding unexpected statistical fluctuation in reconstructed images. To
enable high-resolution imaging with a low amount of statistical data, we developed
a reconstruction method that could suppress statistical noise without degrading the
spatial resolution [1, 10]. The method is based on maximum a posteriori (MAP)
[11] with median root prior (MRP) [12] and uses a resolution recovery technique
[13, 14]. The method also uses an attenuation and normalization weighting tech-
nique. MRP assumes only local monotony and does not need any anatomical
information such as MRI or CT images. MRP is also known as an effectual prior
for reducing noise and preserving edge. Because of various incident angles and
distances to detectors, reconstructed point source images blur into various shapes.
To correct the point spread function (PSF), a 3-D image-space convolution tech-
nique was used [13]. The Gaussian kernel represents the PSF. The algorithm of the
reconstruction method, named “point spread function correction with median root
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, where
λ : pixelvalue j ¼ index, k ¼ iterationð Þ




M : median of the neibourhodd
G : Gaussian-Kernel PSFð Þ
β : prior strength
.
The value y is measured data, and λ is emission image. The matrices p, a, and
n represent probability (geometrical sensitivity), attenuation, and normalization
(sensitivity of each detector), respectively. The value k is the number of iterations,
and i and j are index numbers. The value β controls the effect of reducing noise, and
M is a median of neighbor (3 3 3) voxels’ values. The Gaussian kernel
G represents the PSF. The PSFs were measured for a point source at different
positions in a portion of the field of view. The G was parameterized to correct for
point source location and to smooth for projection noise. When β is zero and G is
not used, the reconstruction method equals attenuation and normalization weighted
OSEM (ANW-OSEM) [15]. The numbers of subsets and iterations were 8 and
5, respectively.
4.2.1.3 Physical Performance Measurement
In accordance with the NEMA NU2-1994 standards [16], a count-rate performance
experiment was conducted with CdTe-PET. In this evaluation, two energy windows
(WEW and PEW described above) were used. The count-rate performance of
CdTe-PET was measured with a standard 20-cm-inner-diameter, 20-cm-long phan-
tom filled with water that contained a 3.7-kBq/cm3 F-18 solution. The phantom was
placed at the center of the FOV and scanned over ten half-lives. The performance
was evaluated in WEW and PEW settings. The noise equivalent count rate
(NEC2R) was calculated by NEC2R¼T*T/(T + S+ 2*R) from the true (T) rate,
scattered (S) rate, and random (R) rate. The random rate was multiplied by a factor
of two because the random rate was evaluated by acquiring events in a delayed time
window. The sensitivity of the scanner was also evaluated using the measurement
data of count-rate performance.
4.2.1.4 Image Quality Evaluation
To evaluate the image quality of CdTe-PET with its energy window set to PEW,
two kinds of experiments and studies, described below, were conducted.
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Hoffman Phantom
A Hoffman phantom (filled with 9.1 kBq/ml F-18 solution) simulated the human
brain was scanned for 10 min so as to equalize the measured count with the clinical
situation. The data was reconstructed by (a) ANW-OSEM, (b) ANW-OSEM with
post-reconstruction Gaussian filter (4-mm FWHM), and (c) PSC-MAP β¼ 0.05.
The three images were compared visually.
Preclinical Evaluation with Rat Tumor Model
To evaluate the feasibility of visualizing intratumoral heterogeneity, a preclinical
study using a rat tumor model was conducted. All animal care and experimental
procedures were performed with the approval of the Laboratory Animal Care and
Use Committee of Hokkaido University. Eight-week-old male Wistar-King-
Aptekman/hok (WKAH) rats (Japan SLC, Inc.) were inoculated with a suspension
of allogenic rat glioma cells (C6, 2 106 cells/0.2 ml) into the left calf muscle to
generate glioma rat models. The rats were allowed free access to water and
laboratory chow until the day before the experiment. When the tumors were
1–2 cm in diameter, the rats were fasted overnight. Under diethyl ether anesthesia,
200 kBq/g body weight of F-18-fluorodeoxyglucose (FDG) was intravenously
injected into each rat. Fifty minutes after the injection of FDG, the rats were
anesthetized with pentobarbital (50 mg/kg body weight, intraperitoneally). One
hour after the FDG injection, each rat was scanned by CdTe-PET for 1 min. Then,
images were reconstructed by PSC-MAP (β¼ 0.05). Four hours after the FDG
injection, the rats were euthanized under deep pentobarbital anesthesia. The ani-
mals were sacrificed, and the whole tumors were quickly excised. Then, the excised
tumors were frozen in isopentane/dry ice. The frozen tumor tissues were sectioned
into slices for autoradiographic (ARG) imaging. The thickness of the sectioned
slices was 0.15 mm. The number of slices was about 19. All of the sectioned slices
were exposed to phosphor imaging plates (BAS-SR 2025, Fuji Photo Film Co.,
Ltd.) together with a set of calibrated standards. The autoradiographic exposure was
performed for 12 h to detect the radioactivity of FDG. After the exposure, the
imaging plates were scanned with a Fuji Bio-imaging Analyzer BAS-5000, and the
units of the images were converted into a unit of Bq/ml by house-made software.
All of the sectioned slices were integrated into a 3-D volume by using a slice-by-
slice image registration technique. Then, the integrated 3-D ARG and PET images
were compared.
Clinical Evaluation
As was previously reported [1, 2], patients with brain tumor or nasopharyngeal
cancer injected FDG (340 MBq ca.) were scanned by CdTe-PET for 30 min. Then,
images were reconstructed by PSC-MAP (β¼ 0.05). The patient volunteers gave
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written, informed consent in accordance with the Helsinki II Declaration. The study
was approved by the ethics committees of both the Hokkaido University Graduate
School of Medicine and Hitachi, Ltd. The capability of using CdTe-PET to measure
the metabolic distribution of tumor was evaluated.
4.2.2 Development and Performance Evaluation of Prototype
CdTe-SPECT
4.2.2.1 Outline of CdTe-SPECT
CdTe-SPECT is a prototype semiconductor SPECT system for human brain imag-
ing. This system is described in detail in previous reports [6, 7]. In brief, CdTe-
SPECT includes two detector heads. Each head consists of 192 96 detector pixels
with a pitch of 1.4 mm, so the field of view of the detector head is 268 134 mm
(tangential axial). The size of each detector pixel is 1.2 1.4 5 mm. The
intrinsic energy resolution (FWHM) of the CdTe detector is 6.6 % at 140.5 keV,
and the count-rate linearity is maintained at 200 kcps per head and under [9]. For
high-sensitivity imaging, a wide aperture parallel-hole collimator (Fig. 4.1), which
we call the “4-pixel matched collimator” (4-PMC), was previously developed
[6, 7]. The hole size of the 4-PMC is matched to four detector pixels, that is,
there are four (2 2) pixels per collimator hole. By contrast, the hole size of the
standard parallel-hole collimator [9] is matched to one detector pixel, that is, a
1-pixel matched collimator (1-PMC). The specifications of both collimators are
shown in Table 4.1. 4-PMC was designed to improve the sensitivity and spatial
resolution in clinical SPECT imaging compared with 1-PMC. The sensitivities of
1-PMC and 4-PMC were 70 and 220 cps/MBq/head, respectively [7]. Therefore,
4-PMC has three times the sensitivity of 1-PMC. The rotation radius of the detector
head is set to 130 mm for brain scans. In SPECT acquisition, each detector head is
rotated by 360 over 3 min.
Fig. 4.1 Geometry of
4-PMC
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4.2.2.2 Image Reconstruction Method
The ordered subset expectation maximization (OSEM) (Hudson and Larkin 1994)
including PSF and attenuation correction was used. The PSF of each collimator
type was obtained by ray-tracing simulation [6, 7]. The attenuation factor of the
gamma rays in a subject was approximated by an exponential function of the line
integral from an image pixel to a detector pixel in an attenuation map. The
projection image matrix size (tangential axial) was 256 96 (pixel
size¼ 1.4 1.4 mm). The number of projection images was 120 over 360. The
reconstructed image matrix size (x y z) was 256 256 96 (pixel
size¼ 1.4 1.4 1.4 mm). The numbers of subsets and iterations were 30 and
20, respectively. The reconstructed images were smoothed with a 14-mm FWHM
Gaussian filter.
4.2.2.3 Performance Evaluation in Phantom Experiment and Clinical
Study
Dual-Radionuclide Character-Shape Phantom
A character-shape dual-radionuclide phantom, which has three kinds of radioactiv-
ity, was scanned (Fig. 4.2). The activities are shown in Table 4.2. The photopeak
energy windows for Tc-99m (141 keV) and I-123(159 keV) were 130–148 keV and
155–170 keV, respectively. An energy window-based scatter correction based on
the triple energy window (TEW) method [17] was used. The measured energy
spectrum and reconstructed images were evaluated.
Simultaneous Dual-Radionuclide Human Brain Study
A healthy volunteer was injected with Tc-99m HAS-D and I-123 IMP and then
scanned by CdTe-SPECT for 21 min as a simultaneous dual-radionuclide brain
study. The healthy volunteer gave written, informed consent in accordance with the
Helsinki II Declaration. The study was approved by the ethics committees of both
the Hokkaido University Graduate School of Medicine and Hitachi, Ltd. The










1-PMC 1.4 1.12 20.0 70
4-PMC 2.8 2.40 26.0 220
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feasibility of using CdTe-SPECT for simultaneous dual-radionuclide study was
evaluated.
4.3 Results and Discussion
4.3.1 Performance Evaluation of CdTe-PET by Phantom
Experiment and Clinical Study
4.3.1.1 Physical Performance of CdTe-PET
Figure 4.3 shows the result of the count-rate performance examination. The left
vertical axis is the count rate of “true” and “random.” The right vertical axis is the
noise equivalent count rate (NEC2R). The horizontal axis is the activity of the
cylinder phantom. Table 4.3 shows the results for sensitivity, NECR, and scatter
fraction. The sensitivity was 22.0 and 8.5 kcps/(kBq/ml) in WEW and PEW,
respectively. The NECR at 7.4 kBq/ml was 45 and 25 kcps in WEW and PEW,
respectively. The scatter fraction was 39 and 12 % inWEW and PEW, respectively.
Comparing PEW with WEW, although the sensitivity was less than a half, the




Table 4.2 Radioactivities of
dual-radionuclide character-
shape phantom
Kinds of vial Tc-99m (kBq/ml) I-123 (kBq/ml)
A (Tc-99m) 44.6 0
B (Dual) 49.3 115.5
C (I-123) 0 101
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4.3.1.2 Image Quality of CdTe-PET
Hoffman Phantom
Shown in Fig. 4.4 are images reconstructed by (a) ANW-OSEM, (b) ANW-OSEM
with a Gaussian filter (4-mm FWHM), and (c) PSC-MAP β¼ 0.05. Even with
filtering, images reconstructed by ANW-OSEM had speckle noise. The
PSC-MAP image was not speckled and not blurred. Therefore, the edge between
gray matter and white matter in the PSC-MAP image was well defined.
Preclinical Evaluation with Rat Tumor Model
The diameter of each tumor was ca. 16 mm. A 3-D ARG volume made by
integrating 19 slices is shown in Fig. 4.5. The heterogeneous intratumoral FDG
distribution in each tumor was visualized by both CdTe-PET and ARG (Figs. 4.5




performances in each energy
window
Energy window WEW PEW
Sensitivity [kcps/(kBq/ml)] 22.0 8.5
Peak NECR [kcps] 51 28
NECR at 3.7 kBq/ml [kcps] 32 18
NECR at 7.4 kBq/ml [kcps] 45 25
Scatter fraction [%] 39 12
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Fig. 4.5 Integrated 3-D ARG volume
Fig. 4.4 Reconstructed image of Hoffman phantom. (a) ANW-OSEM, (b) ANW-OSEM+
Gaussian filter, and (c) PSC-MAP (b¼ 0.05)
Fig. 4.6 Comparison of ARG and PET images. “PET+ARG” shows image fused by image
registration method
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Clinical Evaluation
Reconstructed images of brain tumor and nasopharyngeal cancer patients scanned
by CdTe-PET are shown in Fig. 4.7. CdTe-PET identified intratumoral heteroge-
neity and visualized the tumor’s edge sharply for both cancers.
4.3.2 Performance Evaluation of CdTe-SPECT by Phantom
Experiment and Clinical Study
4.3.2.1 Dual-Radionuclide Character-Shape Phantom
The photopeaks of Tc-99m and I-123 were clearly discriminated in the measured
energy spectrum (Fig. 4.8). The energy resolution of the CdTe semiconductor
detector was high enough to separate the photopeaks of Tc-99m and I-123. The
scatter-corrected images of Tc-99m and I-123 were clearly discriminated in the
character-shape phantom image in Fig. 4.9. Because of the high-energy resolution
of the CdTe semiconductor detector, there was no Tc-99m contamination in the
I-123 window image even without scatter correction. The results suggested that
simultaneous Tc-99m and I-123 study by using CdTe-SPECT was feasible.
4.3.2.2 Simultaneous Dual-Radionuclide Human Brain Study
The result of a simultaneous Tc-99m and I-123 dual-radionuclide scan is shown in
Fig. 4.10. The Tc-99m HSAD and I-123 IMP images were clearly discriminated.
The result suggests that CdTe-SPECT has the potential to produce accurate brain
Fig. 4.7 Clinical image
example of brain tumor
patient and nasopharyngeal
cancer patient
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perfusion images (Tc-99m HSAD) and cerebral blood volume (Tc-99m HSAD)
images simultaneously.
4.4 Conclusion
Prototype CdTe-PET and CdTe-SPECT systems were developed, and their perfor-
mances were evaluated. The results suggest that CdTe-PET enables better identi-
fication of intratumoral metabolic distribution and that CdTe-SPECT will enable








image of simultaneous dual-
radionuclide brain study
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simultaneous dual-radionuclide brain study to become available clinically. Semi-
conductor detectors have the potential to play a significant role in the future of
nuclear medicine.
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Chapter 5
Kinetic Analysis for Cardiac PET
Yuuki Tomiyama and Keiichiro Yoshinaga
Abstract Objective: PET has the ability to evaluate functional information as well
as visualization of radiotracer uptake. Compartmental model is a basic idea to analyze
dynamic PET data. C-HED has been the most frequently used PET tracer for the
evaluation of cardiac sympathetic nervous system (SNS) function. The washout of
norepinephrine from myocardium is associated with increasing SNS activity in heart
failure (HF). However, the existence of washout of 11C-HED from the myocardium is
controversial. Although “retention index” (RI) is commonly calculated to quantify
the uptake of HED, RI is not purely able to distinguish washout parameter and uptake
parameter. Therefore, in this study, we aimed to evaluate whether HED was washed
out from the myocardium using compartment model analysis.
Material and Methods:We compared HED parameters in ten normal volunteers
(32.4 9.6 years) and nine HF patients (age: 57.3 17.3 years, LVEF:
36.1 16.7 %). Each subject underwent rest 11C-HED PET. We estimated RI,
inflow rate K1, and washout rate k2 using single-compartment model analysis
using 11C-HED PET.
Result: HF patients showed lower RI and inflow rate K1 compared to normal
volunteers (RI: 0.06 0.02 vs. 0.15 0.03 min1, p< 0.001, K1: 0.14 0.05 vs
0.20 0.03 ml/min/g, p< 0.001). Washout rate k2 also significantly increased in
HF patients (k2: 0.036 0.026 vs. 0.016 0.011 min1, p¼ 0.041).
Conclusion: HF patients showed reduced RI, reduced K1, and higher washout
rate k2 compared to normal. This result may imply that HED PET is able to
evaluate washout parameter using compartment model.
Keywords Compartment model analysis • 11C-Hydroxyephedrine • Retention
index • Sympathetic nervous system function
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5.1 Introduction
Positron emission tomography (PET) is a powerful tool to evaluate functional
information imaging as well as anatomical information [1, 2]. PET is the most
reliable modality for assessing functional information, especially in cardiovascular
imaging [3, 4]. When biomedical functions are analyzed using PET images, com-
partment model analysis is generally applied [5, 6]. Compartment model analysis
enables to observe the pharmacokinetics of radiotracer in human body. Thus, we
apply compartment model analysis to evaluating pharmacokinetics of 11C-
hydroxyephedrine (HED).
11C- HED has been the most frequently used PET tracer for the estimation of
cardiac sympathetic nervous system (SNS) function [7–9]. In general, 11C- HED
data has been evaluated using the retention index (RI) [8]. RI is a parameter that can
be calculated easily compared to other quantitative parameters. RI includes uptake
and washout parameters. However, RI does not differentiate washout parameters
from cardiac HED data. Cardiac washout parameter is widely used for evaluation of
SNS function and increased cardiac washout is associated with cardiac events in
heart failure (HF) [10]. Therefore, it would be important to evaluate the washout
parameters using HED PET. Compartment model analysis might have a potential to
evaluate precise pharmacokinetics of 11C-HED and also has a potential to evaluate
purely washout parameter [11].
In this study, we aimed to analyze HED uptake parameter and washout param-
eter using single-compartment model analysis in patients with HF.
5.2 Methods
5.2.1 Study Subjects
Ten healthy volunteers and nine HF patients participated in the current study. The
healthy volunteers (ten men, 32.4 9.6 years) had a low pretest likelihood of
coronary artery disease (<5 %) based on risk factors [12]. HF patients were
recruited from a group of patients who underwent HED PET for the assessment
of sympathetic neuronal function. They were six men and three women
(57.3 17.3 years). The study was approved by the Hokkaido University Graduate
School of Medicine Human Research Ethics Board. Written informed consent was
obtained from all participants.
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5.2.2 Positron Emission Tomography/Computed
Tomography 11C-HED PET/CT Imaging
11C-HED was produced from 11C-methyl iodide and metaraminol (free base) using
standard methods with high purity and high specific activity [13].
All participants were instructed to fast overnight. PET/CT imaging was
performed with a 64-slice PET/CT scanner (Biograph Siemens/CTI, Knoxville,
TN, USA). A low-dose CT was performed for attenuation correction. The CT
co-registered to standard orthogonal PET images was then re-sliced into series of
short-axis, horizontal long-axis, and vertical long-axis images.
Immediately after the administration of 5 mCi(185 MBq) of intravenous 11C-
HED, participants underwent 40-min 3D list-mode PET acquisition. The images
were reconstructed using filtered back correction with a12-mm Hann filter and were
reconstructed into 23 frames (10 10 s; 1 60 s; 5 100 s; 3 180 s;
4 300 s) [14].
5.2.3 RI Estimation
RI is obtained by normalizing late phase of tracer activity concentrations
(30–40 min) of left ventricular (LV) myocardium divided by the integral of the
arterial input function (AIF). The time-activity curve was derived from a small
circular region of interest in the left ventricular cavity (Fig. 5.1, [10]).
5.2.4 Compartment Model Analysis
Harms HJ et al. reported the single-tissue model was more robust than two-tissue
compartment model and results obtained were similar to more precise models
[11]. Thus, we used single-compartment model to evaluate 11C-HED washout
parameter.
In single-compartment model analysis, tracer kinetics are consisted by only two
parameters, which are inflow rate K1 and washout rate k2 (Fig. 5.1, [6]). In this
study, K1 and k2 were estimated using the nonlinear least squares method. This
approach used AIF arterial input function and tissue activity carve (TAC) of LV
myocardium [15, 16]. Distribution volume was also calculated [17]. The equation
of distribution volume was inflow rate K1 divided by washout rate k2.
5 Kinetic Analysis for Cardiac PET 69
5.2.5 Statistical Analysis
Data are expressed as mean SD. The differences between the means of two
volumetric results were examined using the unpaired two t-test. Fisher’s exact
tests were used for categorical variables. P-value of less than 0.05 was considered
indicative of a statistically significant difference. Statistical calculations were
carried out using JMP software version 12.0 (SAS Institute, Inc., Cary, NC).
5.3 Results
5.3.1 Subjects’ Background
Table 5.1 summarizes the baseline characteristics of the volunteers and HF patients.
HF patients also had laboratory data and echocardiography data. The HF patients
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Fig. 5.1 Analysis methods of 11C-hydroxyephedrine. (a) Calculation method of retention index:
retention index was obtained by normalizing late activity concentrations of left ventricular
myocardium divided by the integral of the arterial input function.(b) Single-tissue compartment
model: single-tissue compartment model enables to monitor inflow rate K1 and washout rate k2 of
radiotracer between arterial input function (AIF) and tissue activity curve (TAC). AIF and TAC
were obtained from LV cavity and myocardial tissue, respectively
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5.3.2 HED PET Data Normal Volunteers and HF Patients
HF patients significantly decreased RI compared to normal volunteers
(0.060 0.020 vs. 0.150 0.032 1/min, P< 0.001, Fig. 5.2). In compartment
model analysis, HF patients showed decreased inflow rate K1 (0.14 0.03
vs. 0.20 0.05 ml/min/g, P¼ 0.004, Fig. 5.3a) and reduced distribution volume
(5.17 2.93 vs. 22.4 23.1 mL/g, P¼ 0.04, Fig. 5.3c). In addition, HF patients
significantly increased washout rate k2 compared to normal volunteers
(0.036 0.026 vs. 0.016 0.011 1/min, P¼ 0.044, Figs. 5.3b and 5.4.).





Age (year) 32.4 9.6 57.3 17.3 <0.001
Sex (M/F) 10/0 6/3 0.09
Height (cm) 172.7 8.8 162.2 8.4 <0.001
Wight (kg) 68.2 13.5 56.8 17.4 <0.001
Laboratory data
BNP (pg/ml) – 633.7 876.8 –
Plasma noradrenalin (pg/ml) – 469.4 317.7 –
Urinary noradrenaline
(μg/day)
– 127.9 54.5 –
Echocardiography
LVEF (%) – 36.1 16.7 –
LVEDV (ml) – 180.2 95.2 –
Data expressed as mean SD. BNP brain natriuretic peptide, LVEF left ventricular ejection









Fig. 5.2 Difference of
retention index between the
heart failure and normal.
Heart failure patients
showed significantly
decreased RI compared to
normal volunteers




























Fig. 5.3 Difference of parameters calculated using compartment model analysis. Heart failure
patients showed significantly decreased inflow rate K1 and distribution volume (a, c). Heart failure



























RI  = 0.17 (ml/min/g) 
K1 = 0.21 (ml/min/g)
k2  = 0.009 (1/min)
Distribution Volume = 24.1 (ml/g)
RI  = 0.07 (ml/min/g) 
K1 = 0.17 (ml/min/g)
k2 = 0.037 (1/min)







Fig. 5.4 Example of myocardial time activity curveswith11C-hydroxyephedrine. Heart failure
patient’s time-activity curve showed enhanced washout compared to normal volunteer’s one
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5.4 Discussion
HF patients showed decreased RI, inflow rate K1, and distribution volume com-
pared to normal volunteers. In contrast, the HF patients increased washout param-
eter k2.
Many previous studies reported patients with imparted SNS function showed
lower 11C-HED uptake [8, 17]. Thus, the present data agree with previous reports.
In this study, HF patients showed significantly increased washout rate k2
compared to normal volunteers. Previous studies using 123I-MIBG reported HF
patient showed increased washout rate [10, 18]. Previous study also reported that
washout parameter of 11C-HED was well correlated with plasma and cardiac
norepinephrine in experiments with rats [7]. Therefore, current data that HF patient
showed increased washout rate may be considered to be appropriate.
5.4.1 Study Limitation
Our study had a small population and HF patients were significantly older than
normal volunteers. Therefore, further investigations with larger and age-matched
populations are required.
In addition, washout parameters were not compared to other clinical indexes.
Comparison washout of 11C-HED and other clinical parameter such as ejection
fraction, laboratory parameter, and washout of 123I-MIBG should be the next step.
5.5 Conclusion
In this study, we applied compartment model analysis to evaluating washout of 11C-
hydroxyephedrine (HED).
As a result, HF patients showed reduced RI, K1, and distribution volume and
higher washout rate k2 compared to normal. This result may imply that HED PET is
able to evaluate washout parameter using compartment model.
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Part II
Biomarker and Molecular Probes
Chapter 6
How Far Are We from Dose On Demand
of Short-Lived Radiopharmaceuticals?
Giancarlo Pascali and Lidia Matesic
Abstract PET radiopharmaceuticals are currently produced using a centralized
approach, which makes sustainable the distribution to few imaging centers of an
only small set of tracers (virtually only [18F]FDG). However, a wider set of
structures have demonstrated a potential applicability for imaging in a specific
manner several disease condition. In order to allow this wider and more personal-
ized use of PET imaging, the production paradigms need to be changed. In this
contribution we will explain how Dose-On-Demand systems can be conceptualized
and what are the challenges that are still to be overcome in order for such approach
to be of widespread utility.
Keywords Dose On Demand • Microfluidics • PET • Radiochemistry
6.1 Introduction
The clinical production of radiopharmaceuticals or radiotracers for positron-
emitting tomography (PET) is currently performed in centralized locations such
as commercial radiopharmacies or some dedicated radiochemistry facilities. Gen-
erally, these facilities contain a cyclotron to produce the PET radioisotope and
laboratories furnished with lead-shielded hot cells containing automated
radiosynthesis modules to produce the radiotracer. Quality control equipment is
also required to validate and confirm the purity of the radiotracer prior to its
dispatch to the imaging centers.
The majority of radiotracer production facilities synthesize [18F]FDG, the gold
standard for detecting a variety of cancers. Nowadays, [18F]FDG can be produced
in a large batch, making it relatively affordable. Portions can then be dispatched and
transported by road or air to the relevant hospital owing to the half-life of fluorine-
18 (110 min).
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A major challenge in clinical PET radiochemistry is that there are a greater
number of hospitals or PET clinics than there are PET radiotracer production
facilities. Furthermore, the demand for new clinical PET radiotracers is low due
to the cost of production in a centralized location. New PET radiotracers are
overwhelmingly used for research purposes only.
To overcome this obstacle, a decentralized approach has been envisaged
[1]. Here, scientists could produce their radiotracer of interest in-house, economi-
cally and on demand, leading to a concept that we have defined as Dose On Demand
(DOD). This short review will cover the important aspects of DOD and detail the
journey toward the DOD of short-lived radiopharmaceuticals.
6.2 DOD Features
The current production approach of PET radiotracers imposes several limitations
and challenges for guaranteeing the most efficient organization of imaging studies
[2]. A possible way to improve this situation would require a system for which the
type and the quantity of the produced tracer is defined and directly handled by an as
final as possible user (e.g., hospital pharmacy, imaging laboratory). This system
should implement the reduction to the minimum possible of the amounts of
radioactivity and chemicals needed in the preparation, added to an overall simpli-
fication of the production process. Such conceptual process can be defined as “Dose
On Demand” (DOD) [3, 4, 5]: the operation of producing a radiopharmaceutical
in the shortest time possible, using the minimum amount of chemicals and radio-
activity strictly needed for the production of the single (or few) imaging dose
(s) required.
This approach, exemplified in Fig. 6.1, would provide several benefits to the
overall PET community. Firstly, it will hand over flexibility in the application
directly to the hospital/imaging center, which can decide on a patient basis which
tracer to produce and when; this could also happen in small regional centers, thus
not forcing anymore interested patients to commute long distances to the few useful
imaging hospitals. This flexibility will also allow the utilization of rare or research
tracers to be facilitated, as in this system the small amounts of chemicals and
radioactivity needed for a DOD production would be economically sustainable
for a single imaging center. Secondly, while a fault in production from a centralized
approach will have impact on a large number of patients, a fault in one DOD system
will have an impact limited to the patients utilizing those doses only. Lastly, due to
the reduction in raw materials needed (as well as related topics, e.g., safety, storage)
and the redistribution of running costs over more institutes, the imaging doses will
result in a reduced cost and in tracers’ availability to a wider population.
In order to realize a DOD process, few requirements can be envisaged.
Firstly, the production needs to be implemented on an automated instrument that
can implement preset operations, as well as allowing remote interaction of the
operator for minor modifications (i.e., “Automation”). In addition, it has to have
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real-time monitoring and audit trail capabilities for monitoring and trending pur-
poses. Secondly, the instrument used needs to be able to handle small aliquots of
reagents, from fractions to hundreds of μL (i.e., “Discretization”) with accuracy and
repeatability. The handling operations comprise moving, merging, mixing, heating,
and similar processes. In other words, the instrument has to be capable to give a
defined “chemical history” to any given aliquot of reagents used (that can be
different among several aliquots). Thirdly, the processes implemented need to be
serially repeatable with minimum operator intervention (“Restarting”). This can be
achieved by substituting single-use parts in the system or by cleaning it using
validated procedures. A final peculiarity that contributes to achieving DOD is the
need to use the minimum amount of chemicals (“Reduction”), which would max-
imize the atom efficiency of the process, as well as allow an acceptable sacrifice in
employing single-use parts or realize a faster cleaning of the system.
If all these requirements can be respected in a process system, a DOD production
can be implemented and can be used to produce several doses of the same tracer or
of different tracers, using the same system and minimal operator interventions.
6.3 Early Examples Conducible to DOD
The possibility to tailor the production of nuclear medicine (NM) tracers as much as
possible to the needs of the final user has always been present, and indeed some
example of approaches that can be linked to DOD concept can be found in early and
current practices.
Fig. 6.1 Comparison between traditional centralized approach and DOD
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Generators of radioactive raw nuclides have been widely used (e.g., 99mTc,
68Ga) [6]; the elution of the desired radionuclide is generally done upon demand
and followed by simple chemical reactions (generally performed directly in the
same NM department) to obtain the final radiopharmaceutical. This approach
respects the Restarting requirement, though limited to the raw nuclide production
and not to the pharmaceutical preparation; however, it generally does not respect
the Discretization nor the Reduction requirements, as it is difficult to separately
handle the amount of chemicals needed for a single patient (i.e., in the μLs range). It
sometimes respects the Automation requirement, but in most NM departments,
these preparations are performed manually.
The use of very short half-life nuclides can be natively defined as a DOD
application, as their handling must be done shortly before their use in imaging.
Typical examples are the production of [15O]-H2O [7] and [
13N]-NH3 [8]; shortly
after production, the systems utilized can be restarted easily due to their simple
setup and the fast decay of process wastes. However, also in this case, these
processes cannot be properly defined as DOD since they generally respect the
Automation and the Restarting requirements, but neither the Discretization nor
the Reduction (i.e., no difference if the production is used for one or several
contemporary patients). 11C chemistry [8] also falls within the use of very short
half-life nuclides as more productions can be run on the same machine on the same
day. However, also in this case, the typical systems used can be even less defined as
DOD, due to its relatively longer half-life (compared to 15O and 13N).
Currently, the approach that most resembles DOD is represented by the cassette-
based systems. In this case, Automation and Restarting requirements can be easily
achieved; Discretization and Reduction are generally not pursued, because nowa-
days these systems are used for single-batch productions, but the principles under-
lying cassette philosophy could be used to project single-use/single-dose cassettes.
In fact, these systems are basically very compact macrofluidic systems; this under-
standing clarifies how microfluidic concepts can be the ones that should allow a full
implementation of DOD in radiopharmaceutical production.
6.4 DOD Proof-of-Principle Examples
6.4.1 Minicyclotron/Minichemistry/MiniQC
The Biomarker Generator (BG75), made by ABT Molecular Imaging, is a small
(0.37 m 1.25 m) self-shielded 7.5 MeV cyclotron coupled to an aseptic single-use
card-based automated chemical production module and an automated module for
quality control. The BG75 was initially used for the DOD production of [18F]
fluoride and [18F]FDG [9]. Using the computer’s software, the operator is able to
select whether the [18F]fluoride or [18F]FDG is to be produced. For the production
of [18F]fluoride (~1 mCi/min at 5 μA), the process is complete once the product is
delivered into the specified vial. Alternatively, for the production of [18F]FDG, the
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software prompts the operator to prepare the tracer-specific Dose Synthesis Card
(DSC) and the chemistry and quality control modules while the cyclotron is
preparing the [18F]fluoride. The radiosynthesis is then completed on the DSC,
including relevant purification, and dispensed into a shielded, sterile syringe or
vial. An aliquot of the product is removed for quality control (pH determination,
acetonitrile and ethanol residual solvent determination, radiochemical identity and
purity, Kryptofix 2.2.2. determination, and a filter integrity test), which is automat-
ically performed by the system, without any operator input.
The BG75 has been able to consistently produce a 10–13 mCi dose of [18F]FDG
at 40 min intervals up to six times per day, with products meeting the required USP
limits for release [9]. To date, other DOD radiotracers synthesized using the BG75
include Na[18F]F [10] and [18F]FMISO [11, 12].
6.4.2 Continuous Flow Microfluidics
Interestingly, proof-of-concept studies have been recently conducted into the pro-
duction of [18F]FLT using the cyclotron component of the BG75 system and the
Advion NanoTek microfluidic system [13]. Between 70 and 80 mCi of [18F]fluoride
were produced by the minicyclotron and the radiosynthesis was subsequently
performed under continuous-flow microfluidic conditions to yield [18F]FLT in
sufficient quantity and purity for clinical trials. The number of radiochemists
using a microfluidic approach has been steadily accumulating in recent years.
This may be related to the advantages of microfluidic systems over traditional
automated radiochemistry modules, which include a decrease in the amount chem-
ical reagents used, shorter reaction times, greater radiochemical yields, the ability
to use solvents under supercritical conditions, and reduced radiation exposure to the
operator due to the lower amounts of radioactivity used. The NanoTek Microfluidic
Synthesis System by Advion was the first commercially available continuous-flow
microfluidic system. The system comprises a concentrator module to azeotropically
evaporate the [18F]fluoride from the cyclotron and subsequently reconstitute the
isotope into the appropriate solvent; a pump module containing two syringe pumps
and loops to store chemical precursors and a reactor module, which contains a
syringe pump and loop to house the isotope along with thermostatted slots to store
up to four microreactors, where the radiochemical reactions occur.
The previous example of the production of [18F]FLT is the latest in a growing list
of radiotracers prepared using the NanoTek system. The first instance was the
production of [18F]fallypride for use in micro-PET studies [14]. Initially, the
radiochemical optimization of [18F]fallypride was conducted by dispensing 10 μL
solutions of the tosyl-fallypride precursor and [18F]fluoride complex into the
microreactor at 10 μL/min to obtain 1–1.5 mCi doses of [18F]fallypride. These
optimization reactions were performed sequentially and could be considered an
early form of DOD. Once the optimal radiochemical conditions were determined,
the authors were able to prepare a dose of [18F]fallypride sufficient for human
injection (15 mCi) by increasing the volume of the two solutions from 10 μL to
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200 μL. The authors also alluded to the fact that multiple high doses of [18F]
fallypride could be produced using the same microreactor. Soon after, Pascali
et al. [15] described the sequential radiolabeling of ethyl-ditosylate and propyl-
ditosylate in the NanoTek system using the same solution of [18F]fluoride complex
and swapping the precursor between productions by emptying and refilling the
precursor loop with a different substrate. These examples of DOD demonstrated the
economical use of the [18F]fluoride solution to yield two radiotracers on the same
day. The authors also sequentially prepared several injectable doses of [18F]CB102,
a cannabinoid type 2 receptor agonist, for small animal PET imaging, suggesting
that freshly prepared doses using a DOD approach were superior to a batch solution
to be used over a certain shelf life.
To further evaluate the robustness and reliability of a DOD approach, Pascali
et al. were able to produce three sequential doses of three different [18F]
fluorocholines with a total processing time of 13–15 min for each dose, including
SPE purification [5]. While this example includes a modification to the NanoTek
system to incorporate SPE purification, typically, the radiochemical outputs are
purified externally to the NanoTek system, particularly HPLC purification. Recent
examples include the preparation of [18F]FPEB [16], whereby the radiosynthesis
occurred in the NanoTek and the reaction output was sent to a vial preloaded with
water and pre-concentrated onto an Oasis HLB Light SPE cartridge to remove
DMSO present in the reaction mixture. The cartridge was eluted with acetonitrile
and water before being transferred to a GE TRACERlab FXFN synthesis unit to
conduct semi-preparative HPLC purification and formulation. Additionally, the
Tau imaging agent, [18F]T807, was produced with the same modifications
[17]. Three consecutive >100 mCi productions of [18F]T807 were performed for
validation purposes, and [18F]T807 became the first example of human use of a
radiopharmaceutical prepared by continuous-flow microfluidics.
The NanoTek system has been modified recently to include HPLC and SPE
purification [18]. By utilizing the cable harnessing of the system, a custom-made
electrical board was engineered whereby additional switches and analog signals
could be added and be controlled by the NanoTek software to activate externally
powered devices and record external signals (e.g., detectors), if applicable. This
customized system was able to produce 1- or 2-step radiotracers such as [18F]
CB102, [18F]fluoroethylcholine [18], [18F]MEL050 (melanin targeting) [19], [18F]
fallypride, and [18F]PBR111 (TSPO receptor) [20], in a DOD manner. Similarly,
[18F]FMISO has been produced by integrating a HPLC system to the NanoTek
through a six-port valve [21]. By fine-tuning the HPLC conditions for [18F]FMISO,
the authors were able to eliminate the requirement for SPE.
6.4.3 Peptide Labeling
While microfluidic systems have mainly been utilized to radiolabel small mole-
cules, reports of peptide or protein radiolabeling using microfluidics are limited.
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Early work in this area featured the direct [18F]radiolabeling of bombesin deriva-
tives (with 7–8 amino acid residues) that had been modified to incorporate trimethy-
lammonium or triarylsulfonium leaving groups [22]. The peptides could be
radiolabeled reproducibly, suggesting a possible DOD approach; however, due to
the harsh temperature conditions required for radiolabeling, this method would be
unsuitable for protein radiolabeling. An alternative route to radiolabel a peptide is
through the use of a prosthetic group as an indirect radiolabeling method. [18F]SFB
[23] and even, the most abundantly used PET tracer, [18F]FDG [24] have been
utilized as prosthetic groups for the radiolabeling of peptides. Although both
prosthetic groups were synthesized on macroscale equipment, the subsequent
peptide radiolabeling was performed under microfluidic conditions. In each case,
the peptide was radiolabeled in a shorter period of time, in higher radiochemical
yield (RCY), and using a smaller quantity of the peptide compared to conventional
radiolabeling techniques. Only recently has the first microfluidic radiosynthesis of a
prosthetic group and the ensuing peptide radiolabeling been reported [25]. Here, the
[18F]F-Py-TEP prosthetic group was prepared in the first microreactor of an Advion
NanoTek system from [18F]fluoride and the corresponding precursor. After exiting
the microreactor, the [18F]F-Py-TEP was transferred to a second microreactor,
where it reacted with a model peptide containing free amines. Once again, the
peptide coupling was faster than conventional methods and obtained in higher
RCY. These accounts all imply that the DOD of radiolabeled peptides for molecular
imaging is currently being explored and may be employed in the future.
6.4.4 Solid-Phase Approaches
Although the use of microfluidic conditions is leading to radiochemical reactions
being completed in less time than traditional approaches, to further decrease the
overall radiochemical processing times, new methods are required to decrease or
eliminate the time taken to process and activate the starting [18F]fluoride. One
option is to trap the [18F]fluoride onto a resin and subsequently perform on-resin
radiofluorinations, thus eliminating the need for azeotropic evaporations and
re-solubilization of the [18F]fluoride complex. Reusable polymer-supported
phosphazenes have been investigated as suitable resins to perform the [18F]fluoride
trapping and radiofluorination [26]. The PS-P2
tBu resin was able to trap >99% of
[18F]fluoride, with no leaching of activity was observed when the column was
subsequently dried with helium gas. It was found that substrates with sulfonate
leaving groups resulted in the highest RCY when subjected to on-column
radiofluorination. The same phosphazene resin could be recycled at least three
times using the same substrate, or at least two times using a different substrate,
which implies that the DOD production of radiotracers is possible through solid-
phase radiofluorination.
Other work in this area includes a continuous-flow system comprising a
polystyrene-imidazolium-chloride (PS-Im+Cl) monolith which traps [18F]fluoride
[27]. A solution of base and the relevant precursor could then be flowed through the
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PS-Im+[18F]F monolith into a preheated microfluidic chip where the radiochem-
ical reaction takes place. The advantage of this method is that the entire process is
performed in continuous flow and the microfluidic platform has a very small
footprint compared to current processes.
6.4.5 Droplet Systems
An interesting extension in the field of microfluidic radiochemistry is through the
use of droplets. Also sometimes referred to as segmented flow chemistry, it features
droplets (nL- μL) which are separated by an immiscible carrier fluid, similar to oil
droplets in water. Droplets can be thought of as individual nano- or microreactors
and can be used to aid radiolabeling optimization, whereby each droplet is the result
of a predetermined set of reaction parameters. Droplets consisting of approximately
120 nL were formed during the coupling of [18F]FSB with an anti-prostate stem cell
antigen diabody [28]. Using a 5 μL sample of the diabody solution was sufficient to
screen over 100 different reaction conditions using the droplets, and hence, the
optimal reaction conditions were determined rapidly with minimal use of the
precious diabody solution. Droplet systems have also been utilized in
electrowetting-on-dielectric (EWOD) devices. In EWOD systems, droplets are
sandwiched between two plates; the bottom plate consists of electrode pads to
manipulate the movement of the droplets throughout the microchip, while the top
plate electrically grounds the droplets. The EWOD chip was first used in the
synthesis of [18F]FDG [29], but its use has more recently expanded to include
[18F]FLT [30], [18F]fallypride [31], and [18F]SFB [32]. While the EWOD chip
produces these radiolabeled molecules in comparable, if not greater, RCY than
previously, drawbacks of the system include off-chip purification and the potential
for radioactivity and volatile side products to escape since the chip is exposed to air.
It is envisaged that with advances in technology, the EWOD chip could be further
automated, be disposable, and lead to scientists producing their desired radiotracer
on demand.
6.5 Challenges and Future of DOD
As it can be seen, a perfect DOD system is still not existent, but several data are
available demonstrating that such approach should represent the reality in the next
future. However, to witness this paradigmatic change, several challenges need to be
fronted, and they will represent the future of DOD research in radiopharmaceutical
production.
One of the biggest challenges is to understand whether one only system could
achieve the desired spread of operations that a DOD process should implement.
This should cover not only the production steps but also the switching of chemicals,
cleaning, and priming steps. It is very likely that these systems will be based on
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micronized approaches (e.g., microfluidics, nanodroplets), but understanding which
philosophy they should implement is still under discussion. For example, a system
can be projected to implement several different preexisting routes, which would
lead to different products in different quantities, or, on the contrary, be represented
by a fixed framing to which flexibly interface single-use components/modules (i.e.,
similar to microcassettes) to build up the desired process. Another possibility might
also be represented by the possibility to use the exact same system into which
different chemicals are delivered, depending on the production needs. All these
options are amenable to deliver a DOD system, but the choice of one or the other
will drive the final performance and actual ease/flexibility of use.
Even once the underlying philosophy is clarified, some technical problems are
still unsolved or partially addressed. Purification of the finished product represents
probably the most important issue, and while there are several excellent systems to
perform chemical reactions, there is a notable lack in miniaturization of purification
methods or their interfacing with micronized chemistry systems. Some research is
now available on micro-chromatographic systems [33], mainly facilitated by the
advancements of monolith polymers [34] that can be easily integrated with micron-
sized channels/reservoirs [35]. These solutions allow the reduction of inherent void
volumes, therefore improving the atom efficiency in the purification process. Also,
similar solutions may be useful for the cases in which a simple solid-phase
extraction (SPE) would be sufficient to purify the relevant molecule [36, 37]. Poly-
mer chemistry advancement possibly represents the field where useful innovations
can have a relevant impact on miniaturized purifications. As an example, molecu-
larly imprinted polymers (MIP) represent a promising approach that would allow to
streamline the selective separation of the molecule of interest and its efficient
elution [38]. MIP structures are prepared by building the polymer pores around a
desired template molecule; once the template is removed, the material acquires
selectivity of shape and electronic interaction (i.e., with functional groups of
polymer) for the desired molecule [39]. MIP systems are in fact also referred as
“synthetic receptors.”
Another innovation that would be generally useful in radiochemistry but partic-
ularly applicable to DOD systems (due to their preferred micronized nature) is the
use of supported precursors. These systems should be projected in such a way that
the labeling reaction is the only event that would make the molecular structure to
become free from the solid support bond. In this way, no other complex organic
species will be present in the resulting mixture, and only simple filtration and
reformulation steps would be required in order to retrieve the radiopharmaceutical.
Some systems based on supported sulfonates [40] or triazene [41] have been
reported up to date, and patent literature also refers to examples of supported
ionic precursors (e.g., iodonium compounds) [42]. However, none of these systems
have demonstrated a preferential use compared to traditional methods, probably
because of the mismatch between the support active surface and reagent accessi-
bility to it. The use of micronized systems could be beneficial in solving this
mismatch, and indeed the use of sulfonate precursors supported on a monolith
structure grown directly in a microfluidic chip gave satisfying yields of
radiofluorination [43].
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A further modification to this approach, which would facilitate the respect of
DOD requirements, could be the use of reversibly linked precursors. In this concept,
the precursor should form a bond (e.g., covalent coordination) with the support
material, and as usual, the labeling reaction should be able to selectively cleave the
structure from the support; however, in a second “recycling” step, a change in
conditions will allow the recovery of the precursor out of the system and offer a
support free to be reversibly functionalized again with a different precursor. A
recent paper reported the catalysis by TiO2 nanoparticles in radiofluorinating a
tosylate precursor [44]; interestingly enough, the authors suspect that the process is
catalyzed due to selective coordination of the tosylate moiety with the titania
surface, therefore opening to the idea of a reversible functionalization of metal
nanoparticles with several different precursors prior to radiolabeling. Another
possibility, drawn from the field of self-healing materials, might be the use of
reversible click reactions, a nice example of which is represented by the 1,2,4-
triazoline-3,5-dione chemistry (TAD) moieties. This structure reacts in a reversible
way (using different temperatures, Fig. 6.2) with indoles through an ene click
reaction [45]; however, it undergoes fast Diels-Alder reactions with dienes and is
Fig. 6.2 TAD residue in reversible click-chemistry transformations (Taken from [45])
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widely used in biology for its capacity to bind irreversibly tyrosine residues
[46]. Such an approach could be very useful in DOD processes aimed at protein
labeling, for which radiolabeled prosthetic groups enabling click chemistry are now
widely employed [47].
Another important point to clarify is whether DOD systems should produce
product vials (as in the traditional approach), a syringe/cartridge dose, or even
directly deliver the radiopharmaceutical preparation into the vein of the subject (see
Fig. 6.3). Though currently unlikely, the possibility to overcome the concept of
product vial is very appealing on the base of flexibility, atom efficiency, and
procedure streamlining. Therefore, an outstanding challenge is represented by
modifying the regulators’ view [48, 49] on the requirements needed to prepare
injectable radiopharmaceuticals for human use, in order to allow easier and more
personalized modalities of dose delivery. One of the ways to achieve such result is
represented by the change in quality control (QC) paradigms; in fact, the traditional
way to produce a separate vial for QC [50] should be overtaken by the possibility of
realizing a DOD process whose precise control and monitoring would represent
itself a guarantee of good-quality end product.
Fig. 6.3 Idealized concept for a DOD system, used to inject directly in the patient the desired
radiopharmaceutical
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6.6 Conclusions
Miniaturization and optimization of the biochemical hardware involved have cre-
ated a substantial personalization of several medical practices. A typical example of
this trend that has improved the treatment of diabetic subjects is the current
possibility for any person to check their glucose levels using a straightforward
handheld system, instead of reaching the nearest hospital and performing a proper
blood examination. This level of simplicity, flexibility, and personalization is
currently lacking in the important field of radiopharmaceutical production. How-
ever, several studies are starting to demonstrate that new chemical technologies
(e.g., microfluidics, high-tech polymers) can represent useful tools to achieve what
we can define Dose-On-Demand systems. Several challenges are still to be faced
before reaching such a useful target in an efficient and affordable way; we however
think that the realization of this capability will be the main way to allow the use of
rare and disease dedicated tracers whose widespread utilization is currently hin-
dered [51] by the existing radiopharmaceutical production paradigms.
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Chapter 7
Advantages of Radiochemistry in Microliter
Volumes
Pei Yuin Keng, Maxim Sergeev, and R. Michael van Dam
Abstract Positron emission tomography (PET) provides quantitative 3D visuali-
zation of physiological parameters (e.g., metabolic rate, receptor density, gene
expression, blood flow) in real time in the living body. By enabling measurement
of differences in such characteristics between normal and diseased tissues, PET
serves as vital tool for basic research as well as for clinical diagnosis and patient
management. Prior to a PET scan, the patient is injected with a short-lived tracer
labeled with a positron-emitting isotope. Safe preparation of the tracer is an
expensive process, requiring specially trained personnel and high-cost equipment
operated within hot cells. The current centralized manufacturing strategy, in which
large batches are prepared and divided among many patients, enables the most
commonly used tracer (i.e., [18F]FDG) to be obtained at an affordable price.
However, as the diversity of tracers increases, other strategies for cost reduction
will become necessary. This challenge is being addressed by the development of
miniaturized radiochemistry instrumentation based on microfluidics. These com-
pact systems have the potential to significantly reduce equipment cost and shielding
while increasing diversity of tracers produced in a given facility. The most common
approach uses “flow-through” microreactors, which leverage the ability to precisely
control reaction conditions to improve synthesis times and yields. Several groups
have also developed “batch” microreactors which offer significant additional
advantages such as reduced reagent consumption, simpler purifications, and excep-
tionally high specific activity, by reducing operating volumes by orders of magni-
tude. In this chapter, we review these “batch” approaches and the advantages of
using small volumes, with special emphasis on digital microfluidics, in which
reactions have been performed with volumes as low as ~1 μL.
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7.1 Introduction
7.1.1 Radiosynthesis of Positron Emission Tomography
Tracers
Positron emission tomography (PET) is an extremely powerful, noninvasive diag-
nostic imaging technology capable of measuring a plethora of biological processes
in vivo [1]. In research, PET can provide dynamic information about normal or
diseased states of a living organism and, in the clinic, can provide information that
is critical for diagnosis, selection of therapy, or monitoring response to therapy. In
some cases, PET can detect biochemical changes associated with disease before any
anatomical changes can be observed [2].
PET requires injection of a tracer labeled with a positron-emitting isotope, such
as fluorine-18, nitrogen-13, oxygen-15, carbon-11, or a radiometal. Fluorine-18
possesses physical and nuclear properties that are particularly desirable for
radiolabeling and imaging [3]. For example, the low positron energy and range
ensure high-resolution imaging while minimizing radiation exposure to the patient.
In addition, the 110 min half-life is sufficiently long for multistep synthesis,
transport to the imaging site, and imaging over extended periods.
Due to the hazard of working with radioactive materials, a specialized infra-
structure of automated radiosynthesizers operating in radiation-shielded “hot cells”
by expert personnel is required. Due to the high costs, a couple of tracers (including
2-[18F]fluoro-2-deoxy-D-glucose, [18F]FDG) are currently produced in a “satellite”
manner. Radiopharmacies manufacture large batches that are subdivided among
many patients within a local area to leverage economies of scale and offer the
compound at an affordable price. As the diversity of PET tracers used in medical
care and research increases, opportunities to share costs are reduced, and alternative
innovative approaches are needed to reduce the high cost of each batch.
A particularly promising approach is the development of miniaturized
radiosynthesizers based on microfluidic technology that can enable dramatic reduc-
tions in the cost of equipment and the amount of radiation shielding needed. An
additional innovation is the concept of disposable “cassettes,” which allows each
synthesizer to make a wide range of tracers simply by using different cassettes,
rather than being dedicated to production of a single tracer [4].
7.1.2 Microfluidics for Radiosynthesis
It has been well established that the geometry of microfluidic devices offers many
advantages for the synthesis of short-lived radiopharmaceuticals [5–7]. In particu-
lar, the small dimensions enable improved control of reaction conditions via rapid
mixing and efficient heat transfer, leading to faster reactions and improved selec-
tivity, thus higher yields.
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Most commonly in the field of radiochemistry, these devices are based on “flow-
through” microreactors, where reactions occur by flowing reagent streams through
mixers and preheated capillary tubes or microchannels. Numerous groups have
demonstrated the radiosynthesis of [18F]FDG in polymer chips [8], glass chips [9],
and capillary tubes [10]. This technology has been commercialized (e.g., Advion
Biosciences “NanoTek” and Scintomics “μ-ICR”), and dozens of different radio-
tracers labeled with F-18, C-11, N-13, and Tc-99 m have been demonstrated
[11]. Recent advances have enabled the integration of solvent exchange processes
[12, 13], which previously were accomplished via bulky, off-chip subsystems.
Because it is important that flow-through systems are completely filled with
liquid in order to achieve accurate fluid handling, typical operating volumes are
comparable to macroscale systems (i.e., >500 μL). Another class of microfluidic
device based on small (<50 μL) volumes known as “batch” microreactors have also
been used for radiochemistry (Fig. 7.1). These devices are particularly attractive for
radiochemistry because all synthetic steps including solvent exchange can be
integrated into a single chip and because small volumes can reduce reagent con-
sumption, enhance reaction kinetics, improve specific activity, reduce radiolysis,
and simplify purification, as described below.
7.1.3 Platforms for Microliter Volume Synthesis
The first batch microfluidic synthesis of [18F]FDG was demonstrated in a
polydimethylsiloxane (PDMS) chip with 40 nL reaction volume [14]. Microvalves
Fig. 7.1 Batch microfluidics devices for synthesis of PET tracers: (a) PDMS chip with 40 nL reactor
(Adapted from reference [14] with permission from AAAS). (b) Scaled-up PDMS chip with 5 μL
reactor (Adapted from reference [15], Copyright © 2010 by the Society of Nuclear Medicine and
Molecular Imaging, Inc.). (c) Chemically inert polydicyclopentadiene (pDCPD) polymer chip with
5 μL reactor (Reproduced from reference [56]). (d) Chemically inert pDCPD chip with 60 μL reactor
(Reproduced with permission from reference [50], Copyright © 2010 John Wiley & Sons, Ltd.). (e)
PDMSchip for optimizing radiolabeling reaction in variable volume droplets (~100 nL) (Reproduced
with permission from reference [59], Copyright © 2015 IOP Publishing). (f) PDMS chip for
radiometal labeling with 25 μL reaction volume (Reproduced with permission from reference [19],
Copyright © 2013 Elsevier, Inc.) (g) EWOD chip with reaction volume ranging from 2 to 17 μL
7 Advantages of Radiochemistry in Microliter Volumes 95
were used to close the reactor during reaction steps, and the permeability of the
PDMS enabled escape of vapor for solvent exchange processes. By scaling up the
reactor volume to 5 μL, it was possible to produce mCi amounts of [18F]-labeled
tracers [15]. Unfortunately, due to adverse interaction of PDMS with [18F]fluoride
[16], radioactivity losses were high and reliability was low. Using inert plastic
materials as the reaction vessel improved reliability, and a system with 50 μL
reaction volume enabled production of tracers of sufficient quantity and quality
for human imaging [17], establishing the relevance of the micro-batch format.
While the PDMS chip was not suitable for processing [18F]fluoride, the capa-
bility to react small volumes was found to be useful for screening radiolabeling
conditions for the reaction of [18F]SFB with an engineered antibody [18]. Using
<100 nL per droplet, many reaction conditions could be tested, and then the whole
batch could be labeled once optimal conditions were found. A quasi-continuous-
flow PDMS chip using small volumes (25 μL) has also been used for radiolabeling
peptides and proteins with radiometals such as Ga-68 and Cu-64 [19]. The small
volume enabled improved stoichiometry of the label and ligand, dramatically
improving the labeling yield and potentially avoiding the need for extensive
purification.
Recently, our group demonstrated successful radiosynthesis of [18F]FDG and
other molecules using another type of batch microfluidic device based on the digital
manipulation of droplets between two parallel plates [20, 21] known as
electrowetting-on-dielectric (EWOD). Droplets are controlled by on-chip elec-
trodes (Fig. 7.2), eliminating the need for bulky valve actuators, pumps, and
radiation shielding as is needed in the approaches mentioned above. A wide
range of reagents and reaction conditions can be used on these EWOD microchips
because they are constructed from inert and thermally stable materials (glass
substrate, metallic electrode layer, inorganic dielectric layer, and fluoropolymer
layer). Because droplets are surrounded by gas, evaporation and solvent exchange
can readily be performed on the chip. Resistive heating, temperature sensing for
precise temperature control, and impedance sensing for measuring electrical prop-
erties of liquid can all be integrated on the chip without the need of additional bulky
hardware [22].
Using this platform, our laboratory has reported the successful synthesis of [18F]
FDG [20], 3-[18F]fluoro-30-deoxy-fluorothymidine ([18F]FLT) [23], [18F]fallypride
[24], and N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) [25] with radiochemi-
cal yields of 22 8 % (n¼ 11), 63 5 % (n¼ 5), 65 6 % (n¼ 7), and 19 8 %
(n¼ 5), respectively. The final 18F-labeled compounds passed all quality control
tests required by the United States Pharmacopeia for injection into humans and
have been successfully used in preclinical PET. The syntheses of [18F]FDG and
[18F]FLT on a simplified EWOD chip have also been reported by others
[26, 27]. These results suggest that the EWOD-based synthesizer can meet the
requirements for on-demand production of diverse PET tracers to meet preclinical
or clinical needs.
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7.2 Advantages of Radiosynthesis at the Microliter Scale
7.2.1 Miniaturization and Disposability
Perhaps the most significant potential advantage of batch microfluidics in the field
of radiochemistry is the potential to integrate the entire synthesis, purification, and
formulation apparatus into an extremely compact system. Size of the components
that need to be shielded (because they contain or contact radioactivity) has a
tremendous impact on the amount of radiation shielding needed. For a constant
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Fig. 7.2 Structure and operation of EWOD microfluidic chips. (a) Illustration of the
“electrowetting” effect. (b) Schematic of typical EWOD device with droplet sandwiched between
the two plates. (c) Applying a local field to one end of the droplet using a small control electrode
(typically 1 or 2 mm square) can generate a force on the droplet in a direction toward the activated
electrode (Diagram courtesy of Robin Garrell). This force enables several operations, including
(d) droplet transport along a predetermined path, (e) droplet splitting, and (f) droplet dispensing
from an on-chip reservoir. Incorporation of specialized heating electrodes permits additional
operations such as (g) evaporation of solvent. ((d) is reproduced with permission from reference
[60] (Copyright © 2004 American Chemical Society), (e) is reproduced with permission from
reference [61] (Copyright © 2003 IEEE), (f) is reproduced from reference [62] with permission of
The Royal Society of Chemistry.)
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Shielding volume
e
r þ tð Þ3  r3 ¼ 3r2tþ 3rt2 þ t3ð Þ







where r is the dimension of the synthesizer. Assuming a fixed shielding thickness
where t r, the scale factor is proportional to r2. Thus, moving from macroscale
systems with ~20-inch dimensions to microfluidic chips with ~2-inch dimensions
can reduce the needed shielding 100-fold. This reduction could make it practical for
radiochemistry chips to be used in benchtop situations instead of needing to operate
them in specialized facilities equipped with hot cells and mini cells to shield
radiation, thus removing one of the bottlenecks in PET tracer production.
Integrating the fluid pathways of a radiosynthesizer into a microfluidic chip has
other advantages as well. If the chip can be made to be very inexpensive, the entire
fluid pathway can be discarded after each synthesis run, eliminating the need for
developing and validating a cleaning protocol and associated documentation or
cleaning the system on a daily basis. This concept of disposability is increasingly
being used in macroscale synthesizers to simplify setup, cleanup, and compliance
with cGMP manufacturing guidelines for PET tracers that are used in humans
[4]. Disposable cassettes also provide flexibility: with a single synthesizer instru-
ment, the operator can choose to install different disposable cassettes (with different
pre-configured fluid path configurations) along with matching reagent kits to make
different PET tracers [4].
7.2.2 Reduced Radiolysis
Radiolysis is the process of chemical bond cleavage caused by radiation. Molecules
of a PET probe undergo irradiation from both the starting [18F]fluoride (external
radiolysis) and from other radiolabeled molecules (autoradiolysis) [28–30], which
can lead to reduction in the yield of the probe and the formation of radioactive side
products. The mechanism of damage is believed to be related to the formation of
radical species in the solvent by high-energy particles [29]. While the final inject-
able formulation can be stabilized against autoradiolysis with addition of radical
scavengers (e.g., ethanol) to preserve radiochemical purity [30], this is not gener-
ally possible at earlier stages during the radiosynthesis process.
Fluorine-18 emits positrons with high energy (Emax¼ 0.633 MeV) that cause
ionization of the solvent while dissipating their kinetic energy along their travel
range. The range is up to ~2.4 mm, but due to the tortuous path they follow, the
distribution of final displacements of positrons from their origin is characterized by
a smaller range (i.e., full width at one third maximum ~1 mm) [31]. When the
reaction vessel dimensions (e.g., vial, flask, or Eppendorf tube: ~10 mm) are much
greater than this range, each positron deposits all of its energy into the solvent,
leading to extensive radiolysis (Fig. 7.3a).
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Rensch et al. have shown via simulations and experiments that the degree of
radiolysis is geometry dependent [3]. In vessels for which at least one dimension is
significantly smaller than the positron range (e.g., capillary tubing or EWOD
chips), there is significantly reduced radiolysis because positrons can escape the
solvent before depositing very much of their energy (Fig. 7.3b). For example, the
solvent within a 100 μm diameter capillary reactor absorbs only 10 % of the energy
Fig. 7.3 Illustration of radiolysis suppression. (a) Possible positron tracks from decay of a
fluorine-18 atom at the center of a conventional macroscale reaction vessel. Because the positron
range is significantly less than the reactor dimensions, the positron will deposit all of its energy
into the solvent, where it causes radiolysis. This is true of decay events happening throughout the
vial. (b) In contrast, in an EWOD microfluidic chip, one dimension of the solvent volume is very
thin compared to the positron range. Thus, a significant portion of the possible tracks are mostly or
entirely outside the droplet. Thus, most positrons will escape the solvent after having only
deposited a small fraction of their energy in the solvent, reducing radiolysis
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of positrons emitted from within the solvent, and a planar droplet geometry with
100 μm height (similar to the EWOD chip) absorbs only 40 % of the positron
energy [32]. Further reduction could be achieved by reducing the dimensions.
7.2.3 Reagent Minimization
Because batch microfluidic chips such as EWOD handle volumes that are 2–3
orders of magnitude less than conventional systems, the quantity of reagents needed
to perform reactions is proportionately reduced, thereby reducing the per-run
reagent cost. Generally the precursor is the most expensive reagent. In macroscale
synthesis, reagents for common small-molecule PET tracers can cost hundreds of
US$ for a single synthesis run (e.g., 10 mg in ~1 mL). Synthesis in microliter
volumes (e.g., 10–100 μg precursor) could reduce this cost down to dollars per run
(depending on costs of packing this small amount of reagent into vials), making it
economical to produce even small batches on demand for a single user.
Biomolecule-based precursors such as proteins are even more expensive, costing
up to thousands of US$ for a single synthesis. Using microliter volumes, the 100 s
of micrograms quantity typically used for protein labeling could be reduced to
microgram or submicrogram levels. Reducing the reagent consumption enables a
greater number of runs per a given amount of precursor or reduces the cost per run
of precursor.
Minimization of reagents can also simplify purification processes [19]. Typically
in 18F-radiochemistry, the amount of precursor is many of orders of magnitude
higher than the amount of [18F]fluoride to ensure the fluorination reaction occurs as
rapidly as possible. For example, in the synthesis of [18F]FDG, one typically uses
about 40 μmol of mannose triflate [33], compared to the 600 pmol of [18F]fluoride
ion in a 1000 mCi batch, representing an excess of 5 orders of magnitude. Even
accounting for typical final specific activity, the amount of [19F]fluoride + [18F]
fluoride is about 60–600 nmol, meaning there is still an excess of about 2–3 orders
of magnitude of precursor compared to ([18F] + [19F])FDG. This means that at the
end of the synthesis, there are vast amounts of unreacted (or hydrolyzed) precursor
that must be separated from a much smaller amount of the desired product. Because
of the high amounts or precursor, large reaction volume, and the chemical similarity
between precursor (native or hydrolyzed) and product, long semi-preparative
HPLC purification times may be needed, resulting in a large solvent volume in
the purified product. While suitable for patient use, these large volumes can be
problematic for imaging in small animals, where the tracer must be sufficiently
concentrated to inject enough radioactivity for imaging (typically 100–200 μCi)
within the maximum recommended injection volume to avoid physiological per-
turbation (e.g., <100 μL for mice). Using smaller amounts of reagents in
microfluidic formats, several groups have demonstrated that analytical-scale
HPLC is sufficient for purification [24, 34], resulting in more concentrated final
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formulation. Purification has also been successfully performed with on-chip struc-
tures similar to typical macroscale Sep-Pak cartridges [35–37].
Reduced amount of reagents may also simplify the quality control (QC) testing
that is needed prior to injection in humans. In general, the reduced amounts of
reagents and solvents will lead to reduced amounts of residual impurities after the
purification process. An interesting prospect of using extremely tiny volumes is that
if the total amount of reagent added is below the injectable limits set by various
regulatory agencies, then a test for the absence of that particular chemical may
become unnecessary.
7.2.4 High Specific Activity
The specific activity (SA) of a PET tracer (e.g., labeled with fluorine-18) is defined
as the ratio of the number of 18F-labeled molecules to the total number of 18F-
labeled and 19F-labeled molecules and is typically reported in units of radioactivity
per mass (e.g., Ci/μmol). For a certain desired injected dose (e.g., 10 mCi for
humans), the higher the SA, the lower the mass that is injected.
High SA of a PET tracer is important for several reasons. First, because many PET
tracers are based on pharmacologically active compounds, only a very low mass
should be injected to avoid eliciting a pharmacological response. Second, for tracers
that target low-abundance receptors (e.g., in neurological imaging), injecting lower
mass avoids saturation or high occupancy of the receptors. This is especially important
in small animal imaging, in which significantly higher radioactivity is injected (per
mass of the animal) compared to human subjects to achieve sufficient image quality
with the higher resolution (smaller voxel size) scanners that are used for animals
[38]. Third, highSAmay improve image quality by increasing the proportion of targets
occupied by radioactive forms of the tracer while reducing competitive interactions of
the nonradioactive forms. Other reasons to maximize SA are related to the logistics of
PET tracer production. Often, tracers need to be transported from the radiopharmacy
where they are produced to the imaging center. Because of the radioactive decay
during this transport time, the SA is reduced by a factor of 2 for each half-life, and a
high initial SA is needed to ensure sufficient SA at the time of imaging.
For fluorine-18, the maximum theoretical SA is 1710 Ci/μmol; however, the
actual SA of the final tracer is significantly lower, typically 1–10 Ci/μmol [39]. This
means the number of fluorine-18 atoms is dwarfed (~200–2000X) by the number of
fluorine-19 contaminant atoms. Some of the fluorine-19 contamination originates
due to the equipment and materials used in the [18F]fluoride production process
(e.g., [18O]H2O quality, volume of target, target materials, tubing materials, target
loading/unloading process, etc.) [40–42]. While such sources may be out of most
radiochemists’ control, another significant contribution is the contamination of
reaction mixture with extra fluorine-19 fluoride during the synthesis process itself
(i.e., all steps upstream of and including the fluorination step). The main sources are
the QMA cartridges used in the fluoride drying process, fluorinated materials (e.g.,
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Teflon tubing and stirbars) [43], and the reagents used in the synthesis, such as
K2CO3, Kryptofix, etc.
In preliminary studies, our group observed that microfluidic synthesis on EWOD
chips resulted in significantly higher (up to 25–50 times) SA compared to macro-
scale synthesis, starting with the same amount of radioactivity [23, 24]. This
suggested the potential for microfluidics to significantly reduce fluorine-19 con-
tamination in the synthesis process. An in-depth investigation led to the observation
that the dependence of SA on reaction parameters was very different for macroscale
(100–5000 μL) and microscale (2–8 μL) syntheses. At the macroscale, the SA
strongly varied with the reaction volume (amount of reagents) as well as the starting
radioactivity (from 10s to 100 s of mCi), whereas the SA was much higher and
nearly constant (20–23 Ci/μmol), under all conditions when performed in
microdroplets. These results suggest that in the macroscale synthesis, reagents
and solvents are the dominant source of fluorine-19, while in microscale volumes,
these sources have been nearly eliminated and the fluorine-19 contribution from the
cyclotron dominates [44, 45] (Fig. 7.4). The effect of the 120 nm Teflon layer on the
chip was also investigated and no impact on SA was seen [43], perhaps due to the
radiolysis suppression effect described above.
Small volumes are extremely beneficial for another type of reaction, namely,
isotopic exchange (IEX). In IEX reactions, the precursor is identical to the final
product, except for the presence of fluorine-19 instead of fluorine-18, and cannot be
separated after synthesis. Thus it is desirable to minimize the amount of excess
















Fig. 7.4 Illustration of specific activity improvement. (Left) At the macroscale, reagents are the
dominant source of fluorine-19 contamination in the fluorination reaction mixture. (Right) At the
microscale, the reagents add negligible fluorine-19 contamination to that already present from the
cyclotron. After the fluorination reaction, the fluoride (both F-18 and F-19 forms) get incorporated
into the precursor and cannot be separated, resulting in 18F- and 19F-labeled forms of the tracer
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concentration of precursor needs to be sufficiently high for efficient reaction.
However, Perrin et al. have shown that small volume reactions are an effective
way to minimize precursor amount for IEX reactions [46, 47]. It should be noted
that the same principles can be applied to other carrier-added situations or to the
labeling of proteins or other species where the labeled and unlabeled forms cannot
be separated; in all such cases, it is critical to minimize the starting material in order
to obtain high SA. The dependence of SA on starting radioactivity for IEX reactions
was investigated in simplified EWOD chips using rhodamine clicked to an aryl-BF3
moiety [44]. Unlike in nucleophilic substitution reactions, SA of microfluidic IEX
reactions was found to vary with starting radioactivity, but in a nonlinear manner.
This suggests that perhaps the contribution of fluorine-19 from the cyclotron is
comparable to other sources and further reduced volume may be beneficial.
For both nucleophilic substitution and IEX reactions, small volume synthesis
can achieve high SA even from low starting amounts of radioactivity. This is in
contrast to macroscale synthesis, where high SA production typically requires
starting with Ci levels of radioactivity. Depending on the amount of tracer radio-
activity needed, small volume synthesis could therefore reduce the time/cost of
cyclotron bombardment, increase safety, and decrease the required amount of
shielding required for production.
7.3 Practical Considerations
7.3.1 Limits of Volume Reduction
Clearly there are enormous advantages to performing radiochemistry in small
volumes. The current EWOD chip geometry can reliably handle volumes as small
as ~2 μL, which is limited by the size of the electrodes that are used to load and
transport reagent droplets. Scaling down the volume of radiochemical reactions
below 2 μL could enable further reductions in precursor cost, further improvements
in specific activity (for IEX reactions or biomolecule labeling), further simplifica-
tion of purification and QC testing, or reduction in the size of the EWOD chip,
which leads to cost reduction. Even smaller droplets could be manipulated by
scaling down the electrode size and/or reducing the gap between the chip plates.
In fact, using specialized fabrication techniques, Nelson and Kim have shown that
droplets as small as 100 pL can be manipulated in an EWOD chip [48].
As the volume is scaled down, it is important to be mindful of several issues.
First, a certain minimum volume will be needed to solvate the desired amount of the
radioisotope complexed with phase transfer catalyst along with the precursor.
Another limitation will be the droplet lifetime: at extremely small volume scales,
droplets quickly evaporate and may not last sufficiently long to carry out the
fluorination reaction. The limit of volume reduction for radiochemistry applications
remains to be explored.
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7.3.2 Radioisotope Concentration
When considering using small reaction volumes, one must also consider how to
produce sufficient quantity (radioactivity) of the tracer for the particular application
needed. For preclinical imaging, generally a few mCi is sufficient for a study
involving several animals, and with modern scanners, <25–50 μCi is sufficient
for a single mouse. On the other hand, imaging of a single patient requires on the
order of 10 mCi, while producing a large batch in a radiopharmacy for distribution
to imaging centers would require 100s–1000s of mCi. Even higher amounts of the
radioisotope are needed at the beginning of the synthesis due to nonideal yields and
fluid handling, as well as losses due to decay.
Cyclotrons can readily generate multiple Ci levels of [18F]fluoride in [18O]H2O
to satisfy any of these applications. However, the output volume is typically in the
milliliter range, while the capacity of the current EWOD chip (12 mm diameter
reaction zone x 150 μm droplet height) is only ~17 μL, i.e., 1 % of the volume from
the cyclotron. From a high-radioactivity bombardment, it would be possible to load
as much of tens of mCi of radioisotope into the chip without special measures, but it
is not desirable to waste the majority of the radioisotope, and several methods for
efficiently concentrating the radioisotope have been developed (Fig. 7.5a).
One approach is to concentrate the [18F]fluoride prior to loading it into the chip via
a solid-phase extraction (SPE) process. First, the [18F]fluoride/[18O]H2O is flowed
through a strong anion exchange cartridge (e.g., quaternary methyl ammonium,
QMA) to trap the [18F]fluoride. After removing residual water (e.g., with an inert
gas flow), an eluent solution (e.g., aqueous K2CO3/ K2.2.2 or tetrabutylammonium
bicarbonate (TBAB), sometimes with MeCN) is passed through the cartridge to
release the [18F]fluoride. If the cartridge has sufficiently small bed volume, the volume
of eluent solution needed to efficiently collect the [18F]fluoride can be quite low. For
example, using commercial cartridges (OPTI-LYNX, Optimize Technologies),
Elizarov et al. concentrated 92 % of 876 mCi starting [18F]fluoride into a ~5 μL
volume [15], our group demonstrated release into ~12 μL volume [49], and Lebedev
et al. [17] and Bejot et al. [50] demonstrated release into 44 μL volume. This approach
can be integrated with microfluidics by using packed-tubing cartridges [15],
functionalized porous polymer monoliths [51], packed microchannels [52], or resin-
filled inserts [12]. Control of trapping and release processes requires the use of valves
with small internal volumes to choose which solution is flowed into the cartridge inlet
(i.e., [18F]fluoride or eluent) and whether the cartridge outlet is direct to an [18O]H2O
collection reservoir or the microfluidic chip. Most commonly, this is accomplished
with HPLC injection valves, but can also be achievedwith on-chipmicrovalves if they
can be conveniently integrated into the device (Fig. 7.5b, c). Once loaded into the chip,
the concentrated [18F]fluoride solution is generally evaporated to dryness, and then the
subsequent fluorination reaction volume can be controlled by the volume of precursor
solution added, provided there is sufficient solvent to dissolve not only the precursor
but also the fluoride complex with phase transfer catalyst. Similar trap and release of
[18F]fluoride can be accomplished with microfluidic electrochemical flow cells
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Fig. 7.5 (a) Because the volume of batch microfluidic chips is much smaller than the volume of
the radioisotope source, concentration is necessary to ensure sufficient quantity of radioactivity
can be loaded onto the chip. (b) Cartridge-based method for concentration described in Ref.
[49]. Using an HPLC injection valve with small internal volume, the flow path can be configured in
trapping mode, where the [18F]fluoride/[18O]H2O is flowed through a micro-cartridge and the [
18F]
fluoride trapped, or a release mode, where a small volume of eluent solution is passed through the
cartridge to release the [18F]fluoride and deliver it onto the chip. (c) Cartridge-based method using
on-chip microvalves implemented in a polydimethylsiloxane (PDMS) chip. Pressure applied to
“control channels” can open or close nearby “fluid channels” to configure the flow path into
trapping and release modes (Adapted from reference [15] © by the Society of Nuclear Medicine
and Molecular Imaging, Inc.). (d) Scheme for evaporative concentration of [18F]fluoride radio-
isotope. The top images show cross-sectional schematics of the concentration process, and the
bottom images show Cerenkov (radioactivity) images of the top view of the chip at corresponding
times. Orange lines and circles were added to depict the cover plate edge and the reaction site,
respectively. Initially, a 200 μL droplet of [18F]fluoride solution is loaded to the cover plate edge.
By activating a nearby heater, the volume of the droplet is reduced to ~5 μL and then pulled into
the chip by electrode actuation. (Reproduced from Ref. [25] with permission from the Royal
Society of Chemistry.)
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[53, 54] where the [18F]fluoride is trapped at an electrode surface by application of
positive voltage.
A different approach is to perform the [18F]fluoride concentration directly on
chip [25]. A special chip was fabricated where the bottom plate extended beyond
the edge of the cover plate to create a platform. A large droplet of [18F]fluoride
solution (with phase transfer catalyst) was loaded onto this platform adjacent to the
gap between the two EWOD chip plates and then rapidly evaporated down to a
small volume that could be transported between the plates (Fig. 7.5d). Because
some groups have reported that the anion exchange resin can contribute fluorine-19
contamination [55], this approach may reduce the amount of fluorine-19 in the
reaction mixture and thus enable production of PET tracers with higher specific
activity. It also has the advantage of not requiring any valves, but the disadvantage
of requiring larger chip real estate.
With any of these approaches, it is possible to concentrate a significant fraction
of the radioactivity from a cyclotron bombardment into a volume that can be loaded
onto the microfluidic chip, enabling radiochemistry to be performed in microliter
volumes with high radioactivity.
7.3.3 Synthesis Automation
As with radiosynthesis in conventional systems at milliliter volume scales, it is
important that the apparatus is operated in an automated fashion within radiation
shielding to ensure the safety of the operator preparing the PET tracer. Fully
automated synthesizers have been developed based on some of the earlier reports
of batch microfluidic chips, complete with reagent delivery, radioisotope concen-
tration, synthesis, and cartridge-based purification or interfacing with an HPLC
system [15, 17, 50, 56].
For the more recent EWOD microfluidic platform, many aspects of automating
the overall system have been demonstrated. Two approaches have been developed
for loading reagents from off-chip reservoirs (e.g., standard septum-capped glass
reagent vials) into the chip. One simple approach uses an electronically controlled
syringe pump to precisely dispense the desired volume of reagent after compensat-
ing for evaporation losses at the dispensing tip [57]. Another approach was devel-
oped in collaboration with Sofie Biosciences, Inc. to avoid the use of complex,
difficult-to-clean components such as syringe pumps and valves, instead of relying
on simple disposable fluidic elements such as needles and tubing. Inert gas pressure
and gravitational force were used to apply forward and reverse driving forces,
respectively, to deliver repeatable volumes to the chip [58]. A multi-reagent loading
interface was developed based on this principle and was integrated with a simple
cartridge-based method for upstream [18F]fluoride concentration and an automated
method for downstream collection of the crude product from the chip and interfac-
ing with miniature solid-phase extraction cartridges or analytical-scale HPLC for
purification [34]. Some preliminary progress to develop methods for on-chip
purification has also been made including removal of unreacted [18F]fluoride
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using an alumina surface [35] or beads [36], and more complete separation may be
possible by performing on-chip solid-phase extraction. A prototype of a complete
EWOD-based PET tracer production system suitable for benchtop operation is
under development at Sofie Biosciences in collaboration with our group.
7.4 Conclusions and Outlook
The development of batch microfluidic devices may provide an ideal platform to
harness the numerous advantages of performing the synthesis of PET radiotracers in
small volumes, including reduced reagent consumption, improved specific activity,
reduced radiolysis, and synthesizer miniaturization. In particular, the EWOD plat-
form is compatible with diverse reaction conditions and provides a convenient
means to digitally manipulate droplets to perform diverse multistep reactions. By
combining these devices with technologies for concentration of radioisotopes into
an automated platform, it will become possible to produce not only batches on
demand for research use but even large-scale batches in a radiopharmacy for
distribution purposes. This microvolume radiochemistry technique could also be
a particularly good match for isotopic exchange and biomolecule labeling reactions
and could enable novel chemistries by boosting [18F]fluoride concentration by
orders of magnitude. As a tool for remotely and safely handling small volumes,
the EWOD microfluidic platform could open up opportunities for researchers to
uncover additional benefits of radiochemistry in extremely small volumes.
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43. Füchtner F, Preusche S, Mäding P, Zessin J, Steinbach J. Factors affecting the specific activity
of [18F]fluoride from a [18O]water target. Nuklearmedizin. 2008;47:116–9.
44. Berridge MS, Apana SM, Hersh JM. Teflon radiolysis as the major source of carrier in fluorine-
18. J Label Compd Radiopharm. 2009;52:543–8.
45. Lazari M, Sergeev M, Liu Z, Perrin DM, van Dam RM. Study of specific activity in isotopic
exchange radiofluorination performed on a microfluidic device. Seoul: World Molecular
Imaging Congress; 2014.
46. Sergeev M, Lazari M, Collins J, Morgia F, Javed MR, Keng PY, van Dam RM. Investigation of
effect of reaction volume on specific activity in macro- and microscale fluorine-18
radiosynthesis. In: Proceedings of the 6th international symposium on microchemistry and
microsystems (ISMM), Singapore; 2014. p. 77–8.
47. Ting R, Lo J, Adam MJ, Ruth TJ, Perrin DM. Capturing aqueous [18F]-fluoride with an
arylboronic ester for PET: synthesis and aqueous stability of a fluorescent [18F]-labeled
aryltrifluoroborate. J Fluor Chem. 2008;129:349–58.
48. Liu Z, Li Y, Lozada J, Pan J, Lin K-S, Schaffer P, Perrin DM. Rapid, one-step, high yielding
18F-labeling of an aryltrifluoroborate bioconjugate by isotope exchange at very high specific
activity. J Label Compd Radiopharm. 2012;55:491–6.
49. Nelson WC, Kim JY. Monolithic fabrication of EWOD chips for picoliter droplets. J
Microelectromech Syst. 2011;20:1419–27.
50. Lazari M, Narayanam MK, Murphy JM, Van Dam MR. Automated concentration of
18F-fluoride into microliter volumes. In: 21st international symposium on radiopharmaceuti-
cal sciences, Columbia, MO; 2015.
51. Bejot R, Elizarov AM, Ball E, Zhang J, Miraghaie R, Kolb HC, Gouverneur V. Batch-mode
microfluidic radiosynthesis of N-succinimidyl-4-[18F]fluorobenzoate for protein labelling. J
Label Compd Radiopharm. 2011;54:117–22.
52. Ismail R, Irribarren J, Javed MR, Machness A, van Dam M, Keng PY. Cationic imidazolium
polymer monoliths for efficient solvent exchange, activation and fluorination on a continuous
flow system. RSC Adv. 2014;4:25348–56.
53. De Leonardis F, Pascali G, Salvadori PA, Watts P, Pamme N. On-chip pre-concentration and
complexation of [18F]fluoride ions via regenerable anion exchange particles for radiochemical
synthesis of positron emission tomography tracers. J Chromatogr A. 2011;1218:4714–9.
54. Sadeghi S, Liang V, Cheung S, Woo S, Wu C, Ly J, Deng Y, Eddings M, van Dam
RM. Reusable electrochemical cell for rapid separation of [18F]fluoride from [18O]water
for flow-through synthesis of 18F-labeled tracers. Appl Radiat Isot. 2013;75:85–94.
55. Saiki H, Iwata R, Nakanishi H, Wong R, Ishikawa Y, Furumoto S, Yamahara R, Sakamoto K,
Ozeki E. Electrochemical concentration of no-carrier-added [18F]fluoride from [18O]water in
a disposable microfluidic cell for radiosynthesis of 18F-labeled radiopharmaceuticals. Appl
Radiat Isot. 2010;68:1703–8.
56. Lu S, Giamis AM, Pike VW. Synthesis of [18F]fallypride in a micro-reactor: rapid optimiza-
tion and multiple-production in small doses for micro-PET studies. Curr Radiopharm.
2009;2:1–13.
57. Van Dam RM, Elizarov AM, Ball CE, et al. Automated microfluidic-chip-based stand-alone
instrument for the synthesis of radiopharmaceuticals on human-dose scales. In: Technical
proceedings of the 2007 NSTI nanotechnology conference and trade show, Santa Clara, CA.
Boca Raton: CRC Press; 2007. p. 300–3.
58. Ding H, Sadeghi S, Shah GJ, Chen S, Keng PY, Kim CJ, van Dam M. Accurate dispensing of
volatile reagents on demand for chemical reactions in EWOD chips. Lab Chip.
2012;12:3331–40.
59. Shah GJ, Ding H, Sadeghi S, Chen S, Kim C-J, van Dam RM. Milliliter-to-microliter platform
for on-demand loading of aqueous and non-aqueous droplets to digital microfluidics. In:
Proceedings of the 16th international solid-state sensors, actuators and microsystems confer-
ence (TRANSDUCERS), Beijing. Piscataway: IEEE; 2011. p. 1260–3.
110 P.Y. Keng et al.
60. Chen Y-C, Liu K, Shen CK-F, van Dam RM. On-demand generation and mixing of liquid-in-
gas slugs with digitally programmable composition and size. J Micromech Microeng.
2015;25:084006.
61. Wheeler AR, Moon H, Kim C-J, Loo JA, Garrell RL. Electrowetting-based microfluidics for
analysis of peptides and proteins by matrix-assisted laser desorption/ionization mass spec-
trometry. Anal Chem. 2004;76:4833–8.
62. Cho SK, Moon H, Kim C-J. Creating, transporting, cutting, and merging liquid droplets by
electrowetting-based actuation for digital microfluidic circuits. J MEMS. 2003;12:70–80.
63. Barbulovic-Nad I, Yang H, Park P, Wheeler A. Digital microfluidics for cell-based assays. Lab
Chip. 2008;8:519.
7 Advantages of Radiochemistry in Microliter Volumes 111
Chapter 8
Development of a Microreactor for Synthesis
of 18F-Labeled Positron Emission
Tomography Probe
Norihito Kuno, Naomi Manri, Norifumi Abo, Yukako Asano,
Ken-ichi Nishijima, Nagara Tamaki, and Yuji Kuge
Abstract Background: The application of microreactors to positron emission
tomography (PET) probe radiosynthesis has attracted a great deal of interest because
of its potential to increase specific activity and yields of probes and to reduce
reaction time, expensive regent consumption, and the footprint of the device/instru-
ment. To develop a microreactor platform that enables the synthesis of various 18F-
labeled PET probes, a prototype microreactor with a novel “split-flow and interflow
mixing” (split mixing) was fabricated and applied to 18F-labeling reactions.
Methods: The split mixing microreactor, made of Al2O3 resistant to several
solvents, had higher mixing performance than that of the conventional batch
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method. Two 18F-labeling reactions (18F labeling of bovine serum albumin (BSA)
by N-succinimidyl-4-[18F] fluorobenzoate (SFB) and 1-(20-nitro-10-imidazolyl)-2-
O-tetrahydropyranyl-3-O-toluenesulfonylpropanediol (NITTP) by 18F) were
conducted using the microreactor.
Results: The 18F-labeling yield of BSA obtained by using the microreactor was
almost the same as that by using the conventional batch method; however, the
reaction time of the microreactor was slightly shorter than that of the batch method.
Conversely, the 18F-labeling yield of NITTP obtained by using the microreactor
was about half that by using the batch method. The low NITTP-labeling yield was
due to adsorption of naked 18F to the surface of micro-mixing channel in the
microreactor. The prescreening of candidate materials with lower 18F adsorption
for the microreactor was carried out with solvent resistance and solvent absorption
as indexes. As a result of this prescreening, cyclo olefin polymer (COP) was selected
as a candidate. A prototype COP microreactor has been fabricated and is being
evaluated in terms of 18F labeling.
Conclusions: Although the higher mixing performance of the split mixing
microreactor did not significantly contribute to increasing 18F-labeling yield, it
did contribute to shortening reaction time. Moreover, the material used for the
microreactor should be carefully selected from the viewpoint of developing a
microreactor platform that enables the synthesis of various 18F-labeled PET probes.
Keywords Positron emission tomography (PET) • Microreactor • 18F-labeled PET
probe • Cyclo olefin polymer (COP)
8.1 Introduction
Positron emission tomography (PET) is a noninvasive, nuclear imaging technique
that has been widely applied for medical research and clinical diagnosis in the fields
of oncology, neurology, and cardiology [1–4]. PET imaging relies on the utilization
of a PET probe labeled with short-lived positron-emitting radioisotopes such as 11C
(t1/2¼ 20 min) or 18F (t1/2¼ 110 min). Among several PET probes, 2-18F-fluoro-
2-deoxy-d-glucose (18F-FDG), an analog of glucose, is most commonly used in the
diagnosis and assessment of cancer. Moreover, utilized in clinical oncology, it
shows excellent performance as a PET imaging probe [5].
18F-FDG has been extensively utilized as the PET imaging probe in oncologic
application. However, in the last few decades, a large number of non-FDG PET
probes have been developed to measure and elucidate various biological and
physiological processes [6, 7].
With the Increasing variation of PET probes that are applicable to clinical
diagnosis, for diagnosis of individual patients, it is necessary to produce a wide
variety of PET probes in small quantities. It is therefore also necessary to modify
the supply system for PET probe (such as a centralized mass production) and the
commercial delivery system that were established for a single PET probe, i.e., 18F-
FDG [8].
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Meanwhile, decentralized, in-house production of PET probes also has some
difficulties in regard to the production of a wide variety of PET probes in small
quantities, because of the need for a large investment in infrastructure in accordance
with government regulations, an expensive “hot cell” for radiation shielding of PET
probe synthesizer, and high personnel and operating costs. Moreover, the number of
synthesizer that can be installed in a hot cell is restricted because of the limited
workspace in the hot cell; accordingly, it is difficult to accomplish in-house small-
scale production of multiple PET probes.
Recently, to solve the abovementioned problems concerning small-scale pro-
duction of various PET probes, the application of microreactors (or microfluidic
devices) to the PET probe radiosynthesis has attracted a great deal of interest
because of their potential to increase specific activity and yields of the probes and
to reduce reaction time, consumption of expensive reagents, and footprint of the
device/instrument [9, 10].
Microreactor can be categorized as flow-through type or batch type. And both a
flow-through microreactor and a batch microreactor have been applied to
radiosynthesis of PET probes for 18F labeling [11]. Almost all previous studies on
applying microreactors for radiosynthesis of PET probes have been limited to
preclinical PET imaging; however, a few recent studies attempted to apply
microreactors for synthesizing the clinical PET probes such as 18F-fallypride, the
dopamine D2/D3 receptors imaging probe [12]; 7-(6-fluoropyridin-3-yl)-5H-pyrido
[4,3-b]indole (18F-T807), tau imaging probe [13]; and 18F-labeled 3-fluoro-5-
[(pyridin-3-yl)ethynyl]benzonitrile (18F-FPEB), the glutamate receptor subtype
type 5 (mGluR5) imaging probe [14].
Moreover, a microreactor for radiosynthesis of a clinical PET probe has not been
applied as the routine production method for clinical usage. It is still a great
challenge to solve several problems hindering the practical use of microreactors
for synthesizing PET imaging probes for clinical applications.
In a previous study, microreactor systems with novel mixing methods were
established and applied to achieve large-scale and industrial production of
chemicals [15, 16]. In this study, a prototype microreactor with a novel split-flow
and interflow mixing (called “split mixing”) was fabricated and evaluated in regard
to 18F-labeling reactions.
8.2 Materials and Methods
8.2.1 Villermaux-Dushman Method
The mixing performance of the prototype microreactor was evaluated by
Villermaux-Dushman method [17]. Solution X (HCl: 0.1374 M) and solution Y
(KI, 0.01595 M; CH3COONa, 1.33 M; KIO3, 0.003175 M) were separately sup-
plied to the microreactor by Micro Process Server (MPS-α200, Hitachi, Tokyo,
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Japan). The solution mixed in the microreactor was collected and left for two
minutes. The flow rate of the two solutions was set at 0.2, 0.5, 1.0, 2.0, 4.0, and
6.0 mL/min. Absorbance at 350 nm was measured by a UV-visible spectrometer
(U-3010, Hitachi-High Technologies, Tokyo, Japan).
8.2.2 18F Labeling of BSA by 18F-SFB
Succinimidyl-4-[18F]fluorobenzoate (18F-SFB) was synthesized by a method sim-
ilar to that reported by Tang et al. [18]. The synthesized 18F-SFB was evaporated at
100 C under an argon stream and dissolved in 20 % acetonitrile (MeCN)
(0.3 MBq/μL). Bovine serum albumin (BSA) dissolved in 125 mM borate buffer
(pH8.8) (5 mg/mL) was used as a target protein. By the microreactor method,
18F-SFB and BSA solutions were separately injected into the microreactor by using
the MPS-α200. The mixed solution was introduced into a PTFE tube
(φ0.17 250 mm, GL science, Tokyo, Japan) connected to an outlet of the
microreactor. The reaction mixture was collected at times of 2, 10, and 20 min by
driving the MPS-α200, and TFA was added to the reaction mixture to terminate the
reaction. By the conventional batch method, the 18F-SFB and BSA solutions were
mixed in equal amount at room temperature in a 1.5 mL microtube. Trifluoroacetic
acid (TFA) was added to the mixture to terminate the reaction at times of 2, 10, and
20 min.
LC analysis was performed using a Nexera X2 UHPLC/HPLC system
(Shimadzu, Kyoto, Japan). The reaction mixture (20 μL) was loaded onto a C8
reversed-phase column (CAPCELL PAK C8 SG300, Shiseido, Tokyo, Japan). The
LC solvents were (A) 2 % MeCN/0.05 % TFA and (B) 80 % MeCN/0.05 % TFA,
and a gradient (40 % B: 0–1.5 min, 100 % B: 1.5–2.5 min, 40 % B: 2.5–9.0 min)
was used at a flow rate of 0.3 mL/min. The percentage of 18F-benzoic acid
(18F-FBzA),18F-SFB, and 18F-BSA was calculated from the LC data.
8.2.3 18F Labeling of NITTP by 18F
An aqueous solution of 18F, produced by cyclotron using the 18O (p, n) 18F
reaction, was passed through a Sep-Pak Light QMA cartridge (Waters Corporation,
MA, USA). The 18F activity was eluted with a 0.9 mL (0.7 mL MeCN/0.2 mL
water) solution containing 14 mg Kryptofix222 (K222) and 1.4 mg K2CO3. The
eluent was then evaporated at 100 C under an argon stream. The residue,
containing [K/K222]+18F, was dissolved in dimethyl sulfoxide (DMSO)
(0.22 MBq/μL).
1-(20-Nitro-10-imidazolyl)-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-
propanediol (NITTP, ABX GmbH, Radeberg, Germany) was dissolved in DMSO
(1.3 mg/mL). By the microreactor method, [K/K222]+18F and NITTP solutions
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were separately sent to the microreactor by using a dual syringe pump (TSP-202,
YMC, Kyoto, Japan). The solution mixed in the microreactor was then sent to a
PTFE tube (φ0.5 510 mm, GL science) connected to an outlet of the
microreactor, and the reaction in the PTFE tube was allowed to proceed for 3 or
10 min at 80 C. By the batch method, [K/K222]+18F and NITTP solutions were
mixed in equal amount in a 1.5 mL microtube. The reaction was allowed to proceed
for 3 or 10 min at 80 C. LC analysis was performed using a Nexera X2 (Shimadzu).
The reaction mixture (10 μL) was loaded onto a C18 reversed-phase column
(XBridge C18, 5 μm, 4.6 mm 150 mm, Waters Corporation). The LC solvents
were (A) 50 mM (NH4)2HPO4 and (B) MeCN, and isocratic elution (45 % B) was
used at a flow rate of 1 mL/min. Percentage of 18F-NITTP was calculated from the
LC data.
8.2.4 Solvent Resistance Test
The chemical resistance of seven materials (polyvinyl chloride [PVC], polystyrene
[PS], acrylonitrile-butadiene-styrene resin [ABS], methacrylate resin [PMMA],
polycarbonate [PC], polypropylene [PP], and cyclo olefin polymer [COP]) against
five chemicals (acetonitrile [MeCN], dimethyl sulfoxide [DMSO], hydrochlonic
[HCl], sodium hydroxide [NaOH], and ethanol [EtOH]) was tested. A test piece
(size: 10 10 t2 mm) was dropped into each of the chemicals set at 25, 50, 80, or
120 C, and the reaction was allowed to proceed for 30 min. The condition of the
test piece was observed, and the weight of the test piece was measured (W1) after
the reaction was completed. After the test piece was washed with water, it was
dehydrated for 24 h at 50 C. The weight of the test piece was measured again (W2).
The volume of the chemical absorbed in the test piece was calculated from the
difference between W1 and W2.
8.3 Results and Discussion
8.3.1 Microreactor with Novel Mixing System
Two microreactors with different types of mixing, i.e., split-flow and interflow
(“split mixing”) and multilayer channels contracting toward the downstream
(“multimixing”), were fabricated (Fig. 8.1a, b). The split mixing microreactor
was made of Al2O3, and the multimixing one was made of PEEK. Both materials,
Al2O3 and PEEK, were selected from the viewpoint of resistance to several solvents
and fabricability of micro channel structure for mixing.
On the split mixing microreactor, the first liquid (solution A) and the second
liquid (solution B) were injected into the micro channels of the microreactor. The
8 Development of a Microreactor for Synthesis of. . . 117
parallel flow of two fluids (solutions A and B) was split, rotated 90 (inversion), and
interflowed repeatedly (12 times) as the fluids pass through the repeated split
mixing structures of the microreactor. Finally, the flow of two fluids formed an
alternately multilayered thin flow of fluids (Fig. 8.1a). As the thickness of each fluid
became small, the diffusion time of the reactants of fluids (solutions A and B) was
reduced, causing faster mixing of the solutions.
On the multimixing microreactor, the first liquid (solution A) flows from each
nozzle in layer form on top of the chip. In the center of the chip, the second liquid
Fig. 8.1 Schematics of microreactors used in this study. (a) The split-flow and interflow
microreactor. The flow of fluids in the micro channel for mixing is shown in the cross section of
the micro channel. (b) The multilayer channels contracting toward the downstream microreactor
118 N. Kuno et al.
(solution B) supplied from multi-outlet holes flows into the layered first liquid.
Then, both fluids form a multilayered flow at a contraction flow part on the bottom
of the chip to produce the thin flow of fluids (Fig. 8.1b).
8.3.2 Evaluation of Mixing Performance of Prototype
Microreactors
Mixing performance of the prototype microreactors was evaluated by using the
Villermaux-Dushman method [17], shown in Fig. 8.2a. By this method, the side
reaction product, I3
, was spectroscopically measured by using the mean of UV
absorbance at 350 nm. Therefore, lower UV absorbance indicates higher mixing
performance. The mixing performance of the split mixing microreactor was higher
than that of the multimixing microreactor and that of a conventional batch method
(Fig. 8.2b). From this result, the split mixing microreactor was selected for further
analysis of 18F-labeling reaction.
Fig. 8.2 (a) Schematic of the Villermaux-Dushman method. (b) Mixing performance of the split-
flow and interflow (“split mixing”) microreactor (◇) and the multilayer channels contracting
toward the downstream (“multimixing”) microreactor (△)
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8.3.3 18F Labeling of Bovine Serum Albumin (BSA) by
N-succinimidyl-4-18F Fluorobenzoate (18F-SFB)
The 18F-labeling reaction of BSA by 18F-SFB was examined to evaluate the 18F-
labeling performance of the split mixing microreactor. This reaction consists of a
main reaction (18F labeling of BSA) and a side reaction which produce 18F-
fluorobenzoic acid (18F-FBzA) as a by-product (Fig. 8.3a).
As shown in Fig. 8.3b, the 18F-labeling yield of BSA obtained by using the split
mixing microreactor was almost the same as that by using the conventional batch
method (Fig. 8.3b). A by-product, 18F-FBzA, was synthesized in the same manner
as that of batch method. These results suggest that as well as the main reaction, the
side reaction is likely to proceed due to the higher mixing performance of the split
mixing-type microreactor; therefore, the higher mixing performance might not be
effective for increasing the 18F-labeling yield of BSA.
Fig. 8.3 (a) Synthesis of 18F-labeled BSA by N-succinimidyl-4-18F fluorobenzoate (18F-SFB). (b)
Time courses of 18F-BSA (○, ●), 18F-FBzA (△, ~), and 18F-SFB (◇, ◆) synthesis of the split
mixing microreactor (solid line) and the conventional batch method (broken line)
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The reaction time of 18F labeling of BSA was estimated from a reaction rate
constant calculated from the HPLC data. The estimated reaction time (10 min) for
the 18F labeling of BSA by the microreactor method was shorter than that by the
batch method (12 min). This result suggests that high mixing performance contrib-
utes to shortening the reaction time.
8.3.4 18F Labeling of 1-(20-nitro-10-imidazolyl)-2-O-
tetrahydropyranyl-3-O-toluenesulfonylpropanediol
(NITTP) by 18F
To further evaluate the 18F-labeling performance of the split mixing microreactor,
the 18F-labeling reaction of NITTP was investigated (Fig. 8.4a). NITTP is a
precursor for the synthesis of 18F-fluoromisonidazole (18F-FMISO), which is a
PET imaging probe for determining the tumor hypoxia in vivo [19].
The 18F-labeling yield of NITTP (at reaction time of 10 min) obtained by using
the microreactor was 26 %, which is about half of that by using the batch method
(59 %) (Fig. 8.4b). By measuring the total 18F activity of all solutions applied for
the microreactor reaction, only 65 % of the initial 18F activity was recovered, and
about 20 % of that was remained in the micro channels of microreactor. This result
suggests that the low NITTP-labeling yield is due to adsorption of naked 18F to the
Fig. 8.4 (a) Synthesis of 18F-NITTP and 18F-FMISO. (b) Time courses of 18F-NITTP synthesis of
the split mixing microreactor (○, solid line) and the conventional batch method (△, broken line)
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surface of micro channels. To improve the 18F-labeling yield of NITTP attained by
naked 18F, the material used for the microreactor should be reexamined.
8.3.5 Screening of Material for the Split Mixing
Microreactor
As a first step of selecting the material for the microreactor, prescreening of
candidate materials was carried out with solvent resistance and solvent absorption
as indexes. The solvent resistance and absorption of seven kinds of materials,
namely, polyvinyl chloride (PVC), polystyrene (PS), acrylonitrile-butadiene-sty-
rene resin (ABS), methacrylate resin (PMMA), polycarbonate (PC), polypropylene
(PP), and cyclo olefin polymer (COP), were tested for acetonitrile (MeCN),
dimethyl sulfoxide (DMSO), hydrochloric acid (HCl), sodium hydroxide
(NaOH), and ethanol (EtOH) at 25, 50, and 80 C. Among these materials, PP
and COP exhibited relatively better solvent resistant and lower solvent absorption
than other materials. PP and COP exhibited excellent solvent resistant and lower
absorption for HCl, NaOH, and EtOH; however, at the higher temperature, PP
showed a decrease of solvent resistant and COP showed little absorption of solvent
(Table 8.1).
As a candidate material for the microreactor, COP was selected for the
microreactor because of the higher solvent resistance at high temperature (80 C)
of COP. As a preliminary experiment, a prototype COP microreactor was fabri-
cated, and the remaining 18F activity after passing a 18F containing solution through
the micro channels of the COP microreactor was determined. The remaining 18F
activity was about 5 % of total 18F activity injected into the microreactor, which is
lower than that (35 %) in the case of Al2O3 microreactor. This result indicates that
the COP microreactor is applicable to efficient 18F labeling for PET imaging probe.
Table 8.1 Solvent resistance and absorption test
MeCN DMSO
Temp (C) 25 50 80 25 50 80
PP Resistance + +  + + +
Absorption(μl) <5 <5 5 ~ 10 <5 <5 <5
COP Resistance + + + + + +
Absorption(μl) <5 <5 <5 <5 5 ~ 10 5 ~ 10
+, resistance; , nonresistance
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8.4 Conclusion
Although the higher mixing performance of the microreactor did not significantly
contribute to increasing the 18F-labeling yield, it did contribute to shortening the
reaction time. Moreover, selecting the appropriate material for the microreactor is
crucial from the viewpoint of developing a microreactor platform that enables the
synthesis of various 18F-labeled PET probes.
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Chapter 9
Preclinical Evaluation of a Thymidine
Phosphorylase Imaging Probe, [123I]IIMU,
for Translational Research
Ken-ichi Nishijima, Songji Zhao, Fei Feng, Yoichi Shimizu,
Hiromichi Akizawa, Kazue Ohkura, Nagara Tamaki, and Yuji Kuge
Abstract The expression of thymidine phosphorylase (TP) is closely associated
with angiogenesis, tumor invasiveness, and activation of antitumor agents. We
developed a radiolabeled uracil derivative, I-123-labeled 5-iodo-6-[(2-iminoimida-
zolidinyl)methyl]uracil ([123I]IIMU), as a novel SPECT probe for TP. A clinical
study to verify the safety of [123I]IIMU injection was approved by the Institutional
Review Board of Hokkaido University Hospital for Clinical Research, and first-in-
human (FIH) clinical studies of healthy adults were started.
Here, we will introduce our research, including the synthesis of [123I]IIMU and
its efficacy and safety evaluation, toward its FIH clinical study.
Radiosynthesis of [123I]IIMU: [123I]IIMU synthesis was achieved by
radioiodination of the precursor, 6-(2-iminoimidazolidinyl)methyluracil at the
K. Nishijima
Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan
Graduate School of Medicine, Hokkaido University, Sapporo, Japan
S. Zhao • F. Feng
Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Y. Shimizu
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
H. Akizawa
Showa Pharmaceutical University, Machida, Japan
K. Ohkura
Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Sapporo, Japan
N. Tamaki
Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University,
Sapporo, Japan
Y. Kuge (*)
Central Institute of Isotope Science, Hokkaido University Department of Integrated Molecular
Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
e-mail: kuge@ric.hokudai.ac.jp
© The Author(s) 2016
Y. Kuge et al. (eds.), Perspectives on Nuclear Medicine for Molecular Diagnosis
and Integrated Therapy, DOI 10.1007/978-4-431-55894-1_9
125
C-5 position with N-chlorosuccinimide/[123I]NaI. After purification by HPLC,
[123I]IIMU was obtained in high radiochemical yields.
In vitro and in vivo studies: The in vitro and in vivo uptake of [125I]IIMU by the
A431 tumor was attributable to the binding of the radiotracer to its target
enzyme, i.e., TP. SPECT/CT imaging with [123I]IIMU clearly visualized the
A431 tumor 3 h after the injection of n.c.a. [123I]IIMU.
Safety assessment: The human radiation absorbed dose was estimated as 17 μSv/
MBq on the basis of the biodistribution data of [I]IIMU in normal mice. The no
observed adverse effect level (NOAEL) for intravenous administration of
non-radiolabeled IIMU to mice was higher than 1.8 mg/kg. The bacterial reverse
mutation assay showed negative results.
Keywords Thymidine • Phosphorylase • SPECT
9.1 Introduction
Thymidine phosphorylase (TP) catalyzes the reversible phosphorolysis of thymi-
dine to thymine and 2-deoxyribose-1-phosphate. The expression of TP is highly
associated with angiogenesis, infiltration, and metastasis of tumors. The activity
and expression level of TP in many tumors are higher than those in the adjacent
nonneoplastic tissues [1].
We developed a radiolabeled uracil derivative, I-123-labeled 5-iodo-6-
[(2-iminoimidazolidinyl)methyl]uracil ([123I]IIMU, Fig. 9.1), as a novel SPECT
probe for TP.A clinical study to verify the safety of [123I]IIMU injectionwas approved
by the Institutional Review Board of Hokkaido University Hospital for Clinical
Research, and first-in-human (FIH) clinical studies on healthy adults were started.
Here, we will introduce our research, including the synthesis of [123I]IIMU [2, 3]
and its efficacy [4–6] and safety evaluation, toward its FIH clinical study.
9.2 Radiosynthesis of [123I]IIMU [2]
[123I]IIMU was synthesized according to a method previously reported [3]. Briefly,
dry acetone containing N-chlorosuccinimide/AcOH was added to [123I]NaI
(370 MBq) in a reaction vial, and the mixture was allowed to stand for 10 min at
room temperature. Acetone was then removed completely under a stream of N2. A
Fig. 9.1 Structure of [123I]
IIMU hydrochloride
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solution of 6-[(2-iminoimidazolidinyl)methyl]uracil (HIMU-TFA) in aqueous ace-
tonitrile (CH3CN/H2O¼ 2:1) was added to the residue, and the capped vial was
heated for 35 min at 50 C. After removal of the solvent, the crude product was
converted to [123I]IIMU-HCl and purified simultaneously by reversed-phase HPLC
using a solvent system containing HCl. The radioactive fraction was sterilized
through a 0.22 μm membrane filter. The radiochemical purity of [123I]IIMU was
determined with HPLC. Residual organic solvents were determined with
GC. Sterility tests and bacterial endotoxin tests were also performed.
[123I]IIMU for intravenous injection was prepared in 2.5 h with a yield of
205 24 MBq (n¼ 3). The radiochemical purity of [123I]IIMU was found to be
more than 99 % (Table 9.1). The results of the quality control tests are summarized
in Table 9.2. Acetone was not detected in the solution. The ethanol concentration
was 104 111 ppm. Sterility tests and bacterial endotoxin tests showed negative
results (Table 9.2). We successfully prepared [123I]IIMU for intravenous injection
with high purity. Results of quality control tests demonstrate that the [123I]IIMU
preparation is suitable for clinical studies.
9.3 In Vitro Study: Uptake of [125I]IIMU in Cultured A431
and AZ521 Cells [4]
Immunoblotting for the detection of TP demonstrated high enzyme expression in
A431 human epithelial carcinoma cells and very low expression in AZ521 human
gastric cancer cells. A431 or AZ521 cells in 24-well plates were incubated at 37 C
in 1 mL of PBS() containing 37 kBq of [125I]IIMU for 10, 30, 60, or 120 min. The
Table 9.1 Production data for three consecutive syntheses of [123I]IIMU
Parameter
Run number
1 2 3 Mean SD
Yield at the end of preparation (MBq) 232 189 193 205 24
Radiochemical yield (%) 62 51 52 55 6
Radiochemical purity (%) >99 >99 >99 >99
Table 9.2 Results of quality control tests for three consecutive syntheses of [123I]IIMU
Parameter
Run number
1 2 3 Mean SD
pH 7 7 7 7 0
Residual organic solvent (ppm) EtOH 46.8 232.6 33.4 104 111
MeCN 2.2 ND 2.3 1.5 1.3
Acetone ND ND ND –
Tests for bacterial endotoxins Negative Negative Negative –
Sterility test Negative Negative Negative –
ND: Not detected (<1.0)
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incubation solution was removed, and cells were washed and solubilized in 0.7 mL
of 0.2 M NaOH. The radioactivity and protein content of the cell lysate were
evaluated. When the radiotracer was incubated with A431 cells, the uptake level
of the radiotracer increased with an increase in the incubation time, with 5.3 %
dose/mg protein at 2 h of incubation. In the case of AZ521 cells, uptake of
radioactivity was extremely low, 0.68 % dose/mg protein at most, regardless of
incubation time. To confirm whether the observed uptake is due to the binding of
the tracer to TP, similar experiments with A431 tumors were conducted in the
presence of various concentrations of nonlabeled IIMU. The uptake level of [125I]
IIMU in A431 cells was reduced depending on the concentration of
nonlabeled IIMU.
9.4 In Vivo Study: Biodistribution of [125I]IIMU in A431
and AZ521 Tumor-Bearing Nude Mice [4]
The entire experimental protocol was approved by the Laboratory Animal Care and
Use Committee of Hokkaido University. A saline solution of [125I]IIMU (37 kBq,
0.1 mL) was injected into the tail vein of A431 or AZ521 tumor-bearing female
Balb/cAJc1-nu/nu mice (8 weeks old; about 20 g ). At 0.5, 1, 3, and 24 h after
administration, animals were euthanized and the organs of interest and blood were
collected. Radioactivity levels in the blood and muscle were similar in A431 and
AZ521 tumor-bearing mice. However, tumor accumulation levels were markedly
different between the two; the A431 tumor with high TP expression showed high
accumulation, while AZ521 tumor with low TP expression showed low accumula-
tion. To hamper the binding of the tracer to TP, an excess amount of
non-radiolabeled IIMU was administered to A431 tumor-bearing mice and the
biodistribution was evaluated at 0.5 h postinjection. The radioactivity in A431
tumor was reduced by co-injection of nonlabeled IIMU.
The in vitro and in vivo uptake of [125I]IIMU by the A431 tumor was attributable
to the binding of the radiotracer to its target enzyme, i.e., TP.
9.5 SPECT/CT Imaging Study [2]
Small-animal SPECT imaging studies were performed in mice bearing A431
xenografts after intravenous injection of non-carrier-added (n.c.a.) [123I]IIMU or
[123I]IIMU with an excessively large amount of nonlabeled IIMU (n¼ 3 per group)
by using a small-animal PET/SPECT/CT. SPECT/CT imaging with [123I]IIMU
clearly visualized A431 tumor 3 h after the injection of n.c.a. [123I]IIMU
(Fig. 9.2a). The accumulation of [123I]IIMU in the tumor and liver was inhibited
by the co-injection of non-radiolabeled IIMU (Fig. 9.2b).
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9.6 Safety Assessment
To realize the application of [123I]IIMU to clinical studies, we performed safety
assessment of [123I]IIMU. Evaluation of radiation absorbed dose is important for
the safety assessment of radiopharmaceuticals. The human radiation absorbed dose
was estimated as 17 μSv/MBq on the basis of the biodistribution data of [125I]IIMU
in normal mice. The highest radiation dose was of the urinary bladder (130 μGy/
MBq), followed by the liver (75.1 μGy/MBq), thyroid (47.3 μGy/MBq), and
gallbladder (20.4 μGy/MBq). The human radiation absorbed dose of [123I]IIMU
was considered to be within the allowable range and is equal to or less than the
human radiation absorbed dose of [18F]FDG (21 μSv/MBq; ICPR 60).
Also, based on the “guidance for conducting microdose clinical trials,” we
performed an extended single-dose toxicity study and the bacterial reverse mutation
assay (Ames test). In the extended single-dose toxicity study, SD rats were given a
single intravenous dose (0, 0.18, and 1.8 mg/kg) on Day 1, followed by observations
until termination on Day 14. There were no deaths or in-life clinical signs and there
were no microscopic effects. The no observed adverse effect level (NOAEL) for
intravenous administration of nonlabeled IIMU to mice was greater than 1.8 mg/kg.
The bacterial reverse mutation assay showed negative results.
Fig. 9.2 SPECT/CT images of mice bearing A431 tumors. Mice were injected with 25 MBq of
n.c.a. [123I]IIMU (a) or [123I]IIMU with non-radiolabeled IIMU (b)
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9.7 Conclusions
Our findings indicate that [123I]IIMU should be developed as a diagnostic agent for
imaging TP-expressing tumors. It was shown that [123I]IIMU injection can be
safely administered in preclinical studies. Examinations using [123I]IIMU for injec-
tion are expected to provide useful information that is difficult to obtain by other
conventional methods, such as estimation/determination of therapeutic effects of
anticancer drugs, decision-making for a treatment plan, prognostic prediction,
understanding of disease stages, and malignancy assessment.
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Chapter 10
Discovery and Evaluation of Biomarkers
for Atherosclerosis
Differential Proteomics of Plasma and Tissues
Takeshi Sakamoto, Hiroko Hanzawa, Naomi Manri, Mamoru Sakakibara,
Yoichi Shimizu, Yan Zhao, Songji Zhao, Shiro Yamada, Kiwamu Kamiya,
Yutaka Eki, Akihiro Suzuki, Haruhiko Higuchi, Chiaki Sugano,
Hiroyuki Tsutsui, Nagara Tamaki, and Yuji Kuge
Abstract The usage of biomarkers reflecting atherosclerosis progression is impor-
tant for preventing serious incidence of cardiovascular events. To elucidate clini-
cally relevant molecular determinants in atherosclerosis, we have taken a
comprehensive approach to combine mass spectrometry-based differential proteo-
mics using both clinical and animal model specimens. Clinical plasma samples
were collected from patients with acute myocardial infarction (AMI), stable angina
(SA), and healthy/low-risk individuals (H-LR). We also obtained plasma and
arterial tissue samples from apolipoprotein E-deficient and wild-type mice at
various pathognomonic points of age. Cleavable isotope-coded affinity tags were
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used for differential mass spectrometry. Differential proteomics of clinical plasma
samples revealed that more than 10 proteins appeared to be upregulated (relative
abundance AMI/H-LR or SA/H-LR >1.5) and 5 proteins downregulated (AMI/H-
LR or SA/H-LR <1/1.5). These trends associated with the disease progression are
not always coincident with those of mouse ortholog proteins, suggesting a patho-
physiological difference between humans and the mouse model. Among the
downregulated proteins, the complement factor D (CFD) showed monotonic
decrease that was in good agreement with the enzyme-linked immunosorbent
assay. These results suggest that the comprehensive and systematic proteomic
approach may be promising in terms of the selection and evaluation of biomarker
candidates.
Keywords Proteomic study • Atherosclerosis • Inflammation • apoE-deficient
mouse
10.1 Introduction
Atherosclerosis is a chronic inflammatory disease and often causes subsequent
thrombotic complication. It is well known as a main etiology of critical diseases
such as acute coronary syndrome including myocardial infarction, sudden cardiac
death, and stroke [1]. To detect the signs of severe incidences, it is important to
accurately evaluate the progression stages of atherosclerosis, vulnerability, and
rupture risk of atherosclerotic plaques. Therefore, a variety of approaches to
establish novel biomarkers directly reflecting the status of atherosclerosis have
been conducted to date [2]. However, due to the complexity of the disease,
discovery and clinical validation of such biomarkers are still underway in many
institutions.
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Disease proteomics is a profiling technology using mass spectrometry that
makes it possible to identify disease-related alteration of protein expression com-
prehensively in a wide variety of biological specimens including serum or plasma
or extracts from tissues of interests [3]. Numerous studies have been conducted
to develop biomarkers for early diagnosis, selection of appropriate therapy, and
prognosis assessment. A decade of progress to determine changes in disease-related
protein expression has achieved accurate and high-throughput quantification of the
individual proteins within mixtures by using differential stable isotopic labeling,
such as cleavable isotope-coded affinity tags (cICATs) [4]. Either light or heavy
cICATs are labeled at the free thiol groups of cysteine residues of which proteins
are isolated from two distinct samples (i.e., disease and healthy states). The ratio of
protein amount between these states is estimated by comparing MS signal intensity
of the corresponding proteolytic peptide fragments [4].
To elucidate clinically relevant molecular determinants in atherosclerotic devel-
opment, we have taken a comprehensive approach by using mass spectrometry-
based differential proteomics. First, we conducted differential human plasma pro-
teomic studies using clinical samples of patients with atherosclerosis-related car-
diovascular disease and healthy (or low-risk) volunteers. Second, to validate the
results we obtained in the studies, a biomarker candidate, the complement factor D
(CFD) level of patients with atherosclerosis-related cardiovascular disease, was
determined by carrying out an enzyme-linked immunosorbent assay (ELISA).
Then, we tried combining differential proteome of plasma and arterial tissue
obtained from both wild-type (WT) and apoED mice at four pathognomonic time
points of age. Finally, we compared identified proteins in humans with mouse
plasma proteome.
10.2 Materials and Methods
This study was approved by the Ethics Committee of Hokkaido University Hospital
(no. 010–0118) and the institutional ethics committees of Hitachi, Ltd. Clinical
plasma samples were collected prospectively for 48 acute myocardial infarction
(AMI) patients, 73 stable angina (SA) patients, and 69 healthy/low-risk (H-LR)
individuals.
Animal care and animal experiments were conducted at Japan SLC, Inc. (Hama-
matsu, Japan), under the approval of the company’s animal care committee. The
apoED (C57BL/6.KOR/StmSlc-Apoeshl) and WT (C57BL/6) mice were fed a
high-fat diet from 8 weeks of age. Plasma and arterial tissues were collected from
each group of male or female mice at ages of 12, 18, 25, and 35 weeks.
Proteins prepared from plasma or arterial tissue as described above were labeled
with isotope-coded affinity tags using the Cleavable ICAT® Reagent Kit (Applied
Biosystems, Foster City, USA) according to the manufacturer’s instructions with
minor modifications. Tryptic peptides were applied to the strong cation exchange
(SCX) column, and the eluted solution was fractionated into 25 fractions. The SCX
separated fractions were analyzed using NanoFrontier LD, a liquid chromatograph
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mass spectrometry (LC-MS) system (Hitachi High-Technologies Corporation,
Tokyo, Japan). Original MS/MS peak lists (PLs) were generated using built-in PL
generation software in the mass spectrometer, and further protein/peptide identifi-
cation and cICAT quantitative analyses were conducted using a custom developed
software platform with a relational database.
Plasma CFD levels were measured with the use of ELISA kits according to the
manufacturer’s instructions (Quantikine, DFD00, R&D Systems, Inc., Minneapolis,
USA). Plasma levels of known markers including high-sensitive C-reactive protein
(hsCRP), amino-terminal pro-brain natriuretic peptide (NT-pro BNP), and
adiponectin were also determined (SRL, Inc., Tokyo, Japan).
10.3 Results and Discussion
Atherosclerosis is a chronic inflammatory disease, in which atherosclerotic lesions
are formed in blood vessels through complicated molecular processes occurring
between the circulating blood stream and lesions. To identify proteins showing
changes in expression levels associated with atherosclerotic plaque progression, we
Fig. 10.1 Entire research workflow of stage-dependent, mass spectrometry-based differential
proteomics. (a) Clinical proteomic study using human plasma samples. (b) Animal model prote-
omic study using plasma and arterial tissue samples from WT and atherosclerotic model mice
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conducted mass spectrometry-based proteomic analyses. Figure 10.1 shows an
overall picture of the proteomic experiments we have done. Most previous prote-
omic studies have focused on only one point of the disease. However, these
strategies would not be adequate to indentify proteins showing serial quantitative
change in accordance with progression of atherosclerosis. In this study, we
conducted a differential proteome study at several characteristic points of disease
stage and compared the results of identified proteins. The proteins we identified that
showed changes in plasma level according to the severity of the atherosclerosis-
related disease (e.g., ischemic heart disease) or atherosclerosis progression of the
mouse model might be diagnostic or predictive biomarker candidates for blood
testing. On the other hand, the proteins that showed changes, especially an increase
tendency, in arterial tissues might be biomarkers for diagnostic imaging.
10.3.1 Disease Stage-Dependent Differential Proteome
in Human Plasma
As shown in Fig. 10.1, we conducted disease stage-dependent differential human
plasma proteomic experiments using clinical samples. We selected three clinical
conditions, H-LR, SA, and AMI (Table 10.1). Two independent age-matched
plasma pools from each group (n¼ 7) were used for the experiments with combi-
nations of H-LR vs. SA, H-LR vs. AMI, and SA vs. AMI. Table 10.2 shows the
summary of identified proteins by differential proteomics of clinical plasma sam-
ples. We identified about 110 proteins in each trial of differential proteome and
found that 8–13 proteins appeared to be upregulated (relative abundance AMI/H-
LR or SA/H-LR>1.5), and 2–8 proteins were downregulated (AMI/H-LR or SA/H-
LR <1/1.5). Finally, five identical proteins were identified in common between
trials 1 and 2. Three were blood coagulation related, such as von Willebrand factor,
and the other two were categorized as structural-integrity-related or immuno-
response (immunoglobulin)-related proteins. The downregulated proteins identified
in common between trials were found to be apolipoproteins involving cholesterol
homeostasis, blood coagulation, and CFD.
To validate the results we obtained in the differential proteome experiments as
described above, we determined the CFD level of plasma of clinical samples by
ELISA as a representative example. We found that CFD levels in plasma of the
AMI group were the lowest among the three clinical groups. The statistical
Table 10.1 Description of three clinical groups in human plasma proteome







Risk and progression stage
of atherosclerosis
Low Moderate/early High/advanced
10 Discovery and Evaluation of Biomarkers for Atherosclerosis 135
difference of AMI to H-LR was the most pronounced (H/LR vs. AMI,
p¼ 2.4 1010; H/LR vs. SA, p¼ 0.54). The diminished plasma levels of CFD
in AMI patients showed that the results we obtained in our proteomic study were
basically verified. Furthermore, the plasma CFD levels showed no correlation with
body mass index (BMI) (r¼ 0.03, P< 0.05), hsCRP (r¼0.09, P< 0.05),
NT-proBNP (r¼0.03, P< 0.05), and adiponectin (r¼ 0.11, P< 0.05). In recent
years, it has been suggested that the activation of the complement system plays a
role in atherosclerosis progression [5]. Among the components of the complement
pathway, CFD is known as a key regulatory serine protease of the alternative
complement pathway. CFDmRNA and protein are abundantly expressed in adipose
tissue, and the protein is found at high levels in serum [6]. CFD expression levels in
rodent models of obesity are reduced [7]. Our results may suggest some kind of
CFD implication in atherosclerosis.
10.3.2 Disease Stage-Dependent Differential Proteome
in Atherosclerosis Mouse Model
As shown in Fig. 10.1, we conducted differential proteome experiments using
plasma and arterial tissues of WT and apolipoprotein E-deficient (apoED) mice.
Table 10.3 shows phenotypic characteristics of atherosclerotic lesions of WT and
apoED at each point of age. As we previously demonstrated, on a high-fat diet,
early lesions were observed in apoED at 12–18 weeks of age, and advanced lesions
were prominent at 25–35 weeks. No atherosclerotic lesions were found in WT mice
throughout four points of age [8]. At 25 weeks of age, vulnerable atheromatous
lesions were more abundant, but fibroatheromatous lesions were less at 25 weeks
than those at 35 weeks [8]. Table 10.4 shows a summary of identified proteins. In
plasma, the total number of identified proteins and the ratio of their upregulated
Table 10.2 Up- or downregulated proteins detected by differential proteomic analysis in clinical
pooled plasma samples
Group SA/H-LR AMI/H-LR AMI/SA
Total number of identified proteins Trial 1 116 115 110
Trial 2 106 112 114
Upregulated Trial 1 8 8 5
Trial 2 7 8 13
Common 1 5 2
Downregulated Trial 1 4 6 8
Trial 2 7 2 5
Common 2 1 1
H-LR group of healthy control and low-risk volunteers, SA group of patients with stable angina,
AMI group of patients with acute myocardial infarction, Upregulated proteins showed expression
ratio >1.5, Downregulated proteins showed expression ratio <1/1.5
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proteins (expression ratio, apoED/WT;> 1.5) did not significantly change through-
out the time course (Table 10.4). However, the ratio of downregulated proteins
(apoED/WT; <1/1.5) increased on and after 25 weeks of age (Table 10.4). We
finally found 100 proteins in the plasma, and 390 proteins in the arterial tissues were
detected throughout all four time points: 29 were identified in common between
plasma and arterial tissues [data not shown, 9]. Interestingly, we found that disease
stage-dependent quantitative variation patterns did not always correspond between
plasma and arterial tissues. Furthermore, proteins showed characteristic change in
abundance in plasma, and/or arterial tissues were found to be components of
inflammation, thrombus formation, and vascular remodeling [9].
10.3.3 Comparison Between Human and Mouse Plasma
Proteome
In this study, we conducted disease stage-dependent differential proteome experi-
ments in two identical studies: one for human plasma proteome using clinical
samples and one for plasma/arterial tissue proteome using an atherosclerotic
mouse model, apoED. Importantly, we found that the changes associated with the
disease progression in the amount of identified proteins were not always coincident
Table 10.4 Summary of up- or downregulated proteins detected in plasma and arterial tissues by
differential proteome of mouse model
Plasma Arterial tissue
Age (weeks) 12 18 25 35 12 18 25 35
Total number of identified proteins 146 133 119 124 446 616 659 693
Upregulated (%) 7 14 15 11 8 6 16 16
Downregulated (%) 5 5 11 15 2 5 8 9
No change (%) 88 81 74 74 90 89 76 75
Upregulated expression ratio (apoED/WT)>1.5,Downregulated expression ratio (apoED/WT)<
1/1.5, No change 1/1.5< expression ratio (apoED/WT)< 1.5. This table is modified from refer-
ence [9]
Table 10.3 Description of possible progression stages of atherosclerotic lesion of atherosclerosis
mouse model
Age (weeks) 12 18 25 35
Risk and progression stage
of atherosclerosis
WT None None None None
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with those of mouse ortholog proteins in plasma or arterial tissues determined by
proteomic studies (data not shown). In case of CFD, the plasma level of CFD in
humans determined in the proteomic study or ELISA decreased in accordance with
the severity of the clinical conditions. On the other hand, the plasma level of CFD
in mice showed a slight but not significant decreasing tendency determined in
differential proteome between WT mice and the apoED mouse model. We prelim-
inarily determined the plasma level of CFD in mice by ELISA and detected no
statistical significance between WT mice and apoED throughout all four time
points. CD5L, a soluble member of the scavenger receptor cysteine-rich domain
superfamily protein, did not show any significant change in abundance as deter-
mined by human plasma differential analyses. However, the expression ratios
(apoED/WT) of CD5L in mouse plasma were high throughout the four time points
[9]. In addition, we found that CD5L accumulated in advanced lesions of apoED in
accordance with macrophage infiltration by immunohistochemistry. These results
suggest that fundamental mechanisms of atherosclerosis development are similar to
each other; however, there would be a pathophysiological difference between
humans and the mouse model.
10.3.4 Limitation
We failed to detect several known atherosclerotic plaque-related proteins such as
cytokines, monocyte chemoattractant protein-1 (MCP-1), and intercellular adhe-
sion molecule-1(ICAM-1). We assume that there were several technical reasons for
this. For example, the practical detection limit in our mass spectrometry system was
assumed to be 1–10 ng/mL, which is much higher than the normal concentration of
cytokines. We used cICAT labeling reagents, which covalently bind only to
cysteine residues of targeted proteins. Therefore, it becomes difficult to detect
proteins with trypsin-digested peptides with few or no cysteine residues.
10.4 Conclusion
To identify proteins showing changes in expression levels associated with athero-
sclerotic plaque progression, we conducted mass spectrometry-based proteomic
analyses. We adopted two separate study designs: one for human plasma differen-
tial proteome using clinical samples and one for mouse plasma/arterial tissue
differential proteome using samples obtained from wild-type mice and an athero-
sclerotic mouse model apoED. Then several proteins showing quantitative changes
in accordance with disease were found, including the complement factor D (CFD).
The diminished plasma levels of CFD in acute myocardial infarction patients were
verified in an enzyme-linked immunosorbent assay. These results suggest that CFD
might be a potential biomarker for atherosclerosis. The comprehensive and
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systematic proteomic approach using different states of samples is promising in
terms of the selection of biomarker candidates.
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Chapter 11
Radioimmunodetection of Atherosclerotic
Lesions Focusing on the Accumulation
Mechanism of Immunoglobulin G
Yoichi Shimizu, Hiroko Hanzawa, Yan Zhao, Ken-ichi Nishijima,
Sagiri Fukura, Takeshi Sakamoto, Songji Zhao, Nagara Tamaki,
and Yuji Kuge
Abstract In the diagnosis of atherosclerosis, detailed evaluation of biomarkers
related to its lesion formation is desired for estimation of its progression rate. In our
previous proteomic studies of atherosclerosis mice, the protein level of
thrombospondin-4 (TSP4) in the aorta, but not in plasma, elevated relatively with
atherosclerotic plaque formation. Therefore, we supposed that TSP4 would be a
potential biomarker for diagnostic imaging of atherosclerotic progression. Immu-
noglobulin G (IgG) has been widely used as a basic molecule of imaging probes
providing images specific to their target biomolecules, owing to the antigen-
antibody reaction. Therefore, we first developed anti-TSP4 monoclonal IgG
radiolabeled with 99mTc (99mTc-TSP4-mAb). 99mTc-TSP4-mAb showed higher
accumulation in atherosclerotic aortas of apoE/ mice (atherosclerotic model
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mice); however, we found that the non-targeted monoclonal IgG radiolabeled with
99mTc also showed similar distribution in atherosclerotic aortas of apoE/ mice.
IgG has also known to accumulate nonspecifically in the immunological disease
such as inflammatory arthritis. However, the accumulation mechanism of IgG has
still been unclear in detail. In this chapter, we would like to introduce recent topics
on atherosclerotic imaging, focused on our work exploring the accumulation
mechanisms of IgG in atherosclerotic lesions, and elucidating the usefulness of
radiolabeled IgG images in the diagnosis of atherosclerosis.
Keywords Atherosclerosis • Immunoglobulin G • Polarized macrophage
11.1 Introduction
Rupture of vulnerable plaques and the subsequent thrombogenesis induce ischemic
diseases such as cerebral and myocardial infarction [1]. Therefore, it is necessary
to detect vulnerable lesions precisely for the diagnosis of such diseases. Various
biomolecules are expressed or activated as atherosclerosis progresses. Thus, the
detection and imaging of such biomolecules would make possible the determina-
tion of the progression of atherosclerosis in detail. In our previous proteomic
studies of atherosclerotic model mice [2], the relative thrombospondin-4 (TSP4)
levels of atherosclerotic model mice/normal mice in the aorta, but not in plasma,
increased with the atherosclerotic plaque formation. TSP4 belongs to the
thrombospondin families and has been reported to play some roles such as pro-
motion of proliferation of smooth muscle cells and adhesion and migration of
neutrophils [3]. It has also been reported that apoE and TSP4 double knockout
mice showed fewer atherosclerotic lesions than the atherosclerosis apoE knockout
mice, which suggests that TSP4 has a crucial role in the progression of atheroscle-
rotic lesions [4]. Therefore, we supposed that TSP4 would be a potential biomarker
for diagnostic imaging of atherosclerotic progression. Immunoglobulin G (IgG) is
widely used particularly for the target-specific imaging of cancer, because it pro-
vides images specific to their target biomolecules owing to the antigen-antibody
reaction [5]. Thus, we first developed an IgG-based TSP4 targeting SPECT
imaging probe (99mTc-TSP4-mAb). 99mTc-TSP4-mAb accumulated in the athero-
sclerotic lesions of apoE/ mouse aortas. However, 99mTc-NC-mAb, which was
composed of non-targeting IgG, also accumulated highly in the atherosclerotic
lesions similar to 99mTc-TSP4-mAb. IgG itself is known to be delivered to athero-
sclerotic lesions nonspecifically, but the detailed mechanism of the accumulation
is still unknown [6].
In this report, we would like to introduce our above-mentioned work in which
we explored the accumulation mechanisms of IgG in atherosclerotic lesions and
elucidated the usefulness of radiolabeled IgG imaging in the diagnosis of
atherosclerosis.
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11.2 Materials and Methods
11.2.1 Materials
All chemicals used in this study were commercially available and of the highest
purity. HYNIC-N-hydroxysuccinimide was prepared as previously reported
[7]. 99mTc-pertechnetate was purchased from Nihon Medi-Physics Co., Ltd.
(Tokyo, Japan). As a TSP4-targeting monoclonal antibody, we used anti-
thrombospondin-4 mouse IgG2b (Clone #276523, R&D Systems, Abingdon, UK).
As for the negative control non-targeted mouse IgG, we chose mouse IgG2b, a
kappa monoclonal [MG2b-57] isotype control (Abcam, Cambridge, UK) whose
immunogen is trinitrophenol + keyhole-limpet hemocyanin (KLH).
11.2.2 Preparation of Radiolabeled IgG
Anti-TSP4 monoclonal IgG (TSP4-mAb) or non-targeting IgG (NC-mAb) was
radiolabeled with 99mTc after derivatization with 6-hydrazinonicotinic acid
(HYNIC), as previously reported (Fig. 11.1) [8]. In brief, to HYNIC-N-hydroxysuc-
cinimide (8.25 μg) in N,N-dimethylformamide (8.25 μl), TSP4-mAb or NC-mAb
solution in 0.16 M borate buffer (pH 8.0) (250 μl, 2 mg/ml) was added, and the
Fig. 11.1 Scheme of 99mTc-TSP4-mAb or 99mTc-NC-mAb preparation
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mixture was incubated at room temperature for 2 h. The mixture was purified
by size-exclusion filtration using a diafiltration membrane (Amicon Ultra
4 [cutoff molecular weight, 30,000]; Millipore Co., Billerica, MA). 99mTc-
(tricine)2(740 MBq/ml, 300 μl) was prepared by the method of Larsen et al.
[9]. It was added to the purified solution of HYNIC-TSP4-mAb or NC-mAb
solution in 10 mM citrate buffer (pH 5.2) (30 μl, 1 mg/ml), and the mixture was
incubated at room temperature for 1 h. The mixture was then purified on a Sephadex
G-25 column (PD-10, GE Healthcare, Buckinghamshire, UK) equilibrated with
0.1 M PBS (pH7.4) to obtain 99mTc-TSP4-mAb or 99mTc-NC-mAb. The radio-
chemical purity of 99mTc-TSP4-mAb or 99mTc-NC-mAb was measured by size-
exclusion filtration of the PD-10 column and size-exclusion high-performance
liquid chromatography (HPLC). The stability of 99mTc-TSP4-mAb or 99mTc-NC-
mAb in plasma was evaluated by the method described below. First, the probes
(99mTc-TSP4-mAb, 27.7 MBq/ml; 99mTc-NC-mAb, 34.9 MBq/ml; 50 μl) were
incubated with the plasma derived from C57BL/6 (male, 30 weeks) for 24 h, and
then the mixture was analyzed by size-exclusion filtration of the PD-10 column.
11.2.3 Animal Study
Animal care and all experimental procedures were performed with the approval of
the animal care committee of Hokkaido University. Studies were performed using
male C57BL/6J apoE/ mice obtained from the Taconic Gnotobiotic Center
(Germantown, NY, USA) and C57BL/6J mice as the wild-type (WT) mice obtained
from Charles River Laboratories Japan, Inc. (Yokohama, Japan). The animals were
kept in a temperature-controlled facility of the laboratory of animal experiments of
Hokkaido University on a 12-h light cycle with free access to food and water. After
5 weeks of age, the apoE/ mice were maintained on a high-fat diet (21 % fat,
0.15 % cholesterol, without cholate; purchased from Oriental Yeast Ltd., Tokyo,
Japan). At 35 weeks of age, the animals (n¼ 4/group) were anesthetized with
pentobarbital (0.025 mg/kg body weight, intraperitoneally). 99mTc-TSP4-mAb
(200–592 kBq/mouse) or 99mTc-NC-mAb (481–962 kBq/mouse) was intravenously
injected to each animal. Twenty-four hours after the injection, the animals were
euthanized under deep pentobarbital anesthesia, and aortas were fixed by cardiac
perfusion with cold 0.1 M phosphate-buffered saline (pH 7.4) followed by a cold
fixative [4 % paraformaldehyde, 0.1 M phosphate-buffered solution (pH 7.4)]. Each
excised aorta was cut and placed onto glass slides. The dissected aortic root of each
mouse was embedded in Tissue-Tek medium (Sakura Finetechnical Co., Ltd.,
Tokyo, Japan) and frozen in isopentane/dry ice. Serial cross sections of 10-μm
(for autoradiographic study) and 5-μm (for immunohistochemistrical analysis)
thickness were immediately cut and thaw-mounted on glass slides.
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11.2.3.1 Autoradiography (ARG) Study
The excised and cut aortas on glass slides were exposed to phosphor imaging plates
(Fuji Imaging Plate BAS-UR, Fujifilm, Tokyo, Japan) for 12 h, together with a set
of calibrated standards. The autoradiographic images were acquired using a com-
puterized imaging analysis system (Fuji bio-imaging analyzer FLA7000). The
acquired data was analyzed using MultiGauge version 3.2 (Fujifilm).
11.2.4 Histochemical Study
Movat’s pentachrome staining of serial aortic root sections was performed
[10]. Immunohistochemical staining of the serial sections with a mouse
macrophage-specific antibody (Mac-2, clone m3/38, Cedarlane, Ontario, Canada)
was performed in accordance with a previously reported immunohistochemical
procedure [11]. The TSP4 immunohistochemical staining of the serial sections
was performed as shown below. At first, endogenous peroxidase activity was
blocked for 10 min with 3 % hydrogen peroxide after rehydration. Slides were
then incubated with anti-thrombospondin-4 mouse IgG2b (Clone #276523, R&D
Systems) overnight at 4 C, followed by incubation with a peroxidase-labeled
amino acid polymer-conjugated goat anti-mouse F(ab0)2 fragment of IgG (Histofine
Mouse Stain kit, Nichirei, Tokyo, Japan) for 30 min at room temperature. The
bound antibody complex was then visualized by incubation with 3,3-
0-diaminobenzidine tetrahydrochloride. The images of the staining shown above
were captured under a microscope (Biozero BZ-8000; Keyence Co., Osaka, Japan).
11.3 Results
11.3.1 Probe Preparation
99mTc-TSP4-mAb or 99mTc-NC-mAb was obtained with a radiochemical yield of
17.6 3.8 % or 31.8 6.8 % (n¼ 3) and with the radiochemical purity of
99.5 0.1 % or 99.2 0.5 % (n¼ 3). The stability of 99mTc-TSP4-mAb or
99mTc-NC-mAb in the mouse plasma was over 90 % for 24-hour incubation.
11.3.2 In Vivo Study
The distributions of 99mTc-TSP4-mAb in apoE/ mice and wild-type (WT) mice
at 24 h after administration are shown in Table 11.1. The 99mTc-TSP4-mAb
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accumulation levels in the aortas of apoE/ mice were significantly higher than
those in WT mice (5.3 1.1 vs. 2.4 0.3 %ID/g, p< 0.05), whereas the radioac-
tivities in other organs were not significantly different between apoE/ mice and
wild mice. On the other hand, the 99mTc-NC-mAb accumulation levels in the aortas
of apoE/ mice were also significantly higher than those of WT mice (5.1 1.4
vs. 2.8 0.5 %ID/g, p< 0.05), whereas the radioactivities in other organs were not
different between apoE/ mice and wild-type mice.
The ARG images of the apoE/ aortas injected with 99mTc-TSP4-mAb showed
heterogeneous distribution of the radioactivity where the plaque formation was
observed in the bright field (Fig. 11.2). The radioactive distribution in the aortic
roots of apoE/ mice injected with 99mTc-TSP4-mAb measured by ARG was
inside of the atherosclerotic plaque lesions and coincided with the Mac-2-positive
areas (Fig. 11.3). These results suggest that 99mTc-TSP4-mAb accumulated in the




(WT) mice 24 h after
administration
apoE/ WT
Aorta 5.3 1.1 2.4 0.3
Heart 1.8 0.3 1.5 0.2
Lung 1.7 1.4 1.9 1.6
Liver 5.5 1.8 5.9 1.3
Kidney 2.5 0.2 2.3 0.3
Stomach 1.8 0.5 1.1 0.2
Small intestine 1.3 0.2 1.5 0.2
Large intestine 3.8 1.9 2.5 0.3
Pancreas 0.8 0.2 0.7 0.1
Spleen 7.5 1.2 6.7 0.8
Brain 0.1 0.1 0.1 0.0
Muscle 0.5 0.2 0.6 0.1
Blood 17.2 2.1 17.2 1.5
Fig. 11.2 ARG images (left) and bright field images (right) of the excised aortas of apoE/
mouse (upper) and of wild-type (WT) mouse (lower) 24 h after administration of 99mTc-TSP-mAb
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11.3.3 Discussion
In this study, we observed that 99mTc-TSP4-mAb accumulated in the atheroscle-
rotic lesions of apoE/ mouse aortas. However, 99mTc-NC-mAb, which was
composed of non-targeting IgG, also accumulated highly in the atherosclerotic
lesions similar to 99mTc-TSP4-mAb (Fig. 11.2). Moreover, the 99mTc-TSP4-mAb
accumulation area coincided with the Mac-2-positive areas in the plaques in aortic
root (Fig. 11.3), which suggests that IgG itself was delivered and accumulated in
atherosclerotic lesions, especially macrophage infiltration areas.
Previously, various types of polarized macrophage were identified and reported
[12]. Among the polarized macrophages, pro-inflammatory M1-polarized macro-
phages were reported to be abundant in lipids and to localize in areas that are
distinct from those in which anti-inflammatory M2-polarized macrophages (which
are also called alternatively activated macrophages) localize in human plaques
[13]. Although the origin of M1 and polarized macrophages and how polarized
macrophages are involved in the progression of atherosclerotic plaques are still
being unclarified, polarized macrophages would have a critical role in the devel-
opment of atherosclerotic plaques [14]. Therefore, we examined the correlation of
the macrophages, especially polarized macrophages, with IgG accumulation. In our
preliminary in vitro study, M1-polarized macrophages showed a higher uptake of
99mTc-NC-mAb than M2-polarized and non-polarized M0 macrophages [15]. To
clarify the mechanism of 99mTc-NC-mAb accumulation in M1-polarized macro-
phages, we next focus on the expression levels of Fcγ receptors. Fcγ receptors
recognize the Fc region of IgG and play a role in the activation of immune systems
[16]. Furthermore, it has been reported that deficiency of Fcγ receptors induces
Fig. 11.3 ARG images, Movat’s pentachrome staining, TSP4 immunohistochemical staining, and
Mac-2 immunohistochemical staining of the aortic roots of apoE/ mouse (upper) and wild-type
(WT) (lower) mouse 24 h after administration of 99mTc-TSP4-mAb
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protection against atherosclerosis in apoE/ mice [17]. Indeed, the expression
level of some subtypes of Fcγ receptors was higher in M1-polarized macrophages
than those in M2-polarized or non-polarized M0 macrophages in our unreported
in vitro study. We also performed a cellular uptake study under the Fcγ receptor’s
inhibition and found that the accumulation of 99mTc-NC-mAb in M1-polarized
macrophages was significantly suppressed by the pretreatment with an anti-Fcγ
receptor antibody. These findings suggest that IgG itself is accumulated in
M1-polarized macrophages via Fcγ receptors in the atherosclerotic plaques.
During the course of atherosclerotic progression, various biomolecules are
expressed or activated. Thus, various PET/SPECT imaging probes targeting bio-
molecules related to the progression of atherosclerosis have been developed
[18]. Among them, some probes are developed with based on monoclonal IgG
and have been evaluated in animal models such as mouse and rabbit [19, 20]. In
those studies, xenogeneic antibodies were used, whose nonspecific accumulation in
atherosclerotic lesions was not taken into consideration. However, considering that
the probes will be used clinically, the IgG used as a basic component of probes
should be humanized, and it would be necessary to note its nonspecific accumula-
tion as we have seen in this study.
Radiolabeled IgG has been widely applied to the diagnosis of inflammatory
diseases such as rheumatoid arthritis and infections, although the mechanism of its
accumulation is still unclarified [21]. Our preliminary study is the first to show that
pro-inflammatory M1-polarized macrophages contribute to the accumulation of
radiolabeled IgG, which is in agreement with the conventional use of such IgG as
mentioned above.
In the nuclear imaging for diagnosis of atherosclerosis, 18-fluoro-deoxyglucose
(18F-FDG) has been widely used [22]. 18F-FDG is reported to accumulate in
macrophages, particularly M1-polarized macrophages in atherosclerotic lesions
[23], which is similar to radiolabeled IgG behavior. Therefore, radiolabeled IgG
would provide information similarly to 18F-FDG in the diagnosis of atherosclerosis.
In this study, we found that IgG itself can be potentially used for the visualiza-
tion of atherosclerotic plaques, especially atherosclerotic lesions in active inflam-
mation independent of its target biomolecules. However, we also observed the high
retention of radioactivities in blood 24 h after administration of 99mTc-TSP4-mAb
(apoE/, 17.2 2.1 %ID/g; WT, 17.2 1.5 %ID/g), which were about three times
higher than those in aortas. This may be because that IgG has a high molecular
weight (about 150 kDa), which leads to a low rate of clearance from blood. To
overcome this problem, the molecular weight of IgG should be decreased with its
affinity to Fcγ receptors maintained. That is, an Fc fragment (about 50 kDa)
obtained from IgG would be a suitable basic compound for atherosclerotic imaging.
We are now developing an Fc fragment-based probe and evaluating to determine
whether this probe can be used to visualize the inflammatory active areas of
atherosclerotic lesions.
148 Y. Shimizu et al.
Acknowledgments This study was supported in part by MEXT KAKENHI (Grant Numbers:
24890003 and 26860961) and the Creation of Innovation Centers for Advanced Interdisciplinary
Research Areas Program, Ministry of Education, Culture, Sports, Science and Technology, Japan.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
1. Ruberg FL, Leopold JA, Loscalzo J. Atherothrombosis: plaque instability and thrombogenesis.
Prog Cardiovasc Dis. 2002;44:381–94.
2. Hanzawa H, Sakamoto T, Kaneko A, Manri N, Zhao Y, et al. Combined plasma and tissue
proteomic study of atherogenic model mouse: approach to elucidate molecular determinants in
atherosclerosis development. J Proteome Res. 2015;14:4257–69.
3. Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, et al. Thrombospondin-4
and its variants: expression and differential effects on endothelial cells. Circulation.
2003;108:1514–9.
4. Frolova EG, Pluskota E, Krukovets I, Burke T, Drumm C, Smith JD, et al. Thrombospondin-4
regulates vascular inflammation and atherogenesis. Circ Res. 2010;107:1313–25.
5. Larson SM. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl
Med. 1985;26:538–45.
6. Fischman AJ, Rubin RH, Khaw BA, Kramer PB, Wilkinson R, Ahmad M, et al. Radionuclide
imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G. J
Nucl Med. 1989;30:1095–100.
7. Abrams MJ, Juweid M, TenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-
99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imag-
ing focal sites of infection in rats. J Nucl Med. 1990;31:2022–8.
8. Ono M, Arano Y, Mukai T, Uehara T, Fujioka Y, Ogawa K, et al. Plasma protein binding of
(99m)Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. Nucl Med
Biol. 2001;28:155–64.
9. Larsen SK, Solomon HF, Caldwell G, AbramsMJ. [99mTc]tricine: a useful precursor complex
for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem.
1995;6:635–8.
10. Vucic E, Dickson SD, Calcagno C, Rudd JH, Moshier E, Hayashi K, et al. Pioglitazone
modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with
FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging.
2011;4:1100–9.
11. Zhao Y, Kuge Y, Zhao S, Morita K, Inubushi M, Strauss HW, et al. Comparison of 99mTc-
annexin A5 with 18F-FDG for the detection of atherosclerosis in ApoE/ mice. Eur J Nucl
Med Mol Imaging. 2007;34:1747–55.
12. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in
diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86.
11 Radioimmunodetection of Atherosclerotic Lesions Focusing on the. . . 149
13. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, et al. Human
atherosclerotic plaque alternative macrophages display low cholesterol handling but high
phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways.
Circ Res. 2011;108:985–95.
14. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev
Immunol. 2013;13:709–21.
15. Shimizu Y, Hanzawa H, Zhao Y, Fukura S, Nishijima K, Sakamoto T, et al. Accumulation
mechanism of non-targeted immunoglobulin G in atherosclerotic lesions. J Nucl Med. 2015;56
Suppl 3:462.
16. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275–90.
17. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J,
Sanjuan G, et al. Fcgamma receptor deficiency confers protection against atherosclerosis in
apolipoprotein E knockout mice. Circ Res. 2006;99:1188–96.
18. Temma T, Saji H. Radiolabeled probes for imaging of atherosclerotic plaques. Am J Nucl Med
Mol Imaging. 2012;2:432–47.
19. Nakamura I, Hasegawa K, Wada Y, Hirase T, Node K, Watanabe Y. Detection of early stage
atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density
lipoprotein receptor-deficient mice. Biochem Biophys Res Commun. 2013;433:47–51.
20. Temma T, Ogawa Y, Kuge Y, Ishino S, Takai N, Nishigori K, et al. Tissue factor detection for
selectively discriminating unstable plaques in an atherosclerotic rabbit model. J Nucl Med.
2010;51:1979–86.
21. Signore A, Prasad V, Malviya G. Monoclonal antibodies for diagnosis and therapy decision
making in inflammation/infection. Foreword. Q J Nucl Med Mol Imaging. 2010;54:571–3.
22. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging athero-
sclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.
Circulation. 2002;105:2708–11.
23. Satomi T, Ogawa M, Mori I, Ishino S, Kubo K, Magata Y, et al. Comparison of contrast agents
for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superpara-
magnetic iron oxide. J Nucl Med. 2013;54:999–1004.




Noninvasive PET Flow Reserve Imaging
to Direct Optimal Therapies for Myocardial
Ischemia
Robert A. deKemp and Rob SB Beanlands
Abstract Nuclear cardiology imaging with SPECT or PET is used widely in North
America for the diagnosis and management of patients with coronary artery disease.
Conventional myocardial perfusion imaging (MPI) can identify areas of reversible
ischemia as suitable targets for coronary artery revascularization by angioplasty or
bypass surgery. However, the accuracy of this technique is limited in patients with
advanced disease in multiple coronary arteries, where there is no normal reference
territory against which to assess the “relative” perfusion defects. We have devel-
oped methods for the routine quantification of absolute myocardial blood flow
(MBF mL/min/g) and coronary flow reserve (stress/rest MBF) using rubidium-82
dynamic PET imaging. The incremental diagnostic and prognostic value of abso-
lute flow quantification over conventional MPI has been demonstrated in several
recent studies. Clinical use of this added information for patient management to
direct optimal therapy and the potential to improve cardiac outcomes remains
unclear, but may be informed by recent progress and widespread clinical adoption
of invasive fractional flow reserve(FFR)-directed revascularization. This paper
presents recent progress in this field, toward noninvasive CFR image-guided
therapy with cardiac PET and SPECT.
Keywords Noninvasive cardiac imaging • Myocardial ischemia • Myocardial
blood flow • Coronary flow reserve • Positron emission tomography
12.1 Introduction
Improvements in diagnostic imaging and therapeutic methods have helped to
reduce the cardiac death rate in Canada and other developed nations over the past
decade [16]. However, cardiovascular disease is still the number one cause of death
in most industrialized countries [3]. Noninvasive diagnostic imaging is used
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increasingly as a “gatekeeper” to help optimize the most effective use of higher-risk
invasive (and costly) diagnostic and interventional procedures, such as coronary
angiography and revascularization.
This work is motivated in part by the recent FAME trials [7, 38] showing that
impaired flow reserve, when used to identify “flow-limiting” epicardial stenoses for
revascularization, improved clinical outcomes (reduced cardiac death and myocar-
dial infarction rates) and lowered the total cost of treatment. The FAME trials used
invasive angiography measurements of fractional flow reserve (FFR), but with
associated risks of embolic stroke and other complications of coronary artery
catheterization that may be avoided with the use of noninvasive imaging methods.
Myocardial perfusion reserve (MPR) imaging using positron emission tomog-
raphy (PET) may enable diagnosis of patients with microvascular disease (uVD) or
nonobstructive diffuse epicardial disease, who should not be recommended for
coronary revascularization, sparing them the unnecessary risks of invasive angiog-
raphy for diagnosis alone. Some enhancements to the conventional methods of PET
flow reserve imaging are proposed for accurate noninvasive imaging of ischemia, to
improve identification of hemodynamically and physiologically significant “flow-
limiting” lesions that are optimal targets for invasive revascularization. According
to recent AHA/NIH publications [28], “Standard tests used to diagnose CAD are
not designed to detect coronary uVD. More research is needed to find the best
diagnostic tests and treatments for the disease.” The flow reserve concepts used in
this study are illustrated in Fig. 12.1, and the specific terms are defined in
Table 12.1.
Current international practice guidelines [1, 2] recommend the use of treadmill
exercise-ECG testing and stress perfusion imaging for the diagnosis of ischemia
(benefit class I, evidence levels A,B) and the use of invasive flow reserve (FFR)
measurements to direct invasive revascularization (benefit class I, IIa, evidence
level A) for the treatment of symptoms in patients with suspected ischemic heart
disease. Despite a wealth of observational data, stress MPI is still not a class 1
(A) indication to direct revascularization in patients with stable ischemic heart
Fig. 12.1 Epicardial (EFR, FFR)microvascular (MPR, CFR) flow reserve measurements using
PET imaging and ICA. Normal values of MPR and CFR are approximately 3–5 (average 4.0) in
young healthy adults without microvascular disease. Normal epicardial vessels have FFR¼ 1.0,
whereas “flow-limiting” stenoses with FFR< 0.75–0.80 can produce myocardial ischemia. See
Table 12.1 for definitions
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disease because there remains insufficient evidence that ischemia-directed therapy
reduces the risk of death and/or myocardial infarction.
In conjunction with, or following exercise-ECG testing, stress myocardial perfu-
sion imaging (MPI) is used widely in North America for the noninvasive diagnosis of
coronary artery disease. While single-photon emission computed tomography
(SPECT) is used most commonly, rubidium-82 (82Rb) PET has been available in
the USA since 1989 for the diagnosis of obstructive coronary artery disease (CAD).
We recently completed enrolment of >15,000 patients in the Canadian multicenter
trial [8] evaluating 82Rb PET as an alternative radiopharmaceutical for myocardial
perfusion imaging (Rb-ARMI). Initial results confirmed the high accuracy (>90%) of
low-dose 82Rb PET-CT for diagnosis of obstructive coronary artery disease in patients
with epicardial stenoses 50–70% [20]. Recent meta-analyses also confirm that PET
has higher accuracy for diagnosis of CAD compared to SPECT, even when using
current cameras with attenuation correction and ECG-gating [24].
Stress perfusion imaging is also used for the assessment of myocardial ischemia,
to identify patients that will benefit from invasive revascularization therapy pro-
cedures such as coronary angioplasty and bypass surgery [15] as shown in Fig. 12.2.
The efficacy of this approach was suggested initially in the nuclear sub-study of the
Table 12.1 Flow reserve terminology
Name Definition
Coronary artery disease (CAD) Focal or diffuse narrowing of an epicardial coronary artery
lumen due to the formation of atherosclerotic plaque (stenosis
or lesion) in the arterial wall
Microvascular disease (uVD) Damage to the inner lining (endothelium) of the
subepicardial small arteries or arterioles that regulate blood
flow to the heart muscle




Ratio of maximal hyperemic stress/rest perfusion (tissue
flow), including the effects of epicardial and microvascular
disease, typically measured using noninvasive PET imaging
(Fig. 12.1)
Microvascular reserve (uVR) Ratio of endothelium-dependent stress/rest MBF in the small
resistance arteries and arterioles
Epicardial flow reserve (EFR) Ratio of epicardial vessel-dependent stress/rest MBF in the
large conduit arteries. The sum total of uVR+EFR is equal to
MPR
Coronary flow reserve (CFR) Ratio of maximal hyperemic stress/rest blood flow in the
epicardial coronary arteries, reflecting the effects of epicar-
dial and microvascular disease. CFR is typically measured
invasively during adenosine stress using the indicator dilution
technique
Fractional flow reserve (FFR) Fraction of pressure maintained across an epicardial stenosis
during hyperemic stress, measured using invasive angiogra-
phy. It is analogous to the relative MPR value, in single-
vessel disease without uVD
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COURAGE trial [37] and confirmed recently in patients from the DUKE registry
[12], showing survival and outcome benefits from invasive revascularization using
angioplasty in addition to optimal medical (drug) therapy, in patients with at least
5 % ischemic myocardium improvement. The ISCHEMIA trial currently in pro-
gress [23] is intended to verify prospectively, in patients with ischemia by physi-
ological testing (for MPI: at least 10 % ischemic left ventricular (LV) myocardium),
whether or not revascularization compared to medical therapy will result in
improved clinical outcomes. This is a pivotal trial intended to prove conclusively
the value of ischemia detection by stress perfusion imaging. However, but it is
important to recognize that conventional stress MPI (using SPECT or PET) will still
underestimate the extent and severity of ischemia from diffuse or multivessel
Fig. 12.2 Patients with moderate-to-severe ischemia in the COURAGE nuclear sub-study (A) had
a lower rate of death or MI when there was a 5 % improvement (reduction) in ischemic burden
following revascularization. In the DUKE nuclear cardiology registry (B), patients with >5 %
ischemia worsening had increased risk of death or MI. Retrospective analysis of ~14,000 SPECT-
MPI patients (C) indicated that the percent ischemic myocardium (>10–15%) predicted lower risk
(log hazard ratio) of death following early revascularization. In patients with less than 10–15 %
ischemic myocardium, medical therapy was the most effective treatment [Reproduced from
(A) [37], (B) [12], and (C) [15].]
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disease (patients with left-main coronary artery disease are excluded) and will
neither identify - nor direct treatment of - high-risk patients with disease of the
coronary microvasculature.
12.2 Myocardial Blood Flow (Perfusion) Imaging
Some limitations of conventional (relative) MPI can be overcome by quantifying
myocardial perfusion blood flow (MBF) in absolute units of mL/min/g. Dynamic
imaging is required starting from the time of tracer injection, to capture the first-
pass transit through the venous-arterial circulation as shown in Fig. 12.3. The
concentration of tracer is measured over time in the arterial blood and myocardial
tissues, and the rate of uptake or transfer from blood to tissue (influx rate K1
mL/min/g) is related to the absolute myocardial perfusion [21]. Flow quantification
restores the true normal-to-diseased tissue contrast (Fig. 12.4), which is otherwise
underestimated by measurement of the tracer retention (net uptake) alone. It also
allows visualization of the stress/rest perfusion or flow reserve (MPR or MFR) as a
measure of the total coronary vascular dilator capacity.
A one-tissue-compartment model is often used to describe the early kinetics
(e.g., 0–5 min) of tracer exchange between the arterial blood supply and myocardial
target tissues. This model has been validated for rubidium-82 (82Rb) imaging in
humans using nitrogen-13 (13N)-ammonia PET as the reference standard [22] and
Fig. 12.3 Quantification of MBF using dynamic PET imaging. Dynamic images are acquired
starting at the time of tracer injection, then activity in the LV cavity and myocardium is measured
over time and fit to a one-tissue-compartment model of the tracer kinetics. The influx rate of tracer
uptake or transfer from blood to tissue (K1 mL/min/g) is related to MBF, according to a tracer
extraction function E(MBF)
12 Noninvasive PET Flow Reserve Imaging to Direct Optimal Therapies for. . . 157
has been demonstrated to give very reproducible results using several investiga-
tional and commercial implementations as shown in Fig. 12.5a, b [9, 27, 31]. Test-
retest repeatability of the method (Fig. 12.5c) is approximately 10–12 % CV
(coefficient of variation) at rest and 6–7 % during pharmacologic stress [11, 30],
comparable to the theoretical expected values verified recently using Monte-Carlo
and analytic simulations [25].
Resting MBF is known to correlate highly with the metabolic demands of
normal cardiac work [4] as shown in Fig. 12.6; therefore, it is common to adjust
the rest of the MBF values to an average reference standard value (e.g., 8500 in
typical patients). There a normal age-related increase in RPP, which also contrib-
utes to a progressive decline in MPR [10]. The adjusted values at rest represent the
expected MBF under conditions of normal controlled systolic blood pressure and
heart rate, which are often elevated in patients undergoing stress MPI. The
RPP-adjusted MPR represents the flow reserve that would be expected in a patient
with normal resting hemodynamics, which may be used to evaluate impairments in
coronary vasodilator function associated with atherosclerosis that are unbiased by
the effects of resting hypertension.
Because of the wide physiological variability in rest MBF values between
patients, interpretation of absolute PET flow studies is recommended to include
both the stress MBF and the stress/rest perfusion reserve in combination [18] as
illustrated in Fig. 12.7. Abnormalities in both flow reserve< 1.5–2 and stress
MBF< 1 mL/min/g have been suggested to represent ischemic tissues that should
be considered for revascularization [17]. The absolute flow increase (stress–rest
MBF delta) has also been proposed as an alternative method to evaluate the
vasodilator response in some studies of vascular endothelial function [36] but has
not been as widely applied in practice.
The diagnostic utility of PET MPR assessment has been confirmed in patients
with multivessel disease [40]. As shown in Fig. 12.8a, there is a 50 % likelihood of
three-vessel disease in patients with a global LV flow reserve that is severely
Fig. 12.4 Polar-maps of MBF (flow), 82Rb uptake (K1 influx rate), and retention (net
influx efflux) demonstrating the effects of nonlinear tracer extraction and washout. MBF esti-
mation restores the true disease-to-normal tissue contrast and increases the sensitivity to detect
focal disease relative to areas of maximal flow
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impaired (MPR¼ 1), whereas the balance of patients presumably have severe
microvascular disease limiting their ability to increase myocardial perfusion from
rest to peak stress. Measurements of absolute MPR also have prognostic value that
is incremental and independent of the standard assessments of relative MPI [41], as
shown in Fig. 12.8b. Patients with normal MPI (SSS< 4) but abnormal flow reserve
(MFR< 2) are at increased risk of cardiac events. In the case of abnormal MPI, if
Fig. 12.5 MBF values measured using the one-tissue-compartment model are highly reproducible
between several investigational (A) and commercial (B) software implementations. Rest and stress
flow values are generally within 15–20 %, allowing multicenter data to be pooled or combined
between vendors. Test–retest repeatability is 7–10 % at stress and rest (C), for single-session back-
to-back scans
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flow reserve is also impaired, then these patients have the highest rate of cardiac
events within the following year. Similar findings have reported in a separate cohort
of ischemic heart disease patients [26]; those with the lowest values of MPR had the
highest cardiac event rates. Despite these observational studies, there is a lack of
evidence proving that revascularization of ischemic myocardium as identified by
absolute flow imaging will result in a lower risk of cardiac death or myocardial
infarction.
Fig. 12.6 MBF at rest is correlated with the heart rate  systolic blood pressure product (RPP).
Peak stress/rest MPR decreases with age as a result of changes in microvascular reactivity and
diffuse atherosclerosis. A median MPR value of 2.0 is observed at age 65 (red star)
Fig. 12.7 Clinical interpretation of PET quantitative MBF measurements at rest, stress, stress/rest
reserve (MPR), and stress–rest delta. The “regional distribution” map is a combination of the flow
reserve and stress flow maps, according to the scheme shown on the bottom right
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12.3 Fractional Flow Reserve Assessment
Invasive coronary angiography methods have been developed over the past two
decades to quantify the functional or hemodynamic significance of epicardial
coronary artery disease, using proximal-distal pressure measurements of the frac-
tional flow reserve ratio (FFR) [13], as illustrated in Fig. 12.9. FFR is defined as the
fractional pressure drop measured across one or more stenoses in an individual
coronary artery. Interestingly, invasive measurements of FFR were originally
validated against 15O-water PET measurements of relative MPR [5]. As shown in
Fig. 12.10, coronary FFR values were similar to the relative MPR on average,
whereas the myocardial FFR shows a small bias of approximately +10 % vs. the
PET analogous values.
Epicardial stenoses with abnormal FFR< 0.75 were initially shown to identify
the presence of myocardial ischemia with high accuracy compared to a positive test
on one or more of three noninvasive methods: exercise thallium planar imaging, or
dobutamine stress echocardiography, or treadmill exercise ECG (Fig. 12.11)
[33, 34]. This FFR threshold is therefore very sensitive for the detection of
ischemia, because it correlates with ischemia on any of the reference standards
above.
Test-retest repeatability of FFR measurements has been reported in the range of
4–7 % CV [6, 29, 32], similar to the precision of PET stress MBF (Fig. 12.12). This
has led to the adoption of a 5 % “gray zone” of uncertainty in FFR measurements
considered to be hemodynamically significant or flow limiting.
The pivotal FAME trial [38] showed that percutaneous coronary intervention
(PCI) revascularization using coronary stenting of anatomically and hemodynam-
ically significant lesions (stenosis 50 % and FFR 0.80) improved cardiac out-
comes (Fig. 12.13) and reduced the total cost of treatment compared to the standard
practice of revascularization for anatomically significant lesions only
Fig. 12.8 Diagnostic utility of MPR (MFR) in multivessel disease is shown on the left [40].
Patients with global flow reserve< 1 have > 50 % probability of three-vessel disease; the
remaining patients have severe microvascular disease. Patients with reductions in flow reserve
(MFR< 2) have lower event-free survival, regardless of whether their relative perfusion (SSS) is
normal or abnormal [41]
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Fig. 12.9 Fractional flow reserve is measured as the ratio of intracoronary pressure distal to a
stenosis and relative to the (proximal normal) aortic pressure during peak adenosine pharmaco-
logic stress. Comparison of the FFR measurements to coronary angiography allows identification
of flow-limiting stenoses that are optimal targets for revascularization
Fig. 12.10 Invasive measurements of FFR were originally validated against 15O-water PET MBF
studies in a group of N¼ 22 patients with single-vessel coronary artery disease. Coronary
(epicardial) FFR produced values that were ~10 % higher than the relative flow reserve (relative
MPR) values. The myocardial (epicardial +microvascular) FFR values corrected for atrial venous
pressure were more accurate on average, but demonstrated an increasing trend versus PET.
Adapted from [5]
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(stenosis> 50–70 %). However, there remains a significant cost (interventional
pressure wires) and patient morbidity (risk of embolic strokes) associated with this
invasive procedure. While FFR provides a useful physiological assessment of epi-
cardial stenoses, it does not assess the severity of microvascular disease and actually
underestimates the functional significance of epicardial lesions in the presence of
microvascular disease [35]. Despite these limitations, FFR has recently been
upgraded to a class I(A) indication in Europe and class IIa(A) in North America for
use in directing revascularization therapy to improve clinical outcomes.
12.4 Noninvasive PET (MPR) vs. Invasive Coronary
Angiography (FFR)
Reductions in the supply of blood to the myocardium are caused by two separate
consequences of disease: (1) epicardial coronary stenoses and (2) microvascular
dysfunction. The “flow-limiting” epicardial stenoses should be identified ideally
Fig. 12.11 Fractional flow reserve (FFR) compared to ischemia testing in N¼ 45 patients, using
exercise ECG, thallium imaging, and stress echo [34]. Abnormal FFR< 0.75 was reported to have
88 % sensitivity and 100 % specificity to identify ischemia according to stress echo or exercise
thallium imaging or exercise-ECG tests combined(*), but specificity decreases dramatically in the
“gray zone” between the FFR cutoff values of 0.75 to 0.80 and when FFR is compared individually
to the ischemia standard tests. At the FFR cutoff value< 0.80 commonly used to direct revascu-
larization, fewer than 50 % of subjects had exercise-ECG, stress echo, and thallium tests that were
all positive for ischemia
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as targets for revascularization, whereas patients with diffuse or microvascular
disease may be better treated with targeted aggressive medical therapies such
as lipid-lowering statins or other novel drug treatments under development
to improve endothelial function by increasing nitric-oxide bioavailability, for
example.
Myocardial and fractional flow reserve measurements represent different
hemodynamic effects of microvascular and epicardial disease. The interrelated
physiological interpretation of PET MFR vs. invasive FFR measurements has
been the subject of several recent reviews [14, 19]. The discordance between FFR
and MPR is attributed to the differences in epicardial vs microvascular disease
(Fig. 12.14c) and is consistent with our PET data in over 3,000 patients
(Fig. 12.14a, b).
As illustrated in Fig. 12.1, noninvasive PET imaging of MPR measures the
capacity to increase perfusion (and tracer delivery) in the downstream microvas-
culature within the myocardium, reflecting the combined “total” effects of micro-
vascular and epicardial disease. Invasive FFR measures the pressure drop across a
Fig. 12.12 Test-retest repeatability of back-to-back FFR measurements 10 min apart (4 % CV),
reanalyzed from the DEFER study by [32]. The measurement (or classification) uncertainty is shown
as the red-green colorbar, reflecting the probability that a revascularization decision would change
with repeat measurement. The conventional diagnostic uncertainty or “gray zone” of 0.75–0.80 is
shown as the grey-green colorbar
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single epicardial stenosis during hyperemic stress, representing the peak flow
compared to the (restored or expected) normal flow in the absence of stenosis.
FFR determines whether a particular epicardial lesion is “flow limiting”; however,
this measurement assumes that maximal peak-stress vasodilatation was achieved in
the downstream microvasculature. Therefore, in the presence of microvascular
dysfunction, FFR can be overestimated (i.e., the severity of disease underestimated)
due to a submaximal stress flow response, resulting in underdiagnosis and potential
undertreatment of the disease [35].
There is a wide variation in reported MFR values at a given lesion stenosis
severity (Fig. 12.15a) confirming the influence of confounding variables such
as peak-MFR and/or microvascular flow reserve (uVR). Measurements of total
MFR alone cannot separate the fundamental difference in stress flow responses
present in the epicardial conduit arteries vs. the microvascular resistance vessels.
This effect is illustrated in Fig. 12.15b showing that a 70 % stenosis can appear to
have normal or abnormal FFR depending on the peak hyperemic flow response
(peak-MFR).
We have proposed a simple model describing MPR as the sum total of uVR
and epicardial CFR as shown in Fig. 12.15c. This model is consistent with
Fig. 12.13 The FAME randomized controlled trial in N¼ 1005 patients showed that clinical
outcome was improved (87 % vs. 82 % event-free survival; p¼ 0.02) using FFR-guided revascu-
larization by PCI with drug-eluting stents in patients with intermediate-grade stenosis> 50 % and
FFR< 0.80. The FFR-guided approach also resulted in 30 % fewer stents placed per patient
(p< 0.001) and 11 % lower overall costs including the added FFR pressure wires [38]
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previous observations that MFR decreases with increasing lesion stenosis%, but
at different reference levels depending on the burden of microvascular disease.
uVR is presumed to be independent of epicardial stenosis severity, also consistent
with previous invasive measurements of microcirculatory resistance (IMR)
[39]. The model predicts that a particular threshold value (EFR¼MPR – uVR)
for epicardial coronary revascularization will only improve symptoms of ischemia
in patients without severe microvascular disease, e.g., with uVR> 0, as shown in
Fig. 12.15d. Conversely, myocardial ischemia may be overestimated in young
patients without uVD, where an “apparent ischemic” stress perfusion defect in a
patient with very high peak-MFR may still be above the true ischemic threshold
of stress MBF.
Fig. 12.14 Discordance between FFR and MPR is due to the physiological differences in focal
epicardial vs. diffuse or microvascular disease. (A) Invasive [and (B) noninvasive] measures of
CFR [and absolute MPR] vs. FFR [and relative MPR] measurements can be discordant in some
patients, due to the different physiological consequences of focal vs. diffuse microvascular
disease (C). Adapted from [19]
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12.5 Conclusion
Noninvasive nuclear imaging of myocardial blood flow (MBF) and coronary flow
reserve (CFR) is now feasible as part of the clinical routine using positron emission
tomography (PET) imaging. PET measurements of absolute MBF are reliable and
reproducible between imaging centers and software methods, with test–retest
repeatability below 10 % coefficient of variation. Ischemic thresholds have been
proposed for stress MBF and coronary flow reserve in the range of 1.5 [mL/min/g]
and 1.0 [stress/rest MBF], respectively. Prospective trials are needed to determine
whether patient outcomes can be improved using these ischemic thresholds to direct
appropriate revascularization vs. optimal medical therapies.
Fig. 12.15 Total myocardial perfusion (flow) reserve (MPR) is a function of epicardial stenosis
severity (0–100%) andmicrovascular vasodilator response (uVR) as shown in (A,B). In patients with
severemicrovascular (endothelial) dysfunction (e.g. uVR¼−0.5), invasivemeasurement of fractional
flow reserve (FFR)may appear normal in coronary lesions up to 90% stenosis (C), due to the absence
of hyperemic flow response (peak-MFR¼1.0). Epicardial flow reserve (EFR¼MPR–uVR) may be
useful to identify flow-limiting lesions associated with myocardial ischemia (D)
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Chapter 13
The Clinical Value of Cardiac PET in Heart
Failure
Chi-Lun Ko and Yen-Wen Wu
Abstract Heart failure (HF) is a complex clinical syndrome that results from any
structural or functional impairment of ventricular filling or ejection of blood [1].
Approximately 5 million patients in the USA and 15 million patients in Europe
have HF. It is the leading cause of hospitalization in elderly people. Despite
treatment advances, the mortality rate of HF has increased steadily. More patients
are surviving myocardial infarction (MI) due to better standards of care, and
consequently this may increase numbers of patients who subsequently develop
HF. HF places a significant burden on patients, carers, and healthcare systems.
Limited progress has been made in identifying evidence-based, effective treat-
ments for HF over the last decades. Potential contributors include an incomplete
understanding of pathophysiology and poor matching of therapeutic mechanisms.
Positron emission tomography (PET), as a molecular imaging technique, with
various tracers allows noninvasive evaluation of contractile function, myocardial
perfusion, metabolism, and innervation. Molecular imaging approaches using PET
could be further used to evaluate inflammation, angiogenesis, cell death, and
ventricular remodeling. It could provide new insights on the chemotherapy-related
cardiotoxicity and the roles of stem cell monitoring in living bodies for cell-based
therapy from preclinical studies to clinical trials. In conclusion, cardiac PET is a
promising tool to understand the physiologic consequences of HF, resulting in early
detection of patients with HF at risk, improvement of risk stratification, and
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therapeutic strategy planning and treatment response monitoring. Therefore, in
order to give the readers a brief and concise overview, we will mainly review the
latest advances in cardiac PET studies in heart failure.
Keywords Heart failure • Positron emission tomography • Myocardial perfusion •
Myocardial metabolism • Neuroautonomic system
13.1 Perfusion
13.1.1 Coronary Artery Disease (CAD) and Microvascular
Dysfunction
Patients presenting with HF are initially classified based on the etiology of their
disease, i.e., ischemic or nonischemic cardiomyopathy. The diagnosis of HF is clear
if prior MI is reliably documented. With the wide availability of single-photon
emission computed tomography (SPECT) cameras and perfusion tracers, SPECT is
currently the preferred imaging modality of cardiac radionuclide imaging with good
diagnostic accuracy and prognostic significance.
PET provides better image quality because of higher spatial resolution, less
scatter, and fewer attenuation artifacts and may be superior to SPECT with respect
to imaging quality, interpretative confidence, and inter-reader agreement. In addi-
tion, PET allows quantitative measurement of myocardial perfusion (MP) and
metabolism. Cardiac PET with perfusion tracers, such as [15O]-water, [13N]-ammo-
nia, 82rubidium, and [18F]-flurpiridaz [2], allows noninvasive and absolute assess-
ment of regional and global myocardial blood flow (MBF) in ml/min/g. In
conjunction with stress, regional and global coronary flow reserve (CFR) can also
be calculated, which is the ratio between MBF at peak stress and MBF at rest.
CFR measures not only vasodilator capacity but also endothelial reactivity of the
coronary circulation, allowing noninvasive quantitative assessment for patients
with diffuse coronary luminal narrowing or microvascular dysfunction.
Coronary microvascular dysfunction is highly prevalent among at-risk individ-
uals and is associated with adverse outcomes regardless of sex, even in the absence
of overt coronary atherosclerosis [3]. It may reflect the functional alteration of
endothelium, such as hypertension, dyslipidemia, diabetes mellitus, smoking, obe-
sity, or metabolic syndrome, or structural alteration of microangiopathy, myocar-
dial fibrosis, or loss of capillaries. The portion of HF consists predominantly of
older age and high prevalence of comorbidities. The systemic pro-inflammatory
state may induce coronary endothelial inflammation, microvascular dysfunction,
myocardial substrate shift, myocardial and interstitial fibrosis that contribute to
high diastolic left ventricular stiffness, and HF development, even with preserved
LVEF. The potential roles of myocardial perfusion abnormalities in subjects with
cardiovascular risks, metabolic disease, and HF warrant further investigations.
In patients with CAD, a reduced CFR was shown to have prognostic implica-
tions, being a more sensitive predictor for cardiac death than was reduced left
172 C.-L. Ko and Y.-W. Wu
ventricular ejection fraction (LVEF). CFR in patients with CAD was found to be
also reduced in areas supplied by non-stenotic vessels, suggesting a microvascular
component. A recent study showed an association between global CFR and major
adverse cardiovascular events (MACE) independently of angiographic CAD prog-
nostic index (CADPI) [4]. This may attribute to diffuse atherosclerosis or micro-
vascular dysfunction. In addition, global CFR also modified the effect of coronary
revascularization in terms of event-free survival. These emphasize the utility of
cardiac PET in patient risk stratification and the role in decision-making for
coronary revascularization.
13.1.2 Transplant Vasculopathy
Cardiac allograft vasculopathy (CAV) is one of the leading causes of late mortality
after heart transplantation. It is characterized by the diffuse concentric intima
thickening of both epicardial and intramyocardial arteries, which is difficult to be
assessed by traditional coronary angiogram. Intravascular ultrasound (IVUS) has
been proposed to be the most sensitive method for diagnosis of early CAV. Due to
the progressive and diffuse process involving the epicardial and microvascular
coronary system, traditional stress myocardial perfusion SPECT frequently under-
estimates disease severity and extent in patients with CAV. With the absolute-
quantitative nature, PET provides a noninvasive way to deal with this problem. A
good correlation was observed between plaque burden as determined by IVUS and
CFR as assessed by 13N-ammonia PET in recipients with normal coronary angiog-
raphy findings. Quantitative measurement of myocardial flow using dynamic 13N-
ammonia PET is thus clinically feasible [5]. A recent study enrolled
140 posttransplant recipients with median follow-up of 18.2 months; the relative
perfusion defects, mean myocardial flow reserve, and mean stress MBF using
dipyridamole rubidium-82 PET were significant predictors of adverse outcome [6].
13.2 Sympathetic Innervation
Neurohormonal activation is considered as a compensatory mechanism in HF
and maintains perfusion to the heart, yet in the meanwhile is also responsible for
the progression of HF. From a long-term point of view, it is associated with
cardiac remodeling, progressive impairment of ventricular function, symptoms,
and lethal arrhythmia. Despite their critical role in regulation of the heart, local
neurohormonal statuses of patients are not routinely and closely monitored in
clinical practice. Innervation imaging may provide prognostic information as well
as guide selection of therapies. Both a decreased cardiac [123I]-meta-iodobenzyl-
guanidine (MIBG) activity and an increased washout rate are indicative of a poor
prognosis in patients with chronic heart failure [7]. Several PET tracers, including
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[11C]-meta-hydroxyephedrine (HED), a norepinephrine analog, and [11C]-
CGP12177, a beta-adrenoceptor antagonist, not only can be used to visualize global
but also regional defects in myocardial sympathetic innervation. A pilot study
enrolled 10 patients with dilated cardiomyopathy who underwent PET with [11C]-
HED before, acutely and 3 months after cardiac resynchronization (CRT) [8]. It
showed CRT improves cardiac sympathetic nerve activity in responders and seems
to be more effective in those with functionally preserved neuroautonomic system.
Decreased cardiac beta-adrenoceptor density measured by [11C]-CGP12177
PET was observed in a study of patients with nonischemic cardiomyopathy. In
addition the receptor density was significantly correlated with systolic function
[9]. Receptor density correlated with [123I]-MIBG washout rate and delayed heart-
to-mediastinum (H/M) ratio, but not early H/M ratio. Another study showed that
reduced myocardial beta-adrenoceptor density measured by [11C]-CGP12177 early
after myocardial infarction is associated with the incidence of congestive heart
failure on long-term follow-up [10]. Besides [11C]-labeled tracers, [18F]-N-
[3-Bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (LMI1195), an 18F-labeled ana-
log of [123I]-MIBG SPECT agent, is a new PET tracer retained in the heart through
the norepinephrine transporter (NET) and allowing evaluation of the cardiac sym-
pathetic neuronal function by PET imaging [11–13].
13.3 Noninvasive Assessment of Myocardial Metabolism
13.3.1 Myocardial Viability
Myocardial viability, the evaluation of dysfunctional but viable myocardium, can
be assessed by several imaging techniques. In conjunction with dobutamine, con-
tractile reserve can be evaluated by either echocardiography or cardiac magnetic
resonance imaging (MRI). Delayed contrast-enhanced (DCE) MRI and contrast-
enhanced CT can assess scar tissue. Myocardial perfusion SPECT evaluates either
cell membrane or mitochondria integrity. [18F]-fluorodeoxyglucose (FDG) can be
used to assess glucose metabolism and to differentiate the hibernating myocardium
from scar tissue. Dual-isotope simultaneous acquisition (DISA) viability testing,
the combination of [99mTc]-sestamibi and [18F]-FDG SPECT, provides more accu-
rate prediction of post-revascularization functional recovery than thallium-201
[14]. PET using FDG remains the most reliable and noninvasive tool to assess
myocardial viability [15] and tends to replace Tl-201 SPECT imaging in centers
equipped with a PET/CT camera.
For patients with CAD-associated chronic LV dysfunction, noninvasive detec-
tion of myocardial viability is crucial for decision-making of the treatment. Myo-
cardial viability imaging can be used to inform the often difficult clinical decision
regarding revascularization in patients with CAD and left ventricular systolic
dysfunction, providing data on the potential benefit to balance against the known
risks [15]. FDG PET has a higher sensitivity than DCE MRI, but comparable
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specificity, in predicting functional recovery [16]. The post hoc subgroup analysis
of the PET and Recovery Following Revascularization (PARR-2) trial suggested
that FDG PET-guided management reduces the composite of cardiovascular events
in patients with ischemic cardiomyopathy in a center with an experienced imaging
team [17].
Despite that several studies have emphasized the utility of viability imaging in
identifying patients who may benefit from revascularization, a recent meta-analysis
shows confusing results [18]. Patients with viable myocardium appear to benefit
from revascularization, but the same benefits were observed in patients without
viable myocardium. Some suggested this might be resulted from mixed traditional
(SPECT and dobutamine echocardiography) and the advanced (MRI and PET)
imaging techniques, but this was still not conclusive [19, 20]. A large prospective
randomized trial regarding Alternative Imaging Modalities in Ischemic Heart
Failure (AIMI-HF) has conducted in 2013 [21], which will complement the results
of the Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy
and the PET and PARR-2 trial to answer this unsolved issue.
13.3.2 Cardiac Efficiency
[11C]-acetate, a well-known myocardial PET tracer, is directly metabolized into
[11C]-acetyl-CoA in mitochondria and enters the Krebs cycle. [11C]-acetate PET
imaging provides noninvasive and reproducible measurements of cardiac oxidative
metabolism (MVO2) [22]. Heterogeneously decreased oxidative metabolism was
observed in patients with ischemic and nonischemic cardiomyopathy [23]. In
chronic HF MI porcine model, myocardial perfusion and oxygen consumption in
the remote non-infarcted myocardium were preserved in HF pigs as compared to
controls. Global LV work and efficiency were significantly lower in HF than
controls and were associated with increased wall stress [24]. It can also be used
to evaluate cardiac efficiency under variable conditions, especially after treatments
of heart failure. Surgical intervention with LV volume reduction and mitral regur-
gitation correction significantly improved cardiac efficiency in patients with
end-stage heart failure, which is observed in both nonischemic and ischemic
etiologies [25].
On the other hand, myocardial oxygen metabolism was increased in patients
with aortic stenosis (AS), which was decreased after aortic valve replacement
[26]. It is suggested that the increased myocardial oxidative metabolism in AS
was largely attributable to the pressure overload of the left ventricle and normalized
after unload.
In a study of diastolic heart failure patients, decreased cardiac efficiency is
associated with increased LV filling pressure but does not primarily cause diastolic
dysfunction or diastolic heart failure in normal hearts [27]. They suggest that
improvement of cardiac efficiency may be a target for the treatment of heart failure
with preserved ejection fraction (HFpEF).
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13.3.3 Cardiac Resynchronization Therapy (CRT)
CRT can correct cardiac dyssynchrony and augment LV systolic function. PET is
the only noninvasive imaging technique that can provide information on alternations
of myocardial blood flow, glucose utilization, and oxygen consumption. [11C]-
acetate PET can also be used to evaluate the efficacy of CRT in patients with severe
heart failure [8, 28–31]. CRT could improve cardiac systolic function, but global
resting MBF and global MVO2 are not always altered by CRT, even under stress
condition [28]. A more homogeneous myocardial glucose uptake was observed,
which implies CRTmay induce a more balanced wall stress and energy requirement.
Another study demonstrated that decreased oxygen consumption was observed in
patients showing good response to CRT. The decrease in oxygen consumption
assessed by PET in the early period after CRT is useful to predict improvement of
cardiac function and major cardiac events during the first year of follow-up [31].
13.3.4 Chemotherapy-Related Heart Failure
[11C]-acetoacetate, a ketone body tracer, is expected to have some similarities to
[11C]-acetate. In mitochondria, acetoacetate is first converted into acetoacetyl-CoA
and then into acetyl-CoA. In cytoplasm, acetoacetate can also be directly incorpo-
rated into the lipogenesis pathway. Contrary to [11C]-acetate and other MBF PET
tracers, [11C]-acetoacetate together with dynamic gated PET imaging was able to
identify doxorubicin-induced heart failure at an early stage in a resting state. Thus,
[11C]-acetoacetate is promising for the assessment of cardiomyopathy [32].
13.3.5 Metabolic Therapy
Heart failure severity, substrate availability, hormonal status, and coexisting insulin
resistance contribute to the metabolic change. Optimizing myocardial energy
metabolism has been studied as a novel form of therapy [33]. Metabolic therapy
is a promising new avenue for the treatment of heart failure. Suitable targets for
therapy include substrate utilization, oxidative phosphorylation, and the availability
of high-energy phosphates [34].
Insulin resistance is a recognized phenomenon leading to heart failure. The
change in myocardial metabolism can be visualized using PET with metabolic
tracers. A prospective study utilized [15O]-water, [11C]-acetate, [11C]-glucose, and
[11C]-palmitate PET studies and found that obesity and gender independently
modulate MBF and MVO2. Moreover, gender and obesity may interact in
predicting myocardial glucose uptake and insulin sensitivity [35]. FDG PET can
also be used in evaluation of the effect of therapy on glucose metabolism. In a
transgenic mice model, G protein-coupled receptor kinase 2 inhibition delays the
reduction in glucose uptake and protects insulin signaling in the heart, preserving
cardiac dimension and function [36].
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13.4 Molecular Imaging Approaches of Cardiac
Remodeling
13.4.1 Imaging of Matrix Metalloproteinases
The matrix metalloproteinases (MMPs) play a role in physiologic extracellular
matrix (ECM) turnover and response to cardiac disease. During the progression
of HF, the level of MMPs is increased. The excessive degradation of ECM may
result in wall thinning, dilatation, and heart failure. Post-MI myocardial LV
remodeling is also associated with changes within the myocardial extracellular
matrix and often leads to heart failure. MI results in the activation of the renin-
angiotensin-aldosterone system, which in turn results in the activating of MMPs
within the heart. Molecular imaging of MMPs has the potential to allow early and
serial evaluation of underlying alterations that accompany progression of LV
remodeling [37]. The activation of MMPs in infarcted murine myocardium can
be imaged by [111In]- and [99mTc]-labeled single-photon ligands [38]. Several PET
tracers have also been synthesized [39]. However, to date there are only limited
publications, especially in the field of HF.
13.4.2 Angiogenesis
Angiogenesis occurs in response to ischemia and inflammation being part of the
healing process after ischemic tissue injury. [18F]-galacto-RGD allows noninvasive
imaging of the expression of αvβ3 integrin that is highly expressed in the endothe-
lium of angiogenic vessels. Noninvasive imaging using [18F]-galacto-RGD PET
appears promising for the monitoring of therapies aiming to stimulate angiogenesis
in ischemic heart disease and preventing the development of HF [40].
13.4.3 Myocardial Inflammation
FDG PET may be useful in the study of inflammatory process since inflammatory
cells accumulate glucose. However, a recent study showed some limitations to
study the inflammatory process after myocardial infarction even when active uptake
of FDG in normal myocardial tissue is suppressed. In the presence of large region of
microvascular obstruction, FDG may not reliably and accurately represent the
degree of inflammatory cell activity. Even in areas without microvascular obstruc-
tion, the degree of inflammation may be underestimated or even overestimated [41].
Besides the usefulness as a molecular target for neuroendocrine tumor imaging,
some of the somatostatin receptors are also expressed by activated macrophage. A
recent animal study compared [68Ga]-citrate, [68Ga]-DOTATATE, and [18F]-FDG
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in a postinfarction mouse model [42]. They conclude that FDG with myocardial
suppression is the most practical imaging marker of postinfarction inflammation.
However, there are also some studies in human that emphasize the usefulness of the
somatostatin receptor imaging in the assessment of sarcoidosis [43] and infarction
[44]-related myocardial inflammation. Compared with the nonspecific FDG, this is
a new potential biomarker that may be useful in evaluation of myocardial inflam-
mation and predicting cardiac remodeling and progression toward heart failure.
13.5 Conclusions
Advances in the application of cardiac PET may play an increasingly critical role in
diagnosis, prognosis, and clinical treatment of cardiovascular diseases. Molecular
imaging approaches using PET could evaluate myocardial pathophysiology at
different stages of HF. It further provides insights on the HF preventive strategies,
tracking patients’ clinical status, novel drug therapies, expanding indications for HF





























































Fig. 13.1 Potential roles of PET imaging in different stages of American College of Cardiology
(ACC)/American Heart Association (AHA) classification of heart failure. CAV cardiac allograft
vasculopathy, CFR coronary flow reserve, HRQOL health-related quality of life, ICD implantable
cardioverter defibrillator, MBF myocardial blood flow, LV left ventricular, LVAD left ventricular
assist device
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Chapter 14
Emerging Trends and Future Perspective
of Novel Cardiac SPECT Technology
Masao Miyagawa, Yoshiko Nishiyama, Hayato Ishimura,
Rami Tashiro, Kana Ide, and Teruhito Mochizuki
Abstract In response to concerns about overuse and increasing radiation exposure
of myocardial perfusion imaging, nuclear medicine societies have declared state-
ments aimed at lowering its radiation dose and costs. Simultaneously, two vendors
have launched novel SPECT scanners with solid-state semiconductor detectors.
Discovery NM 530c and D-SPECT utilize the same cadmium zinc telluride (CZT)
detectors with a different combination of high-sensitivity multi-pinhole or parallel-
hole collimator which focuses on the heart. The physical performance of those is
dramatically higher than that of conventional Anger cameras; however, 2 CZT
cameras are inherently different.
Although 99mTc-labeled myocardial perfusion tracers might not be ideal agents,
estimation of absolute myocardial blood flow or myocardial flow reserve (MFR)
using dynamic CZT SPECT is a challenging subject and attracts a great deal of
interest in the field. Thus, novel software which allows automatic calculation of
MFR index with dynamic CZT SPECT is currently under development and vali-
dated in our institution. This technology will hold promise if the several issues can
be solved through future studies.
Keywords Cadmium zinc telluride • Cardiac SPECT • Coronary flow reserve •
Effective dose • Dynamic imaging
14.1 Introduction
The overall utilization for stress myocardial perfusion imaging (MPI) reached its
height in 2006 with over 10 million studies and Medicare payment over 1 billion
dollars [1]. The National Council on Radiation Protection and Measurements
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reported that since the early 1980s, a six-fold increase in radiation exposure to the
US population from medical procedures [2] emphasizes that more than 10 % of the
entire radiation burden was related to MPI [3]. In response to these concerns,
professional societies have declared statements aimed at lowering its radiation
dose and costs [4, 5].
Simultaneously, vendors have developed dedicated cardiac SPECT scanners
with solid-state semiconductor detectors in order to do something about radiation
dose and long imaging time. Two vendors have introduced novel scanners: Dis-
covery NM 530c, (D530c); GE Healthcare and D-SPECT; and Spectrum Dynamics
utilizing the same cadmium zinc telluride (CZT) detectors, with a different combi-
nation of high-sensitivity multi-pinhole or parallel-hole collimators which focuses
on the myocardium [6, 7]. More than 300 of such cardiac CZT SPECT scanners are
currently available in the world, and the number is increasing by more than
100 per year.
Firstly, we focus on the latest advances in MPI procedures which ought to be
able to maximize the value of SPECT cameras with CZT detectors. Secondly, we
try to develop a novel software for calculating the myocardial flow reserve (MFR)
index using these cameras and to validate its utility for screening patients with
multi-vessel coronary artery disease (CAD).
14.2 Materials and Methods
Initially, we conducted a comparative study using 99mTc line-source phantoms with
and without photon scattering caused by water in the cylinder [8]. D530c had a
more than two-fold spatial resolution than did the conventional Anger camera
with a dual detector (Infinia; GE Healthcare). We also found that a D530c has
better energy resolution compared to Infinia, which is as narrow as 5 %. Therefore,
energy window width could be narrowed enough to be feasible for performing dual
radioisotope simultaneous SPECT with 99mTc-tetrofosmin and 123I-BMIPP [9].
MPI protocol for routine clinical practice of our institution at present is summa-
rized in Fig. 14.1. We adopt a stress-first one-day protocol with 99mTc-perfusion
tracers. CZT camera has a 5-times higher sensitivity; therefore, patients are given
an injection of only 3 MBq/kg body weight (4–5 mCi) of 99mTc-perfusion tracers at
peak stress. Supine and prone imaging with 5 min each is routinely performed
[10]. Same-day rest imaging was performed after 9 MBq/kg of tracer injection. If
we apply a strategy of stress-only protocol to our routine clinical practice, we will
get further reduction in the effective radiation dose of patients and higher laboratory
throughput.
Dynamic MPI starting with the bolus administration of 99mTc-perfusion tracers
as described above was also performed during adenosine stress and at rest using the
CZT camera. We intravenously injected saline followed by radionuclide, using an
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automatic injector at a constant rate of 1 milliliter per second for 30 s (Fig. 14.2).
Before dynamic imaging, we carefully detected the border of the heart by chest
percussion or test injection of 0.5 mCi of tracers in order to adjust the position of the
heart appropriately in the quality field of view [11]. The interval between stress and
rest imaging was 3 h and a 30-s pre-scan count was subtracted from the dynamic
data at rest. 10-min dynamic SPECT data with list mode acquisition were
reconstructed using a maximum likelihood expectation maximization (MLEM)
algorithm with 40–50 iterations. We generated 200 3-D volumes integrating 3-s
time frames in the course of 600 s. Routine MPI were also acquired thereafter.
The software allows the automatic edge detection of volume of interest for the
blood pool in the left ventricle and the myocardium. Global time-activity curves
were fitted to a one-tissue two-compartment kinetic model (2-com), a Patlak plot
analysis (PPA), and a dose uptake ratio of MPI (DUR) with input function. K1 and
K2 were calculated for the stress and rest images. MFR index was calculated as
follows: MFR index¼K1 stress/K1 at rest.
The validation study included 64 consecutive pts who underwent CZT SPECT
and invasive coronary angiography within 2 weeks (35 males, 67 10 years old).
15 pts had single-vessel CAD, and 22 pts had multi-vessel CAD (10 had two-vessel
and 12 had three-vessel CAD) and 27 pts with no significant coronary stenosis
less than 70 %.
0 
supine prone 
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acquisition 
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acquisition 
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Fig. 14.1 We adopt a stress/rest one-day protocol with Tc-99m perfusion radiotracers. Supine and
prone positioning are routinely performed. The total effective dose ranged 3.4–6.7 mSv. Stress-
only MPI can be performed with the effective dose averaging 1 mSv
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14.3 Results and Discussion
14.3.1 Reduction in Injection Dose of Radiopharmaceuticals
The introduction of CZT cameras has opened the possibility of reducing radiation
dose of SPECTMPI. Oddstig et al. [12] reported that they performed a 1-day 99mTc-
tetrofosmin stress-rest protocol using D530c in 150 patients who were divided into
three subgroups (50 patients in each group) with 4, 3, and 2.5 MBq/kg body weight
of administered activity in the stress MPI, respectively. The total effective dose
(stress and rest) decreased from 9.3 mSv in the 4 MBq/kg group to 5.8 mSv in the
2.5 MBq/kg group. The image acquisition times for 2.5 MBq/kg were 8 and 5 min
(stress and rest, respectively) compared to 15 min for each when using conventional
SPECT. The average image quality for the stress and the rest showed no statistically
significant difference among the 4, 3, and 2.5 MBq/kg groups.
Starting the MPS protocol with examination at stress and analyzing the stress
images before deciding of the need for rest examination (i.e., to say “stress-only
protocol”) reduce the effective dose [13, 14]. The effective dose was no more than
1.4 mSv for a patient receiving 2.5 MBq/kg, who underwent the stress-only
Fig. 14.2 For bolus administration of tracer, we intravenously injected saline, using an automatic
injector at a constant rate of 1 milliliter per second for 30 s. We started the dynamic data
acquisition just after the bolus injection
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protocol. The total effective radiation dose ranged 3 to 6 mSv with the stress-rest
protocol in our institution. If applied, stress-only protocol would be performed with
the effective dose averaging 1 mSv. Novel CZT technology can considerably
decrease the effective dose for MPI with preserved high image quality.
Moreover, the high sensitivity of D530c allows for a shorter acquisition time;
actually, 5 min is sufficient for QGS in the clinical setting. Although CZT detectors
are higher in cost, they have been shown to provide an eight- to ten-fold increase in
sensitivity, coupled with a two-fold improvement in spatial resolution, and higher
energy resolution enabling a significant reduction in imaging time and dose of
isotopes and a dual radionuclide simultaneous SPECT with 99mTc and 123I [6, 7].
Imbert et al. also conducted analyses of phantom and human SPECT images,
comparing the D530c and D-SPECT CZT cameras with Anger cameras, and
reported that the physical performance of CZT cameras is dramatically higher
than that of Anger cameras; however, 2 CZT cameras are inherently different.
Spatial resolution and contrast-to-noise ratio are better with the Discovery NM
530c, whereas detection sensitivity is markedly higher with the D-SPECT [15].
14.3.2 Attempts to Estimate Coronary Flow Reserve Using
CZT SPECT
At present, coronary flow reserve (CFR) has been mostly replaced by FFR primarily
due to its technical simplicity in the catheterization lab. In contrast, in the nonin-
vasive field, PET-derived CFR is an emerging index used for improving both the
diagnosis and risk stratification in patients with suspected CAD. And with the
increased use, reliable evidences have been suggested that CFR is a powerful
independent predictor of cardiac events and mortality [16–19].
In parallel to the work on these PET studies, some studies have continuously
reported that using first-pass planar scintigraphy in humans [20–24] or dynamic
SPECT in animals [25] provides evidences that the estimates of CFR can be also
derived from conventional SPECT MPI. Although fair agreements have been noted
between CFR estimated by SPECT and PET or intracoronary Doppler flow studies,
they also highlighted the limitations of conventional gamma camera for the
dynamic data collection during rapidly changing radiotracer concentrations [26].
The CZT cameras provide higher temporal and spatial resolution. Dynamic
SPECT imaging during the first pass of a tracer was attained with the use of these
cameras. From the list data, time-activity curves (TAC) would be generated for the
left ventricular cavity (input function) and for myocardial tissue (output function)
during stress and rest. Ben-Haim et al. [27] firstly reported the feasibility of
dynamic 99mTc-MIBI SPECT and quantitation of global and regional CFRs using
the D-SPECT. They calculated CFR index as the ratio of the stress and rest K1
values. Global CFR index was higher in patients with normal MPI than in patients
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with abnormal MPI. The CFR index was lower in territories supplied by stenotic
coronary arteries than in non-stenotic arteries.
Novel software is currently under development in our institution [28]. TACs by
dynamic 99mTc-tetrofosmin SPECT using the D530c during adenosine stress and
rest are shown in Fig. 14.3. TAC can be extracted by averaging the signal intensity
in the volume of interest (VOI) in each time frame and then expressed in counts per
cubic mm3/s. Global TAC was fitted to a 2-com model with input functions which
was served by the blood pool curves. In the validation study, Global MFR index
estimated by the 2-com model is significantly lower in patients with multi-vessel
disease, than those without the disease. In addition, MFR index in the segments of
vascular territories with significant coronary stenosis is significantly lower than
those without coronary stenosis.
Most recently, Wells et al. applied the D530c to a study with a pig model for
quantitation of absolute myocardial blood flow (MBF) using common perfusion
tracers as 99mTc-MIBI, 99mTc-tetrofosmin, and thallium-201 [29]. Dynamic images
were reconstructed with CT-based attenuation correction and energy window-based
scatter correction and then processed with kinetic analysis using a 1-tissue 2-com
model to obtain the uptake rate constant K1 as a function of microsphere MBF.
Converting K1 back to MBF using the measured extraction fractions produced
Fig. 14.3 Dynamic acquisition images were transferred to a workstation for analysis using a novel
software. It allows an automatic definition of a volume of interest (VOI) for the blood pool in the
left ventricle and the left ventricular myocardium. The time-activity curve (TAC) can be extracted
by averaging the signal intensity in the VOI in each time frame and then expressed in counts per
mm3/s
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accurate values and good correlations with microsphere MBF. They have demon-
strated that dynamic SPECT by the CZT camera may be feasible to estimate
absolute MBF.
14.3.3 Advantages and Disadvantages of the Measurement
of CFR with SPECT
At the current moment, PET plays a major role in accurate estimation of MBF or
CFR. However, it has limited value for routine clinical studies because of its higher
cost and more complicated procedures, including the production of short-half-lived
positron tracers by in-house cyclotrons. Therefore, the advantage of SPECT-
measured technique utilizing common technetium-99 m perfusion tracers is that it
would increase the utility of CFR measurement in the clinical setting with a much
smaller financial cost.
On the other hand, the disadvantage of quantifying CFR with SPECT may be the
underestimation of the CFR value, compared to that with PET. The reasons for this
underestimation could be mainly due to the limited extraction of technetium-99 m
perfusion tracers at high flow rates, at which the extraction of the tracer becomes
limited by membrane transport [26].
14.4 Conclusions
We need to explore patient-centered, radiation exposure-controlled, and appropri-
ately designed protocols which do not sacrifice image quality or diagnostic accu-
racy of the new modality. Although 99mTc-labeled radiotracers might not be ideal
flow agents, estimation of absolute MBF or CFR using dynamic CZT SPECT is
challenging and of great interest. This technology will hold great promise if the
several issues can be solved through future studies.
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Chapter 15
Right Ventricular Metabolism and Its
Efficiency
Clinical Aspects and Future Directions
Keiichiro Yoshinaga, Hiroshi Ohira, Ichizo Tsujino, Osamu Manabe,
Takahiro Sato, Chietsugu Katoh, Katsuhiko Kasai, Yuuki Tomiyama,
Masaharu Nishimura, and Nagara Tamaki
Abstract Background: Elevated pulmonary arterial pressure may increase right
ventricular (RV) oxidative metabolism in patients with pulmonary hypertension
(PH) and heart failure (HF). 11C- acetate positron emission tomography (PET) can
be used to measure RV oxidative metabolism noninvasively. The combination of
RV oxidative metabolism and cardiac work, as estimated by cardiac magnetic reso-
nance imaging (CMR), indicates RV efficiency and can provide new insights.
However, the clinical importance of these markers has not been fully studied.
The purpose of this study was to investigate the possible impacts of these markers
in patients with PH through 11C-acetate PET.
Methods: Ventricular function was assessed using magnetic resonance imaging
(MRI). Dynamic 11C-acetate PET was used to simultaneously measure RV and
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left ventricular (LV) oxidative metabolism (kmono). The RV myocardial work per
oxygen consumption index was calculated as follows: [RV stroke volume index
(SVI)/RV kmono]. PH patients who had additional or increased doses of PH-specific
vasodilator(s), based on the joint guidelines of the European Society of Cardiology
(ESC) and European Respiratory Society (ERS) for the diagnosis and management
of PH, were compared with five PH patients who had no treatment modification
(control group).
Results: PH patients showed higher RV kmono than did controls (P< 0.05). RV
oxidative metabolism was correlated with the mean pulmonary arterial pressure
(mPAP) (r¼ 0.44, P¼ 0.021), pulmonary vascular resistance (PVR) (R¼ 0.56,
P¼ 0.002), and brain natriuretic peptide (BNP) (R¼ 0.42, P¼ 0.029). Members
of the PH therapy group had reduced RV oxidative metabolism (P¼ 0.002) and
improved RV work/oxygen consumption index (P< 0.001).
Conclusions: RV oxidative metabolism increased as the correlation between
mPAP and PVR increased. PH-specific treatments reduced RV oxidative meta-
bolism. Therefore, RV metabolism and its efficiency can provide new pathophysio-
logical insights and will be a new therapeutic marker in patients with PH.
Keywords Metabolism • Pulmonary hypertension • Right ventricle • Tomography
15.1 Introduction
The right ventricle (RV) is the anterior cardiac chamber located just behind the
sternum. The RV receives systemic venous return and pumps it into the pulmonary
arteries [1]. Under normal conditions, the RV requires little energy to pump venous
blood to the pulmonary arteries since pulmonary circulation has a much lower
vascular resistance than does systemic circulation [2]. The RV therefore usually has
low oxygen consumption.
Until recently, most cardiology research was concerned with left ventricle
(LV) physiologies and pathologies. In fact, in the early twentieth century, some
groups hypothesized that human circulation could be maintained without RV func-
tion [3]. However, cardiovascular surgeons recognized the importance of RV func-
tion, and RV dysfunction appeared to be associated with major cardiovascular
events in heart failure (HF) [4]. In addition, development of state-of-the-art cardio-
vascular imaging modalities such as echocardiography, cardiac magnetic resonance
(CMR) imaging, and positron emission tomography (PET) have made it possible to
noninvasively evaluate the functional and physiological characteristics of RV myo-
cardium [5, 6]. Based on this background, research on the RV has progressed
intensively in recent years.
One of the major causes of RV dysfunction is pulmonary hypertension (PH). PH
is categorized into five groups as follows: Group 1, pulmonary artery hypertension
(PAH); Group 2, PH with LV disease; Group 3, PH associated with lung disease
and/or hypoxia; Group 4, PH due to chronic thrombosis and/or embolism; and
Group 5, miscellaneous [7]. Elevated pulmonary arterial pressure (PAP) and pul-
monary vascular resistance (PVR) may induce RV dysfunction in patients with PH
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[7]. However, the RV has a high capacity to adapt to pressure or volume overload
before failing in its function [8]. Before myocardial fibrosis and RV heart failure
develop, moderate to severe PH often leads to initial RV adaptation [9]. Given the
increased arterial pressure in pulmonary circulation, the RV may require a signifi-
cant power output in response to increased afterload, and this may increase the
demand for oxygen in the RV [10]. In this circumstance, the RV may require
improved mechanical efficiency in order to increase the power output. A study by
Wong et al. showed that idiopathic PH with RV dysfunction was associated with
increased RV myocardial oxygen consumption (MVO2) and reduced RV efficiency
[11], a situation possibly mirroring the case of LV energetics in heart failure [12–
14]. However, the study by Wong et al. lacked control subjects [11]. Yoshinaga
et al. evaluated the RV oxidative metabolism in patients with PH and showed that
patients with PH had increased oxidative metabolism in comparison with that of
normal individuals [15]. Increasing RV oxidative metabolism was associated with
several prognostic markers such as mean PAP (mPAP), PVR, and brain natriuretic
peptide (BNP). These findings suggest that elevated RV oxidative metabolism may
be a prognostic marker.
11C-acetate PET is a noninvasive technique for measuring regional and global
myocardial oxidative metabolism [13, 16–19], which is correlated with tricarbo-
xylic acid cycle flux and MVO2 [16]. RV myocardial oxidative metabolism can also
be measured noninvasively using 11C-acetate PET [15, 17, 20–22]. HF therapies
such as beta-blockers that reduce MVO2 are considered to improve the survival of
patients with HF [23]. LV cardiac efficiency can be estimated noninvasively [12] by
combining the mechanical work with the oxidative metabolism as measured by 11C-
acetate PET. This form of LV efficiency measurement has been applied to evaluate
several new HF treatments including beta-blockers, cardiac resynchronized ther-
apy, surgical reconstruction therapy, and obstructive sleep apnea (OSA) syndrome
treatments [13, 14, 24–26].
PH-specific vasodilators such as endothelin receptor antagonists, phospho-
diesterase-5 inhibitors, and prostacyclin decrease pulmonary arterial pressure
[7, 27]. These new vasodilators indeed improve survival in PH patients. Oikawa
et al. reported that reducing mPAP through the use of epoprostenol was associated
with reduced RV glucose metabolism observed by 18F-fluorodeoxyglucose (FDG)
PET [28]. However, it is not clear whether such a treatment favorably affects RV
myocardial oxidative metabolism.
The purpose of this study was to investigate the possible impacts of the intensified
PH-specific vasodilator therapy on myocardial energetics using 11C-acetate PET.
15.2 Materials and Methods
15.2.1 Study Subjects
Study subjects were recruited from the first department of medicine at the Hokkaido
University Hospital. The patient inclusion criteria were as follows: (1) a resting
mPAP 25 mmHg and a pulmonary capillary wedge pressure (PCWP)
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15 mmHg [7], (2) symptoms of PH in accordance with World Health Organization
(WHO) functional class II or III, (3) PH subtypes chronic thromboembolic pulmo-
nary hypertension (CTEPH) or PAH [29], and (4) stable condition (unchanged
for> 4 weeks).
Exclusion criteria were secondary PH due to LV disease, unstable condition of
patients, and permanent pacemaker implantation.
The study was approved by the Hokkaido University Graduate School of Medi-
cine Human Research Ethics Board. Written informed consent was obtained from
all patients.
15.2.2 Experimental Protocol
14 PH patients underwent right heart catheterization. Precapillary PH was diag-
nosed based on a mPAP 25 mmHg at rest and a PCWP 15 mmHg [7]. Among
the 14 PH patients, nine patients started or added the PH-specific vasodilators based
on the combined guidelines of the European Society of Cardiology (ESC) and the
European Respiratory Society (ERS), and these nine patients were categorized as
the intensified treatment group [30]. The remaining five patients did not change
their treatments and served as a control group.
Within 7 days of right heart catheterization, all patients underwent blood sam-
pling, CMR, and 11C-acetate PET at rest on the same day [15]. CMR and 11C-
acetate PET were repeated after 10.7 6.5 months for the intensified treatment
group (Fig. 15.1). Patients with PH but without OSA served as the control group
Fig. 15.1 Study design of the current study. BNP brain natriuretic peptide, CMR cardiac magnetic
resonance, RHC right heart catheterization, TX treatment
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and underwent CMR and 11C-acetate PET at rest at baseline and after
10.6 6.3 months (P¼NS).
WHO functional class evaluation and blood tests including BNP were measured
at baseline and follow-up.
15.2.3 Right Heart Catheterization
A complete hemodynamic evaluation was performed in all PH patients using the
standard technique for right heart catheterization. The hemodynamic measurements
included mean right atrial pressure, mPAP, and mean PCWP. Cardiac output was
determined through thermodilution. PVR was calculated as (mPAP – mean PCWP)
divided by cardiac output.
15.2.4 Measurements of BNP
Blood samples were obtained for fasting conditions the morning before the PET
studies. BNP data were obtained for all patients. Plasma BNP was measured using
immunoradiometric assay [31].
15.2.5 Cardiac Magnetic Resonance Imaging
CMR imaging studies were performed using a 1.5-T Achieva magnetic resonance
imaging system (Philips Medical Systems, Best, the Netherlands) equipped with
master gradients (maximum gradient amplitude 33 mT/m and maximum slew rate
100 mT/m/msec). CMR data acquisition was performed on patients in the supine
position with breath-holding in expiration. We used a five-element cardiac phased-
array coil and a vector cardiographic method for electrocardiogram (ECG)-gating
images. We performed localizing scans with breath-hold cine imaging and axial
orientation. Coronal images were used for cardiac anatomy evaluation. CMR
images spanned from bronchial bifurcation to diaphragm level thus allowing for
whole-heart analysis. We obtained 12 short-axis cine slices during a steady-state
free precession pulse sequence. The precession pulse sequence was as follows:
repetition time¼ 2.8 msec, echo time¼ 1.4 msec, flip angle¼ 60, acquisition
matrix¼ 192 256, field of view¼ 380 mm, slice thickness¼ 10 mm, inter-slice
gap¼ 0 mm, and phases/cardiac cycle¼ 20 [32].
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15.2.6 CMR Data Analysis
CMR images were analyzed using commercially available software (Extended MR
Work Space: version 2.6.3, Philips Medical Systems, Amsterdam, the Netherlands).
RV and LV volumes were measured using cine long-axis images. RV and LV
endocardial borders were semiautomatically traced. We then calculated the RV
ejection fraction (EF), LVEF, and RV volumes using this information [15]. RVEF
was measured in transverse (axial) orientation. LVEF was measured in short-axial
orientation [33]. All CMR images were analyzed by clinicians blinded to the
clinical and imaging data.
15.2.7 Positron Emission Tomography
All patients were instructed to fast overnight. PH patients who had vasodilator
treatments took their morning medications before the PET and CMR studies.
Patients were positioned with the heart centered in the field of view in a whole-
body PET scanner (ECAT HR+, Siemens/CTI Knoxville, TN) [34]. Dynamic PET
acquisition was initiated (10 10 s (s); 2 30s; 5 100 s; 3 180 s; 2 300 s)
[14] followed by intravenous administration of 20 mCi (mCi) [740 megabecquerel
(MBq)] 11C-acetate.
15.2.8 11C-Acetate PET Data Analysis
The reconstructed dynamic PET images were analyzed by applying a region of
interest over the whole LV and free wall of the RV myocardium in 3–5 mid-
ventricular transaxial planes [15, 20, 26]. A mono-exponential function was fit to
the myocardial time-activity data. The clearance rate constant (kmono) was deter-
mined as described previously [13, 14, 34]. The mono-exponential fit began at the
point when the blood pool was stable (usually 2–4 min after injection) (Fig. 15.2).
All data were analyzed by clinicians blinded to the clinical and imaging data.
15.2.9 RV Work Per MVO2 Index Calculation
The 11C-acetate clearance data were combined with the stroke work data to derive
myocardial efficiency using the LV work metabolic index (WMI) using the follow-
ing equation [13, 14, 26].
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WMI¼ SVI SBPHR/kmono; where SVI is the stroke volume index deter-
mined by CMR, SBP is systolic blood pressure, HR is heart rate, and kmono is the
mono-exponential rate constant for 11C-acetate clearance from the myocardium.
As a modified LV work metabolic index equation, the RV work per MVO2 index
was calculated as the ratio of RV SVI measured by CMR divided by RV MVO2.
The equation was as follows [35]:
RV work per MVO2index ¼ RV SVI = RV kmono  RV mass  20
15.2.10 Statistical Analysis
Continuous variables (using a logarithmic transformation on skewed distributions
as appropriate) are presented as mean and standard deviations. Categorical vari-
ables are presented as frequencies with percentages. Differences in results for the
PH group and the control group were examined for statistical significance with a
two-sample t-test for continuous variables. A P value of less than 0.05 was
considered indicative of a statistically significant difference. Statistical calculations
were carried out using SAS software version 9.2 (SAS Institute, Inc., Cary, NC).
15.3 Results
15.3.1 Patient Characteristics
A total of 14WHO functional class II or III PH patients were prospectively enrolled
in the study between December 2009 and July 2011, and all PH patients completed
the study protocol.
Fig. 15.2 Example of left and right myocardial time-activity data from a 11C-acetate PET acqui-
sition. A mono-exponential function fit to the myocardial clearance yields a clearance rate
constant; kmono represents the rate of oxidative metabolism and reflects MVO2. Blue line repre-
sents left ventricular (LV) myocardium time-activity curve. Orange line represents right ventri-
cular (RV) myocardium time-activity curve. Red line indicates blood time-activity curve
15 Right Ventricular Metabolism and Its Efficiency 199
The baseline characteristics of the participants are shown in Table 15.1. There
was no significant difference in mean age between members of the intensified PH
treatment patient group and those of the control group.
15.3.2 Right Heart Catheterization
The baseline right heart catheterization data is shown in Table 15.1. There was no
significant difference in the systolic PAP, diastolic PAP, mPAP, and PVR of the
intensified PH treatment group and those of the control group.
15.3.3 LV and RV Systolic Function
The RVEF and LVEF were similar in both the intensified PH treatment group and
the control group (Table 15.2).





P value intensified treatment
vs. control
Characteristics
Age (y) 48.4 12.9 52.8 17.5 NS
Male/female 3/6 2/3 NS
Medications
Vasodilators






60.9 19.5 53.2 8.8 0.14
Diastolic PAP
(mmHg)
24.8 6.4 19.4 8.0 0.54
Mean PAP (mmHg) 37.8 9.2 32.6 7.4 0.7
PVR (dynes
+ s1 + cm5)
564.4 246.93 514.6 149.4 0.35
Values are mean SD when appropriate
PAP pulmonary arterial pressure, PVR pulmonary vascular resistance
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15.3.4 LV and RV Oxidative Metabolism
There was no statistically significant difference between the LV oxidative meta-
bolism, kmono, of the intensified PH treatment group and that of the controls
(P¼ 0.72). There was also no statistically significant difference between the RV
oxidative metabolism, kmono, of the intensified PH treatment group and that of the
controls (P¼ 0.18) (Table 15.2). In addition, the RV SVI per RV kmono was similar
in both the intensified PH treatment group and the control group (P¼ 0.31).
15.3.5 Longer-Term Effects of Intensified PH-Specific
Therapy on RV Metabolism and Work per Oxygen
Consumption
The intensified PH therapy group tended to have reduced PVR compared with that
of the control group (20.6 41.7 vs. 3.4 33.2 %, P¼ 0.29). Intensified PH
therapy tended to reduce BNP (377.2 694.5 to 70.8 132.6 mol/mL, P¼ 0.18).
Intensified PH therapy significantly reduced RV oxidative metabolism
(0.044 0.008 to 0.039 0.007/min, P¼ 0.002) while increasing SVI
(31.4 10.1 to 39.3 9.6 mL/m2, P¼ 0.017) (Fig. 15.3). As a result, the intensified
PH-specific therapy significantly improved the RV work/oxygen consumption
index (730.8 253.6 to 1038.5 262.7 mL/min +m2, P< 0.001) (Fig. 15.4).
There was no significant change in LV kmono in this group (0.052 0.008 to
0.050 0.006/min, P¼ 0.35). The control group showed no changes in these
parameters (RV kmono: 0.041 0.006 to 0.049 0.01/min, P¼ 0.15, RV work/
oxygen consumption index: 829.1 362.9 to 721.5 241.2 mL/min +m2,
P¼ 0.69).





P value intensified treatment
vs. control
LVEF (%) 57.5 10.5 61.0 7.3 0.50
RVEF (%) 32.1 13.0 34.7 9.7 0.59
LV kmono (min
1) 0.052 0.008 0.058 0.006 0.72
RV kmono (min
1) 0.043 0.008 0.044 0.01 0.18
SVI/RV kmono
(mL/min1∙m2)
730.8 253.6 829.1 362.9 0.31
Values are mean SD when appropriate
LV left ventricular, LVEF left ventricular ejection fraction, RV right ventricular, RVEF right
ventricular ejection fraction, RVSV right ventricular stroke volume
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Fig. 15.3 Representative case of PAH patient who had intensified PH-specific vasodilator
therapy. LV kmono did not change after the intensified PH-specific vasodilator treatment. In
contrast, RV kmono was markedly reduced after the intensified PH-specific vasodilator therapy
Fig. 15.4 Effects of intensified PH-specific vasodilator therapy on RV work per oxygen con-
sumption index. Patients who had intensified PH-specific vasodilator therapy had a significantly
improved RV work per oxygen consumption index. In contrast, there was no significant difference
in RV work per oxygen consumption index in control group. PH pulmonary hypertension, RV right
ventricle, TX therapy
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15.4 Discussion
Intensified PH-specific vasodilator therapy tended to reduce PVR and BNP. The
intensive PH-specific therapy led to reduction in right ventricular oxidative meta-
bolism and a significant improvement in right ventricular work per oxygen con-
sumption index in patients with pulmonary hypertension.
15.4.1 Increased RV Oxidative Metabolism in Patients
with PH
The major determinants of myocardial metabolism are heart rate, contractility, and
wall stress [36, 37]. Oxygen demand in the RV may also increase with elevated
PAP [10].
In LV, heart failure is considered to be an energy-depleted state. Improved
survival through the use of beta-blockers and vasodilator therapy is in part associ-
ated with the energy-sparing effects of these medications [38].
RV MVO2 was originally measured through right coronary venous blood sam-
pling [10]. As noninvasive approaches, 11C-acetate and 15O-labeled tracers PET
have also been applied for RV oxidative measurements in HF and PH [15, 17, 22,
26, 39, 40]. The current data revealed increased RV oxidative metabolism in
patients with PH and reduced RV contraction. The current data agreed with findings
of our previous study and the study by Wong et al. [15, 39].
15.4.2 Study Population and Effects of PH-Specific
Vasodilator Therapy
In the current study, eight PH patients did not have PH-specific vasodilator therapy.
One patient had a PH-specific vasodilator, but the PH control did not reach the
standard control level. Therefore, these nine patients either started or added the
PH-specific vasodilator. The remaining five patients already received PH-specific
vasodilator treatments and they were stable. These five patients did not meet the
criteria to add further vasodilators to control their PH based on ESC and ERS
guidelines [30].
The intensified PH therapy group tended to have reduced mPAP. Although the
mPAP did not reach statistically significant levels, this finding may be due to the
small sample size, but it may still indicate that intensified PH-specific therapy had
beneficial effects. In fact, BNP also tended to be reduced after the therapy, a finding
that may indicate a secondary reduction in wall stress due to reduced mPAP. It may
therefore be appropriate to evaluate the therapeutic effects on RV energetics in this
study population.
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15.4.3 Effects of PH-Specific Vasodilator Therapy on RV
Oxidative Metabolism and Work per MVO2 Index
In the previous study, we evaluated RV power and RV efficiency using the
following equation: RV efficiency¼HRmPAP SV 1.33 104/RV
kmonoRV mass 20 [35]. Using this equation, WHO functional classification II
and III PH patients actually had increased RV power and RV efficiency compared
to patients in the control group [15]. The increasing power and RV efficiency may
be adaptive processes associated with increasing mPAP. In the LV, the LV effi-
ciency is estimated using the WMI. The WMI was calculated as follows:
WMI¼ SVI SBPHR/kmono [13]. LVHF treatments usually do not significantly
change the HR and SBP [14]. In contrast, PH-specific vasodilators significantly
reduce the mPAP [27]. Therefore, if the equation proposed by Sun et al. is simply
applied to RV efficiency measurements [35], RV efficiency may be reduced after
PH-specific vasodilator therapy since the reduction of mPAP would play a signifi-
cant role over the increasing SVI. The afterload of pulmonary circulation is usually
lower than that of systemic circulation [1, 41]. Therefore, the RV may have volume
efficiency rather than pressure efficiency as would apply in the case of the
LV. Therefore, we applied SVI per MVO2 index instead of Sun’s equation in the
current study.
The SVI per MVO2 index shows that the intensified PH-specific vasodilator
therapy significantly improved this parameter in comparison with that of controls.
The trend of mPAP reduction may contribute to these improvements. Therefore,
improving volume efficiency in the RV may be one of the therapeutic effects of
PH-specific vasodilators, and doing so may contribute to the improvement of
outcomes in patients with PH. This hypothesis should be tested in a larger study
population in the future.
15.4.4 Limitations
The thickness of the RV free wall is usually 4–5 mm, which is thinner than the LV
free wall. However, the current study population had thicker RV walls. When
radiotracer uptake is measured, the partial volume effect may significantly attenuate
the data. However, we analyzed the oxidative metabolism using mono-exponential
fitting. This approach measures clearance of the radiotracer from the myocardium.
Thus, the partial volume effect should be minimal.
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15.5 Conclusion
Intensified PH-specific vasodilator therapy led to a reduction in right ventricular
oxidative metabolism and a significant improvement in right ventricular work per
oxygen consumption index in patients with pulmonary hypertension. These effects
may contribute to the benefits of intensified PH-specific vasodilator therapy.
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Chapter 16
Usefulness of 18F-FDG PET in Diagnosing
Cardiac Sarcoidosis
Osamu Manabe, Keiichiro Yoshinaga, Hiroshi Ohira,
and Noriko Oyama-Manabe
Abstract Sarcoidosis is a multisystem granulomatous disorder of unknown etio-
logy. The number of patients with cardiac involvement is considered to be limited,
but cardiac sarcoidosis is a very serious and unpredictable aspect of sarcoidosis
resulting in conduction-system abnormalities and heart failure. The severity of
cardiac involvement depends on the extent and location of the granulomatous
lesions.
When establishing a diagnosis, 18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET) is a useful tool to detect active inflammatory lesions
associated with sarcoidosis. The heart uses different energy sources including free
fatty acids (FFA), glucose, and others. The 18F-FDG is an analog of glucose, and for
the precise evaluation of the extent and severity of cardiac involvement, recent
studies have focused on reducing physiological myocardial 18F-FDG uptake. Long
fasting and dietary modification, such as observing a low-carbohydrate or high-fat
diet, are the recommended regimens for preparations to make a precise evaluation.
The FFA level before the PET scan could be a predictor of the success to the
suppression of the physiological 18F-FDG accumulation.
With 18F-FDG PET therapy monitoring or risk stratification based on quanti-
tative 18F-FDG accumulation becomes possible. The quantification of the volume
and intensity of 18F-FDG uptake could assist in predicting the clinical outcomes and
in evaluating the efficiency of steroid treatments.
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This report provides a summary of the usefulness of 18F-FDG PET in its
current status as a diagnostic modality for cardiac sarcoidosis.
Keywords Cardiac sarcoidosis • Positron emission tomography •
Fluorodeoxyglucose
16.1 Background
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology. It is
characterized by noncaseating, epithelioid granulomas. Typically, young or middle-
aged adults are affected. In Japan, the annual incidence ranges from 1 to 2 cases per
100,000 of the population. The bilateral hilar and mediastinal lymph nodes, lungs,
skin, musculoskeletal system, and eyes are well known to be involved in lesions.
Essentially all organs, including the heart, may potentially be involved [1, 2].
Sarcoidosis patient treatment generally follows a favorable clinical course.
However, about 30 % of patients suffer chronically or experience recurrence.
Granulomas forming in an organ can affect how the organ functions and be a
cause of signs and symptoms. Especially, prognosis is related to the presence of
cardiac lesions [3].
The frequency of cardiac involvement varies and is significantly influenced by
ancetstry. In Japan over 25 % of cases with sarcoidosis experience symptomatic
cardiac involvement, whereas in the USA and Europe, only about 5 % of cases
present cardiac involvement. Autopsy studies in the USA have shown the frequency
of cardiac involvement to be about 20 %, whereas autopsy studies in Japan have
shown a frequency above 50 % [4–6].
16.2 Diagnostic Criteria for Cardiac Sarcoidosis
Histologic analysis of operative or endomyocardial biopsy specimens could be the
irrefutably best standard in diagnosing cardiac sarcoidosis. However, it is not
feasible to perform endomyocardial biopsies on all suspected regions, and myo-
cardial biopsies tend to have lower sensitivity in the diagnosis of cardiac sarcoid-
osis. Therefore, the Japanese Ministry of Health and Welfare (JMHW) guidelines
for diagnostic imaging have been used as the diagnostic standard since early times
[7]. The JMHW criteria include both the histologic and the clinical diagnosis
groups. For the clinical diagnosis group, the positive findings of electrocardio-
graphy, echocardiography, and 67Ga scintigraphy are the major criteria; minor
criteria include findings of electrocardiography, echocardiography, perfusion
images, and cardiac magnetic resonance images. Among the criteria, 18F-fluoro-
deoxyglucose (18F-FDG) positron emission tomography (PET) is not included in
the 2006 criteria; it is only noted as a comment that abnormal 18F-FDG accumu-
lation in the heart is a diagnostically useful finding. However, the usefulness of 18F-
FDG PET has been increasingly recognized; the Japanese health insurance system
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approved it for detection of inflammation sites in cardiac sarcoidosis on April 2012.
Recently, the Heart Rhythm Society of the USA also proposed the diagnosis and
management of cardiac sarcoidosis with 18F-FDG PET and MRI recommended for
the evaluation of cardiac sarcoidosis, if there is a cardiac history and abnormality in
the electrocardiogram or echocardiography in sarcoidosis patients [8].
16.3 Cardiac Metabolism
For the cardiac metabolism, under long fasting conditions, glucose production and
glucose oxidation would decrease. As a result, free fatty acid (FFA) is mobilized
from adipose tissue, and the increase in available FFA becomes an alternative
source of energy in the myocardium. The 18F-FDG is a glucose analog used clinic-
ally in PET to indicate glucose utilization (Fig. 16.1), and physiological myocardial
uptake has been reported. The levels of the cardiac uptake vary regardless of
blood glucose levels [9].
16.4 18F-FDG Uptake Patterns in Evaluations of Cardiac
Sarcoidosis
To evaluate cardiac sarcoidosis, uptake patterns of 18F-FDG were divided into four
kinds as suggested in Fig. 16.2 [7]. Without myocardial 18F-FDG uptake is consi-
dered to be negative in active cardiac lesions. A distinct diffuse 18F-FDG uptake in
the entire left ventricular wall without localized high 18F-FDG uptake generally is
Fig. 16.1 Chemical structural formula of D-glucose and 18F-FDG.
The chemical structural formulas of the glucose and 18F-fluorodeoxyglucose (18F-FDG) are shown
in panels A and B, respectively. 18F-FDG is a glucose analog widely used in PET studies of
glucose metabolism. 18F-FDG is taken up by plasma-membrane transporters and phosphorylated
by the intracellular enzymes in the same manner as glucose. The metabolism of 18F-FDG stops
after 6-phosphorylation which is different from glucose and provides an advantage in metabolism
studies
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thought to represent a physiological uptake, not indicating an abnormality. Focal
and focal on diffuse 18F-FDG uptakes in the left ventricular wall are considered to
be positive indicators of cardiac sarcoidosis.
16.5 Preparation for the 18F-FDG PET to Evaluate
Cardiac Lesions
The physiological myocardial 18F-FDG uptake may mislead when attempting to
establish cardiac sarcoidosis. Proper preparation such as extended fasting with a
low-carbohydrate diet before the scan is needed to suppress the physiological
cardiac uptake [10]. We have confirmed the usefulness of the effect of 18 h of
fasting with a low-carbohydrate diet compared to a minimum 6-h fasting prepar-
ation [9]. Patients with at least 6 h of fasting showed a higher diffuse left ventricular
(LV) 18F-FDG uptake than patients with longer fasting and low-carbohydrate diets.
Patients who fasted for longer and observed a low-carbohydrate diet showed
higher FFA levels than a shorter fasting group. In the shorter fasting group, patients
with diffuse LV 18F-FDG uptake showed significantly lower FFA levels than
patients without a diffuse LV uptake. This shows that the FFA level is an important
marker to suppress physiological 18F-FDG uptake. The protocol to obtain better
18F-FDG PET images in cardiac sarcoidosis patients is shown in Fig. 16.3.
Fig. 16.2 18F-FDG uptake patterns to evaluate cardiac sarcoidosis.
Uptake patterns were divided into four groups. No 18F-fluorodeoxyglucose (18F-FDG) uptake is
considered to be a negative sign for any active cardiac lesion (a). A diffuse 18F-FDG uptake in the
entire left ventricular wall without any localized high 18F-FDG uptake is generally thought to be a
physiological uptake (b). With slight accumulation in (b), it was not possible to determine if this
was caused by cardiac sarcoidosis. Focal uptake (c) and focal on diffuse uptakes (d) of 18F-FDG in
the left ventricular wall are considered to be positive signs for cardiac sarcoidosis
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16.6 Location of the 18F-FDG Uptake
Cardiac sarcoidosis provoked the conduction disturbance such as atrioventricular
block. There is a relationship between electrocardiogram abnormalities and myo-
cardial 18F-FDG uptake. In particular, the focal 18F-FDG uptake in the inter-
ventricular septum in cardiac sarcoidosis is associated with atrioventricular
blockage. Therefore, to identify the location of the 18F-FDG uptake is an important
issue of potentially great benefit in treatment planning [11].
The 18F-FDG uptake due to inflammation in the LV wall is sometimes difficult
to distinguish from the physiological uptake. On the other hand, the physiological
uptake in the right ventricle (RV) is less common and less intense. Therefore,
although less frequent of the sarcoidosis involvement, the 18F-FDG uptake in the
RV due to cardiac sarcoidosis may be useful in diagnosing in sarcoidosis [12].
16.7 Relationship Between 18F-FDG Accumulation
and Activity of Sarcoidosis
The significant 18F-FDG accumulation in cardiac sarcoidosis is caused by active
inflammatory changes involving activated inflammatory cells like neutrophils,
macrophages, and lymphocytes [13], and the 18F-FDG uptake may reflect an active
inflammation condition. This makes 18F-FDG PET useful both for the detection of
cardiac sarcoidosis as well as for monitoring the treatment response and early
recurrence [14].
The maximum standardized uptake value (SUVmax) has been used for semi-
quantitative measurements to assess the intensity of 18F-FDG uptake. Recently, the
availability of volume-based analysis, such as metabolic volume and total lesion
glycolysis, has been widely used to evaluate the extent and activity of the 18F-FDG
uptake in malignant tumors [15]. Ahmadian et al. applied volume-based analysis to
cardiac sarcoidosis and reported that the metabolic activity estimated by 18F-FDG
PET was a reliable independent predictor of cardiac events in cardiac sarcoidosis
patients [16]. A volume-based quantification of 18F-FDG uptake could be of value
Fig. 16.3 The protocol for the 18F-FDG PET scanning for cardiac sarcoidosis.
Patients were instructed to observe a low-carbohydrate or high-fat diet on the day prior to the
scanning, with additional fasting for more than 18 h. The PET images were acquired 60 min after
injection of the 18F-FDG
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Fig. 16.4 Representative case.
This is a case of a cardiac sarcoidosis patient with uveitis and respiratory discomfort. She had a
right bundle branch block and right axis deviation on the electrocardiograph and thinning of the
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in a number of fields of cardiac and inflammation diseases like it is for malignant
tumors (Fig. 16.4).
16.8 Conclusions
Observations from 18F-FDG PET images are a useful diagnostic tool to detect
active inflammatory lesions associated with cardiac sarcoidosis. For a precise evalu-
ation of the extent and severity of cardiac involvement, long fasting and dietary
modifications, such as observing a low-carbohydrate or a high-fat diet, are recom-
mended approaches to reduce physiological myocardial 18F-FDG uptake. The FFA
level before the PET data acquisition could be a predictor for success in the suppres-
sion of physiological 18F-FDG accumulation. Such 18F-FDG PET images also
enable therapy monitoring or risk stratification based on the quantitative accumu-
lation determination. The quantification of the volume and intensity of 18F-FDG
uptake may also help predict the clinical outcomes and evaluate the efficiency of
steroid treatment.
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Fig. 16.4 (continued) septal wall with severe hypokinesis on the echocardiograph. There was a
clearly abnormal 18F-FDG uptake in the LV wall as well as in the lymph nodes which indicated
active inflammatory changes associated with sarcoidosis (a). The estimated maximum standard-
ized uptake value (SUVmax) was 10.6, and the volume of the uptake was 76.1 ml (the threshold
was obtained from the liver uptake) at the cardiac lesion. The 18F-FDG PET [revealed the
dramatic] showed a nearly total disappearance of the abnormal cardiac uptake after 4 weeks of
therapy with prednisolone (b). However, the 18F-FDG PET during the tapering of the prednisolone
showed renewed 18F-FDG uptake. Here, the estimated maximum standardized uptake value
(SUVmax) was 6.2, and the volume of the uptake was 7.83 ml (the threshold was obtained from
the liver uptake). This case indicates that 18F-FDG was useful to evaluate the sarcoidosis activity
and indicated the improvement during the therapy as well as the recurrence of the active
sarcoidosis
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PET Quantification in Molecular Brain
Imaging Taking into Account
the Contribution of the Radiometabolite
Entering the Brain
Masanori Ichise, Yasuyuki Kimura, Hitoshi Shimada, Makoto Higuchi,
and Tetsuya Suhara
Abstract A good understanding of the in vivo pharmacokinetics of radioligands is
important for accurate PET quantification in molecular brain imaging. For many
reversibly binding radioligands for which there exists a brain region devoid of
molecular target binding sites called “reference tissue,” data analysis methods that
do not require blood data including the standardized uptake value ratio of target-to-
reference tissue at a “fixed time point” (SUVR) and reference tissue model to
estimate binding potential (BPND) are commonly used, the latter being directly
proportional to the binding site density (Bavail). Theoretically, BPND is the tissue
ratio minus 1 at equilibrium. It is generally believed that radioligands should not
ideally produce radiometabolites that can enter the brain because they might
complicate accurate quantification of specific binding of the parent radioligand.
However, the tissue ratio that contains the contribution of radiometabolite can also
be theoretically a valid parameter that reflects the target binding site density. This
article describes the validation of the tissue ratio concept using, as an example of
our recent PET data analysis approach for a novel radioligand, 11C-PBB3, to
quantify pathological tau accumulations in the brain of Alzheimer’s disease patients
in which the SUVR and reference tissue model methods using the cerebellar cortex
as the reference tissue were validated by the dual-input graphical analysis model
that uses the plasma parent and radiometabolite activity as input functions in order
to take into account the contribution of the radiometabolite entering the brain.
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17.1 Introduction
Molecular brain imaging with positron emission tomography (PET) using
radiolabeled ligands (radioligands) that target neuroreceptors/transporters and neu-
ropathological biomarker proteins such as amyloid β (Aβ) proteins and pathological
tau proteins has many exciting clinical and research applications. The major
advantage of PET imaging is that PET using suitable radioligands allows for the
accurate quantification of the target binding site density. For accurate PET quanti-
fication, however, a good understanding of the in vivo pharmacokinetics of
radioligands is important.
For many reversibly binding radioligands for which there exists a brain region
devoid of molecular target binding sites called “reference tissue,” data analysis
methods that do not require blood data including the standardized uptake value ratio
(SUVR) method and reference tissue models to estimate binding potential (BPND)
are commonly used to quantify specific molecular target binding sites. The validity
of these simple methods can be evaluated by detailed pharmacokinetic modeling of
dynamically acquired PET data and radiometabolite corrected arterial plasma
parent radioligand activity as an input function. In this respect, it is generally
believed that radioligands should not ideally produce metabolites that can enter
the brain because they might complicate accurate quantification of specific binding
of the parent radioligand.
The purpose of this article is to show that PET quantification using the SUVR
and reference tissue model methods can also be valid even when the metabolite
contributes to the measured brain radioactivity. In the theory section, the concept of
PET measured “brain tissue ratios” in the context of radiometabolites entering the
brain will be explored first, and then our recent PET data analysis approach for a
novel radioligand, 11C-PBB3 (2-((1E,3E)-4-(6-(11C-methylamino)pyridin-3-yl)
buta-1,3-dienyl) benzo[d]thiazol-6-ol) [1], to quantify pathological tau accumula-
tions in the brain of Alzheimer’s disease (AD) [2] will be highlighted as an example
in which the SUVR and reference tissue model methods were validated by the dual-
input graphical analysis model [3] that takes into account the contribution of the
radiometabolite entering the brain.
17.2 Materials and Methods
17.2.1 Theory
PET data in molecular brain imaging are commonly analyzed by applying kinetic
compartment models, which assume a compartmental system and derive the target
binding parameters that reflect the densities of target binding sites in brain regions
of interest (ROIs) [4]. Brain regions containing target binding sites (target tissue)
have at least three compartments (or two-tissue (2T) compartments) (Fig. 17.1a
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top). The first compartment is the arterial plasma (Ca), from which the
unmetabolized parent radioligand passes into the second compartment or the first
tissue compartment known as the nondisplaceable compartment (CND). The third
compartment or the second tissue compartment (CS) is the specific target binding
sites. Reference tissue regions do not have the specific binding compartment (CS)
(Fig. 17.1a bottom). In Fig. 17.1a, K1 (mLmL1min1) is the delivery rate
constant; k2 (min
1), k3 (min
1), and k4 (min
1) are the first-order kinetic rate
constants. Throughout the text, the prime sign is used to indicate the reference
tissue. CB tð Þ ¼ CND tð Þ þ CS tð Þ and C0BðtÞ ¼ C
0
NDðtÞ represent the target and refer-
ence tissue time activity, respectively, and Ca(t) is the plasma parent radioligand
activity at time t after the bolus radioligand administration.
Using Ca(t) as an input function, compartment model approaches allow for the
estimation of the distribution volume, V, which is the brain-to-plasma radioactivity
ratio, CB(t)/Ca(t), at equilibrium in which there is no net transfer of radioligand
activity between all compartments. Of note is that this equilibrium condition cannot
be achieved in the PET experimental paradigm with a bolus radioligand adminis-
tration. However, the compartment model analysis allows for the estimation of
parameters defined at equilibrium. By assuming that the nondisplaceable distribu-
tion volume in the target tissue (VND) is the same as in the reference tissue (V
0
ND),
the target binding parameter, binding potential (BPND), is calculated as
V  V 0=V 0 ¼ VS=VND, which is directly proportional to the binding site density
Bavail, i.e., BPND ¼ fND Bavail=KDð Þ, where fND and KD represent the fraction of
Fig. 17.1 Compartment configurations used to model in vivo radioligand kinetics when the parent
only enters the brain (a) and both the parent and metabolite enter the brain (b). Terms are defined
in the text
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nondisplaceable compartment from which the radioligand can exchange with the
specifically bound compartment (free tissue fraction) and the equilibrium dissoci-
ation constant for radioligand-binding site complex, respectively [5]. The above
relationship between BPND and Bavail is derived from the principle used in in vitro
binding assays, which is in turn based on the bimolecular enzymatic reaction
described by Michaelis and Menten [6]. Of note is that BPND can also be expressed
as



















where t represents the time at which the compartment system is in equilibrium.
BPND is, therefore, equivalent to the tissue ratio minus 1 at equilibrium.
Reference tissue models derived from the above compartment model estimate
BPND by using C
0
B(t) as an input function without requiring arterial plasma data
(Ca(t)) [4]. On the other hand, SUVR is the target-to-reference tissue ratio measured
at a “fixed time point” after the bolus radioligand administration. The advantage of
SUVR is that it can be calculated from static PET imaging data without the
requirement of arterial data. SUVR ¼ CB tð Þ=C0B tð Þ is, therefore, closely related to
BPND (Eq. 17.1), the differences between the two being that BPND is independent of
radioligand delivery (blood flow) or its systemic clearance because it is defined at
equilibrium,
On the other hand, in the situation where the metabolite enters the brain, the
compartment system is more complex as shown in Fig. 17.1b in which superscripts
P and M refer to “parent” and “metabolite,” respectively, and the metabolite is
assumed not to bind specifically to targets (see the discussion about the situation
where the metabolite also binds specifically) [3]. Here, let’s consider the tissue ratio
minus 1 at equilibrium assuming that VND is the same in the reference and target






 1 ¼ C
P
B tð Þ þ CMB tð Þ
C
0 P
B tð Þ þ C
0 M
B tð Þ
 1 ¼ V
P þ δVM
V
0P þ δV 0M
 1
¼ VS
V PND þ δVMND
ð17:2Þ
where δ is the metabolite-to-parent activity ratio in plasma at equilibrium
δ ¼ CMa tð Þ=CPa tð Þ
 
and it is a constant value. This tissue ratio minus 1 at equilib-
rium has an additional term, δVMND, the contribution of the metabolite
nondisplaceable distribution volume in the denominator of Eq. 17.2, and it is here
denoted by BP*ND to distinguish it from BPND, which is the tissue ratio minus 1 at
equilibrium when only the parent enters the brain. To estimate this tissue ratio
minus 1 by the reference tissue model, in fact, no knowledge of the metabolite
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status is needed because it uses CB tð Þ as an input function. The same argument
applies to the SUVR. Importantly, BP*ND like BPND is directly proportional to the
target binding site density, Bavail, as shown below.
BP*ND ¼
VS











where f PP or f
M
P the free fraction of parent (P) or metabolite (M) in plasma is a
constant and so are f PND, f
M
ND, and δ in the same individual. Note that VS ¼ f PPBavail
=KD and VND can be expressed as fP/fND because the free radioligand or metabolite
activity in the plasma and the tissue compartments are the same at equilibrium
f PCa tð Þ ¼ fNDCND tð Þð Þ [4, 5]. The validation of the reference tissue model BPND
can be accomplished by the dual-input graphical analysis model derived from the
model illustrated by Fig. 17.1b that takes into account the contribution of
radiometabolites entering the brain using the combined plasma radioactivity
CPa tð Þ þ CMa tð Þ
 




CB tð Þ ¼ α tð Þ
ð t
0
CPa tð Þ þ CMa tð Þ
 
dt
CB tð Þ þ β tð Þ ð17:4Þ
Eq. 17.4 becomes linear when the system reaches transient equilibrium between the
brain and plasma compartments at time t* and both the slope α and intercept β can








The tissue ratio minus 1 at equilibrium can also be estimated by the traditional
compartment model (Fig. 17.1a) using the parent-only input function (CPa (t)) if data
fitting can be adequately accomplished. However, it may not match the tissue ratio
minus 1 estimated by the reference tissue model or the dual-input model if a
significant amount of the metabolite is entering the brain because the tissue
radioactivity includes the metabolite contribution, which is not accounted for by
the traditional compartment model (Fig. 17.1a).
17.2.2 Radioligand
11C-PBB3 is a novel radioligand developed at the National Institute of Radiological
Sciences, Chiba, Japan, for PET imaging of pathological tau aggregates in the brain
[1]. Neurofibrillary tau tangles are one of the two pathological hallmarks of AD, the
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other being the senile plaques containing Aβ deposition [7]. 11C-PBB3 binds
reversibly to neurofibrillary tau tangles of a wide range of isoform compositions
with high affinity (KD¼ 2.5 nM) and selectivity [1]. 11C-PBB3 upon intravenous
administration is rapidly converted in plasma to one major radiometabolite identi-
cal chemically in both humans and mice, a significant amount of which enters the
mouse brain (30% of radioactivity in brain 5 min after injection) [8]. 11C-PBB3
SUVR in AD patients has previously been shown to reflect the known pathological
tau distribution at various stages of AD [9].
17.2.3 PET Data
The reader is referred to our recent 11C-PBB3 PET data analysis study [2] regarding
the detail of PET data acquisition and full data analysis. Here, the description is
limited to information relevant to illustrating the concept of tissue ratio estimation
considering the contribution of radiometabolite to the brain activity.
11C-PBB3 PET data consisted of 70 min dynamic scans after a bolus injection of
approximately 400 MBq of 11C-PBB3 in 7 AD patients (76 7 y) and 7 elderly
healthy control subjects (70 6 y). Input functions (CPa (t) and CMa (t)) were obtained
from multiple arterial samples by determining plasma fractions of the parent and its
radiometabolites with high-performance liquid chromatography.
To improve the statistical quality of PET ROI data, we generated cerebral
cortical ROIs pooling all voxels of high (>0.3, high), medium (0.15–0.3, middle),
low (0–0.15, low), and non-binding (<0) BP*ND values on preliminarily generated
parametric images by the original multilinear reference tissue model (MRTMO)[10]
using the cerebellar cortex as the reference tissue because tau accumulation is
known to be histopathologically absent in the cerebellar cortex of either normal
or AD brains [11].
17.2.4 Data Analysis
The tissue ratio minus 1 was estimated in four ways using cerebral cortical ROI data
with the cerebellar cortex as the reference tissue:
1) BPND estimation by the dual-input graphical analysis using C
P
a tð Þ þ CMa tð Þ
 
as
an input function (Eq. 17.4)
2) BPND estimation by 2T compartment kinetic analysis using C
P
a (t) as an input
function (Fig. 17.1a)
3) BPND estimation by the reference tissue model MRTMO using C
0
B(t) as an input
function
4) SUVR minus 1 at a fixed time point (50 min–70 min)
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The tissue ratio minus 1 values obtained by the above 4 methods were then
compared to validate the use of SUVR and the reference tissue model BPND.
Additionally, parametric images of MRTMO and (SUVR-1) were generated and
compared.
17.3 Results
The brain 11C-PBB3 time activity curves (TACs) quickly peaked within a few
minutes of intravenous injection of 11C-PBB3 with gradual decreases thereafter
with a significantly slower washout for high binding cerebral cortex in ADs than in
HCs (Fig. 17.2a). Plasma parent TACs peaked very quickly and decreased also
quickly thereafter (Fig. 17.2b). One major radiometabolite of 11C-PBB3 appeared
very quickly in the plasma and slowly decreased thereafter (Fig 17.2b). Both
plasma parent and metabolite TACs in ADs and HCs were very similar (Fig. 17.2b)
Graphical plots (Eq. 17.4) with a combinedCPa tð Þ þ CMa tð Þ plasma input became
linear beyond t*¼ 11 min when both α and β could be considered constant. BPND
estimations were very stable for all regions. On the other hand, the 2T kinetic
analysis to estimate BPND was unstable in some regions with a large parameter
estimation variability in the rest of the regions. The 2TC BPND values were
numerically quite different from the corresponding BPND values with a very poor
correlation between the two-tissue ratio minus 1 estimations (BPND ¼ 1:06 0:66
vs. BP*ND ¼ 0:36 0:07 with r2¼ 0.04 in the high binding region, for example.
The reference tissue model MRTMO robustly estimated BP
*
ND for the ROI data
and enabled stable voxel-wise parametric imaging ofBP*ND. TheBP
*
ND estimated by
the ROI-based MRTMO analysis closely matched the corresponding BP

ND
Fig. 17.2 Time activity curves (TACs) in the brain (a) and arterial plasma (b) after the injection of
11C-PBB3 in AD patients and healthy controls (HCs). (a) TACs are shown for the high tau binding
(~) cerebral cortical region and cerebellar cortex (◆) in ADs, and the cerebral cortical region (△)
and the cerebellar cortex (◇) in HCs. (B) Plasma TACs are shown for the total radioactivity (thick
(ADs) and thin (HCs) solid lines), metabolite (thick (ADs) and thin (HCs) dotted lines), and parent
(thick (ADs) and thin (HCs) dashed lines). Data represent mean of all 7 ADs or 7 HCs
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estimated by the dual-input graphical analysis with a perfect correlation between
the two (r2¼ 1.00) (Fig. 17.3a). On the other hand, SUVR minus 1 values (calcu-
lated from the averaged 50 min to 70 min data) overestimated MRTMO BP

ND
values by up to 38%. However, there was an excellent correlation between the two
(r2¼ 0.97) (Fig. 17.3b). Both the MRTMO BPND parametric images and SUVR
minus 1 images showed a clear delineation of tau pathology in the cerebral cortices
including the hippocampal formation in AD (Fig. 17.4a, c) compared with HC
(Fig. 17.4b, d).
17.4 Discussion
In the present article, we have shown that the reference tissue model-based binding
potential (BPND) that reflects the target binding site density (Bavail) is theoretically
equivalent to the tissue ratio minus 1 at equilibrium, whereas closely related SUVR
minus 1 is the tissue ratio minus 1 at a fixed time point after the bolus radioligand
administration. We have shown that the tissue ratio minus 1 at equilibrium (BPND)
also reflects Bavail even in the situation where the radiometabolite enters the brain.
The definition of binding potential, BPND, therefore can be extended to this
situation (expressed as BPND here). The validity of the reference tissue model
BPND and SUVR, both of which do not require arterial plasma data, can be
evaluated by the dual-input CPa tð Þ þ CMa tð Þ
 
model but not by the conventional
single input (CPa (t)) model because the tissue ratio minus 1 at equilibrium includes
the radiometabolite contribution to the tissue activity, which is not accounted for by
the parent-only model. Of note is that the reference tissueBP*ND or SUVR estimation
Fig. 17.3 (a) Correlation of ROI BP*ND estimated by dual-input graphical model and reference
tissue model MRTMO. (b) Correlation of ROI BP
*
ND estimated by MRTMO and SUVR minus
1 (50 min–70 min)
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does not require any assumption of metabolite, because the estimation is performed
without blood data.
Although we assumed here that the radiometabolite does not bind to the target
site, it can be shown that BPND is also directly proportional to Bavail when the
metabolite binds specifically (17.2). BPND has additional term, δV
M
ND, in the denom-
inator (Eq. 17.2), which may increase the intersubject variability of BPND compared
with BPND. In our
11C-PBB3 analyses, there was no difference in the mean
V PND þ δVMND
 
values between ADs and HCs [2].
SUVR minus 1 at 50 min–70 min overestimated BPND. However, there was an
excellent correlation between the two. SUVR is potentially affected by blood flow
and systemic radioligand clearance, while BPND is independent of these factors
because BPND represents the tissue ratio minus 1 at equilibrium. Therefore, a larger
variability of cerebral blood flow in AD patents than in normal elderly subjects may
result in a larger intersubject SUVR variability compared with BPND, although a
longer dynamic imaging needed for BPND estimation might be less well tolerated
for elderly patients than a shorter static imaging for SUVR measurements. The
advantage of the reference tissue model-based estimation of the tissue ratio over the
SUVR measurement has recently been shown for a long-term longitudinal Aβ PET
imaging study [12].
Fig. 17.4 Coronal parametric images of AD and HC. The MRTMO BP
*
ND images in ADs (a) and
HCs (b). SUVR-1 images (50 min–70 min) in ADs (c) and HCs (d)
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17.5 Conclusions
The reference tissue-based binding potential (BPND) that reflects the target binding
site density (Bavail) is equivalent to the tissue ratio minus 1 at equilibrium. The
tissue ratio minus 1 at equilibrium (BPND) also reflects Bavail even in the situation
where the radiometabolite enters the brain. The validity of the reference tissue
model BPND and SUVR can be evaluated by the dual-input model not by the
conventional single input model because the tissue ratio minus 1 at equilibrium
includes the radiometabolite contribution to the tissue activity, which is not
accounted for by the parent-only model.
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Chapter 18
Hypoxia Imaging with 18F-FMISO PET
for Brain Tumors
Kenji Hirata, Kentaro Kobayashi, and Nagara Tamaki
Abstract Tumor hypoxia is an important object for imaging because hypoxia is
associated with tumor aggressiveness and resistance to radiation therapy. Here, 18F-
fluoromisonidazole (FMISO) has been used for many years as the most commonly
employed hypoxia imaging tracer. Unlike F-18 fluorodeoxyglucose (FDG), FMISO
does not accumulate in normal brain tissue making it able to provide images of
hypoxic brain tumors with high contrast. Clinical evidence has suggested that
FMISO PET can predict patient prognosis and treatment response. Among gliomas
of various grades (WHO 2007), it has been known that grade IV glioblastoma
resides under severe hypoxia and is a cause of development of necrosis in the
tumor. For this study we tested whether FMISO can distinguish the oxygen condi-
tion of glioblastomas and lower-grade gliomas. Twenty-three glioma patients
underwent FMISO PET for the study. All the glioblastoma patients (N¼ 14)
showed high FMISO uptakes in the tumor, whereas none of the other patients
(i.e., gliomas of grade III or lower, N¼ 9) did, demonstrated by both qualitative
and quantitative assessments. The data suggest that FMISO PET may be a useful
tool to distinguish glioblastomas from lower-grade gliomas. Our results, however,
were slightly different from previous investigations reporting that some lower-
grade gliomas (e.g., grade III) showed positive FMISO uptake. Many of these
acquired the FMISO PET images 2 h after the FMISO injection, while for the
study here we waited 4 h to be able to collect hypoxia-specific signals rather than
perfusion signals as FMISO clearance from plasma is slow due to its lipophilic
nature. No optimum uptake time for FMISO has been established, and we directly
compared the 2-h vs. the 4-h images with the same patients (N¼ 17). At 2 h, the
gray matter had significantly higher standardized uptake value (SUV) than the
white matter, possibly due to different degrees of perfusion but not due to hypoxia.
At 4 h, there were no differences between gray and white matter without any
significant increase in the noise level measured by the coefficient of variation
between the 2-h and the 4-h images. At 2 h, 6/8 (75 %) of glioblastoma patients
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showed higher uptakes in the tumor than in the surrounding brain tissue, whereas at
4 h this was the case for 8/8 (100 %). In addition, at 2 h, 3/4 (75 %) of patients with
lower-grade gliomas showed moderate uptakes, while at 4 h none did (0/4 or 0 %).
These data indicate that 4-h images are better than 2-h images for the purpose of glioma
grading. In conclusion, we evaluated the diagnostic performance of FMISO PET for
gliomas and suggest that FMISO PET may be able to assist in the diagnosis of
glioblastomas when PET images are acquired at 4 h post injection.
Keywords Hypoxia • 18 F-Fluoromisonidazole • Glioma • Glioblastoma
18.1 Introduction
This review article summarizes our recent studies with 18F-fluoromisonidazole
(FMISO) positron emission tomography (PET) applied to brain tumors [1, 2]. A
variety of tumors which can be divided into two categories develop in the brain:
primary brain tumors that originate from the brain tissue and metastatic brain tumors
that originate from malignant tumors in other organs. Gliomas account for 60 % of
primary brain tumors. Gliomas comprise a range of tumors, from benign to malignant,
that are derived from glial cells such as astrocytes, oligodendrocytes, and ependymal
cells. Among gliomas, the glioblastoma is the most aggressive astrocytic tumor.
Glioblastomas are categorized as grade IV in theWHO classification [3]. The standard
treatment for glioblastomas is surgery followed by radiotherapy and chemotherapy [4].
With state-of-the-art multidisciplinary therapy, the 1-year survival rate of glioblas-
toma patients is reported to be 56 %, which is significantly poorer than with grade III
(78 %) or less malignant gliomas [5]. A pathological diagnosis of surgical specimens
by biopsy or resection is necessary to establish the diagnosis for glioblastomas [6], but
brain surgery involving eloquent regions can exacerbate the prognosis by causing
neurological morbidity and should be avoided if possible [7]. Patients with impaired
performance status or elderly patients especially would benefit from nonsurgical
methods of establishing the diagnosis, substituting surgical tissue sampling.
The basic in vivo imaging modality for brain tumors is magnetic resonance
(MR) imaging. Intratumoral characteristics and tumor expansion states are shown
accurately with MR imaging. The use of PET with 18F-fluorodeoxyglucose (FDG)
is a well-established method for many different types of tumors in the body,
including lung cancer, head and neck cancers, and others. FDG PET also plays
important roles in the diagnosis of glioblastomas. The diagnosis of a glioblastoma is
generally suggested if there is a ringlike enhancement by gadolinium onMR images
or an intense uptake of FDG [6, 8–15]. However, there are cases of false-negative
MRI findings as some glioblastoma lack the ringlike enhancement [6]. In discrim-
inating glioblastoma from grade III tumors, FDG PET is also not always adequate
as a large number of patients of grade III gliomas show high FDG uptakes [13, 14].
This makes a biopsy necessary in many cases, and a noninvasive in vivo
imaging tool would be of benefit to omit invasive biopsy procedures in clinical
settings [11].
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The WHO 2007 criteria determine the glioma grade based on microscopic
characteristics present in the malignancy. Grade II tumors show cell atypia and
grade III tumors tissue anaplasia and cell mitosis in addition to cell atypia. Grade IV
glioblastomas have pathological features that are not found in grade III or lower-
grade gliomas, particularly microvascular proliferation and necrosis [3]. Basically,
necrosis is considered to be closely related to hypoxia as low oxygen concentrations
do not allow the energy metabolism to proceed as in unaffected tissue. In fact,
glioblastomas are known to be in a state of severe hypoxia possibly due to vascular
abnormalities and high oxygen demand, whereas the hypoxia of grade III or lower-
grade gliomas is less severe [16–19]. We hypothesized that imaging the hypoxia of
glioblastomas could be useful to distinguish glioblastomas from lower-grade
gliomas.
Measuring hypoxia in living tissue uses needle electrodes; however, this tech-
nique presents significant shortcomings. First, it is invasive to insert a needle into
deep layers of tissue in humans. Second, it requires considerable skill and the
reproducibility is not high. Third, needles may alter the tissue structure and so
influence the local oxygen partial pressure, and for these reasons needle electrodes
are not used in clinical practice. An alternative is presented by 18F-fluoromiso-
nidazole (FMISO) PET which is a widely used method for in vivo hypoxia imaging
[20–23]. Valk et al. first introduced the use of FMISO for glioma imaging in 1992
[24], and the usefulness of FMISO for glioma imaging has been extensively
investigated [25–32]. The FMISO is also known to accumulate in severe hypoxic
structures but not in mildly hypoxic structures, suggesting that FMISO would be
able to discriminate severe from mild hypoxia. This made us hypothesize that much
FMISO may accumulate in glioblastomas and only little in lower-grade gliomas. If
such a difference could be substantiated, hypoxia imaging using FMISO would
provide an avenue to discriminate glioblastomas from lower-grade gliomas. The
first paper of our project was to test the hypothesis [1]. We evaluated the diagnostic
usefulness of FMISO PET in terms of glioma grading in comparison with diagnosis
with FDG PET in patients suspected of having glioblastomas on MR images.
With FMISO there is a trade-off problem regarding uptake time (the interval
between the FMISO injection and the PET emission scanning). A longer uptake
time is theoretically desirable to image hypoxia with good lesion-to-background
signal ratios, but the longer time leads to lower signal-to-noise ratios due to
radiological decay of the F-18. Early reports by Grunbaum et al. [33] and
Thorwarth et al. [34] addressing this issue suggested a 4-h acquisition as suitable.
Despite this, most research adopted 2-h protocols [24, 25, 27–32], possibly because
a shorter protocol would be more generally acceptable in clinical settings. Based on
this, the second part of our project was to directly compare 2-h and 4-h images from
the same patients [2].
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18.2 Materials and Methods
The first of the studies reported here was conducted for the purpose of testing the
ability to discriminate between glioblastomas and lower-grade gliomas with
FMISO PET. Twenty-seven patients with possible high-grade gliomas were con-
sidered for the study [1]. The patients included showed cerebral parenchymal
tumors surrounded by edematous tissue on MR images but no known malignancy
in other organs. We excluded patients where previous tumorectomy, chemotherapy,
or radiotherapy for lesions had been performed. The only exception was a patient
with a recurrent tumor 6 years after tumorectomy combined with
chemoradiotherapy for a low-grade glioma. Among the 27 patients, two were
excluded because they had contraindications of surgical operations. The remaining
25 patients underwent either a tumoral resection (n¼ 16) or biopsy (n¼ 9) at most
2 weeks after the PET scanning. The surgical specimen was investigated by two
experienced neuropathologists to determine the pathological diagnosis based on the
2007 WHO classification. Among the 25 patients, two were diagnosed as having
metastatic adenocarcinoma and multiple sclerosis, respectively, and these two
patients were excluded from the analysis. Finally 23 patients (M/F¼ 10:13, age
57 15 years old) all with the pathological diagnosis of gliomas were included in
the study.
With these 23 patients, we acquired FMISO and FDG PET images following the
same protocol for all the patients. The interval between FMISO and FDG was at
most 1 week. The FMISO synthesis protocol was previously described in detail
elsewhere [35, 36]. On the day of FMISO, the patient was not asked to fast before
the PET, and 400 MBq of FMISO was intravenously injected. Then, 4 h later, the
emission scanning was initiated to acquire static PET images of the entire brain.
FDG PET was performed on another day; here the dosage of FDG was also
400 MBq. The uptake time for FDG was 1 h, and the scanning range for the FDG
PET was the same for the FMISO PET with a high-resolution PET scanner (ECAT
HR+ scanner; Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan) operated
in a three-dimensional mode for 22 patients. For one patient the FMISO images
were acquired using an integrated PET-CT scanner (Biograph 64 PET-CT scanner;
Asahi-Siemens Medical Technologies Ltd., Tokyo, Japan). The duration of the
emission scanning using the ECAT HR+ scanner was 10 min. The duration of the
transmission scanning using the ECAT HR+ scanner with a 68Ge/68Ga retractable
line source was 3 min. This acquisition protocol was the same for both FDG and
FMISO. With the Biograph 64 PET-CT scanner, the duration of the emission
scanning was also 10 min. The transmission scanning was performed using an X-
ray CT, and the attenuation correction used the CT images. The attenuation-
corrected radioactivity images from both scanners were reconstructed using a
filtered back projection with a 4 mm full width at half maximum Hann filter.
For our second study, to compare the 2-h vs. 4-h images of FMISO PET, we
investigated 17 different patients with brain tumors (M/F¼ 7:10, age 62 14 years
old, range 33–85 years old). The study populations for first and second studies were
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different, and none of the patients included in the first study were included in the
second study. The PET images for each patient in the second study were acquired
twice, 2 and 4 h following the injection. The injected dosage of FMISO was
399 25 MBq. The first scanning took place 115.9 14.6 min after the injection
and the second 227.4 15.1 min after injection. The scanner was a Gemini GXL 16
PET-CT (Philips). The duration of the emission scanning was 20 min. Transmission
scanning was performed using the X-ray CT which was used for attenuation
correction. Attenuation-corrected radioactivity images were reconstructed using
ordered subset expectation maximization.
For the first study, the images were analyzed both qualitatively and quantita-
tively. An experienced nuclear physician who was blinded from the pathological
diagnosis visually evaluated all the images in the qualitative assessment for the first
study. In the qualitative assessment of the FMISO PET images, the FMISO uptake
was visually categorized into three groups. Where the highest uptake in the tumor
was weaker than that in the surrounding brain tissue, the patient was considered as
showing low FMISO uptake. Where the highest uptake in the tumor was equal to
that in the surrounding brain tissue, the patient was considered as showing inter-
mediate FMISO uptake. Where the highest uptake in the tumor was stronger than
that in the surrounding brain tissue, the patient was considered as showing high
FMISO uptake. This grouping rule was however not efficient as no patients were
assigned to show low FMISO uptake. As a result the low FMISO uptake and the
intermediate FMISO uptake patients were combined in one group of FMISO-
negative patients. The remaining patients, those assigned to the high FMISO uptake
group, were designated as FMISO-positive patients. This binary division was
presented in a previous paper [27]. Similarly, in the qualitative assessment of the
FDG PET images, we evaluated the FDG accumulation in the tumor using the
grouping detailed elsewhere [14]. First, the FDG uptake was visually categorized
into three groups: low, intermediate, and high. Where the highest uptake in the
tumor was weaker than or equal to that in the contralateral white matter, the patient
was considered as showing low FDG uptake. Where the highest uptake in the tumor
was stronger than that in the contralateral white matter but weaker than that in the
contralateral gray matter, the patient was considered as showing intermediate FDG
uptake. Where the highest uptake in the tumor was equal to or stronger than that in
the contralateral gray matter, the patient was considered as showing high FDG
uptake. Like the FMISO categorization, the low FDG uptake and intermediate FDG
uptake patients were combined and termed FDG-negative patients, and those of
high FDG uptake were termed FDG-positive patients.
For the second study, the grouping of the FMISO uptake in the tumor was
performed slightly differently, here it was visually assessed. The degree of uptake
was assigned as either high, medium, or low. Low uptake here means the uptake
compared to the surrounding brain tissue.
Such qualitative assessments may be subjective and a quantitative assessment
was also made. For the first study, the PET images were coregistered with individ-
ual MR images (FLAIR) using a mutual information technique implemented in the
NEUROSTAT software package [37, 38]. Then, polygonal regions of interest
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(ROI) were manually drawn to enclose the entire tumor on every slice that also
included peritumoral edematous regions. The single voxel having the highest
radioactivity concentration in the tumor was determined in the PET images using
in-house software. The highest radioactivity concentration was used to calculate a
maximum standardized uptake value (SUVmax). A SUVpeak value has recently
come into use to overcome the shortcomings of SUVmax. However, the concept
of SUVpeak is not unique as different researchers use different definitions. Here, we
use the term SUV10mm to explicitly show the meaning: a 10-mm-diameter circular
ROI with the center at the maximum voxel was created. The averaged value for the
circular ROI was assigned as SUV10mm, and the SUV was calculated as (tissue
radioactivity [Bq/ml])*(body weight [g])/(injected radioactivity [Bq]). Next, fur-
ther ROIs were created on the following reference regions: the cerebellar cortex, the
contralateral frontoparietal cortex on the level of the centrum semiovale, and the
contralateral frontoparietal white matter on the level of the centrum semiovale. The
lesion-to-cerebellum ratio of the FMISO was determined as the ratio of the
SUV10mm to the cerebellar averaged SUV. The lesion-to-gray matter and lesion-
to-white matter ratios of the FDG were the ratios of SUV10mm to gray matter and
white matter SUV, respectively [13]. The ROI placement process was performed by
an experienced nuclear physician, and where the tumor occupied bilateral lobes, the
hemisphere with the larger part of the tumor was considered as the tumor side. We
further measured the hypoxic tissue volume showing significant FMISO uptake in
the tumor with the cerebellum used as the reference tissue for this purpose. The
voxels having higher SUV than 1.3 times that of the cerebellar SUV were extracted
in the tumoral polygonal ROI described above. No threshold for FMISO uptake
volumes has been established, and the 1.3 value was empirically adopted from
image segmentation in 11C-methionine brain PET [31, 39, 40]. The FMISO uptake
volumes were expressed as a percentage of the extracted voxels in the whole
tumoral ROI.
For the second study, the 2-h and 4-h images were coregistered to CT. To obtain
reference values from normal tissue, circular 10-mm-diameter ROIs were defined
on gray matter, white matter, and the cerebellar cortex. The SUVmean, standard
deviation (SD), and coefficient of variation (CV) were measured within these ROIs.
To express tumor uptake values, the SUVmax and lesion-to-cerebellum ratios were
calculated in the same way as in the first study.
In the following, all parametric data are expressed as means SD. The patients
with grade III or with less malignant gliomas were grouped together as non-
glioblastoma patients to simplify the analysis. The relationship between the histo-
pathological diagnosis and the visual assessment results was examined using
Fisher’s exact test. The differences in age, tumor size, SUVs, lesion-to-normal
tissue ratios, and uptake volume for glioblastoma vs. non-glioblastoma patients
were examined using the Mann-Whitney U-test. The 2-h vs. 4-h values were
compared using paired t-tests; P-values smaller than 0.05 were considered statisti-
cally significant. The statistical analysis and figure drawing used R 2.14.0 and R
3.1.3 for Windows.
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18.3 Results
In the first study, 14 patients were diagnosed with glioblastomas and categorized as
grade IV in the WHO classification. Among the remaining nine patients, one had
anaplastic astrocytoma (grade III), one had anaplastic oligodendroglioma (grade
III), three had anaplastic oligoastrocytomas (grade III), one had diffuse astrocytoma
(grade II), one had oligodendroglioma (grade II), and two had oligoastrocytomas
(grade II). Necrosis was identified in all the glioblastoma patients, while none of the
non-glioblastoma patients showed necrosis within the tumor. The age of the
glioblastoma patients was 65.5 9.9 years, and the age of non-glioblastoma
patients was 43.7 12.2 years; the age difference was statistically significant
( p< 0.01). The tumor sizes were measured on FLAIR MR images and were not
significantly different for glioblastomas vs. non-glioblastomas (64.4 17.5 mm vs.
77.6 22.5 mm in diameter) ( p¼NS). Gadolinium enhancement was observed in
3/9 non-glioblastoma patients and in14/14 glioblastoma patients. By visual assess-
ment, all of the glioblastoma patients (14/14) were classified as FMISO positive and
all of the non-glioblastoma patients as FMISO negative. There was a significant
association by Fisher’s exact test between the histology (glioblastoma or non-
glioblastoma) and FMISO uptake (FMISO positive or FMISO negative)
( p< 0.001). This visual assessment of the FMISO PET images correctly discrim-
inated glioblastoma patients from non-glioblastoma patients with sensitivity, spec-
ificity, and accuracy of 100 %, 100 %, and 100 %, respectively. For the FDG PET
results, after excluding a diabetic patient with hyperglycemia at the time of the FDG
PET, all glioblastoma patients (13/13) were FDG positive and 3/9 non-glioblastoma
patients were FDG positive. This relationship reached statistical difference
( p< 0.01), but the diagnostic performance of the FDG PET was poorer than the
FMISO PET, with sensitivity, specificity, and accuracy being 100 %, 66 %, and
86 %, respectively. Figures 18.1, 18.2, 18.3, 18.4, and 18.5 show representative
cases.
In the quantitative assessment of the first study, the SUVmax of the FMISO was
3.09 0.62 (range, 2.22–4.31) in glioblastoma patients, significantly higher than in
non-glioblastoma patients (1.73 0.36; range, 1.36–2.39) ( p< 0.001). As detailed
above, we introduced the SUV10mm term to be able to minimize noise effects. The
SUV10mm of FMISO was similar to the SUVmax of FMISO, with the values being
3.00 0.61 (range, 2.15–4.18), significantly higher than in non-glioblastoma
patients (1.64 0.38; range, 1.29–2.35) ( p< 0.001). The lesion-to-cerebellum
ratio of the FMISO (the SUV10mm/cerebellar SUV) was higher in the glioblastoma
patients (2.74 0.60; range, 1.71–3.81) than in the non-glioblastoma patients
(1.22 0.06; range, 1.09–1.29) ( p< 0.001). The quantitative results of the FDG
PET were slightly different from those of the FMISO PET. Here the diabetic patient
was also excluded from the analyses of SUV and the lesion-to-normal tissue ratio of
the FDG PET. The SUVmax of the FDG was not significantly different for the
glioblastoma and non-glioblastoma patients (7.55 3.72; range, 4.34–16.38, vs.
8.21 6.04; range, 4.75–23.49) ( p¼ 0.95). Similarly, the SUV10mm of the
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FDG was not significantly different for the glioblastoma and non-glioblastoma
patients (7.41 3.63; range, 4.26–15.90, vs. 8.03 5.96; range, 4.64–23.12)
( p¼ 0.95). The lesion-to-gray matter ratio of the FDG (the SUV10mm/SUV in the
contralateral gray matter) was higher in the glioblastoma patients (1.46 0.75;
range, 0.91–3.79) than in the non-glioblastoma patients (1.07 0.62; range,
0.66–2.95, p< 0.05). The lesion-to-white matter ratio of the FDG (the SUV10mm/
SUV in the contralateral white matter) was not significantly different for the
glioblastoma (2.81 1.23; range, 1.87–6.44) and non-glioblastoma (2.66 1.60;
Fig. 18.1 A glioblastoma case. (a) The FLAIR image showed a high-signal tumor in the left
hemisphere. (b) The tumor was enhanced by gadolinium contrast material. (c) The FDG uptake in
the tumor was comparable to that of contralateral cerebral cortex. (d) The FMISO uptake was
higher in the tumor than in the surrounding brain tissue
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range, 1.71–6.51) ( p¼ 0.16) patients. Finally, the uptake volume of FMISO was
larger in the glioblastoma than in non-glioblastoma patients (27.18 10.46 %;
range, 14.02–46.67 %, vs. 6.07 2.50 %; range, 2.12–9.22 %), ( p< 0.001).
In the second study, the 2-h images and the 4-h images of FMISO PET were
directly compared for the same subjects. Figure 18.6 shows representative images
that do not show tumors. Visually, the SUV in the brain was higher at 2 h than at 4 h.
More specifically, the gray matter SUV was higher at 2 h than at 4 h, whereas the
white matter SUV was comparable in the images at 2 h and 4 h. Profile curves
Fig. 18.2 A glioblastoma case. (a) The FLAIR image showed a tumor in the left frontal lobe. (b)
The tumor showed a ringlike enhancement by gadolinium contrast material. (c) The FDG uptake
was observed in a part of the gadolinium-enhanced area. The FDG uptake was comparable to the
right cerebral cortex. (d) The FMISO PET showed a similar distribution of FMISO as FDG but
with stronger tumor-to-background contrast than FDG
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demonstrate these differences in Figure 18.6. At 2 h, the gray matter was distin-
guishable from the white matter, as the gray matter showed higher SUV than the
white matter while at 4 h; the curve was almost flat. Figure 18.7 shows scatter plots
of gray and white matter SUV at 2 h vs. 4 h. In all cases the gray matter SUV
decreased with time and all the points plot under the line of identity. White matter
SUV was not significantly different at 2 and 4 h. Figure 18.8 shows the CV of gray
and white matter, compared at 2 h and 4 h. The gray matter CV increased slightly
from 2 to 4 h (P¼ 0.0008), while the white matter CV was not significantly
different at 2 and 4 h.
Fig. 18.3 An anaplastic oligoastrocytoma case (grade III). (a) The FLAIR image showed a tumor
in the right frontal lobe. (b) A small part of the tumor is enhanced after treatment with gadolinium
contrast material (arrowhead). (c) The FDG uptake was observed in the enhanced part (arrow-
head). The FDG uptake was higher than that in the left cerebral cortex. (d) No FMISO accumu-
lated in the tumor
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In the visual assessment of the tumors, we first looked into grade IV tumors
because based on the first study we believed that the grade IV tumors would have a
hypoxic volume and thus should show FMISO uptake. At 2 h, six out of eight grade
IV patients showed high FMISO uptakes, and the remaining two patients showed
medium uptakes. At 4 h, however, eight out of eight (100 %) patients showed high
FMISO uptakes. Then, we looked into grade II and III tumors that we thought
would not have developed severe hypoxia and thus would not show FMISO uptake.
At 2 h, three out of four patients showed medium uptakes and the fourth patient
showed a low uptake. This was changed at 4 h where four out of four (100 %)
patients showed low uptakes. The results of the visual assessment can be
Fig. 18.4 An anaplastic oligodendroglioma case (grade III). (a) The FLAIR image showed a
tumor in the left frontal lobe. (b) A part of the tumor enhanced by gadolinium contrast material. (c)
The FDG uptake was observed even outside the enhancing area. The FDG uptake was much higher
than that in the right cerebral cortex. (d) No FMISO uptake was observed in the tumor
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summarized as those 4-h images provide more definitive information for discrim-
inating grade IV tumors from lower-grade tumors. The quantitative analysis further
supported this; in all the cases, the SUVmax and tumor-to-normal ratio increased
from 2 h to 4 h (Fig. 18.9). Here, lower-grade gliomas (grades II and III) showed
decreases in SUVmax and in the tumor-to-normal ratio from 2 h to 4 h (Fig. 18.10).
Fig. 18.5 An oligodendroglioma case (grade II). (a) The FLAIR image showed a tumor in the left
temporal lobe. (b) The tumor slightly enhanced by gadolinium contrast material. (c) The FDG
uptake was weaker than in the right cerebral cortex. (d) No FMISO uptake was observed in the
tumor
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Fig. 18.6 A brain slice FMISO PET image (a) 2 h after administration of FMISO and (b) after 4 h.
No tumor existed on these slices. (c) 2-h SUV profile corresponding to the horizontal line in (a).
The red arrows indicate gray matter, and the white arrows indicate white matter. (d) 4-h profile
corresponding to the horizontal line (b)
Fig. 18.7 SUV of (a) gray and (b) white matter at 2 h vs. 4 h
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Fig. 18.8 Plot of variation (CV) of (a) gray and (b) white matter at 2 h vs. 4 h
Fig. 18.9 All glioblastoma cases showed increases in both the (a) SUVmax and (b) tumor-to-
normal ratio from 2 h to 4 h
Fig. 18.10 All grade II to III cases showed decrease in (a) SUVmax, and 3/4 cases showed
decrease in (b) tumor-to-normal ratio from 2 h to 4 h
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18.4 Discussion
We have detailed two studies in this article. The results of the first indicated that
much FMISO accumulated in all the glioblastomas here but not in the lower-grade
gliomas. Different from this, FDG accumulated in both glioblastomas (100 %) and
in some lower-grade gliomas (33 %). This suggests that FMISO PET is superior to
FDG PET in a differential diagnosis. Visual analysis was confirmed by analyses of
the SUV, lesion-to-normal tissue ratio, and FMISO uptake volume. The results of
the second study indicated that FMISO PET 4 h after administration is superior to
the images after 2 h in differentiating glioblastomas from non-glioblastomas.
In the 2007 WHO definition, grade IV gliomas show microvascular proliferation
and necrosis as well as anaplasia and mitotic activity [3]; necrotic tissue is not
observed in grade III or lower-grade gliomas. In brain tumor specimens, necrotic
change is an important histopathological landmark that distinguishes glioblastomas
from lower-grade gliomas. In previous reports, the necrosis in glioblastoma is
considered to be associated with tissue hypoxia [16, 17]. The FMISO PET identi-
fication of hypoxia proceeds through several steps. Injected FMISO is first
transported by the blood flow and taken up by viable cells. Then, FMISO is
oxidized by intracellular oxygen if there is a sufficient amount of oxygen available
in a cell, and the oxidized FMISO is excreted from the cell. The FMISO is not
oxidized when there is insufficient oxygen available (hypoxic conditions) and the
FMISO is here retained in the cell [41]. Considering these mechanisms, we may
expect that FMISO accumulates in perinecrotic hypoxic tissue but not in the central
necrotic region. We observed that only little FMISO accumulates in non-glioblas-
toma patients. Some studies used needle electrodes to measure oxygen partial
pressures in human gliomas [18, 19, 42] and have suggested that both glioblastomas
and grade II and III gliomas are present under hypoxic conditions. Lower-grade
gliomas do not develop necrosis and may be expected to suffer from only a milder
degree of hypoxia than that of glioblastomas [18, 19]. FMISO accumulation
requires severe hypoxic conditions (pO2< 10 mmHg) [43, 44], and the results
here are consistent with this.
Cher et al. investigated FMISO uptake in various tumors and the correlation with
histological findings [27]. They reported that all grade IV tumors showed high
FMISO uptakes (they were FMISO positive as we define it here) and that all grade I
and II tumors showed FMISO uptakes comparable to the surrounding tissue (they
were FMISO negative as we define it). However, there was a slightly elevated
FMISO uptake in one of three grade III patients and low uptakes in the remaining
two grade III patients [27]. Our results in the first study are consistent with this
previous data, except for the grade III patients, as all of our grade III gliomas were
FMISO negative. Cher et al. used 2 h as the waiting time before conducting the
FMISO PET scanning, while the study here used 4 h. Many FMISO PET protocols
have used 2 h as the uptake time [24, 25, 27–32], while Thorwarth et al. questioned
the adequacy of 2 h for imaging of FMISO [34]. There, the kinetic analysis of
dynamic datasets of FMISO PET suggested that the hot spots at 2 h did not reflect
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actual hypoxia but rather showed a high initial influx of the FMISO due to increased
blood flow to the tumor. In our first study, no grade III patients showed high FMISO
uptakes, and we speculated that this was possibly because the relatively long uptake
time allowed the tracer to be excreted from the tissue without severe hypoxia. To
further elucidate this, we conducted the second study, to directly compare images at
2 and 4 h after FMISO injection in the same patients. At 4 h, the background gray
matter SUV was lower, and the presence of the tumor uptake was fully substanti-
ated: all the glioblastomas were FMISO positive, and all the non-glioblastomas
were FMISO negative. These results are consistent with the Thorwarth observations
[34].
Recent advances in molecular targeting therapies and image guided therapies are
remarkable, and it may be expected that in the near future the therapy of first choice
for glioblastomas will be chemo- or radiotherapy rather than surgery. In such cases,
new techniques like FMISO PET may help avoid a biopsy followed by a patholog-
ical investigation. Aged patients or patients with impaired performance status
would particularly benefit from such techniques.
The FDG PET reflects the histological aggressiveness of gliomas, and glioblas-
tomas commonly show the highest FDG uptake among gliomas [12–14]. In the first
study here, a high FDG uptake was unexceptionally observed in glioblastoma
patients. At the same time, however, three of nine non-glioblastoma patients also
showed high FDG uptakes. These findings are consistent with the previous data [13,
14], and the results indicate that FDG PET is useful for histological grading but
inconclusive when a differential diagnosis of glioblastomas from lower-grade
gliomas is at issue. This leads us to suggest that FMISO PET may play a more
important role when a tumor shows a high FDG uptake (equal to or greater than the
uptake in the surrounding gray matter). Another important PET tracer for brain
tumor imaging is 11C-methionine (MET). For MET the uptake intensity
corresponding to each tumor grade can be summarized as in Fig. 18.11. It is well
Fig. 18.11 A scheme of the
suggested roles of 11C-
methionine (MET), 18F-
FDG, and 18F-FMISO PET
in differential diagnosis of
gliomas
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known that even grade II tumors may show high MET uptakes, especially in the
case of tumors with oligodendroglial components [45, 46], and that MET is good at
showing the tumor boundary. The FDG uptake increases with the tumor grade [47],
and the results here suggest that FMISO uptake is absent in grades II and III, but
strong in grade IV. Altogether these tracers will provide significant information to
assist in distinguishing tumor type and stage.
In the first study, the FMISO PET images were evaluated in different manners by
visual assessment, SUV, lesion-to-normal tissue ratio, and uptake volume. The
results of these analyses were consistent in showing the relationship between
FMISO uptake and glioma grade. In clinical settings the findings suggest that a
visual assessment is sufficient for a diagnosis, as the numerical values provide
information consistent with the visual assessment. The numerical values may
however be useful for purposes like assessing the prognosis and treatment response.
Both the SUVmax and SUV10mm with FMISO were higher in glioblastoma patients
than in non-glioblastoma patients; the range of the values for the groups overlaps,
possibly explained by inter-subject variability in the SUV. The lesion-to-cerebel-
lum ratio clearly distinguished glioblastoma patients from non-glioblastoma
patients. The usefulness of the lesion-to-cerebellum ratio has also been demon-
strated by Bruehlmeier et al. [26], by showing that lesion-to-cerebellum ratios were
comparable with the distribution of FMISO volumes. It may be argued that cerebral
glioma patients often show asymmetric blood flows in the cerebellum (the so-called
crossed cerebellar diaschisis) and that the cerebellar value may not be uniquely
useful as a reference. In the study here, FMISO accumulation of the left and right
cerebellar cortex did not show significant asymmetry (data not shown); however,
this may be assumed not to be a problem in using the lesion-to-cerebellum ratio.
To further confirm the findings, the uptake volume of FMISO in the tumor was
measured and compared for glioblastoma and non-glioblastoma patients. This
comparison showed that glioblastomas exhibited significantly larger uptake vol-
umes of FMISO than non-glioblastomas. In general, the hypoxic volume is distin-
guished with tissue-to-blood ratios 1.2 in images acquired 2 h after FMISO
injection with venous blood samples [28–31]. In brain tumor segmentation for
MET PET, a tumor-to-normal ratio 1.3 is frequently used [31, 39, 40, 48]. The
study here did not collect blood samples at the scanning but showed intratumoral
volumes in excess of a 1.3-fold cerebellum mean, which we consider an adequate
substitute. The method here did not directly quantify the hypoxic volume, and this
is one of the limitations of the study. As another limitation, the number of patients
included in this study is small, and further study with more patients is necessary to
substantiate the findings. In particular, such studies need to focus on small glio-
blastoma lesions and aggressive grade III tumors, because these could be a source
of false-negative or positive results. Third, we did not investigate specific immu-
nohistochemical features of hypoxia, like the hypoxia-inducible factor-1α (HIF-
1α). Investigating HIF-1α further reveals the oxygen condition in the tumor.
Finally, in clinical settings, metastatic brain tumors and malignant lymphomas
also require a diagnosis that will distinguish them from glioblastomas. Further,
additional and different types of brain tumors will need to be investigated.
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We also wish to briefly discuss PET tracers other than FMISO [23]. The slow
clearance of FMISO from tissue is a shortcoming in clinical settings. If the uptake
time could be shortened to maybe 1 h, this would improve the feasibility of hypoxia
imaging. Currently, FMISO is the tracer where most evidence has been accumu-
lated, but promising data have been published for other tracers as well. A review
article by Kurihara et al. on preclinical and clinical applications of hypoxia PET
tracers including FMISO also mentions 18F-fluoroerythronitroimidazole
(FETNIM), 18F-fluoroazomycin-arabinofuranoside (FAZA), and 62Cu or 64Cu-
diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) [49]. Among these,
FETNIM has not been used with brain tumors, while FAZA is less lipophilic than
FMISO, suggesting that background activity in the plasma could be excreted more
quickly than FMISO. This point is important for shortening the uptake time.
However, in an animal study, Sorger et al. have showed that faster clearance of
FAZA resulted in lower FAZA uptake in the tumor than with FMISO [50]. It is not
easy to solve this dilemma between uptake time and contrast. Postema et al.
conducted a study of FAZA PET in 50 patients with a number of different
malignant tumors, including seven glioblastoma patients [51]. Here images were
acquired 2–3 h after injection, and the image quality was reported as good, but not
superior to FMISO. With Cu-ATSM there is the advantage that the radionuclide
62Cu can be provided by a 62Zn/62Cu generator, which at present does not require an
on-site cyclotron to image hypoxia. O’Donoghue et al. conducted an animal study
using a R3327-AT tumor model and found a correlation between the 19-h images of
Cu-ATSM and FMISO images at 2–4 h as well as oxygen probe measurements [52].
However, 1-h images of Cu-ATSM did not correlate with the FMISO images. A
more recent study by Dence et al. compared Cu-ATSM with FMISO, FDG, and
18 F-fluorothymidine (FLT) using a 9 L gliosarcoma model. Here, autoradiography
showed a strong correlation between the Cu-ATSM and FMISO distributions [53].
Tateishi et al. acquired Cu-ATSM PET for glioma patients and demonstrated a
correlation between Cu-ATSM uptake and glioma grades [54]. Despite evidence, it
is still not substantiated whether Cu-ATSM represents hypoxia. Further, 18F-EF5,
2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide, was
first tested in an animal study by Ziemer [55]. Evens et al. found that EF5 uptake
correlated with a poor prognosis in glioma patients [18]. They also reported
correlations of EF5 uptake with microscopic findings of vasculature [56] and
radiation responses [57].
18.5 Conclusions
This article summarizes our recent findings in two studies related to FMISO PET
for brain tumors. The first study demonstrated that much FMISO accumulated in
glioblastomas but not in lower-grade gliomas. The second study demonstrated that
FMISO PET images acquired 4 h after administration were better at showing
hypoxic tumors than the images acquired 2 h after injection. Combining these
246 K. Hirata et al.
results, the 4-h FMISO PET may be useful in preoperatively discriminating glio-
blastomas from lower-grade gliomas.
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Chapter 19
Evolution and Protection of Cerebral
Infarction Evaluated by PET and SPECT
Eku Shimosegawa
Abstract Since cerebral infarction results from a reduction of cerebral blood flow
(CBF) by the occlusion or stenosis of carotid or intracranial arteries, CBF is a
primary parameter to predict of ischemic brain injury. Single-photon emission
tomography (SPECT) and positron emission tomography (PET) contributed to
evaluate loss of cerebral autoregulation, uncoupling state between CBF and brain
metabolism, and ischemic penumbra. Measurement of CBF and oxygen meta-
bolism by 15O PET revealed the process of infarct growth in hyperacute stage of
cerebral infarction and areas with depressed oxygen metabolism, but normal water
diffusion in magnetic resonance imaging (MRI) was termed as “metabolic penum-
bra.” Recently, some researchers shed light on the role of glial cells in the energy
metabolism of the brain and 11C-acetate PET and demonstrated that astrocytic
energy metabolism in TCA cycle was protective against ischemia. SPECT and
PET studies for secondary reaction after ischemia (i.e., selective neuronal loss by
123I-iomazenil SPECT and 11C-flumazenil PET, tissue hypoxia by 18F-FMISO
PET, and neuroinflammation by TSPO-PET) are expected as new biomarkers.
Combining these imaging biomarkers with classical CBF measurement may contri-
bute to develop innovative drugs for pharmacological neuroprotection in the ther-
apy of cerebral infarction.
Keywords Cerebral infarction • SPECT • PET • Hypoxia • TSPO-PET
19.1 Introduction
Cerebral infarction results from a reduction in cerebral blood flow (CBF) arising
from the occlusion or stenosis of carotid or intracranial arteries, and the progression
of this event typically ends with the necrosis of various brain tissue components,
including neurons. Since tissue damage varies according to the severity of brain
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ischemia, CBF is a primary parameter for predicting the extent of ischemic brain
injury.
Positron emission tomography (PET) and single-photon emission computed
tomography (SPECT) have contributed to the elucidation of the disease process
responsible for brain ischemia from an acute to chronic stage. PET studies have
mainly measured CBF and oxygen metabolism but have been expanded to include
the detection of neuronal loss, tissue hypoxia, and neuroinflammation. Quantitative
15O PET measurements can provide information on CBF, the cerebral metabolic
rate of oxygen (CMRO2), the cerebral blood volume (CBV), and the oxygen extrac-
tion fraction (OEF), and these parameters enable impaired cerebral autoregulation
and the uncoupling of perfusion and metabolism to be diagnosed based on absolute
values. The SPECT studies can visualize the magnitude and extent of ischemia in a
clinical setting. Neurons are more vulnerable than other cell groups in the brain, and
selective neuronal loss sometimes occurs in patients with mild to moderate brain
ischemia. PET and SPECT are advantageous for demonstrating this type of brain
injury, which cannot be visualized by comparing computed tomography (CT) and
magnetic resonance imaging (MRI) findings. PET imaging of tissue hypoxia is
expected to distinguish permanent and temporal ischemic areas surrounding the
ischemic core. Translocator protein (TSPO) PET can represent neuroinflammation
in areas with evolving infarcts and may become a biomarker for neuroprotective
therapy. Recently, important roles of astrocytes in the energy metabolism of the
brain have been reported. The imaging of astrocytes using 11C-acetate PET may
provide a sensitive marker for evaluating glial metabolism in the ischemic brain.
The purpose of using these imaging probes depends on the course or stage of
Fig. 19.1 Time course of infarct evolution and related PET/SPECT imaging
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cerebral infarction (Fig. 19.1). In this chapter, we introduce the use of PET and
SPECT imaging in studies to clarify the process of cerebral infarction.
19.2 Perfusion and Oxygen Metabolism in Brain Ischemia
CBF is a key parameter of ischemic brain damage that can be quantitatively
measured using PET and SPECT. A decrease in the cerebral perfusion pressure
(CPP) induces primary damage to the supply of oxygen and energy substance to the
brain. Protective mechanisms against reductions in the CPP can be evaluated using
PET and SPECT. The first mechanism is “cerebral autoregulation,” the origin of
which is cardiac pump function. CBF is constant within a mean arterial blood
pressure (MABP) range of 60–160 mmHg [1]. To maintain a constant CBF,
cerebral precapillary arterioles can dilate when the CPP decreases and can constrict
when the CPP increases. Although this mechanism of dilation and constriction for
cerebral autoregulation remains unclear, recent studies have indicated that CBF
control is initiated in the cerebral capillaries, where pericytes can constrict capil-
laries in response to the effect of noradrenaline [2]. Cerebral autoregulation is
disturbed by brain ischemia [3], and its capacity can be estimated using the cerebral
vasoreactivity (CVR) to the change in the arterial partial pressure of carbon dioxide
(PaCO2). In SPECT studies, acetazolamide, which is another vasodilating agent, is
used to test CVR. A reduced CVR in patients with steno-occlusive carotid artery
disease is a major predictor of stroke recurrence [4, 5].
By combining this information with data on CBF and oxygen metabolism
measured using 15O PET, we can evaluate other protective states against CPP
reduction (Fig. 19.2). When cerebral autoregulation is functioning well, CBF
remains normal and the CBV increases, indicating the dilatation of collateral
vessels. When the CPP is reduced beyond the point of compensation by vaso-
dilatation, the cerebral autoregulation is exhausted and the CBF begins to decrease.
Fig. 19.2
15O PET images in a patient with right carotid and MCA occlusion. PET images of (a)
CBF, (b) CBV, (c) CPP, and (d) OEF. The CPP images were created by dividing CBF and CBV.
The area with a severe CPP reduction corresponded to the area with an elevated OEF (misery
perfusion)
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When CMRO2 is preserved, then the OEF starts to increase. Such increases in the
OEF are known as “misery perfusion” and can be observed during the acute stage of
cerebral infarction (Fig. 19.3). In the chronic stage of cerebral infarction, misery
perfusion in patients with unilateral carotid artery occlusion suggests a high prob-
ability of stroke recurrence [6–8]. Powers et al. classified the severity of cerebral
ischemia from Stage 0 to Stage II according to CBF, CBV, and OEF [9]. Stage II is
equal to the state of misery perfusion. The 5-year stroke recurrence rate for Stage II
patients with unilateral steno-occlusive internal carotid artery (ICA) was 70 %,
whereas it was 20 % for Stage 0 and I patients [8].
19.3 Infarct Growth in Acute Cerebral Infarction
The ischemic threshold of CBF has been thoroughly evaluated in both experimental
studies and clinical studies. Symon and colleagues revealed a relationship between
CBF, neurological deficits, and tissue damage in baboon models of cerebral ische-
mia [10]. They showed that the electric activity of somatosensory evoked potentials
in cerebral tissue was preserved at a CBF above 20 mL/100 g/min (40 % of normal
level), whereas it was impaired when the CBF decreased to 10–20 mL/100 g/min.
Fig. 19.3 Misery perfusion in a patient with acute left MCA occlusion. PET images of (a) CBF,
(b) CMRO2, (c) OEF, and (d) CBV examined on the day of stroke onset. The CBF in the left MCA
territory reduced, whereas the CMRO2 in the corresponding area was relatively preserved. The
OEF was elevated in the same area, indicating an uncoupled state between perfusion and oxygen
metabolism (misery perfusion). A CT image obtained on the same day (e) did not show any
morphological changes
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Although this impaired electric activity was reversible by recirculation, irreversible
damage resulting from an elevated extracellular potassium concentration and sub-
sequent cell death occurred when the CBF was reduced to less than 6–10 mL/100 g/
min. Astrup, Siesjo, and Symon defined the ischemic penumbra as brain tissue with
CBF thresholds between electric (20 mL/100 g/min) and membrane failure
(6–10 mL/100 g/min) [11]. In a baboon model, Jones et al. found that a longer
period of ischemia was associated with a higher threshold for membrane failure
[12]. Their studies indicated that the ischemic penumbra should be restored as early
as possible to reduce the volume of cerebral infarction. Clinical SPECT studies
have demonstrated the validity of evaluating the ischemic threshold during the
acute stage of infarction. Shimosegawa et al. evaluated SPECT images within 6 h of
onset in ischemic stroke patients and revealed that a CBF of less than 30–50 % of
that in unaffected brain regions was capable of inducing cerebral infarction [13]
(Fig. 19.4). When the CBF was less than 20 % of that in the unaffected hemisphere,
the probability of hemorrhagic infarction after recanalization therapy
increased [14].
Although the CBF threshold has been established in both experimental and
clinical studies, the metabolic threshold and its relation to the development of
infarction has not yet been clarified. In a 15O PET study of patients with cerebral
infarction where imaging was performed within 6 h of onset, Shimosegawa
et al. demonstrated that infarct growth occurred in brain lesions with a depressed
CMRO2 but normal water diffusion on diffusion-weighted imaging (DWI) [15]
(Fig. 19.5). Peri-infarct areas with a CMRO2 of less than 45–62 % of that in
unaffected brain regions on the initial 15O PET showed volume expansion of the
brain infarction at 3 days after onset, and they named this phenomenon “metabolic
penumbra.” The normal diffusion in these areas indicated that adenosine triphos-
phate (ATP) synthesis was still preserved to a degree sufficient to maintain an
Fig. 19.4 Prediction of cerebral infarction by acute CBF-SPECT. A diffusion-weighted MR
image obtained at 1.3 h after onset (a) demonstrated only a small lesion in the frontal lobe. A
99mHMPAO-SPECT image obtained at 2.3 h after onset (b) showed a broad reduction in CBF in
the left cerebral hemisphere. A CBF reduction of more than 50 %, compared with the contralateral
region, was observed in the left frontal lobe, and this area progressed into a complete infarction
visible on a CT image obtained 4 days after onset (c)
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ATP-dependent neuronal membrane ion pump in the area of the evolving infarct as
early as 6 h after onset. Therefore, a metabolic penumbra with a moderate decrease
in CMRO2would be a critical treatment target, using early reperfusion and pharmaco-
logical neuroprotection to reduce the volume expansion of the brain infarction.
19.4 Role of Astrocytic Function in Brain Ischemia
Recently, some researchers have shed light on the role of glial cells in energy
metabolism in the brain. Glutamate is a major excitatory neurotransmitter of the
brain, and glutamate in the synaptic cleft is removed by astrocytes surrounding
glutaminergic synapses. The removed glutamate is converted into glutamine in
astrocytes by glutamine synthetase. Glutamine is released by astrocytes and taken
Fig. 19.5 Metabolic penumbra in acute brain infarction. (a) DWI of MRI obtained 4 h after onset,
(b) perfusion-weighted image (PWI) obtained 4 h after onset, (c) DWI obtained 3 days after onset,
(d) CBF obtained 3 h after onset, (e) CMRO2 obtained 3 h after onset, and (f) OEF obtained 3 h of
onset in a patient with right ICA embolic occlusion. An MRI examination indicated PWI–DWI
mismatch in the territory of the right ICA. DWI on day 3 indicated an evolution of the infarction
within the mismatch. The initial PET examination indicated that the PWI–DWI mismatch lesion
exhibited reductions in CBF and CMRO2 associated with misery perfusion (increased OEF, white
arrow). The PWI–DWI mismatch corresponded to suppressed energy metabolism that was still
higher than the threshold for ion pump failure (Reprinted from Brain Mapping: An Encyclopedic
Reference, Vol. 3/1st edition, Arthur W. Toga (Editor in Chief), Hemodynamic and Metabolic
Disturbances in Acute Cerebral Infarction (title)/Clinical Brain Mapping (chapter), written by
E. Shimosegawa, p. 829–838, 2015, with permission from Elsevier)
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up by neuronal terminals, where it is enzymatically reconverted to glutamate and
stored in the neurotransmitter pool for the next transmission. This process is called
“glutamate-glutamine cycle” and requires ATP [16]. Furthermore, astrocytes play
an important role in glycolysis in the brain. Activation by the glutamate transporter
on the astrocytic membrane stimulates glucose uptake into astrocytes. This glucose
is processed glycolytically, resulting in the release of lactate as an energy substrate
for neurons. Lactate produced by this process is transferred to neurons for oxidation
(the astrocyte-neuron lactate shuttle: ANLS) [17]. This lactate produces two ATP
molecules, which contribute to the Na-K ion pump function and the synthesis of
glutamine from glutamate. In ischemic brain where ATP synthesis is restricted, the
conversion of glutamate in the synaptic cleft is disturbed. Continuous stimulation
by glutamate induces an influx of Ca2+ ion, resulting in anoxic depolarization, and
leads to inflammation and apoptosis. Therefore, the glutamate-glutamine cycle and
ANLS are deeply related to astrocytic function and plays a critical role in the
evolution from penumbra to infarction.
For the specific imaging of astrocyte, acetate is expected to be useful as a
selective marker of astrocytic energy metabolism [18, 19]. 14C-acetate is rapidly
incorporated into glutamine via glutamate by glutamine synthetase localized in
astrocytic cells [20]. Hosoi et al. demonstrated that 14C-acetate uptake is dramat-
ically decreased in a 3-min ischemia and reperfusion model, indicating that the
metabolic and functional impairment of astrocytes continues after the restoration of
CBF [21]. 11C-labeled acetate could be a promising PET tracer for the evaluation of
astrocytic metabolism in human studies (Fig. 19.6).
Fig. 19.6 Qualitative and quantitative 11C-acetate PET imaging for astrocytic energy metabolism.
(a) An averaged 11C-acetate PET image (from 0 to 40 min) and (b) an averaged Kmono image in a
healthy volunteer. The energy metabolism evaluated using the Kmono image was different from
the normal oxygen metabolism evaluated using the CMRO2 image (c)
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19.5 Selective Neuronal Loss in Ischemic Brain Injury
Tissue vulnerability differs among neurons, glial cells, and blood vessels. Selective
neuronal necrosis is known to occur in neuron-specific ischemic injury, where other
cell components are preserved, and is associated with the expression of apoptosis-
related DNA damages and repair genes [22]. In PET and SPECT imaging, 11C-
flumazenil and 123I-iomazenil are considered to be neuron-specific tracers that bind
central benzodiazepine receptors that are specifically localized on the membranes
of cortical neurons. Preserved 11C-flumazenil accumulation in acute ischemic brain
can predict the probability of surviving an infarct [23, 24]. Hatazawa
et al. examined 123I-iomazenil SPECT in patients with cortical and subcortical
infarction. They reported a patient with global aphasia who had a purely subcortical
infarction and significantly diminished 123I-iomazenil uptake in CT-negative Broca
and Wernicke areas [25]. This result indicated that 123I-iomazenil SPECT could
sensitively detect lesions responsible for clinical symptoms, compared with morpho-
logical examinations (Fig. 19.7).
19.6 Detection of Tissue Hypoxia
Tissue hypoxia can be visualized using 18F-labeled nitroimidazole derivatives or
62/64Cu-labeled lipophilic chelate compounds. 18F-fluoromisonidazole (18F-FMISO)
PET is a representative hypoxic marker. Under hypoxic conditions, 18F-FMISO
Fig. 19.7 Selective neuronal loss: (a) T2-weighted image (T2WI) in a patient with subcortical
infarction of the left putamen 1.5 months after onset, (b) CBF image of the corresponding slice
obtained by 123I-IMP SPECT, and (c) 123I-iomazenil SPECT image of the corresponding slice. The
MR image showed no obvious lesion in the left cortical area, whereas 123I-iomazenil SPECT
demonstrated a decrease in accumulation (white arrow), indicating selective neuronal loss. The
CBF reduction extended beyond the cortical areas of 123I-iomazenil reduction (Reprinted from
Brain Mapping: An Encyclopedic Reference, Vol. 3/1st edition, Arthur W. Toga (Editor in Chief),
Hemodynamic and Metabolic Disturbances in Acute Cerebral Infarction (title)/Clinical Brain
Mapping (chapter), written by E. Shimosegawa, p. 829–838, 2015, with permission from Elsevier)
258 E. Shimosegawa
passively diffuses into cells and is reduced by nitroreductase enzymes and trapped
by intracellular molecules. The retention of 18F-FMISO is inversely proportional to
the tissue partial pressure of O2. Takasawa et al. revealed that the selective accumu-
lation of 18F-FMISO was found in permanent and temporal ischemic areas sur-
rounding the ischemic core [26]. They demonstrated that 18F-FMISO uptake in the
ischemic brain was only elevated during the early phase of middle cerebral artery
(MCA) occlusion. After early reperfusion, no demonstrable tracer retention was
observed. In patients with an acute MCA territory stroke, Markus et al. reported that
18F-FMISO PET showed the temporal evolution of tissue hypoxia [27]. A higher
hypoxic volume was observed in the core of the infarct within 6 h of onset, and the
location moved to the periphery or external to the infarct at later time points. They
also showed that tissue without 18F-FMISO uptake within the final infarct was
presumed to have infarcted by the time of the acute 18F-FMISO PET. These experi-
mental and clinical results are very interesting because they suggested that 18F-
FMISO uptake changes continuously during the course of brain infarction. Since
18F-FMISO PET is unable to discriminate between complete infarcted area and
non-hypoxic viable tissue during the acute stage of infarction, the timing of the PET
examination is likely to be critical for diagnosing whether the tissue is salvageable.
19.7 Imaging of Neuroinflammation
In focal brain ischemia, inflammatory reactions mainly occur in the peri-infarct area
and lead to an overexpression of peripheral benzodiazepine receptors (PBR)/18-
kDa TSPO on the membrane of activated microglia, macrophages, and activated
astrocytes. Several PET tracers that specifically bind to TSPO have been developed
as biomarkers of neuroinflammation. Imaizumi et al. demonstrated that 11C-PBR28
accumulated in the peri-infarct lesions of a rat ischemia model, indicating that
neuroinflammation does not occur in the ischemic core but in penumbral lesions
[28]. In our preclinical study using a temporary MCA occlusion model, 11C-DPA-
713 uptake increased in the area surrounding the infarct core after 4 days of
ischemia, where the expression of microglia/macrophages was positive using
CD11b immunostaining (Fig. 19.8). In an impressive study, Martı́n et al. reported
that 18F-DPA-714 uptake decreased at 7 days after cerebral ischemia in rats treated
with minocycline, compared with saline-treated animals [29]. Whether the
increased regional microglia/macrophage activation visualized by TSPO PET is a
good biomarker remains controversial. TSPO molecular imaging, however, might
have diagnostic potential for assessing therapeutic strategies, such as the use of
neuroprotective or anti-inflammatory drugs during the acute or subacute stage of
cerebral infarction.
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19.8 Summary
Measurements of hemodynamic and metabolic disturbances using PET and SPECT
have been utilized to study the acute and chronic stages of cerebral infarction. CBF,
CMRO2, CBV, OEF, and CVR are basic parameters for estimating CPP reduction.
An acute metabolic penumbra (decreased CMRO2 in peri-infarct area on initial
PET) and misery perfusion (areas with decreased CBF with maintained CMRO2 in
ischemic brain) during the acute and chronic stages are indicators of evolving
infarction. Astrocytes have a protective role against cerebral infarction by reducing
the glutamate concentration during ischemia, and 11C-acetate PET may provide
information regarding glial cell function. Neuron-specific imaging can only be
performed using PET and SPECT, and it would be useful to collate the clinical
symptoms with neuronal damage. PET tracers for tissue hypoxia and neuro-
inflammation have been developed and are promising biomarkers for detecting
infarct growth and salvageable tissue and are expected to become useful as probes
in future therapeutic interventions.
Fig. 19.8 TSPO PET image of rat ischemic model. (a) 11C-DPA713 PET and (b) the corres-
ponding CD11b immunostaining image. 11C-DPA713 accumulated in the peripheral region of the
ischemic core at 4 days after 60 min of MCA occlusion and reperfusion (white arrows). The
CD11b-positive findings agreed with the uptake of 11C-DPA713 (white arrow heads), indicating
that macrophages/microglia were activated by neuroinflammation after brain ischemia
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Chapter 20
Brain Development and Aging Using Large
Brain MRI Database
Yasuyuki Taki
Abstract Now we confront a super aging society in Japan. In the situation, it is
important to preserve our cognitive function for entire life by preventing us from
pathological brain aging. To perform the aim, we have built a large brain magnetic
resonance imaging (MRI) database from around 3,000 subjects aged from 5 to 80 in
order to reveal how brain develops and ages. We have also collected several
cognitive functions, lifestyle such as eating and sleeping habits, and genetic data.
Using the database, we have revealed normal brain development and aging and also
have revealed what factors affect brain development and aging. For example, sleep
duration is significantly associated with the gray matter volume of the bilateral
hippocampi. In addition, there were significant negative correlation between alco-
hol drinking and gray matter volume of the frontoparietal region and body mass
index and gray matter volume of the hippocampus in cross-sectional analysis. In
addition, having intellectual curiosity showed significant negative correlation with
regional gray matter volume decline rate in the temporoparietal region. These
findings help understanding the mechanism of brain development and aging as
well as performing differential diagnosis or diagnosis at an early stage of several
diseases/disorders such as autism and Alzheimer’s disease.
Keywords Brain development • Brain aging • Magnetic resonance imaging •
Database • Preventive medicine • Normal subject
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20.1 Introduction
Now we confront a super aging society in Japan. In the situation, it is important to
preserve our cognitive function for entire life by preventing us from pathological
brain aging. Recently, the importance of human neuroimaging database was rec-
ognized greatly. The normal brain structure and function database can be used as
the references not only for neuroimaging study for humans but also for early
diagnosis and computer-aided automated diagnosis of the brain diseases. The
most remarkable recently developed method for brain image analysis is voxel-
based morphometry (VBM). It includes anatomical standardization of the brain to a
standard brain, brain tissue segmentation and finally voxel-based statistical analysis
based on general linear model. This technique enables us to extract brain regions
which show correlations between tissue volume and variables, such as age, sex, and
other subject’s characteristics. We can analyze not only age-related normal changes
but also diseased brain, such as dementia and schizophrenia. It has been believed
that functional imaging precede structural imaging to detect early pathological
findings of the diseases. However, recent development of high-resolution structural
imaging and sophisticated analytical technique enable us to detect the brain disease
at very early stage. Now we have collected over 3,000 brain MRI of healthy
Japanese aged from 5 to 80 and constructed an MRI database together with their
characteristics such as age, sex, lifestyle information, blood pressure, present and
past disease history, and cognitive functions. This is a largest brain MRI database in
Japan and one of the largest one in the world.
20.2 Imaging Studies of Brain Development
20.2.1 Correlation Between Gray Matter Density-Adjusted
Brain Perfusion and Age Using Brain MR Images
of 202 Healthy Children
In understanding brain aging, the knowledge of brain maturation is very important,
for the relationship between brain maturation and brain aging is regarding as a
“mirror pattern.” In detail, brain regions that mature earlier such as occipital regions
are robust in brain aging, whereas brain regions that mature rather late such as
prefrontal regions are vulnerable for aging. Brain development continues through
childhood and adolescence. Recently, it has been revealed that human brain devel-
opment is a structurally and functionally nonlinear process. However, despite this
growing wealth of knowledge about maturational changes in brain structure in
children, the trajectory of brain perfusion with age in healthy children is not yet
well documented.
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Recently, arterial spin-labeling (ASL) perfusion magnetic resonance imaging
(MRI) has been developed for evaluating brain perfusion. We examined the corre-
lation between brain perfusion and age using pulsed ASL MRI in a large number of
healthy children.
We collected data on brain structural and ASL perfusion MRI in 202 healthy
children aged 5–18 years. Structural MRI data were segmented and normalized,
applying a voxel-based morphometric analysis. Perfusion MRI was normalized
using the normalization parameter of the corresponding structural MRI. We calcu-
lated brain perfusion with an adjustment for gray matter density (BP-GMD) by
dividing normalized ASL MRI by normalized gray matter segments in 22 regions.
Next, we analyzed the correlation between BP-GMD and age in each region by
estimating linear, quadratic, and cubic polynomial functions, using the Akaike
information criterion (Fig. 20.1).
As a result, the correlation between BP-GMD and age showed an inverted U
shape followed by a U-shaped trajectory in most regions [1–3]. In addition, age at
which BP-GMD was highest was different among the lobes and gray matter
regions, and the BP-GMD association with age increased from the occipital to the
frontal lobe via the temporal and parietal lobes.
In the frontal lobe, all gray matter regions showed an inverted U-shaped trajec-
tory for the correlation between BP-GMD and age, and the best fit was a negative
quadratic or positive cubic polynomial function. The estimated age at which
BP-GMD was highest was earlier in the precentral gyrus, cingulate gyrus, and
anterior cingulate cortex than in the superior, middle, and inferior frontal gyri
(Fig. 20.2).
Fig. 20.1 Schematic of the image analysis
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We demonstrated a correlation between BP-GMD and age using ASL brain
perfusion MRI in a large number of healthy children over a wide age range. As a
result, the trajectory of the correlation between BP-GMD and age showed an
inverted U-shaped second-order polynomial function in most regions in the frontal
lobe, a third-order polynomial function in the parietal and temporal lobes, and a
U-shaped second-order and negative linear correlation in the occipital lobe. Our
results indicate that higher-order association cortices mature after the lower-order
cortices in terms of brain perfusion. As a result, the trajectory of the correlation
between BP-GMD and age showed an inverted U shape followed by a U-shaped
trajectory in most regions. In addition, the age at which BP-GMD was highest was
different among the lobes and gray matter regions, showing a progression from the
occipital lobe to the frontal lobe, via the temporal and parietal lobes. Our results
indicate that higher-order association cortices mature after the lower-order cortices
mature. This may help not only clarify the mechanisms of normal brain maturation
from the viewpoint of brain perfusion but also distinguish normal from develop-
mental disorders that show abnormal brain perfusion patterns.
Fig. 20.2 Correlation between brain perfusion, adjusted for gray matter density, and age in the
frontal lobe, parietal lobe, occipital lobe, and temporal lobe in each hemisphere
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20.2.2 Correlation Between Sleep Duration and Gray Matter
Volume Using Brain MR Images of 290 Healthy
Children
Sleep is essential for living beings, and sleep loss has been shown to affect
hippocampal structure and function in rats by inhibiting cell proliferation and
neurogenesis in this region of the brain. We aimed to analyze the correlation
between sleep duration and the hippocampal volume using brain magnetic reso-
nance images of 290 healthy children aged 5–18 years. We examined the volume of
gray matter, white matter, and the cerebrospinal fluid (CSF) space in the brain using
a fully automated and established neuroimaging technique, voxel-based morphom-
etry, which enabled global analysis of brain structure without bias toward any
specific brain region while permitting the identification of potential differences or
abnormalities in brain structures. We found that the regional gray matter volume of
the bilateral hippocampal body was significantly positively correlated with sleep
duration during weekdays after adjusting for age, sex, and intracranial volume
[4]. Our results indicated that sleep duration affects the hippocampal regional
gray matter volume of healthy children. These findings advance our understanding
of the importance of sleep habits in the daily lives of healthy children.
20.3 Imaging Studies of Brain Aging
20.3.1 Correlation Between Baseline Regional Gray Matter
Volume and Global Gray Matter Volume Decline Rate
Evaluating whole-brain or global gray matter volume decline rate is important in
distinguishing neurodegenerative diseases from normal aging and in anticipating
cognitive decline over a given period in non-demented subjects. Whether a signif-
icant negative correlation exists between baseline regional gray matter volume of
several regions and global gray matter volume decline in the subsequent time
period in healthy subjects has not yet been clarified. Therefore, we analyzed the
correlation between baseline regional gray matter volumes and the rate of global
gray matter volume decline in the period following baseline using magnetic reso-
nance images of the brains of 381 healthy subjects by applying a longitudinal
design over 6 years using voxel-based morphometry.
All subjects were Japanese individuals recruited from our previous brain-
imaging project. We selected participants who had lived in Sendai City at the
time of the previous study, whose collected data had no missing values and who
had no serious medical problems from an initial 1604 eligible persons. All partic-
ipants were screened with a mail-in health questionnaire and underwent telephone
and personal interviews. Persons who reported a history of any malignant tumor,
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head trauma with loss of consciousness for >5 min, cerebrovascular disease,
epilepsy, any psychiatric disease, or claustrophobia were excluded from the
study. All subjects were screened for dementia using the Mini-Mental State Exam-
ination (MMSE). An experienced neuroradiologist examined the MR scans for any
tumors and cerebrovascular disease. The final sample consisted of 381 participants
(40.1 % of the eligible cohort: 158 men, 223 women). All images were collected
using the same 0.5 T MR scanner, including baseline images using MP-RAGE
pulse sequences. After the image acquisition, all MR images were analyzed using
statistical parametric mapping 2 in Matlab. We calculated gray matter volume and
white matter volume using fully automated techniques. To normalize the head size
of each subject, we defined the gray matter ratio (GMR) as the percentage of gray
matter volume divided by the intracranial volume. Next, to reveal the annualized
rate of change in GMR with age, we determined the annual percentage change in
GMR (APCGMR) for each subject. We determined regional gray matter volume
using voxel-based morphometry. To investigate the correlation between baseline
regional gray matter volume and APCGMR, we performed a multiple regression
analysis with age, gender, intracranial volume, and APCGMR as independent valu-
ables and baseline regional gray matter volume as a dependent valuable. We used
the random field theory method to correct for the Familywise Error Rate (FWE);
any resulting P-value less than 0.05 was considered significant. Next, we tested
whether the gray matter regional volume that showed the significant negative
correlation with APCGMR at baseline could predict whether the APCGMR was
above or below the APCGMR mean by applying a standard (not stepwise) linear
discriminant analysis in SPSS11.5. For the discriminant analysis, we used the mean
gray matter volume over a cluster in each region, and the regional gray matter
volume as defined by multiple regression analysis. We set the significance level at
P< 0.05.
As a result, the gray matter regions showing significant negative correlation with
APCGMR adjusted for age, gender, and intracranial volume are shown in Fig. 20.1.
Baseline regional gray matter volumes of the right PCC/precuneus and the left
hippocampus showed significant negative correlations with APCGMR after
adjusting for age, gender, and intracranial volume (right PCC/precuneus, t¼ 5.42,
P¼ 0.020; left hippocampus, t¼ 5.29, P¼ 0.035) [1]. Therefore, we used the gray
matter regions of the right PCC/precuneus and the left hippocampus in the next
discriminant analysis. Baseline regional gray matter volume of both the right
PCC/precuneus and the left hippocampus significantly distinguished whether
APCGMR was above or below the APCGMR mean. The F-value, p-value, and
discriminant function coefficient were 13.51, <0.001, and 0.833 in the right
PCC/precuneus and 5.71, 0.017, and 0.350 in the left hippocampus, respectively.
Overall, 58.4 % of the APCGMR (55.8 % of APCGMR below the mean of APCGMR
and 60.9 % of APCGMR above the mean of APCGMR) was correctly distinguished
using the discriminant function (Fig. 20.3).
This study provides the first longitudinal findings showing that baseline regional
gray matter volumes in the right PCC/precuneus and the left hippocampus show a
significant negative correlation with the rate of global gray matter volume decline
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in the following period, as represented by APCGMR, adjusting for age, gender, and
intracranial volume. In addition, baseline regional gray matter volumes of both the
right PCC/precuneus and the left hippocampus significantly distinguished whether
the APCGMR was above or below the APCGMR mean. These results indicate that
subjects who had smaller baseline regional gray matter volumes in those regions
showed higher rate of global gray matter volume decline in the following period.
In summary, using a longitudinal design over 6 years in 381 community-
dwelling healthy individuals, we examined the correlation between baseline
regional gray matter volume and the rate of global gray matter volume decline in
the following period. We found a significant negative correlation between APCGMR
and the baseline regional gray matter volumes of the right PCC/precunei and the left
hippocampus after adjusting for age and gender. In addition, baseline regional gray
Fig. 20.3 Gray matter
regions showing significant
negative correlations with
annual percent change of
the gray matter ratio
(APCGMR) adjusted for age,
gender, and intracranial
volume
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matter volume of both the right PCC/precuneus and the left hippocampus signifi-
cantly distinguished whether the APCGMR was above or below the APCGMR mean.
Our results suggest that baseline regional gray matter volume predicts the rate of
global gray matter volume decline in the following period in healthy subjects. Our
study may contribute to distinguishing neurodegenerative diseases from normal
aging and to predicting cognitive decline.
20.3.2 Correlation Between Degree of White Matter
Hyperintensities and Global Gray Matter Volume
Decline Rate
Whether the degree of white matter hyperintensities (WMHs) shows a significant
correlation with the rate of global gray matter volume decline over a period
following initial baseline measurement remains unclear. The purpose of the present
study was to reveal the relationship between the degree of WMHs at baseline and
the rate of global gray matter volume decline by applying a longitudinal design.
Using a 6-year longitudinal design and magnetic resonance images of the brains of
160 healthy individuals aged over 50 years and living in the community, we
analyzed the correlation between degree of WMHs using Fazekas scaling at
baseline and rate of global gray matter volume decline 6 years later. To obtain
the rate of global gray matter volume decline, we calculated global gray matter
volume and intracranial volume at baseline and at follow-up using a fully auto-
mated method. As a result, the annual percentage change in the gray matter ratio
(GMR, APCGMR), in which GMR represents the percentage of gray matter volume
in the intracranial volume, showed a significant positive correlation with the degree
of deep WMHs and periventricular WMHs at baseline, after adjusting for age,
gender, present history of hypertension, and diabetes mellitus [2].
The degree of WMHs, both DWMH and PVWMH, at baseline showed a
significant positive correlation with the rate of global gray matter volume decline,
represented by APCGMR, adjusting for age, gender, and present history of hyper-
tension and diabetes mellitus in healthy subjects using longitudinal analysis. To our
knowledge, we are the first to show the correlation between the degree of WMHs at
baseline and the rate of subsequent global gray matter volume decline in healthy
elderly individuals. Our result is partially consistent with recent studies that showed
a significant positive correlation between the degree or load of WMHs and
decreases in gray matter volume in healthy elderly people, although those studies
were conducted using cross-sectional design. However, another recent study using
longitudinal analysis has shown that WMH is not a predictor of brain atrophy rate in
elderly subjects. The inconsistency between the findings of the recent study and the
present study may have arisen from differences in the volume that was measured. In
the present study, we focused on the rate of decline of gray matter volume, not
whole-brain volume, because gray matter volume is significantly correlated with
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several cognitive functions. Our results suggest that the rate of global gray matter
volume decline could be predicted using the degree of WMHs at baseline, evaluated
by simple visual scaling.
In summary, using a longitudinal design over 6 years in 160 community-
dwelling healthy individuals, the degree of WMHs was measured at baseline, and
the rate of global gray matter volume decline was obtained. As a result, APCGMR
showed a significant positive correlation with the degree of deep WMHs and
periventricular WMHs at baseline adjusting for age, gender, and present history
of hypertension and diabetes mellitus. Our results suggest that degree of WMHs at
baseline predicts the rate of subsequent gray matter volume decline and also
suggests that simple visual scaling of WMHs could contribute to the prediction of
the rate of global gray matter volume decline.
20.3.3 Risk Factors for Brain Volume Decrease
20.3.3.1 Alcohol Drinking
We also tested the correlation between gray matter ratio and lifetime alcohol intake.
There was a strong negative correlation between the log-transformed lifetime
alcohol intake and the gray matter ratio [5]. Figure 20.4 shows the gray matter
regions that had a significant negative correlation between the lifetime alcohol
intake and the regional gray matter volume. The gray matter volume of the bilateral
middle frontal gyri showed a significant negative correlation with the
log-transformed lifetime alcohol intake.
Fig. 20.4 Brain regions that showed negative correction between gray matter volume and lifetime
alcohol intake
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20.3.3.2 Obesity
We tested correlation between gray matter ratio and obesity. As an indicator for
obesity, body mass index (BMI) was used. Volumetric analysis revealed that there
are significant negative correlations between BMI and the gray matter ratio, which
represents the percentage of gray matter volume in the intracranial volume, in men
( p< 0.001, adjusting for age, systolic blood pressure, and lifetime alcohol intake),
whereas not in women. VBM revealed that regional gray matter volumes of the
bilateral medial temporal lobe, occipital lobe, frontal lobe, and anterior lobe of the
cerebellum show significant negative correlation with BMI, and those of the
posterior lobe of the cerebellum, perisylvian regions of the bilateral frontal and
temporal lobes, and bilateral orbitofrontal gyri show significant positive correlation
with BMI in men [6] (Fig. 20.5).
20.4 Conclusion
We constructed a large-scale brain MRI database for healthy Japanese and clarified
age-related volume changes of the human brain and their risk factors. Several
factors such as hypertension, alcohol drinking, and obesity are related with gray
matter volume reduction of several regions. In addition, we have shown that several
factors such as baseline gray matter volume structure and white matter lesions
predict the global gray matter volume decline rate. These results may contribute to












Fig. 20.5 T brain regions that showed correlations between gray matter volume and body mass
index (BMI). Red and blue color indicated negative and positive correlations, respectively
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Back to the Future: Nuclear Medicine
Rediscovers Its Therapeutic Roots
Rodney J. Hicks
Abstract Before the advent of diagnostic imaging, nuclear medicine was a treat-
ment modality. The first therapeutic application of radioisotopes was almost con-
temporaneous with the discovery of radioactivity. P-32 became one of the first
effective therapies for a range of malignant blood disorders; I-131 was established
as the benchmark for the treatment of metastatic thyroid cancer; Sr-89 was
recognised to provide palliative benefit in advanced prostate cancer. The develop-
ment of tomographic imaging with SPECT and PET, further enhanced by hybrid
CT or MRI devices, has recently focussed the speciality of nuclear medicine on the
diagnostic use of isotopes. Against this trend there has been renewed awareness on
the ability of radiotracers to identify potential therapeutic targets and to use this
information to select patients for and to monitor the efficacy of targeted therapies
using radioisotopes. This process has been termed “theranostics”. A significant
factor in the rebirth of therapeutic nuclear medicine has been the development of
peptides labelled with Ga-68 and Lu-177. Ga-68 DOTA-octreotate PET/CT and
Lu-177 DOTA-octreotate peptide receptor radionuclide therapy (PRRT) provides
the modern prototype of the theranostic paradigm. Experience with PRRT has,
however, emphasised the need for a more rigorous scientific approach to radionu-
clide therapy. The future holds promise of wide range of therapeutic options based
on diagnostic/therapeutic pairs including I-124/I-131 and Cu-64/Cu-67. Quantita-
tive SPECT/CT and PET/CT will be key platform technologies for planning and
monitoring such therapy and will realise the true promise of molecular imaging in
characterising rather than just finding disease.
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21.1 Introduction
Many current practitioners working in nuclear medicine are unaware of its rich
history as a therapeutic modality. For interested readers, a delightful series of
anecdotes and historical vignettes are contained in Marshall Brucer’s “A Chronol-
ogy of Nuclear Medicine” (Publisher: Robert R Butaine (September 1990) ISBN-
10: 096256740X, ISBN-13: 978–0962567407). To summarise this fascinating tale
of discovery, serendipity and human sacrifice are beyond the scope of this paper but
I will try to cover its key events in order to provide a background to current
advances in nuclear medicine practice that I believe will be fundamental to its
future evolution.
21.2 Radioisotopes Become Therapeutic Tools
Shortly after the discovery of radioactivity in naturally occurring elements by Henri
Becquerel in 1896 and the subsequent isolation of radium byMarie and Pierre Curie
in 1898, Pierre Curie became aware of the potential of radioactive elements to
damage cells, when he himself sustained a very slow healing radiation ulcer on his
chest after carrying a sample of radium to a lecture at the Sorbonne in Paris. Louis
Pasteur opined that chance favours the prepared mind. In this case, this simulta-
neously unfortunate but fortuitous event led Pierre Curie to ponder whether radium
might have potential therapeutic application in the treatment of malignant skin
lesions. In a seminal example of translational research, he discussed this with a
medical colleague, Henri-Alexandre Danlos, who successfully treated patients with
aggressive squamous cell and basal cell cancers. This quickly led to the dissemi-
nation of radium throughout the world for treatment, first of skin cancers and, later,
of all manner of malignancies. Intra-tumoural administration of radium was a
forerunner of modern brachytherapy. However, it soon became clear that despite,
at times, dramatic therapeutic effects, this treatment, particularly when adminis-
tered systemically, could have significant side effects, including death but, partic-
ularly, haematological disorders and, in the case of radium, osteosarcoma. Marie
Curie herself died of aplastic anaemia. Although this has been attributed to her
exposure to radioisotopes, she also would have received substantial radiation while
using unshielded X-rays while operating a field ambulance service in World War 1.
The development of the cyclotron by Ernest O. Lawrence provided a range of
new isotopes [1]. One of these, P-32, was found to suppress blood counts, and again
in a serendipitous manner, Lawrence’s brother was a haematologist and decided to
try this agent for the treatment of a patient. This patient was, in fact, a medical
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student, with chronic myeloid leukaemia. The dramatic benefit from this treatment
led to its use in a range of other blood malignancies. P-32 remains a useful
treatment for myeloproliferative syndromes, especially in the elderly who tolerate
chemotherapy poorly. In studying calcium metabolism using Sr-89, a Belgian by
the name of Charles Pecher believed he had discovered a cure for metastatic
prostate cancer following dramatic and complete pain relief in a patient suffering
from advanced stages of this disease. Although this discovery was lost for a period
of time due to a combination of the untimely death by suicide of Pecher and
suppression of information about the American nuclear weapons program, it was
“rediscovered” in the 1970s and was the first of a range of bone-seeking radiophar-
maceuticals that came into widespread use in the 1980s and 1990s [2]. In studying
thyroid function using I-130 in the 1930s, the development of hypothyroidism was
recognised and leveraged for the treatment of thyrotoxicosis. Subsequently, Glenn
Seaborg and John Livingood made I-131 and Sam Seidlin applied it to the treatment
of metastatic thyroid cancer in the 1940s [3]. It has since become an integral part of
the management of thyroid cancer. The ability to iodinate biologically relevant
molecules was translated into other therapies including I-131 metaiodobenzyl-
guanidine. I was privileged to be trained in therapeutic nuclear medicine at the
University of Michigan by the some of the pioneers of this therapy, James Sisson
and Brahm Shapiro [4]. This treatment remains an important therapeutic option for
the treatment of metastatic phaeochromocytoma and paraganglioma and also in
refractory neuroblastoma [5]. While these therapeutic techniques have continued to
be used by nuclear medicine physicians, with the exception of I-131 therapy of
thyroid cancer, they are often seen as the treatment of last resort after surgery,
chemotherapy, targeted agents and radiotherapy have failed.
21.3 The Rise and Rise of Imaging
In evaluating the uptake and retention of I-131 in thyroid cancer metastases, Sam
Seidlin used a Geiger-Muller counter since nuclear imaging hadn’t been conceived.
It wasn’t until the advent of the rectilinear scanner, conceived by Benedict Cassen,
that it became possible to image the internal distribution of radiopharmaceuticals.
In the first of many seminal contributions to the field of nuclear medicine, David
Kuhl combined photographic film to the rectilinear scanner to create the
photoscanner [6]. He subsequently developed the principles of tomographic imag-
ing while being a resident in the Radiology Department of the University of
Pennsylvania [7]. Using an Am-245 source, he created the first transmission scan,
a forerunner of X-ray computed tomography [8], and also performed emission
tomography, the forerunner of single-photon emission computed tomography
(SPECT) [9]. Gordon Brownell developed coincidence detection to acquire
multiplanar images from positron-emitting radionuclides, and Michael Phelps and
Ed Hoffman adopted this approach and combined it with the tomographic method
developed by Kuhl to create positron emission tomography (PET). The first human
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scanner was released in 1976 [10]. The real revolution in PET came with the
development of the glucose analogue F-18 fluorodeoxyglucose (FDG) [11]. It
was both fortunate and tragic that FDG was one of the first PET tracers to become
available. Its excellent performance for evaluating diseases of the heart [12] and
brain [13] and more recently cancer has stifled the clinical application of other PET
tracers. Even its lack of specificity in whole-body imaging mode has found appli-
cation for the imaging of infection and inflammation.
Throughout the world FDG PET/CT has become the dominant molecular imag-
ing technique for evaluating cancer with demonstrated effectiveness in diagnosis,
staging, therapeutic response assessment and restaging. Further, it provides infor-
mation of about the biological aggressiveness of tumours. With the addition of
anatomical landmarks from CT, some see FDG as the ideal “contrast agent” for
cancer detection and has encouraged many to consider nuclear medicine as a
diagnostic imaging technique that should be integrated into radiology. This view
has been strengthened by the development of hybrid PET-MRI scanners, which
have a particular strength in localisation of disease sites.
The wider availability of PET/CT scanners has, however, made positron-
emitting radiopharmaceuticals that were developed and used in the era of rectilinear
scanners but which fell out of favour with the introduction of the gamma camera,
attractive again. F-18 sodium fluoride (NaF) was formerly a widely used agent for
bone scanning but was replaced by Tc-99 m bisphosphonates in routine nuclear
medicine practice as the gamma camera replaced rectilinear scanners. NaF PET/CT
is, however, clearly superior to Tc-99 m MDP SPECT/CT in terms of spatial and
contrast resolution, enhancing both sensitivity and specificity [14]. Gallium-68 is
another example of an old radionuclide being seen in a new light and will be
addressed later.
The major focus of much PET radiopharmaceutical development has, however,
been on compounds labelled with fluorine-18. This is a radionuclide that is easily
produced in small cyclotrons in abundant quantities after a relatively short period of
target irradiation. Its physical half-life is attractive both for distribution and imag-
ing. In my own department we chose to establish fluorinated PET tracers in
addressing areas in which FDG has demonstrable weaknesses and the alternative
SPECT agents are also suboptimal. As a result, the amino acid analogue, F-18
fluoro-ethyl-tyrosine (FET), which has low uptake in normal brain tissue but
enhanced transport into brain tumours, has replaced both FDG PET and Tl-201
SPECT brain tumour imaging in our facility [15], as it has in many other centres
[16]. Similarly, the proliferation tracer, F-18 fluorothymidine (FLT) provides a
conceptually more robust evaluation of the status of bone marrow function than
does a range of techniques previously used to assess this using a gamma camera.
Whereas we previously utilised either radiolabelled white blood cells or Tc-99 m
antimony colloid scanning, we now exclusively use FLT to assess bone marrow
reserves [17] or to assess unexplained cytopaenias. Preliminary data suggests a
potential role of this agent for assessing leukaemias [18]. Similarly, agents such as
F-18 fluoro-methyl-choline (FCH) have also found a clinical role in the evaluation
of cancers that tend to have low uptake of the conventional oncological PET tracer,
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FDG [19]. Prostate cancer and lobular breast cancer are notable examples
[20]. Table 21.1 provides a list of fluorinated agents routinely used in my depart-
ment for oncological indications. We have a range of other F-18-labelled agents
that are still being evaluated in clinical trials. These include an agent with high
specificity for melanin, an attractive target for imaging malignant melanoma.
Despite the attraction of F-18, there remained many aspects of oncological
imaging practice that were still best served by single-photon-emitting radionu-
clides. This situation has more recently been addressed by development of gal-
lium-68-based tracers. The germanium-gallium-68 generator has reintroduced a
radionuclide that was first described more than 50 years ago. Providing an alterna-
tive to the technetium-99 m generator, Ga-68 provides the option of centres without
immediate access to a cyclotron, or even those with access to cyclotron products, to
a potentially wide array of radiotracers that can replace existing nuclear medicine
techniques.
The most established of these tracers are the somatostatin analogues, which have
significantly impacted the management of patients with a range of neuroendocrine
tumour (NET) [21]. Where available, these Ga-68 agents have largely replaced the
conventional nuclear medicine imaging technique of In-111 DTPA-octreotide
scintigraphy due to a combination of significantly enhanced diagnostic accuracy,
greater patient convenience and more favourable radiation dosimetry. However,
there is a range of other agents that could rapidly enter into routine nuclear
medicine practice. These include agents for renal scanning [22] and ventilation-
perfusion imaging [23]. Table 21.2 provides a list of Ga-68-labelled agents that are
used clinically in my department.
There has also been a move to replace I-131, which has unfavourable imaging
and radiation dose characteristics with I-123 for SPECT/CT diagnostic imaging.
We clearly preferred this agent to I-131, but when comparing it to FDG, the
technical differences between the scans often limited comparison of tracer avidity,
particularly for small lesions. Accordingly, we have moved to using I-124, partic-
ularly in patients likely to come to I-131-based therapy. The treatment of metastatic
thyroid cancer, phaeochromocytoma/paraganglioma, neuroblastoma and
Table 21.1 Fluorinated tracers used clinically at the Peter MacCallum Cancer Centre





18F-fluoro-thymidine FLT Cell proliferation Marrow status
Tumour proliferation




Prostate cancer, lobular breast
cancer





FAZA Hypoxia Assessment for hypoxia
cytotoxins
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lymphoma with iodinated products has opened the way for the “theranostic”
application of I-124-labelled tracers. Table 21.3 provides a list of I-124 compounds
used clinically in my department.
In addition to these tracers, we are involved in developing further agents for
clinical PET scanning or validating agents that have been developed elsewhere.
These include agents labelled with Cu-64 and Zr-89. These agents will play, we
believe, an important role in further advancing the safety and efficacy of radionu-
clide therapy as well as putting it on a solid scientific footing. Table 21.4 provides a
list of agents that are being evaluated prior to moving into routine clinical use.
This catalogue of tracers is not limited by opportunities for further relevant
clinical applications but rather by the challenges posed by producing such a large
array of tracers in an academic department, particularly in the context of increas-
ingly stringent requirements for product to comply with good manufacturing
practice (GMP). We have partly overcome these issues by partnering with a
commercial supplier of PET tracers who have helped to transition tracers from
the research domain into routine clinical practice by producing and distributing
GMP-certified agents more widely. By achieving economies of scale not feasible in
a hospital-based radiopharmacy, tracers like FLT, FET and NaF are now readily
available to other PET facilities in our region. As experience with these tracers has
grown, the role of PET has become ever more enthusiastically embraced by medical
Table 21.2 Gallium-68 tracers used clinically at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
68Ga-DOTA-octreotate GaTate SSTR NET
Phaeo/PGL
68Ga-DOTA-exendin-4 Ga-GLP-1 GLP-1 receptor Insulinoma/MTC
68Ga-nano-aerosol Galligas Ventilation VQ scanning
68Ga-macro-aggregated
albumin
Ga-MAA Lung perfusion VQ scanning
68Ga-EDTA Ga-EDTA Renal filtration Renal scanning




68Ga-nano-colloid Ga-colloid Phagocytosis SLN imaging
68Ga-tropolone Ga-RBC Blood products Blood pool
imaging
SSTR somatostatin receptor, NET neuroendocrine tumour, Phaeo/PGL phaeochromocytoma/
paraganglioma, SNL sentinel lymph node, RBC red blood cell
Table 21.3 Iodine-124 tracers used clinically at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
124I-iodide I-124 NaI symporter Thyroid cancer




and radiation oncologists as well as by surgeons. There are, in many countries,
impediments to dissemination of these techniques as a result of health technology
assessment regimes that require a significantly higher level of evidence than existed
for older technologies prior to allowing their use and, particularly, reimbursing their
cost. Notwithstanding these limitations, it seems inevitable that hybrid PET devices
will become the preferred diagnostic imaging technique in cancer at least [24].
21.4 The Slow Rebirth of Radionuclide Therapy
Many hoped that small-molecule kinase inhibitors that target specific mutations in
cancer cells would be the final solution in cancer therapy. The dramatic metabolic
responses seen in gastrointestinal stromal tumours (GISTs) provided great excite-
ment, as this was a disease previously without effective therapies. The use of BRAF
inhibitors to combat the most common mutation in malignant melanoma was
similarly ground-breaking and again accompanied by marked and early metabolic
response in FDG PET [25]. However, it has become very clear that resistance to
such agents develops almost universally, sometimes after only a brief response.
This resistance arises due to genomic heterogeneity and evolution of tumours under
the selective pressure of signal transduction blockade. If cells lack the specific
therapeutic target or develop a means of bypassing its role in promoting tumour
growth, the therapy ceases to work. Similarly, if delivery of the drug to the tumour
is impaired, inadequate drug levels may allow cells to survive. While radionuclide
therapy also relies on target expression, it is possible to measure the expression of
any given target in individual lesions serially over time and on a whole-body scale.
Thus, the task of selecting patients for radionuclide therapy and predicting which
lesions will respond, and those that are unlikely to, is significantly easier than it is
for targeted therapies where treatment selection is typically made on the basis of a
tiny piece of biopsy material, which is assumed to be representative of all sites of
disease. Furthermore, unlike drugs that require each cell to express the target, the
particle range of many therapeutic isotopes means that a cell with high uptake can
lethally irradiate nearby cancer cells that might themselves either lack the target or
take up insufficient of the agent to have a direct toxic effect. The recognition of
microscopic tissue heterogeneity within tumours provides a strong rational basis for
Table 21.4 Other tracers being evaluated at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
18F-Fluoronicotinamide MEL-50 Melanin Melanoma
64Cu-SAT-octreotate CuSARTATE SSTR NET
79Zr-trastuzumab Zr-CEPTIN HER-2 receptor Breast cancer
124I-metomidate I-124 rituxan Cortisol synthesis Adrenocortical cancer
SSTR somatostatin receptor, NET neuroendocrine tumour
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radionuclide therapy with crossfire effect overcoming spatial heterogeneity of
target expression, at least at the microscopic scale.
While the old war horses, I-131 and Y-90, remain important therapeutic radio-
nuclides, the renaissance of radionuclide therapy has been driven y the development
of Lu-177. The physical characteristics of this isotope make it highly attractive for
therapy. Although it has sufficient gamma emissions to allow reasonably highly-
quality post-therapy imaging, they are not so abundant to pose a major external
radiation hazard allowing treatment to usually be performed on an outpatient basis.
The decay rate delivers radiation over several weeks but the beta-particle range of
only 1–2 mm means that relatively little radiation is delivered to normal cells close
to tumour deposits. This is especially beneficial for treating patients with rather
heavy infiltration of the liver or bone marrow. Recent studies have also indicated
the potential of alpha-particle-emitting radionuclides such as Ra-223 [26], which
deliver radiation over only a few cell diameters.
Lu-177 DOTA-octreotate (LuTate) has revolutionised our treatment of NET.
Building on the pioneering work of the Erasmus Medical Center in Rotterdam,
Holland, we added radiosensitising chemotherapy to the therapeutic regimen [27]
and have achieved excellent progression-free and overall survival rates even in
patients who would be considered to have a poor prognosis based on the presence of
high FDG avidity [28]. The key to achieving such outcomes has, however, been
ensuring that there are no lesions with FDG uptake that lack sufficient somatostatin
receptor to deliver effective radiation [29]. Again, this reflects a cogent example of
the theranostic paradigm wherein personalised selection of treatment can be based
on “if you can see it, you can treat it”.
Another example of this approach has been the development of PSMA-binding
ligands that are labelled with either I-131 [30] or Lu-177 [31]. Although prelimi-
nary, the results look impressive in patients with advanced castrate-resistant pros-
tate cancer. As is often the case, the patients referred for such trials have often been
heavily pretreated with several lines of therapy and have large burdens of disease.
Our own “compassionate use” eligibility criteria similarly allowed treatment of
patients who would almost certainly be ineligible for most industry-sponsored trials
of novel chemotherapy or targeted agents.
Herein lies a major future issue for nuclear medicine. We see patients who are
often at death’s door; we usually referred them only when another oncologist has
effectively abandoned the patient’s care for lack of any other options and has little
incentive to ever see the patient again. We see the wonderful benefit that some,
indeed many, patients derive, but this is usually reported in case series that lack
rigorous prospective design, defined eligibility criteria or standardised response and
toxicity assessment. Accordingly, the medical community often view these trials as
being flawed at best and anecdotal at worst.
If we are going to have radionuclide therapy assume the respectability it
deserves as a cancer therapy, we need to adopt the trial methodology used by
drug companies and stick to clearly defined protocols. There are certainly encour-
aging moves in this direction with both industry-funded and cooperative group
trials being developed that integrate radionuclide therapy.
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21.5 Long-Lived PET Isotopes with Therapeutic Pairs
Provide the Vehicle for Improved Radionuclide
Therapy Selection and Planning
One of the major impediments to establishing a scientific foundation for radionu-
clide therapy has been the inability to both predict and verify the radiation dose
delivered to both tumour and normal tissues. Although planar imaging has been
able to provide estimates of radiation to normal organs, the development of three-
dimensional and quantitative capability of hybrid scanners have made it possible to
use PET/CT to perform predictive dosimetry while quantitative SPECT/CT is being
refined to allow dose verification.
My group has established methods for quantitative Lu-177 SPECT/CT [32]. This
has taught us that while uptake of GaTate on pretreatment PET/CT provides a
reasonable estimate of what radiation will be delivered to tumour deposits, it is
clear that clearance kinetics of normal organs, particularly the kidneys, varies
considerably between patients and cannot be adequately modelled using short-
lived tracers. This is where longer-lived PET radionuclides will play an important
role. For predictive dosimetry of I-131 agents, I-124 provides the ideal combination
of a reasonably comparable physical half-life and excellent imaging characteristics.
Cu-64 provides an interesting opportunity for predictive dosimetry of its therapeu-
tic pair Cu-67 but could also be used as a PET surrogate for Lu-177 [33]. Zr-89 and
Y-90 provide another interesting combination with respect to
radioimmunotherapies.
In the future, the theranostic paradigm will hopefully change from a rather
empiric approach of “see it, guess an administered activity and treat it in hope” to
one that could be characterised as “see it, measure it, predict and verify therapeutic
radiation delivery within tolerance of normal tissues”. As is often the case, the past
can teach us useful lessons.
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Chapter 22
Interactive Communication Between PET
Specialists and Oncologists
Huiting Che, Ying Zhang, Ying Dong, Wensheng Pan, Ling Chen,
Hong Zhang, and Mei Tian
Abstract With an increasing number of positron emission tomography (PET)
facilities while a growing shortage of PET specialists in mainland China, interac-
tive communication between PET specialists and oncologists plays a crucial role in
individualized management of cancer patients and survivors. It is essential that PET
specialists should be well informed by oncologists of their patients’ history, current
problem, treatments, and particularly, the follow-up information. Vice versa, oncol-
ogists should be advised by PET specialists on their thorough interrogation, detailed
observations, as well as potential false-positive or false-negative findings – some of
which might be ignored in their reports. Improving communication and coordina-
tion between PET specialists and oncologists has been linked not only to greater
understanding and cooperation but also better patient management. In addition, this
interactive communication is an essential element of good collaboration for multi-
center clinical trials, for instance, how to make PET as an imaging biomarker to
evaluate efficacy more rapidly and to increase the probability of success in a clinical
trial and how to move non-FDG radiopharmaceutical forward, etc. Here, our review
focuses on the conceptual framework, key features, current problems, and future
perspectives on this topic.
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22.1 Introduction
With an increasing number of positron emission tomography (PET) facilities while
a growing shortage of PET specialists in China, interactive communication between
PET specialists and oncologists plays a crucial role in individualized management
of cancer patients and survivors [1]. In most of clinical settings, cancer patients
receive direct or indirect care from a multidisciplinary medical team, including PET
specialists and oncologists. The interactive communication regarding patient care
is extremely important for diagnostic consistency and therapeutic efficiency [2].
Usually, oncologists select their therapeutic strategy largely on patient history,
laboratory tests, and imaging studies including X-ray, ultrasound (US), computed
tomography (CT), magnetic resonance imaging (MRI), single photon emission
computed tomography (SPECT), or hybrid imaging modalities (i.e., SPECT/CT,
PET/CT, or PET/MRI) [3]. PET specialists commonly use PET/CT with 18F-FDG
or other radiolabeled imaging agents to evaluate the accumulation or binding
activity of a particular biological target or evaluate the functional or metabolic
changes after a certain kind of therapy. Among all the current commercially
available PET imaging agents, 18F-FDG, the most commonly and widely used
in the clinic, has the highest sensitivity, specificity, or accuracy in detecting many
glucose-avid cancers compared to the other conventional anatomical imaging
modalities. By visualized or semiquantitative analysis of the biochemical or bio-
physical information on whole-body PET images, PET specialists are being
able to not only provide an accurate cancer stage (pinpoint the primary and/or
metastatic lesions throughout the body) but also help to select particular targeted
patients for the targeted therapy [4–7]. In addition, PET is helpful to assess a
specific therapeutic efficacy and detect metastasis or recurrence much earlier than
the other imaging modalities in many common cancers [8–11]. Obviously, in every
process of patients’ management, PET specialists could provide assistance to
oncologists. Therefore, a strong cooperative relationship between them can offer
efficient care to the cancer patients.
22.2 Oncologists
Defined in the American Society of Clinical Oncology (ASCO), an oncologist is a
physician who is specialized in treating people with cancer [12]. There are three
major types of oncologists: medical, surgical, and radiation. A medical oncologist is
specialized in treating cancer with chemo-, immuno-, hormonal, or targeted ther-
apy, while a surgical oncologist is specialized in the removal of the tumor and
surrounding related tissues. And a radiation oncologist is specialized in radiation
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therapy. Usually, these different types of oncologists need to work together in a
relative late stage of cancer patient management.
22.3 PET Specialists and 18F-FDG PET/CT
A PET specialist is a physician who is specialized in selecting the optimal imaging
agent and acquisition protocol, interpreting PET or PET/CT images on the basis of
physiological and biochemical information of the whole body and localized organs
or tissues. In China, with an increasing number of PET facilities and lacking of PET
specialists, most of the new PET specialists have been working as radiologists.
From their point of view, PET may equal to the contrast CT or enhanced MRI.
Nevertheless, they admit that PET is an important imaging approach in cancer
patient management.
PET/CT technology is a novel combined method by which functional molecular
information (PET) and anatomical information (CT) can be achieved simulta-
neously [4]. There are many radiotracers that can be used for PET/CT imaging,
including 18F-FDG, 18F- or 11C-acetate, 18F- or 11C-choline, etc. [13]. 18F-FDG is
the most widely used radiolabeled agent (or tracer) which is actively taken up and
accumulated in cancer cells [4]. Since 18F-FDG PET/CT can detect cancer cells at
cellular and molecular levels, it is regarded as the most sensitive and specified
method among current imaging modalities [14–16].
22.4 Important Roles of Oncologists and PET Specialists
Cancer is a group of disease, involving abnormal cell growth with the potential to
invade or spread to other parts of the body [17]. In clinical practice, when a patient
comes for unknown reasons like fever, weight loss, fatigue or elevated tumor
markers, abnormal findings on US or X-ray, or in physical examinations, an
experienced physician will consider “cancer” as one of her/his assumptions. If the
patient has risk factors to cancer, oncologists will order specific laboratory tests and
imaging examinations (including PET/CT, if available) for the patient. With
patient’s medical history and PET/CT images, PET specialists can provide a
valuable diagnosis for oncologists. If the patient is confirmed as having cancer,
the oncologist will choose an appropriate treatment for him. After the treatment,
PET specialists can evaluate its efficacy with PET or PET/CT. If the treatment is
effective, the patient will be followed up for a certain period of time, otherwise, the
oncologists will help the patient to choose another plan. Usually, during the post-
therapeutic follow-up, PET specialists can use PET or PET/CT to detect the
functional or metabolic change or recurrence much earlier than other imagining
modalities (Fig. 22.1).
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22.5 Communication Process
Communication is the process of passing information from a source to a receiver,
which is classified into two models: linear and interactive. For the linear model,
information is transmitted from sender to receiver via a channel without the sender
receiving any feedback, i.e., PET specialist ! report ! oncologist ! patient
referring ! PET specialist. While for the interactive model, it allows the sender
to know that the message was received, i.e.: PET specialist $ oncologist. Interac-
tive communication between PET specialists and oncologists allows these two
groups to determine if the message was received and how accurately it was
received.
Interactive communication is also considered as teamwork, which has the
following characteristics:
1. Mutual respect and trust between team members
2. An equal voice for all members – different opinions valued
3. Resolution of conflict between team members
4. Encouragement of constructive discussion or debate
5. Ability to request and provide clarification if anything is unclear
Fig. 22.1 Important roles of oncologists and PET specialists in cancer patient management
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22.6 What PET Specialists Can Do for Oncologists
PET specialists can effectively provide assistance for oncologists, such as (1) offer-
ing valuable diagnosis with important functional or metabolic information; (2) pro-
viding noninvasive overview of cancer stage; (3) monitoring therapeutic response,
especially for the early stage of functional or metabolic changes after treatment;
(4) follow-up and metastasis or recurrence detection; and (5) collaborating for
clinical trials or other research projects.
22.6.1 Offering Valuable Diagnostic Information
A correct diagnosis is the key to suitable treatment. However, when a patient
presenting nonspecific signs or symptoms (i.e., fever, tiredness, or weight loss)
and when traditional imaging (i.e., X-ray, US, CT, or MRI) results are negative or
controversial, PET or PET/CT could be used for an alternative diagnostic approach,
and therefore, PET specialists can offer functional or metabolic diagnostic infor-
mation to oncologists [18, 19].
Here is a case with unknown reason fever (Case 1):
A 71-year-old female patient who was admitted to the Department of Internal
Medicine for fever with unknown reason. The fever lasted for 18 days and was
treated with cefmetazole. The peak temperature reached 38.4 C. In addition, she
had a history of right hip pain 2 days prior to her fever. On her physical
examination, she presented right hip tenderness without erythema, edema, or
plump. On the laboratory results, tumor markers and other tests were in normal
limits. She had performed Doppler ultrasound in the abdomen, lower limb
arteries and deep veins, and cardiovascular and urinary systems with no remark-
able findings. CT and enhanced MR in pelvic indicated a right iliac fossa
abscess. In order to explore the cause to fever, she had a whole-body 18F-FDG
PET/CT scan. Surprisingly on PET/CT images, her ascending colon showed a
hypermetabolic mass which was suspected for colon cancer (A). Therefore, she
had colonoscopy that found a polypoid lesion (Is + IIc lesion) of 15-mm diameter
in the ascending colon, with hyperemia and pedunculus (Fig. 22.2B). The
patient and her family requested for an operation. After the operation, routine
hematoxylin and eosin (HE) staining confirmed “moderately differentiated ade-
nocarcinoma” with submucosal invasion (Fig. 22.2C).
For the suspected cancer patients with positive lab tests or imaging findings, the
golden standard of diagnosis is pathological confirmation, which needs surgical
resection or biopsy. Since these invasive operations might increase the risk of
cancer spreading, and false-negative results may occur especially in a heteroge-
neous large lesion, noninvasive and sensitive imaging techniques are extremely
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needed. Since 18F-FDG is actively accumulated in glucose-avid cancer cells, it
could distinguish these cancer cells from the other noncancerous cells [4, 20]. There-
fore, by using PET/CT imaging, PET specialists could offer valuable diagnostic
information for oncologists.
22.6.2 Noninvasive Overview of Cancer Staging
Oncologists make treatment plan depending on various factors, for instance, a
certain type of cancer, stage, gender, age, etc. Among these factors, cancer stage
is the most crucial but most difficult to determine. Incorrect cancer stage will lead to
poor prognosis of the patient. Underestimating the stage of the disease may lead to
“positive resection margins” or unnecessary laparotomy, while overestimation of
the stage may yield to ineffective treatment [21]. Although PET imaging studies are
costly, it provides oncologists with important noninvasive overview of staging for
making optimal choice of cancer patients.
For example, to determine the stage of non-small-cell lung cancer (NSCLC),
multiple laboratory tests and imaging exams are required. Among all these exam-
inations, high-resolution CT is currently the most frequently used in clinic. How-
ever, even if this imaging approach could provide accurate assessment of local
tumor depth invasion (T), it lacks sensitivity and specificity in the assessment of
Fig. 22.2 (a) 18 F-FDG PET/CT images showed an area of intensive abnormal 18 F-FDG uptake
in the ascending colon (arrows) with SUVmax¼ 6.00(1 h), 9.52(2 h). There was no increased
18F-FDG uptake in the right lower limb. (b) Colonoscopy image. (c) Hematoxylin and eosin
(HE) staining
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regional lymph node invasion (N) and distant metastasis (M). Although PET only is
not so effective in assessing T, it has great superiority in assessing N and
M. Recently, hybrid PET/CT has become one of the optimal imaging technologies
for lung cancer staging, and significantly improved the detectability of local and
distant metastases in patients with NSCLC, and reduced both the total number of
thoracotomies and the number of futile thoracotomies [5, 22–24].
Here is a case of a tongue cancer patient with distant metastases (Case 2):
A 68-year-old male patient who was admitted to the Department of Oral and
Maxillofacial Surgery. The patient presented left tongue ulcer for two months;
incisional biopsy confirmed the diagnosis of squamous cell carcinoma in left
ventral tongue at 1 week before PET/CT scan. On physical examination, his vital
signs were normal, and he presented a size of 20-mm*18-mm, firm, ill-defined,
and cauliflower-like neoplasm located in the left ventral tongue with obvious
tenderness, but no palpable enlarged lymph nodes were found. On laboratory
workup, PSA was 196.89 ng/ml and other tests were within the normal limits.
After performing the head and neck CT and MR examinations (Fig. 22.3a and b),
he was intended to have a surgical operation. However, the presurgical PET/CT
indicated distant metastases (Fig. 22.3c). Therefore, he was performed a fine
needle aspiration in the enlarged left inguinal lymph node and confirmed the
diagnosis of metastasis from the left tongue (Case 2, Fig. 22.3d). Accordingly,
he was treated with chemotherapy and radiotherapy.
Fig. 22.3 (a) CT imaging detected a mass located in the left edge of the tongue (arrow). (b) MR
imaging revealed a mass with long T1 and long T2 signals on the left edge of tongue, a size of
20-mm*10-mm, ill-defined margins (arrow). (c) 18F-FDG PET/CT imaging showed intensive
FDG uptake in the left tongue (SUVmax¼ 13.83), clavicle and axillary lymph nodes
(SUVmax¼ 16.26), mediastinum (SUVmax¼ 17.35), ventral prostate (SUVmax¼ 14.40 at 1 h
and SUVmax¼20.46 at 2 h post 18F-FDG injection), in retroperitoneum, bottom of mesentery, and
left inguinal region’s lymph nodes (SUVmax¼ 21.47). (d) Fine needle aspiration confirmed for
squamous cell carcinoma
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Through the preoperative communication between the PET specialist and the
oncologist, this patient avoided unnecessary surgery and administrated optimal care
plan. Namely, with the noninvasive overview on 18F-FDG PET/CT images, PET
specialists are able to provide functional or metabolic information on T, but also
more important information on N and M stages by the whole-body or total body
images [25, 26].
22.6.3 Monitoring Efficacy of Treatments
The most common evaluation of a certain therapy to cancer is based on the initial
diagnosis of TNM stage, which may reveal the current status and might predict the
therapeutic outcome [27]. However, the morphologic and metabolic responses of
cancer cells to a specific treatment are incongruent. For example, cetuximab and
other targeted therapies inhibit cancer cell growth by inhibiting the proliferation,
angiogenesis, and metastatic spread and by promoting apoptosis [28–30], which
should be cytostatic rather than cytotoxic [27]. However, in many cases, especially
in the early-phase post-therapy, the change of cellular or biochemical function may
be significant, but a measurable reduction in tumor size may not occur. Therefore,
tumor size can remain relatively unchanged while tumor metabolism can be
markedly reduced immediately [31].
As a result, PET specialists play an important role in offering oncologists
the real-time efficacy of a specific therapy and help oncologists to make adjustment
to the current therapy or change to another option.
22.6.4 Detecting Metastasis or Recurrence in Follow-Up
The chance of survival depends on the type of cancer and extent of disease at the
start of treatment. However, even with the rapid development of surgical, chemo-,
radio-, hormonal, and gene therapy and targeted therapies, cancers cannot be
completely cured in most cases [32]. Therefore, early detection of metastasis or
recurrence is clinically important and helpful for improvement of the prognosis or
survival of cancer patients [33].
Here is a case of non-Hodgkin’s lymphoma with recurrence detected in the
follow-up PET imaging (Case 3):
A 65-year-old Chinese female was admitted to the Department of Hematology for
the right back pain which lasted for 2 weeks. She was diagnosed with
non-Hodgkin’s lymphoma 11 years ago and had an operation followed by six
cycles of postoperative chemotherapy. Recurrence was detected 6 years ago and
four cycles of chemotherapy was performed. One year prior to this admission,
she had severe right back pain. 18F-FDG PET/CT images found enlarged lymph
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nodes in the neck and multiple bones (Fig. 22.4a). After that, vertebral body
biopsy confirmed diffuse large B-cell lymphoma and indicated recurrent with
transformation. Therefore, the patient was performed eight cycles of chemother-
apy. Immediately after the completion of chemotherapy, PET/CT showed neg-
ative FDG uptake in all lymph nodes (Fig. 22.4b). For this time, the patient felt
backache again, PET/CT revealed intensive FDG uptake in bones, bowels, and
cervical lymph nodes, which indicated the recurrence (Fig. 22.4c).
At present, multiple studies found that increased tumor marker level do not
indicate localization of cancer. Although increasing of tumor marker levels may be
the earliest indication of recurrent cancer, false-positive results may be found in
some benign and physiologic conditions as well. Thus, follow-up PET/CT scans
have an impact on patient management since it can provide the extended whole-
body functional overview of recurrence or metastasis [11, 34, 35].
22.6.5 Research Collaborations
PET, including small-animal (or micro) PET and clinical PET, has become a
requisite of cancer research in this century. The most significant advantage of
PET method is that radiolabeled imaging agent (or radiotracer) could penetrate
into the cell and thus make it possible to reveal the in vivo biodistribution and
biochemical process of living cells [4]. Furthermore, not only limited to FDG, a
glucose analogue, there are many other radiotracers, for instance, 11C-choline used
in prostate carcinoma [36], 11C-acetate used in hepatocellular carcinoma [37],
Fig. 22.4 (a) PET/CT showed increased FDG uptake in multiple bones, including sternum,
vertebras, ribs, pelvis, etc. with maximum SUV of 6.65 in the left clavicle, 11.70 in the L1
vertebra, 5.18 in the ribs, and 5.40 in the right ilium. (b) PET/CT images showed normal FDG
uptake in the whole body. (c) PET/CT images presented intensive FDG uptake in bowels with
SUVmax of 5.69–10.22 in bones
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13N-ammonia used in pancreatic necrosis [38], etc. Hence, with the assistance of
different PET imaging tracers, PET specialists could help oncologists to visualize
different targets in the living body and test the efficacy of novel treatment [39, 40].
22.7 What Oncologists Can Do for PET Specialists?
Oncologists can also provide assistance to PET specialists, such as (1) referring
appropriate patients, (2) provide patient education and (3) provide more detailed
patient medical history, and (4) scientific research collaboration.
22.7.1 Referring Appropriate Patients
PET is a highly sensitive imaging method for the detection of early stage of cancer,
occult recurrence, and metastasis since cancer-related metabolic abnormalities
usually precede structural changes and are readily detected by PET [33]. However,
if without clear clinical indication, excessive PET scanning is likely to identify
harmless findings that lead to more tests, biopsy, or unnecessary surgery. Therefore,
referring appropriate cancer or suspicious patients for PET imaging is the key to get
better prognosis for patients.
22.7.2 Providing Detailed Medical History
FDG is not a cancer-specific agent, and false-positive findings in benign diseases
may occur [41–43]. Infectious diseases (mycobacterial, fungal, bacterial infection),
sarcoidosis, radiation pneumonitis, and postoperative surgical conditions have
shown intense uptake, while tumors with low glycolytic activity such as adenomas,
bronchoalveolar carcinomas, carcinoid tumors, low-grade lymphomas, and small-
sized tumors have revealed false-negative findings on PET images.
Here is a false-positive case with tuberculosis (Case 4):
A 22-year-old Chinese male was admitted to the thoracic surgical department for
right chest pain. It is a moderate and tolerable pain presented after taking a deep
breath which lasted for about 1 year. He had no smoking and drinking history.
On physical examination, his vital signs were normal, and he presented rough
breath sounds without any other symptoms. On laboratory tests, his T-SPOT test
was positive, and other tests were in normal limits, including tumor markers. He
had performed X-ray and high-resolution CT in the chest. High-resolution CT
indicated a 13-mm*6-mm nodule in the lateral segment of the right middle lung
(Fig. 22.5b). In order to determine whether the nodule was of malignant
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etiology, the patient was referred for 18F-FDG PET/CT imaging. On PET/CT
images, a 12.9-mm*7.7-mm mass with intensive 18F-FDG uptake was found in
the lateral segment of the right middle lung (Fig. 22.5a). Based on the medical
history (young man, nonsmoking, and moderate symptom), the PET specialist
highly suspected for nonneoplastic diseases, such as tuberculosis or other
inflammation despite the increased SUV value. However, the patient preferred
to perform surgical resection. The pathological diagnosis verified it was inflam-
matory pseudotumor, tuberculosis (Fig. 22.5c).
22.7.3 Research Collaboration
PET is a functional molecular imaging technique which is based on radionuclide
imaging of regional biochemistry in vivo. Biochemistry is considered the basis of
diagnosis and of the planning and monitoring of treatment since the treatment of
many diseases involves biochemical reactions. A number of radiolabeled PET
tracers have been designed and developed to imaging the functional and biochem-
ical process of tissues or cells which can be applied for experimental or clinical
research, and can be initiated by either PET specialists or oncologists. The hybrid
PET/CT not only can provide highly spatial resolution but also can reflect abnormal
lesions, glucose, amino acid, nucleic acid, and gene. It is the only current imaging
Fig. 22.5 (a) 18F-FDG PET/CT images demonstrated a 12.9-mm*7.7-mm mass of intensive FDG
uptake in the right middle lung (red arrow) with SUVmax¼ 5.33. (b) Diagnostic CT image
showed a 13-mm*6-mm nodule in the lateral segment of the right middle lung. (c) Routine
pathology of the mass revealed “chronic granulomatous inflammation”
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method available from a physiological perspective and the molecular level for
quantitative evaluation of biochemical changes. Oncologists pay more attention to
the efficacy of different therapies, while PET specialists focus more on the applica-
tions of various radiotracers. Through collaborative research and interactive com-
munication, PET specialists and oncologists may explore more on underlying
mechanism of cancers.
22.8 Future Perspectives
Awareness of the impact of interactive communication between PET specialists and
oncologists, particularly on patient referring, monitoring, and follow-up, is critical
to the proper management of cancer patient. A PET specialist is different from a
conventional radiologist, and proper interpretation of a PET image is different from
a radiological film reading. PET specialists have to integrate the clinical, labora-
tory, pathophysiological, and even biochemical understandings on a specific dis-
ease and related disease progress. With the new development of molecular imaging
agents and hybrid imaging modalities including PET/CT or PET/MRI, interactive
multidisciplinary communications and international collaborations become more
and more important [44, 45]. In the future, interactive communication methods
include, but not limited to regular specialist attendance at team meetings, telephone
discussions but also shared electric archives and massive open online course
(MOOC). We assume that when cloud-based medical practice is applied for the
future clinical practice, interactive communication will be even more important and
more related to the better patient management.
22.9 Conclusions
Interactive communication is feedback and teamwork. Awareness of the impact of
interactive communication between PET specialists and oncologists is critical to
the proper management of cancer patient.
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Chapter 23
Clinical Efficacy of PET/CT Using
68Ga-DOTATOC for Diagnostic Imaging
Yuji Nakamoto, Takayoshi Ishimori, and Kaori Togashi
Abstract Positron emission tomography/computed tomography (PET/CT) using
68Ga-labelled DOTA0-Tyr3 octreotide (DOTATOC) is one of the diagnostic imag-
ing tools in somatostatin receptor scintigraphy. There have been many studies
demonstrating the clinical usefulness of this diagnostic imaging method, especially
for detecting neuroendocrine tumors (NETs). It often yields clinically relevant
information for determining therapeutic management in NET patients. However,
we have found that the usefulness of the information provided depends on the
clinical situation; for example, it was considered especially helpful when recur-
rence/metastasis was suspected after surgery for histopathologically proven NET.
In addition to NETs, DOTATOC PET/CT sometimes provides useful information
in patients with tumor-induced osteomalacia (TIO), in which fibroblast growth
factor 23 produced by a mesenchymal tumor causes hypophosphatemia, resulting
in osteomalacia. As these mesenchymal tumors frequently express somatostatin
receptors, DOTATOC PET/CT would be expected to detect causative lesions in
TIO. Furthermore, many renal cell carcinomas (RCC) are not FDG avid.
DOTATOC PET/CT could be helpful for detecting unexpected lesions when
recurrence or metastasis is suspected after surgery for RCC. DOTATOC PET/CT
is also able to reveal additional findings even in sarcoidosis, an inflammatory
disease. The clinical value of DOTATOC PET/CT is discussed, based on our
clinical experience.
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23.1 Current Status of Somatostatin Receptor
Scintigraphy in Japan
In diagnostic imaging of cancers, positron emission tomography (PET) using 18F-
labeled fluorodeoxyglucose (FDG) has been widely accepted clinically for staging
and restaging, monitoring therapy response, and detecting unknown primary sites.
However, there are some tumors for which FDG PET/CT does not provide relevant
information owing to their insufficient FDG avidity. Such tumors include well-
differentiated neuroendocrine tumors (NETs), which often cannot be identified as
hypermetabolic areas on FDG PET/CT [1]. A major characteristic of NETs is that
they express somatostatin receptors. For scintigraphy targeting such receptors, a
radiolabeled octreotide, which has high affinity for somatostatin receptors and is
very stable in vivo, has been used in Europe and the United States. Compounds
labeled with 111In or 99mTc are used as tracers for single photon emission computed
tomography (SPECT), and tracers labeled with 68Ga are used for PET.
111In-pentetreotide (OctreoScan) is a commercially available radiopharmaceuti-
cal. It is routinely used clinically in Europe and the United States. However, it is not
currently approved for use in Japan (as of July 2015), although clinical trials were
conducted about the year 2000. Patients must travel to Europe to receive this
examination or personally arrange importation of this radiopharmaceutical to
enable them to undergo scintigraphy in one of several academic institutions. The
number of patients with gastroenteropancreatic NETs is relatively small compared
with the number with other common cancers, but its incidence has been increasing
[2] so that it is becoming a serious issue. In our institution, PET/CT with 68Ga-
DOTATOC for somatostatin receptor scintigraphy has performed since 2011. More
than 300 patients have had this examination here over the last 4 years.
23.2 Usefulness in NET According to Clinical Situation
There have been many reports demonstrating the clinical usefulness of PET/CT
with 68Ga-DOTATOC or other 68Ga-labeled PET tracers in NETs. It has been
reported that it is superior to FDG PET/CT in well-differentiated NET and medul-
lary thyroid cancer [3–5] and scintigraphy using 111In-labeled compounds [6]. Its
diagnostic accuracy, including sensitivity and specificity, is reasonably high (more
than 90 %) according to a few meta-analyses [7, 8]. However, there are some
patients with high hormone levels, indicating the presence of NETs, in whom
DOTATOC PET/CT reveals no additional information.
We investigated the clinical value of DOTATOC PET/CT in relation to the
clinical situation [9]. We divided patients into three groups: groups A, B, and C. In
group A, PET/CT was performed after metastatic NET had been confirmed histo-
pathologically, but the primary tumor had not been identified by other conventional
imaging modalities. In group B, PET/CT was performed to evaluate suspected
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recurrent lesions due to high hormone levels after the patient had undergone
curative surgery for histologically proven NET. Conventional imaging had been
negative before DOTATOC PET/CT. In group C, NET was suspected based on
laboratory data without definitive localization of the primary site by conventional
imaging.
In group A, there were 14 patients who were suspected of having a primary NET
because of pathologically proven liver metastasis (9 patients), nodal metastasis
(3 patients), or bone metastasis (2 patients). In four of the nine patients with liver
metastasis, DOTATOC PET/CT demonstrated positive findings, indicating a
suspected primary tumor in the duodenum (2 patients), jejunum (1 patient), and
pancreatic tail (1 patient) with the maximum standardized uptake value (SUVmax)
ranging from 2.8 to 19.7. DOTATOC PET/CT showed no abnormal findings in the
remaining five patients. In three patients with nodal metastasis, DOTATOC
PET/CT revealed abnormal uptake in the duodenum (1 patient) and jejunum
(2 patients). In two patients with bone metastasis, DOTATOC PET/CT was nega-
tive in one but showed intense focal uptake in the prostate in the other, suggesting
prostate cancer. However, the uptake was found, by biopsy, to be due to benign
prostatic hypertrophy. Thus, a final diagnosis of a gastroenteropancreatic NET was
obtained in 7 of the 14 patients (50 %).
In group B, seven patients underwent surgery for a NET. Except for one patient
with a high insulin level, DOTATOC PET/CT detected ten lesions in six patients
with the SUVmax ranging from 7.9 to 70.1. Two patients had histopathological
confirmation after surgery, and the remaining four patients were followed up with
no surgical treatment. Thus, DOTATOC PET/CT provided additional information
in six of seven patients (86 %). PET/CT imaging in a representative patient with
nodal metastasis is shown in Fig. 23.1.
In group C, a total of 25 patients with suspected NET due to high hormone levels
underwent DOTATOC PET/CT. A pancreatic NET with SUVmax 68.5 was clearly
shown by DOTATOC PET/CT in a patient with a suspected ACTH-producing
tumor, followed by surgical confirmation. In the remaining 24 patients, DOTATOC
Fig. 23.1 A 51-year-old woman with suspected recurrent gastrinoma. Axial CT (a), DOTATOC
PET (b), and fused (c) images are shown. A duodenal gastrinoma was removed by surgery, but
recurrence was suspected because of rising serum gastrin levels. Intense focal uptake around the
lateral segment of the liver is apparent on the DOTATOC PET and fused images (arrows). A
lymph node metastasis was confirmed by surgery
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PET/CT did not provide any additional clinically relevant information. The detec-
tion rate was significantly lower than in the other groups (Fisher’s exact test,
p< 0.01).
We concluded that DOTATOC PET/CT is useful for detecting NET, especially
when recurrence or metastases are suspected because of high hormone levels after
surgery for a primary NET and that it is hardly helpful in patients in whom only the
hormone levels are high and the tumor has not been localized.
It is reasonable that DOTATOC PET/CT would be expected to yield relevant
information when recurrence or metastasis is suspected due to high hormone levels
after surgery for a functioning NET, since the pretest probability is high. In the
patient shown in Fig. 23.1, a small lymph node was visualized retrospectively on
contrast-enhanced CT (figure not shown), but it was difficult to distinguish from a
benign inflammatory node on the basis of size. In addition, it would take time to
confirm the characteristics during follow-up owing to its slow growth. The high
accumulation of DOTATOC in a subcentimeter node is considered a useful finding
for raising the suspicion of recurrence or metastasis after surgery for NET. Con-
versely, among the patients without a history of NET, only in one patient was
DOTATOC PET/CT helpful, and it was negative in the remaining 24 patients.
Some reasons might be considered. Primary sites may be too small to be detected by
imaging modalities. If lesions are extremely small, uptake of DOTATOC could be
underestimated because of the partial volume phenomenon. Also, when the primary
tumor is located in the upper abdomen or alimentary tract, uptake could easily
be influenced by respiratory motion or peristalsis, resulting in underestimation of
uptake. In addition, high hormone levels do not always mean the presence of NET
because hyperfunctioning can cause high hormone levels, e.g., nesidioblastosis in
hyperinsulinemia or G-cell hyperplasia in hypergastrinemia. Furthermore, it has
been reported that somatostatin receptor subtypes 2 and 5 are not well expressed in
many insulinomas [10]. For these reasons, DOTATOC PET/CT may fail to show
the primary tumor.
Peptide receptor radionuclide therapy (PRRT) using 177Lu-labeled or
90Y-labeled octreotide has been used to treat NETs in Europe. To stratify patients
according to their expected response to therapy, somatostatin receptor scintigraphy,
including DOTATOC PET/CT, can be considered. However, we have no sufficient
data so far on this subject because PRRT has not yet been performed in our country.
23.3 Localization of Causative Lesions in Tumor-Induced
Osteomalacia
It is known that DOTATOC PET/CT is useful not only in the imaging of NETs but
also in other diseases. Tumor-induced osteomalacia (TIO) is considered a suitable
target for somatostatin receptor scintigraphy. TIO, which is also known as onco-
genic osteomalacia, is a rare paraneoplastic syndrome. Phosphaturic mesenchymal
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tumors secrete fibroblast growth factor 23 (FGF-23), causing hypophosphatemia
due to suppression of the reabsorption of phosphorus in the proximal renal tubule
and activation of vitamin D synthesis. Consequently, these tumors cause osteoma-
lacia. Total resection of this mesenchymal tumor is essential to achieve complete
cure, but localization of the causative lesions remains a challenge because they are
usually small, slow growing, and are located at peculiar sites. Therefore, somato-
statin receptor scintigraphy can be expected to be useful because these tumors often
express somatostatin receptors [11].
There have been several studies investigating the potential usefulness of somato-
statin receptor scintigraphy for detecting these mesenchymal tumors. As a prelimi-
nary evaluation in our institution, DOTATOC PET/CT has been performed for this
purpose. We analyzed 14 patients (5 men and 9 women, mean age 46 years) with
TIO who underwent DOTATOC PET/CT. All these patients had been suspected of
having TIO due to hypophosphatemia (<2.5 mg/dl) and a high serum FGF-23 level
(49–1,020 pg/ml). Overall, DOTATOC PET/CT showed 12 sites of abnormal
uptake in eight patients. However, three lesions corresponding to bone were
found to be fractured or pseudofractured, i.e., false-positive. Therefore, nine lesions
in seven patients were finally considered to be the cause of the TIO. These lesions
were located in the sphenoid bone, spine, rib, pelvic bone, tibia, and muscles. In the
remaining six patients, DOTATOC PET/CT was negative. One patient is shown in
Fig. 23.2. The serum FGF-23 levels in seven patients with true-positive DOTATOC
PET/CT findings tended to be higher than in patients who had no causative tumor
detected, but the difference was not significant. FDG PET/CT revealed only two
abnormal foci in this population. Our preliminary data suggest that DOTATOC
PET/CT would be a useful noninvasive technique for localizing causative tumors in
patients with TIO and that fractures or pseudofractures caused by osteomalacia can
be a pitfall in interpreting DOTATOC PET/CT images.
This is one of the hot topics in somatostatin receptor scintigraphy. Chong
et al. found that 111In-octreotide SPECT(/CT) was better than FDG PET/CT in
detecting primary mesenchymal tumors causing TIO, with a sensitivity of 95 %
[12]. Jing et al. showed the clinical value of 99mTc-HYNIC-TOC with a sensitivity
of 86 % [13]. Other studies have demonstrated 100 % sensitivity of DOTATATE
PET/CT in detecting causative lesions, although the number of cases is small [14–
16]. In our experience, DOTATOC PET/CT does not always show the causative
lesions, but this noninvasive technique may be considered even when TIO is
suspected and the results of venous sampling are positive, because unexpected
lesions can sometimes be detected by DOTATOC PET/CT.
23.4 Restaging in Renal Cell Carcinoma
Renal cell carcinoma (RCC) may be a target for somatostatin receptor scintigraphy
because some recurrent or metastatic lesions from RCC are not FDG avid [17] and
it has been reported that OctreoScan shows RCC metastasis [18]. At this time,
experience with DOTATOC PET/CT in RCC is limited [19]. We have performed a
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preliminary evaluation of the clinical efficacy of DOTATOC PET/CT in patients
with suspected recurrent RCC after surgery. Seven consecutive patients who had
surgery for histologically proven RCC and who were suspected of having recur-
rence of RCC underwent DOTATOC PET/CT for restaging. We retrospectively
reviewed the PET/CT images and compared available FDG PET/CT findings. In
this investigation, there were 18 recurrent or metastatic lesions in seven patients. Of
the 18 lesions, 13 in six patients with clear-cell carcinoma were clearly shown on
DOTATOC PET/CT, with SUVmax ranging from 2.8 to 23.3 (average 9.7).
Excluding 2 of 13 lesions that were not assessed by FDG PET/CT, only three
lesions were positive on FDG PET/CT. Four lesions were negative on DOTATOC
PET/CT, but positive on FDG PET/CT in a patient with papillary carcinoma.
Fig. 23.2 A 54-year-old man with tumor-induced osteomalacia. Sagittal DOTATOC PET (a) and
fused (b) images are shown. This patient was suspected of having tumor-induced osteomalacia due
to his high FGF-23 level and hypophosphatemia. Intense focal uptake in the lumbar spine is
apparent on the DOTATOC PET and fused images (arrows). The lesion was resected, and the
patient’s phosphorus level returned to normal
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Overall, the sensitivities of DOTATOC PET/CT and FDG PET/CT were 86 % and
67 %, respectively, on a patient basis and 72 % and 56 %, respectively, on a lesion
basis, in our population.
A hypervascular tumor seen in the pancreas in a patient with a history of RCC
may be difficult to differentiate from pancreatic NET and metastasis from RCC
(Fig. 23.3). However, when inconclusive findings are obtained by conventional
imaging, DOTATOC PET/CT would be useful for detecting unexpected additional
metastatic lesions, just as FDG PET sometimes provides useful information if
FDG-avid tumors are present.
23.5 Sarcoidosis
As somatostatin receptors are expressed on activated lymphocytes, it is expected
that sarcoidosis, an inflammatory disorder, may also be visualized. The use of
somatostatin receptor scintigraphy with 111In-pentetreotide in patients with
Fig. 23.3 A 76-year-old man with a hypervascular pancreatic tumor. Contrast-enhanced MR (a),
FDG PET (b), FDG PET/CT (c), DOTATOC PET (d), and DOTATOC PET/CT (e) images are
shown. The contrast-enhanced MR image (a) shows a well-enhanced mass in the pancreatic head
(arrow). The FDG PET image (b) shows no abnormal uptake corresponding to this lesion, but the
DOTATOC PET (d) and the DOTATOC PET/CT (e) images show DOTATOC accumulation in
this tumor (arrows). A pancreatic neuroendocrine tumor and pancreatic metastasis from renal cell
carcinoma was suspected. The final diagnosis was metastatic pancreatic tumor from renal cell
carcinoma. Physiological uptake in a part of pancreas is also seen on the DOTATOC PET images
(arrowheads)
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sarcoidosis was investigated in one study [20]. The somatostatin receptor imaging
was able to demonstrate active granulomatous disease in the patients with sarcoid-
osis, and pathological uptake of radioactivity in the parotid glands during imaging
was correlated with higher serum ACE concentrations. However, the efficacy of
somatostatin receptor imaging in sarcoidosis has not yet been established, and there
are few articles regarding the clinical utility of DOTATOC PET/CT in sarcoidosis.
In our experience, DOTATOC PET/CT reveals a similar or greater number of
lesions than a conventional gallium scan. As compared with FDG PET/CT, uptake
may be lower in involved nodes, but DOTATOC PET/CT could be useful for
evaluating involvement of the myocardium in patients with cardiac sarcoidosis,
because physiological uptake in the myocardium can make FDG PET/CT images
difficult to evaluate. A representative patient with sarcoidosis is shown in Fig. 23.4.
Fig. 23.4 A 65-year-old woman with suspected sarcoidosis. A maximum intensity projection
image (a) and axial CT (b), DOTATOC PET (c), and fused (d) images are shown. Moderate to
intense uptake of DOTATOC is observed in hilar and mediastinal lymph nodes (arrows)
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23.6 Conclusion
DOTATOC PET/CT is a useful imaging modality for detecting NETs, as has been
reported in many articles; however, its efficacy depends on the clinical situation. It
may be helpful especially when recurrence or metastasis is suspected after surgery
of NET, but additional information might not be obtained simply when hormone
levels are high. DOTATOC PET/CT is also considered helpful for identifying
causative lesions in TIO, although fracture or pseudofracture can be a pitfall.
DOTATOC PET/CT could have a clinical impact in restaging of RCC or in
detecting involved lesions in sarcoidosis, but further investigations with more
patients are required.
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Chapter 24
Correlation of 40-[methyl-11C]-Thiothymidine
Uptake with Ki-67 Immunohistochemistry
in Patients with Newly Diagnosed
and Recurrent Gliomas
Yuka Yamamoto and Yoshihiro Nishiyama
Abstract Purpose: 40-[methyl-11C]-thiothymidine (4DST) has been developed as
an in vivo cell proliferation marker based on the DNA incorporation method. We
evaluated 4DST uptake on PET in patients with newly diagnosed and recurrent
gliomas and correlated the results with proliferative activity.
Methods: 4DST PET was investigated in 32 patients, including 21 with newly
diagnosed gliomas and 11 with recurrent gliomas. PET imaging was performed at
15 min after 4DST injection. The standardized uptake value (SUV) was determined
by region-of-interest analysis. The maximal SUV for tumor (T) and the mean SUV
for contralateral normal brain tissue (N) were calculated and T/N ratio was deter-
mined. Proliferative activity as indicated by the Ki-67 index was estimated in tissue
specimens.
Results: The sensitivity of 4DST PET for the detection of newly diagnosed and
recurrent gliomas was 86 % and 100 %, respectively. In newly diagnosed gliomas,
there was a weak correlation between T/N ratio and Ki-67 index (r¼ 0.45;
p< 0.05). In recurrent gliomas, there was no significant difference between T/N
ratio and Ki-67 index.
Conclusion: In newly diagnosed gliomas, 4DST PET seems to be useful in the
noninvasive assessment of proliferation.
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24.1 Introduction
Markers of proliferative activity are essential for individualized patient therapy and
management of brain gliomas [1]. Because tissue sampling is often obtained by
stereotactic biopsy and, therefore, represents only a small part of the primary tumor,
there is a probability of true malignant potential being underestimated [2]. Thus,
noninvasive imaging-based technology for the detection of malignant progression
is required to select the best possible treatment regimen.
Positron emission tomography (PET) is now an indispensable modality for
assessment of various tumors. The radiotracer 30-deoxy-30-[18F]fluorothymidine
(FLT) has been investigated as a promising PET tracer for evaluating tumor
proliferating activity in brain tumors [3–5]. A theoretic limitation of FLT as a
radiotracer for the salvage pathway of DNA synthesis is that it is not incorporated
into DNA because of the lack of a 30-hydroxyl [6].
Toyohara et al. developed 40-thiothymidine labeled with 11C at the methyl group
(40-[methyl-11C]-thiothymidine [4DST]), as a new candidate for cell proliferation
imaging that is resistant to degradation by thymidine phosphorylase and is incor-
porated into DNA [7, 8]. A 11C-4DST PET pilot study of 6 patients with various
brain tumors showed that 11C-4DST PET is feasible for brain tumor imaging and
can be performed with acceptable dosimetry and pharmacologic safety at a suitable
dose for adequate imaging [9]. In a mixed population of patients with newly
diagnosed and recurrent gliomas, Toyota et al. has recently demonstrated that
4DST PET is feasible for evaluating cell proliferation [10]. These results indicate
that 4DST has great potential for imaging cell proliferation.
The purpose of this study was to evaluate 4DST uptake in patients with newly
diagnosed and recurrent gliomas and to correlate the results with proliferative
activity as indicated by the Ki-67 index.
24.2 Materials and Methods
24.2.1 Patients
A total of 32 patients (15 men, 17 women) with brain gliomas who underwent 4DST
PET examination were selected. Of the patients, 21 had newly diagnosed gliomas
and 11 presented with recurrent gliomas that had been treated with surgery,
chemotherapy and radiotherapy previously.
Pathologic diagnosis had been obtained by stereotactic biopsy or open surgery.
Grading of the tumor was performed according to the World Health Organization
(WHO) classification for neuroepithelial tumors [11]. Distribution of tumor grades
according to WHO classification was as follows: grade II (n¼ 7), grade III (n¼ 9),
and grade IV (n¼ 16).
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24.2.2 4DST Synthesis and PET Imaging
The radiotracer 4DST was produced using an automated synthesis system with
HM-18 cyclotron (QUPID; Sumitomo Heavy Industries Ltd, Tokyo, Japan). The
4DST was synthesized using the method described by Toyohara et al. [9].
All acquisitions were performed using a Biograph mCT 64-slice PET/CT scan-
ner (Siemens Medical Solutions USA Inc., Knoxville, TN, USA). Data acquisition
began with CT at the following settings: no contrast agent, 120 kV, 192 mA, 1.0-s
tube rotation time, 3-mm slice thickness, 3-mm increments, and pitch 0.55. PET
emission scanning of the head region with a 15-min acquisition of one bed position
was performed 15 min after intravenous injection of 4DST (6 MBq/kg). The PET
data were acquired in three-dimensional mode and were reconstructed by the
baseline ordered-subset expectation maximization (OSEM) bases, with incorporat-
ing correction with point spread-function and time-of-flight model (5 iterations,
21 subsets).
24.2.3 Data Analysis
Visual image analysis was performed by an experienced nuclear physician. Tumor
lesions were identified as areas of focally increased uptake, exceeding that of
normal brain background.
Semiquantitative analysis was performed using the standardized uptake value
(SUV). The region of interest (ROI) was placed over the entire tumor using the
transverse PET image. For the reference tissue, a circular ROI of 15 15 mm was
manually placed on the uninvolved contralateral hemisphere in the same plane that
showed maximum 4DST tumor uptake. Radioactivity concentration values mea-
sured in the ROI were normalized to injected dose per patient’s body weight by
calculation of SUV. The maximal SUV for tumor and the mean SUV for reference
tissue were calculated. Tumor-to-contralateral normal brain tissue (T/N) ratio was
determined by dividing the tumor SUV by that of the contralateral hemisphere.
24.2.4 Ki-67 Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of resected specimens from brain
tumor were made for immunohistochemical staining. The Ki-67 index was esti-
mated as the percentage of Ki-67-positive cell nuclei per 500–1,000 cells in the
region of the tumor with the greatest density of staining.
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24.2.5 Statistical Analysis
All semiquantitative data were expressed as mean SD. The Ki-67 index and the
T/N ratio were compared using linear regression analysis. Differences were con-
sidered statistically significant at p< 0.05.
24.3 Results
24.3.1 4DST Uptake
In newly diagnosed gliomas, 4DST PET detected 3 of 7 grade II gliomas, all 6 grade
III gliomas, and all 8 grade IV gliomas. In recurrent gliomas, 4DST PET detected
all 3 grade III gliomas and all 8 grade IV gliomas. Although 4DST PET in newly
diagnosed gliomas showed a slightly lower detection rate than that in recurrent
gliomas (86 % vs. 100 %), the difference was not statistically significant.
24.3.2 4DST Uptake and Ki-67 Immunohistochemistry
In newly diagnosed gliomas, linear regression analysis indicated a weak correlation
between T/N ratio and the Ki-67 index (r¼ 0.45, p< 0.05; Fig. 24.1a). In recurrent
gliomas, there was no significant difference between T/N ratio and the Ki-67 index
(r¼ 0.31, p¼ 0.36; Fig. 24.1b).
Fig. 24.1 Linear regression analysis demonstrates a weak correlation between 4DST T/N ratio
and proliferative activity (Ki-67 index) in newly diagnosed gliomas (r¼ 0.45, p< 0.05) (A). There
was no significant correlation between 4DST T/N ratio and proliferative activity (Ki-67 index) in
recurrent gliomas (r¼ 0.31, p¼ 0.36) (B)
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24.4 Discussion
In the present study, we evaluated 4DST uptake in patients with newly diagnosed
and recurrent gliomas. 4DST PET was feasible for imaging both newly diagnosed
and recurrent gliomas. 4DST PET was found to be useful in the assessment of tumor
proliferation in newly diagnosed gliomas.
Increased cell proliferation and DNA replication is a characteristic of malignant
transformation [12]. The assessment of cellular proliferation rate by means of PET
is useful as a noninvasive clinical approach. In a previous study, an initial clinical
trial in only 6 patients with brain tumor was indicated that 4DST PET was feasible
for imaging brain tumors [9]. Toyota et al. evaluated 4DST uptake and proliferative
activity in 20 patients with gliomas, including 11 recurrent gliomas [10]. They
showed a weak correlation between 4DST T/N ratio and Ki-67 index [10]. The
present study also showed a weak correlation between 4DST T/N ratio and Ki-67
index in newly diagnosed gliomas. Minamimoto et al. evaluated 4DST uptake and
Ki-67 index in patients with non-small cell lung cancer [13]. They showed a
significant correlation between 4DST maximal SUV and Ki-67 index [13]. How-
ever, Ito et al. showed no significant correlation between 4DST maximal SUV and
Ki-67 index in head and neck squamous cell carcinoma [14]. One possible reason
for Ito et al.’s findings may be that the Ki-67 index was mainly obtained from
biopsy specimens and not from resected specimens.
The present study showed no significant correlation between 4DST T/N ratio
and Ki-67 index in recurrent gliomas. Eleven patients with recurrent gliomas in the
present study had received chemoradiotherapy before the PET study. Radiation and
chemoradiotherapy, used as an adjuvant therapy of gliomas, can cause loosening of
endothelial tight junctions, vascular leakage, or endothelial cell death and increase
vascular permeability [15]. Radiation could also act to increase vascular perme-
ability not only in the blood-brain barrier (BBB) but also in the blood-tumor barrier
(BTB) [15]. We suspect that in recurrent gliomas, breakdown of BBB and BTB
contributes to the degree of 4DST uptake in addition to increased proliferation.
Furthermore, there is biological difference between newly diagnosed and recurrent
gliomas. In recurrent gliomas, recurrent tumor and treatment-induced necrosis
frequently coexist.
Because the most proliferating part of the tumor is mainly responsible for tumor
progression, 4DST analysis enables a more precise estimation of the malignancy.
More important indication is the possibility that the cell proliferation imaging could
be used for early evaluation of treatment effects. In the report by Toyohara et al.,
although 11C-methionine PET detected all the contrast-enhanced lesions visualized
with MRI, a clinically stable tumor with contrast enhancement was not detected
with 4DST [9]. The role of 4DST in therapy monitoring has not been evaluated so
far. Further prospective studies involving a larger number of patients in a variety of
tumor types are required to determine the clinical usefulness of 4DST PET for early
evaluation of treatment response.
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24.5 Conclusion
4DST PET was feasible for imaging both newly diagnosed and recurrent gliomas.
4DST PET seems to be useful in assessment of noninvasive tumor proliferation in
newly diagnosed gliomas.
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Chapter 25
Impact of Respiratory-Gated FMISO-PET/CT
for the Quantitative Evaluation of Hypoxia
in Non-small Cell Lung Cancer
Shiro Watanabe, Kenji Hirata, Shozo Okamoto, and Nagara Tamaki
Abstract Hypoxia is present in various solid tumors, including non-small cell lung
cancer (NSCLC) and is associated with treatment resistance and poor prognosis.
18F-Fluoromisonidazole (FMISO) is a major PET tracer for hypoxia imaging.
Previous studies have evaluated the potential role of FMISO-PET as a prognostic
tool and assessed tumor reoxygenation following nonsurgical treatment in NSCLC.
However, for cancers located in the thorax or abdomen, the patient’s breathing
causes motion artifacts and misregistration between PET and CT images. PET/CT
with the respiratory-gating technique improves the measurement of lesion uptake
and tumor volume. We investigated the usefulness of respiratory gating for FMISO-
PET/CT-based quantification of hypoxia. Among the 14 patients examined, hyp-
oxia was observed in three patients with non-gated acquisition and in five patients
with respiratory gating. The SUVmax, tumor-to-muscle ratio, tumor-to-blood ratio,
and hypoxic volume were statistically significantly higher in respiratory-gated
(RG) images than in non-respiratory-gated (NG) images. RG FMISO-PET/CT
may be useful for the accurate quantification of hypoxia.
Keywords Non-small cell lung cancer • Hypoxia • FMISO • Respiratory gating
25.1 Background
Lung cancer is one of the most common cancers and is the leading cause of cancer
death worldwide. Although survival rates have improved in non-small cell lung
cancer (NSCLC), the long-term outcome remains poor compared with other can-
cers. Locoregional failure is not rare, particularly after chemoradiotherapy, and
may be attributed to intrinsic tumor resistance to radiotherapy and/or chemotherapy
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[1]. Intratumoral hypoxia accelerates radioresistance and chemoresistance, and thus
hypoxic tumors require a 2.5–3 times radiotherapy dose to achieve the same
cytotoxic effect [2]. Hypoxia may also promote metastatic spread [3].
18F-Fluoromisonidazole (FMISO) is a major PET tracer for hypoxia imaging.
The combination of positron emission tomography (PET) and computed tomogra-
phy (CT) is valuable in cancer diagnosis, follow-up, and treatment management.
Previous studies have evaluated the potential role of FMISO-PET as a prognostic
tool and in the assessment of the presence of tumor reoxygenation following
nonsurgical treatment of NSCLC [1, 4].
However, if the tumor is located in the thorax or abdomen, the patient’s breathing
causes motion artifacts, resulting in misregistration between PET and CT images
(Fig. 25.1) [5]. Because CT is used for attenuation correction of PET images, such
misregistration affects image reconstruction. The patient’s breathing leads to marked
displacement of most of the internal organs, from the apical region of the lungs down
to the abdominal organs. Internal organ movement has a degrading effect on image
quality and quantitative values in terms of spatial resolution and contrast [6]. Respi-
ratory gating is a technique for improving the measurement of lesion uptake and
tumor volume in PET/CT [7]. Motion management is becoming an important issue
in both diagnostic and therapeutic applications. A series of studies in 18F-
fluorodeoxyglucose PET/CT have shown that respiratory-gated (RG) 4D-PET/CT
and breath-holding protocols allow compensation for image degradation and arti-
facts induced by respiratory movements [6]. In contrast, there has been no study in
which RG FMISO-PET/CT was evaluated. We investigated the usefulness of respi-
ratory gating in FMISO-PET/CT-based quantification of hypoxia.
25.2 Materials and Methods
25.2.1 Subjects
We examined 14 patients [8 men, 6 women; median age (range) 78 (50–90) year]
with pretreatment stages I–III NSCLC (Table 25.1). None of the patients had ever
Fig. 25.1 Coronal (a) and sagittal (b) sections of thorax of a NSCLC patient in FMISO-PET/CT.
The PET scan shows significant blurring and misregistration of a malignant lung lesion and the
liver boundary compared with the CT scan
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received radiotherapy. The respiratory status of the patients was not considered as
an exclusion criterion. All these patients gave their written informed consent to
participate in this study. This study was approved by the Institutional Review Board
of Hokkaido University.
25.2.2 FMISO-PET/CT Studies
PET images were acquired using a whole-body time-of-flight PET/CT scanner
(GEMINI-TF; Philips). We administered 400 MBq of 18F-FMISO intravenously.
Four hours after injection, static emission scans with the field of view covering the
entire thorax were obtained in the 3D mode. Our protocol included a 4D CT scan
and a 30-min list-mode PET acquisition in one bed position centered on the primary
tumor. Respiratory signals were detected using a respiratory monitor system
(Philips Bellows) with a length sensor in a belt strapped around the patient’s
upper abdomen.
The PET scanning protocol is shown in Fig. 25.2. To reconstruct RG images, the
respiratory cycle was divided into five phases of the same duration. The third phase,
which corresponds to expiration, was used for reconstruction. Non-respiratory-
gated (NG) images were reconstructed with 6 min of acquisition of PET data
(i.e., sub-dataset of 12–18 min were extracted from the complete dataset of
30 min). For all PET image reconstructions, photon attenuation was corrected
using 4D CT images. Reconstructions were performed using 3D-RAMLA (ordered
subset expectation maximization).
25.2.3 Image Analysis
FMISO uptake 4 h after injection was quantified using (1) standardized uptake
values (SUV¼ 1 g/mL X measured radioactivity X body weight/injected radioac-
tivity), (2) tumor-to-muscle ratio (TMR), and (3) tumor-to-blood ratio (TBR).
Paraspinal muscles were used as the reference muscle. Venous blood was




Male (Female) 8 (6)
Median age (range) [year] 78 (50–90)





Tumor length (range) [mm] 29.3 (12.0–53.8)
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using a cross-calibrated well counter. We also calculated hypoxic volume (HV) as
an area TBR higher than 1.5 [8]. Patients having nonzero HV were considered as
having hypoxic tumor. Differences in SUVmax, TMR, TBR, and HV between
RG and NG images were statistically analyzed for significance.
25.2.4 Statistical Analysis
All results are expressed here as mean standard deviation (SD). A statistical
paired t-test was employed to evaluate the statistical significance of the differences
in SUVmax, TMR, and TBR between RG and NG. HV was compared between RG
and NG images using the Wilcoxon signed-rank test because of the non-normal
distribution of HV. P values smaller than 0.05 were considered statistically
significant.
25.3 Results and Discussion
In all the 14 patients, the tumor was visually identifiable from its higher signal
intensities than the surrounding lung tissues (Figs. 25.3 and 25.4). Quantitatively,
SUVmax, TMR, and TBR were all significantly higher on RG images (1.93 1.11,
Fig. 25.2 Summary of the PET scan protocol. All the acquisitions lasted 30 min. For respiratory-
gated imaging, the third phase, which corresponds to expiration, was used for reconstruction. Non-
respiratory-gated images were reconstructed with 6 min of acquired PET data (i.e., 12–18 min)
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1.46 0.78, and 1.42 0.87, respectively) than on NG images (2.09 1.11,
1.61 0.78, and 1.53 0.87, respectively) (Table 25.2, Fig. 25.5).
Whereas the NG images showed tumor hypoxia in three patients, the RG images
identified tumor hypoxia in two more patients (i.e., a total of 5 patients). In patients
with hypoxia, HV on NG images was 12.8 22.6, whereas that on RG images was
13.2 22.7, which was significantly higher (Table 25.3).
The results of this study showed significant differences in various quantitative
values between RG and NG. Theoretically, RG is less affected by motion artifacts,
and thus the images acquired with RG are considered to be more accurate than those
with NG. Our data suggest the risk of using non-respiratory gating for FMISO PET
in NSCLC, because non-respiratory gating could significantly underestimate tumor
hypoxia. Instead, the use of respiratory gating is recommended as a standard
technique for treatments targeting a hypoxic region.
The ability to determine the degree and extent of hypoxia in NSCLC is not only
important prognostically but also in the selection of candidate patients for hypoxia-
modifying treatments. [9] Among different treatments, radiotherapy would most
benefit from hypoxia imaging techniques. Radiobiological modeling suggests that
hypoxia would have a greater impact on the efficacy of a single-large-fraction
treatment than on that of fractionated treatment because of the lack of
Fig. 25.3 Axial and coronal sections of NG and RG PET images of a patient with a NSCLC lesion
in the left lower lobe. In addition to the difference in morphological appearances of the lesion
between the NG and RG images, there are considerable increases in SUVmax, TMR, and TBR
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reoxygenation in the former [9]. Information on tumor hypoxia may be used to
modify the radiation planning, especially the treatment fraction, to maximize
cytotoxic effects.
However, as mentioned above, respiratory motion during PET image quantifi-
cation can introduce image misregistration errors, and if uncorrected images are
acquired, such errors may eventually hinder adequate patient management [10]. As
a combined treatment strategy with functional information provided by PET imag-
ing, correction of PET images for respiratory motion artifacts may increase the
efficacy of individually tailored therapy. If FMISO-PET imaging predicts local
failure, then it can be used for guiding the selection of patients who would benefit
from dose escalation, modification of fractionation, or additional treatment with a
hypoxic cell radiosensitizer.
Fig. 25.4 Images of an 87-year-old female with stage II NSCLC in the right lower lobe. In non-
respiratory-gated maximum intensity projection (MIP) imaging, no primary lesion was detected.
However, in respiratory-gated MIP imaging, the lesion was visually detected
Table 25.2 SUVmax, TMR,
and TBR of lesions on RG and
NG images
SUVmax TMR TBR
NG RG NG RG NG RG
Mean 1.93 2.09 1.46 1.61 1.42 1.53
SD 1.11 1.11 0.78 0.78 0.87 0.86
Abbreviations: NG non-gating, RG respiratory gating, SD stan-
dard deviation, SUVmax maximum standardized uptake value,
TBR tumor-to-blood ratio, TMR tumor-to-muscle ratio
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One of the limitations of our study was the relatively small number of patients
examined. Further clinical study will be required to clarify the diagnostic value of
the quantitative evaluation of hypoxia with RG in association with local recurrence
and prognosis.
25.4 Conclusion
Respiratory gating in FMISO-PET/CT could provide higher sensitivity of hypoxic
evaluation and accurate quantification of hypoxia.
Fig. 25.5 SUVmax, TMR, and TBR were significantly higher on RG images than on NG images
(*p< 0.05, paired t-test)
Table 25.3 Increase in HV
with RG
Age Sex HV in NG HV in RG
72 Male 0 0.19
50 Male 9.15 9.92
62 Female 52.54 53.12
85 Male 2.05 2.69
81 Male 0.00 0.13
Mean 12.8 13.2
SD 22.6 22.7
Abbreviations: HV hypoxic volume, NG non-gating, RG respira-
tory gating, SD standard deviation
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